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Abstract 
Over the past decades, the transition metal-catalysed intramolecular activation of unactivated 
C-H bonds has emerged as a powerful tool for organic chemists according to the abundance of 
such bonds. Selective functionalizations of C-H bonds provide a rapid access to molecular 
complexity in an atom- and step-economical fashion. The research in our group is centered on 
the activation and functionalization of C(sp3)-H bonds that lead to the development of new 
methodologies and applications including asymmetric catalysis, mechanistic studies and total 
synthesis of natural products. 
Within this field, my Ph.D. thesis was focused on the development of new methodologies 
involving Pd0/PdII catalysed C(sp3)-H activation to access valuable heterocyclics building 
blocks or natural products. My thesis is divided into two distinct parts, namely “direct C(sp3)-
H functionalization” and “remote C(sp3)-H functionalization”. 
In the first part of this thesis, we present the synthesis of lycorine alkaloids, in an elegant and 
straightforward manner. Then, we propose a new synthesis of -lactams, using carbamoylation 
reaction. The last chapter of this part is focusing on the synthesis of benzoxazine, after 
benzazetidine rearrangement.  
In the second part of this thesis, we developed new synthetic methods for the remote 
functionalization of distal C-H bonds. First, the synthesis of -lactams and indanones after 
palladium migration. Then, the synthesis of benzofurans, indolines and chromanones using a 
similar methodology. 
Keywords : C-H functionalization, C-H activation, organometallic catalysis, palladium, natural 
products, lycorine alkaloids, -lactams, benzazetidines, benzoxazines, 1,4-Pd shift, migration, 
-lactams, indanones, benzofurans, indolines, chromanones. 
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Abbreviations:  
 
Ac: Acetyl 
 
Ac2O: Acetic anhydride  
AcOH: Acetic acid 
Ad: Adamantyl 
 
Ar: Aryl 
 
Atm: atmospheric pressure 
 
B.C.: Before Christ 
BCB: Benzocyclobutene 
BDE: Bond Dissociation Energy 
Cat.: catalytic 
CDC: cross dehydrogenative coupling 
Choi: 2-Carboxy-6-hydroxyoctahydroindole 
CMD: Concerted Metalation Deprotonation 
COgen: Carbon monoxide generator; 9-Methylfluorene-9-carbonyl chloride 
Cy: Cyclohexyl 
Cyp: Cyclopentyl 
d.r.: Diastereoisomeric ratio 
dba: Dibenzylideneacetone 
Dba: Dibenzylideneacetone 
DCE: 1,2-dichloroethane 
DCM: Dichloromethane 
DFT: Density functional theory 
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DHB: Dihydrobenzofuran 
DKP: Diketopiperazine 
DibAl-H: Diisobutylaluminium hydride 
DMAP: N,N-dimethylaminopyridine 
DMF: Dimethylformamide 
DMSO: Dimethylsulfoxide  
 
e.r.: Enantiomeric ratio 
equiv.: Equivalent 
Et: Ethyl 
FG: Functional Group 
F-TOTP: tri(5-fluoro-2-methylphenyl)phosphine 
HFIP: Hexafluoroisopropanol 
HPLA: Hydroxyphenyllactic acid 
 
HPLC: High pressure liquid chromatography  
 
IAC: Intramolecular acylal cyclisation  
KIE: Kinetic isotopic effect 
L: Ligand 
MHz: Megahertz 
MS: Molecular sieve 
NBE: norbornene 
NBS: N-bromosuccinimide 
n-Bu: 1-Butyl 
NHCs: N-heterocyclic carbenes 
NMR: Nuclear magnetic resonance 
PBP: penicillin-binding proteins 
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PCC: Pyridinium Chloro Chromate 
Ph: Phenyl 
PhI(DMM): phenyl-iodonium dimethylmalonate 
PivOCs: Cesium pivalate 
PivOH : Pivalic acid 
PivOK: Potassium pivalate 
PtBu3: Tri-tert-butylphosphine 
Py: Pyridine 
RT: Room temperature 
SM: Starting material 
T°C: Temperature 
TADDOL: α,α,α',α'-Tetraaryl-2,2-disubstituted 1,3-dioxolane-4,5-dimethanol 
TBS: tert-Butyldimethylsilyl 
Tf: Triflyl 
TFA: Trifluoroacetic acid 
TFAA: Trifluoroacetic anhydride 
TFE: 2,2,2-trifluoroethanol 
THF: Tetrahydrofuran 
TMB: Trimethoxybenzyle 
TMEDA: Tetramethylethylene diamine 
-H : -Hydride 
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Introduction and bibliographic part 
1. Generality 
Before the discovery of organic chemistry with the synthesis of urea by Wöhler in 1828 and the 
rationalization of catalysis, chemistry was in a way, already mastered by human civilizations 
with the process of bread cooking or beer brewing using enzyme catalysis (estimated 14000 
B.C. and 7000 B.C. respectively).[1] 
The 20th century has then witnessed the emergence of organic chemistry as a tool for industrial 
development in the field of pharmaceutical, petroleum, plastics or polymers. Some of the 
subsequent developed industrial processes are still used nowadays.[2]  
The ultimate goal of synthetic chemistry is the assembly of molecules from commercial 
feedstocks, with minimal waste generation and in an efficient manner. Over the past century, 
the classical approach to access chemical diversity was based on strategy of functional-group 
interconversion, requiring tedious and time-consuming manipulations (Scheme 1).[3]  
New synthetic processes have then been investigated to answer the need of modern organic 
synthesis. 
 
Scheme 1: Modification of functional groups using classical synthetic approach 
More recently, transition-metal-catalysis tremendously expended the synthetic organic 
chemistry toolbox to develop new efficient transformations. Among those, palladium-catalysis 
has emerged as a new way to form carbon-carbon or carbon-heteroatom bonds and has been 
developped to access molecular complexity in a straightforward, convenient and selective 
fashion.[4] Palladium-catalyzed cross-coupling reactions are nowadays used as routines 
reactions in academic laboratories and industries.[5] The impact of these transformations 
drastically changed the vision of organic chemistry, and the main actors of this revolution were 
gratifingly rewarded by a Nobel Chemistry Prize in 2010. (R. F. Heck, E. Negishi and A. 
Suzuki).[6]  
These reactions require pre-functionalized starting materials (halide/pseudohalide-
functionalized substrate) and involve an oxidative addition and reductive elimination to 
furnished the coupled product. 
21 
 
In a mechanistic point of view, the Heck reaction differs from a Negishi or Suzuki-Miyaura 
cross-coupling (Figure 1). This reaction is initiated by oxidative addition of Pd0 into a carbon-
leaving group bond (leaving group = halide or pseudohalide) of a pre-functionalized starting 
material. Complexation of the olefin to the Pd complex, followed by migratory insertion 
generates an alkylpalladium moiety, which after -hydride elimination, undergoes the 
functionalized olefin. The presence of a base regerenates the active Pd0 catalyst to insure the 
turn-over of the reaction. 
 
 
Figure 1: Overview of the Heck coupling 
In the Negishi or Suzuki-Miyaura cross-coupling, the reaction is also initiated by the oxidative 
addition of a Pd0 complex into a carbon-halide/pseudohalide bond generating an electrophilic 
PdII species (Figure 2). After transmetallation with a nucleophilic organometallic compound 
(Zinc or Boron), and reductive elimination, the cross-coupled product can be afforded.  
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Figure 2: General mechanism for Suzuki and Negishi coupling 
While those methods proved their robustness and usefulness through multiple applications, the 
necessity to pre-functionalize the starting material and the generation of stoichiometric wastes 
motivated chemists to direct their research in the field of C-H functionalization. 
Considering the abundance of C-H bonds in organic feedstocks or elaborated molecules (Figure 
3), such as simple hydrocarbons, bioactives molecules, biopolymers or organic materials, 
selective functionalizations of C-H bonds would deliver a method of choice for organic 
derivatizations.
 
Figure 3: Abundance of C-H bonds in organic feedstocks or elaborated molecules 
However, the low reactivity of intrinsic C-H bonds, combined with selectivity issues for the 
direct functionalization of complex structures, motivated chemists to develop new methods 
involving transition-metal catalysts to answer the need of transformations based on C-H 
activation. This introduction will highlight the main advances in the field of C-H activation 
allowing to overcome the aforementioned limitations. 
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2. C(sp2)-H functionalization 
Initially introduced in the first half of the 20th century,[7] transition-metal-catalyzed C−H bond 
functionalization has been exponentially developed since the 21th century, with the emergence 
of methods to generate new carbon−carbon and carbon−heteroatom bonds from diverse C−H 
bonds.[8] In most cases, the reaction substrates are readily accessible, leading to valuable 
functionalized products in a step-economical manner. The power of these catalytic methods has 
been translated into numerous applications including the synthesis of natural products,[9] 
pharmacologically active substances, and organic functional materials.[10] 
The C(sp2)-H functionalization has rapidly emerged in the field of transition-metal-catalyzed 
reactions.[11] The metal can engage the C-H cleavage with the target C-H bond after an initial -
orbital interaction with the substrate (Scheme 2). The initial report for such transformation using 
palladium was described by Fujiwara[12] and co-workers in 1968, for the formation of stillbene 
from styrene. Coordination-directed metalation has also been well exploited for selective C-H 
functionalization at arene rings in the ortho position to a suitable functional group (Scheme 2). 
The key discovery in this area was made by Murai and co-workers who demonstrated the first 
efficient, catalytic and selective coupling of an arene C-H bond and an alkene.[13]  
 
Scheme 2: Arene C-H functionalization  
3. C(sp3)-H functionalizations 
Among all types of C-H bonds, C(sp3)-H bonds of alkyl have been recognized as particularly 
difficult to cleave because they possess additional conformational degrees of freedom and as 
they don’t benefit from precoordination of the transition-metal to a π or π* orbitals.  
One of the biggest synthetic challenge over the past 60 years was the selective conversion of 
light alkanes to alcohols or olefins using selective C(sp3)-H functionalization (Figure 4). The 
simple transformation of methane to the high-value-added methanol would allow  gaseous 
methane [14] to be transported as liquid product or methanol to be used in reactions that form C-
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C bonds in higher hydrocarbons.[15] Nowadays, none of these goals have been achieved in a 
practical fashion. 
 
Figure 4: Abundant alkane feedstock and plausible functionalization 
While considering the “parafins” C(sp3)-H bonds, the poor reactivity of such bonds is often 
explained by their high energies (90 to 100 kcal/mol), their low acidity (pKa = 45-60) and their 
unreactive molecular orbitals.[16]  
However, even if the C(sp3)-H bonds are more difficult than others to cleave, they have proved 
to not be completely inert. Alkanes can react with extremely active species such as radicals, 
carbenes and highly acidic compounds. Additionally, the obstinacy of chemists to make new 
developments in this field brought a library of transition-metal-catalysed reactions which allows 
the functionalization of such C-H bonds.[8] 
The fields of C-H functionalizations or C-H activations are really broad, and in permanent 
development. After the initial reports of Corey[17] in 1958 and later Shilov in C(sp3)-H 
halogenation,[18] Woodward in C-H amination,[19] Cory, Scott and DeCicco in C-H insertion,[20] 
Bergman in iridium-catalysed C(sp3)-H activation[21] and the great development of C(sp2)-H 
arylation initiated by Ames,[22] the emergence of palladium-catalysed C(sp3)-H activation has 
proved to be a method of choice for such functionalization. 
4. Palladium-catalysed C(sp3)-H functionalizations: 
4.1-  C(sp3)-H activation of alkanes using palladium catalysis: 
Among the library of reactions for C-H bonds functionalizations, only few depicts the selective 
functionalization of C(sp3)-H bonds of alkanes. Indeed, most of them are carried out on 
symmetric or relatively simple alkanes. Among these few examples, Fujiwara reported in 1989 
the functionalization of cyclohexane using Pd(II)-catalysed C(sp3)-H carboxylation to afford 
the corresponding carboxylic acid (Scheme 3).[23] In their conditions, the cyclohexane is used 
as solvent, under high pressure of CO (20-40 atm), Pd(II)/Cu(II) as catalytic system in 
trifluoroacetic acid at 80°C and afforded the cyclohexanecarboxylic acid 1 in 4.3% yield based 
on cyclohexane. In a similar fashion, they reported later the carboxylation of gaseous propane 
under similar conditions (Scheme 3). While using a high pressure of propane (10 atm), with 
high pressure of CO (20 atm) and Pd(O2CEt)2, CuSO4, and K2S2O8 in TFA at 80°C, a mixture 
of isobutyric  and butyric acids isomers were obtained respectively in 360% and 300% based 
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on Pd. To explain these reactions, they proposed the in situ generation of a cationic [Pd(TFA)]+ 
species as electrophilic intermediate, which could undergo a nucleophilic addition of a C(sp3)-
H bond of the alkane to generate an [alkyl-Pd-TFA] intermediate. Further carbonylation and 
oxidation would then generate the corresponding carboxylic acids.  
 
Scheme 3: Early examples of alkanes functionalization by Fujiwara 
In 2002, Strassner and co-workers reported the use of a Pd/NHC complex as catalyst for the 
C(sp3)-H activation of methane (Scheme 4).[24] A mixture of catalyst 5, with K2S2O8 as 
stoichiometric oxidant, TFA and trifluoroacetic anhydride (TFAA) under 30 bars of methane 
led to the formation of trifluoroacetic acid methyl ester 6 in 3000% based on 5. The authors 
proposed a C(sp3)-H activation by Pd(II) followed by bromine oxidation to undergo a Pd(IV) 
intermediate for C-H functionalization.[24]  
 
Scheme 4: Oxidation of methane to trifluoroacetic acid methyl ester 
According to the lack of reports and as shown with these few examples, alkanes are non-polar 
and hydrophobic and thereby, react weakly with Pd species. However, with a large excess of 
the alkane reagent, with highly reactive Pd species and harsch conditions, the functionalization 
of such feedstock is possible. Nevertheless, such an approach cannot allow the control of regio- 
and chemoselectivity, and can undergo overfunctionalization. Therefore, the Pd-catalysed 
C(sp3)-H activation using substrates bearing pre-existing functional groups as directing group 
(DG) to coordinate the Pd species has then emerged as a powerful tool for selective 
functionalizations. 
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5. Directed palladium-catalysed C(sp3)-H activation  
With the issues encountered for the selective functionalization of alkanes, the use of substrates 
containing one or several functional groups that can chelate the Pd catalyst allows the selective 
functionalization of C-H bonds. Traditionally, the strong -donor or -acceptor of nitrogen, 
sulfur, or phosphorus-containing moieties are required and can be used as non-covalent 
directing groups for the coordination to palladium to direct C-H activation, and form stable, 
well-defined palladacycles (Figure 5).[25] The central point of this methodology is based on the 
formation of a stable 5- or 6-membered palladacycle. The formation of such palladacycles 
intermediates lowers the activation energy barrier during the C(sp3)−H cleavage step, 
underlining the importance of directing group for achieving high reactivity in Pd-catalysed 
C(sp3)−H activation.  
In addition to non-covalent directing groups for selective C-H activation, oxidative addition of 
palladium into a carbon-leaving group such as halides (I, Br or Cl) or pseudo-halides (OTf) can 
be used (Figure 5). In this case, the substrate becomes the ligand of the metal. The C(sp3)-H 
activation directed by carbon-leaving group bonds will be discussed later and used as a central 
point for this thesis. 
 
Figure 5: Directed C(sp3)-H activation by non-covalent directing group or from oxidative addition 
5.1.  Palladium-catalysed C(sp3)-H activation directed by non-covalent directing group  
First introduced by Trofimenko in 1973, the term cyclometalation involves the cleavage of 
C(sp2)-H and C(sp3)-H bonds by transition-metals to form [M-R] species.[26] Different metals, 
as well as different mechanisms can be involved in this process. The main mechanisms for 
cyclometalation include oxidative addition, electrophilic activation, concerted 
metalation/deprotonation (CMD) and -bond metathesis. 
According to the more reactive C(sp2)-H towards C(sp3)-H bonds, numerous examples of 
cyclopalladation have been reported on the former in the early literature.[27] However, only few 
examples described the cyclopalladation of unactivated aliphatic C(sp3)-H bonds.  
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Early examples are using oximes, pyridines or amines as strongly coordinating directing 
groups.[28] Further developments using less-coordinating directing groups, such as carboxylic 
acids, hydroxamic acids, amides were then developed to enhance the reactivity of the in situ 
formed palladacycle.[29] [30] 
In 1978, Shaw and co-workers induced the formation of the 5-membered palladacycle dimer 8 
after C(sp3)-H bond cleavage using a stoichiometric Pd source (Na2PdCl4) and NaOAc with the 
tert-butyl-methyl ketone oxime 7 (Scheme 5).[31] This stable palladium moiety has been fully 
characterized using NMR and IR studies.  
A 6-membered palladacycle 10 was isolated by Hiraki and co-workers in 1983, after C(sp3)-H 
cleavage directed by a pyridine moiety (Scheme 5).[32] In both cases, the presence of a 
quaternary carbon in - to the cleaved C-H bonds avoid from -H elimination. 
 
Scheme 5: 5- and 6-membered palladacyles resulting from C(sp3)-H activation 
These isolated and stables palladacycles have then been subjected to a range of conditions to 
afford a C(sp3)-C or C(sp3)-heteroatom coupled product. Baldwin and co-workers converted 
Shaw’s palladacycle 8 to the alkyl-halide product 11 after treatment with chlorine in CCl4, and 
subsequent reduction with sodium cyanoborohydride (Scheme 6).[33] The product 11 resulting 
from Pd-Cl exchange was isolated in 64% yield. Moreover, a ligand exchange with pyridine 
from 8 could lead to the monomeric palladacycle 12. Further treatment with Pb(OAc)4 and 
reduction furnished the acetoxylated product 13 in quantitative yield. 
 
Scheme 6: Baldwin conversion of Shaw’s palladacycle to alkyl-chloride or acetoxylated oxime 
Sanford and co-workers developed in 2004 the catalytic version of such reaction in the presence 
of a stoichiometric oxidant (Scheme 7).[34] While using a less-chelating methoxy-oxime 
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directing group and with a fine tuning of the reaction conditions, the desired acetoxylated oxime 
14 was obtained from 15, after formation of a 5-membered palladacycle.  
Later, the applicability of such oxime-directed acetoxylation was demonstrated for the synthesis 
of the natural product paspaline by Johnson and co-workers (Scheme 7).[35]  
 
Scheme 7: Sanford methodology and application by Johnson for the synthesis of paspaline 
5.2. Intramolecular C(sp3)-H activation directed by carbon-halogen bonds 
In addition to non-covalent directing groups for C-H functionalizations, oxidative addition of 
palladium into a carbon-leaving also allows such selective functionalization. 
In 1992, Dyker reported the first C(sp3)-H activation of a methoxy group directed by oxidative 
addition (Scheme 8).[36] Starting from 18, and while using Pd(OAc)2 as catalyst, K2CO3 as 
stoichiometric base in DMF, he could afford the dimer 20 via formation of the palladacycle 19. 
The method was extended later to the C(sp3)-H activation of a tert-butyl moiety for the synthesis 
of benzocyclobutene 22 (BCB), using similar conditions with an external aryl-bromide reagent 
21.[37] These first two examples are now considered as the starting point for the development of 
palladium-catalysed C(sp3)-H activation for the synthesis of medium-sized rings.  
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Scheme 8: Early examples of C(sp3)-H activation by Dyker 
The mechanism for BCB synthesis is described scheme 9. The reaction starts with the oxidative 
addition of in situ formed Pd(0) into the C-I bond of 21, to form a Pd(II) intermediate 23. Then, 
the C(sp3)-H activation of the tert-butyl moiety after CMD process promoted by K2CO3, 
undergo the formation of the palladacycle 24. At this point, the presence of an external aryl-
bromide can undergo oxidative addition to palladium, and give the highly oxidize Pd(IV) 
intermediate 25. This intermediate can then undergo reductive elimination, to form the aryl-aryl 
bond, and generate an alkylpalladium moiety 26. The proximity of the C-H bond on the 
aromatic ring can then undergo a C(sp2)-H arylation reaction to form the 5-membered 
palladacycle 27. Finally, reductive elimination furnished the BCB 22 and regenerate the Pd(0) 
catalyst to insure the turn-over of the reaction.  
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Scheme 9: Mecanistic blueprint for the synthesis of BCB by Dyker 
With the absence of ligand in Dyker’s reports, the reaction suffer from a lack of control and 
undergoes aryl-aryl coupling and BCB formation. However, these two pioneer results 
represents a great proof-of-concept in the field of palladium-catalysed C(sp3)-H activation to 
afford valuable products in a straightforward manner. Dozens of reports in this field will then 
follow, extanding the library of possibilities for ring constructions and finding applications in 
the fields of bioactive compounds or natural products synthesis.[38]  
5.3.  Early improvement using a phosphine ligand 
In 2003, Baudoin reported the first example of Pd(0)/Pd(II) catalysed C(sp3)-H activation with 
the presence of a phosphine ligand starting from aryl bromide 28 (Scheme 10).[39] In their 
improved synthesis of BCB, the use of tri-orthotolylphosphine (TOTP) shuts down the second 
oxidative addition, preventing the formation of oligomeric products. In addition, Baudoin and 
co-workers showed that methylene C-H bonds could also be activated, thereby furnishing after 
-hydride elimination, a mixture of olefins 31 and 32. Indeed, the reductive elimination after 
cleavage of the later is difficult notably for steric hindrance reasons, leading exclusively to the 
alkenes.  
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Scheme 10: BCB and olefins synthesis: early report by Baudoin 
After further investigations, they found out that two phosphines could favor each reaction 
pathway to obtain either olefins 35 or BCB 36 (Scheme 11). A fine design of reaction substrates, 
combined with adapted conditions were necessary. First, the use of a relatively electron-
deficient triarylphosphine ligand (tri(5-fluoro-2-methylphenyl)phosphine : F-TOTP) could 
decrease the required reaction temperature from 150°C to 100°C and favored olefins formation, 
increase the selectivity for internal olefins and reactivity for hindered substrates (Scheme 11).[40] 
On the other hand, they discovered that the bulky PtBu3 ligand allows a higher efficiency and 
a broader scope for the synthesis of BCB as well as the use of aryl chlorides as starting 
materials.[41] This work underlines the importance of phosphine ligands in such reaction.  
 
Scheme 11: Selective synthesis of olefins and BCB by Baudoin 
5.4. Reaction mechanism  
With the development of transition-metal-catalysed C(sp2)-H activation in aryl-aryl couplings, 
reaction mechanisms have been investigated. Computational studies by Davies[42] and 
McGregor,[43] combined with the work of Echavarren and Maseras[44] excluded 
32 
 
carbopalladation, electrophilic aromatic substitution or -bond metathesis (SBM) as 
mechanism pathway to propose the concerted-metalation-deprotonation (CMD) mechanism in 
the C(sp2)-H cleavage.[45]  
Then, Baudoin[41] and Fagnou[46] proved that this CMD mechanism was as well involved in the 
C(sp3)-H activation.[47] As shown for the synthesis of BCB or olefins (Figure 6), the reaction 
mechanism starts with oxidative addition of palladium into the carbon-halide bond of 37. Pd(0) 
is generated in situ from Pd(II) and the phosphine ligand (L). Ligand exchange with a carbonate 
or carboxylate undergo the formation of the electrophilic Pd(II) species 38. Then, the CMD 
mechanism occurs to form a palladacycle 39. Depending of the design of the substrate, 5-, 6- 
or even 7-membered palladacycles can be formed. The formation of such palladacyle is 
generally favoured with strong Thorpe-Ingold effect (R1 and R2). Further decoordination of the 
base and reductive elimination undergo the formation of the cyclic product 36. Another pathway 
can be the proton transfer of 39 to generate the alkylpalladium intermediate 40. This 
intermediate, as in the Heck reaction can then undergo -hydride elimination and form the 
olefin 35. 
 
Figure 6: Reaction mechanism for the obtention of BCB or olefin 
For the C-H cleavage step, DFT calculations were made by Baudoin and Clot for the synthesis 
of the BCB 45 (Figure 7).[48] After simplifying the system (use of carbonate and PtBu3 as 
phosphine ligand) on the substrate 41, they proposed two plausible reaction pathways. They 
suggested two similar transition states (TS), operating in an intramolecular fashion: 
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- First, a cis-activation model, previously proposed by Fagnou and Gorelsky was 
simulated, via the formation of a stable precomplex 42 involving 2-carbonate 
coordination (Figure 7). According to calculations, this model possesses a high 
activation barrier (37.9 kcal/mol) for the C-H activation step.  
- Then, Baudoin and Clot proposed a trans-activation giving rise to a less stable pre-
complex 46, but a lower activation barrier (26.2 kcal/mol) (Figure 7). Interestingly, 
compared to 42, agostic interaction was observed in the precomplex 46 which enhances 
the protic character of the geminal proton. Thanks to this interaction and 1-precomplex 
coordination, a lower activation barrier is required to reach the transition state. The C-
H bond cleaved in this mode is not the agnostic one, but the geminal. 
Baudoin and Clot concluded that the trans-coordination appears to be the favored one according 
to DFT calculations for the formation of BCB, but both mechanisms should be considered in 
the case of other substrates.  
 
Figure 7: Proposed TSs for C-H activation step after DFT calculations 
Thanks to these computational studies and accumulated experimental data, a selectivity 
guideline for the Pd(0)-catalysed intramolecular C(sp3)-H activation has been proposed. This 
selectivity trend is ruled by several factors: 
-  First, the acidity of the cleaved C-H bonds 
(benzylic>aromatic>cyclopropyl>methyl>methylene>methine) are of first importance.  
- Then, the size of the palladacycle formed after C-H cleavage (5-membered>6-
membered>>7-membered) which translate into the following preference for the 
formation of cyclic produts: 4-membered>5-membered>>6-membered.  
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These are guidelines, and of course other factors should be taken in consideration: the steric 
environment (Thorpe-Ingold effect, steric hindrance…), the stability and ring-strain of the 
product as well as reaction conditions can influence the reaction outcome.[49]  
Depending of the substrates, the main side reactions involve proto-debromination, homo-
coupling, -hydride elimination or nucleophilic addition of palladium. Keeping all this factors 
in mind is crucial for the design of new reactions. 
5.5. Intramolecular activation of unactivated C(sp3)-H bonds using Pd0/PdII catalysis: 
representative examples 
With these parameters, developments have been made for the synthesis of medium-sized rings 
involving C(sp3)-H activation reaction. According to the accumulated reports, two distincts 
reaction conditions appeared to be relevant for the synthesis of (fused)-cyclic products:  
- First, a combination of inorganic base, in a high-boiling and polar solvent, with the 
presence of Pd0/Ligand as catalytic system 
- Then, a combination of organic base (carboxylate, phosphate, pivalamide…) with an 
inorganic base in a high-boiling apolar solvent can be used and Pd0/Ligand as catalytic 
system. 
Generally, reactions require temperatures > 90°C to operate. Both conditions can be used as 
starting point for a reaction screening. 
After the initial reports exposed earlier, several research group started to be interested in this 
methodology for the construction of medium-sized rings. The scheme 12 depicts a non-
exhaustive list of relevant examples. 
Hetero- or non-heterocyclic products can be obtained with different sizes, including 
dihydrobenzofurans 49,[50] indolines 50,[51] indanones 51,[46] lactams,[46] hexahydroindoles 53 
[52] or quinolinones 54.[53] Most of the reports depicts the formation of 5-membered rings, for 
their high stability and the well-favoured formation of the 6-membered palladacycles. These 
methodologies allowed the formation of valuable scaffolds for drug discovery or natural 
product synthesis, in an atom-economical and straightforward manner.  
35 
 
 
Scheme 12: Representative cyclic products from C(sp3)-H activation of unactivated positions 
The usefulness of such methodology has been translated into several applications, notably for 
the construction of natural product scaffolds or bioactive molecules. Moreover, the C(sp3)-H 
activation showed its robustness for the synthesis of valuable building blocks over gram scale, 
with excellent yield and selectivity. 
In 2012, Baudoin and co-workers constructed the tricyclic core of the natural product glionitrin 
B after intramolecular C(sp3)-H activation on the diketopiperazine derivative 56 (DKP)(Scheme 
13).[54] The reaction proceeded with good yield while using the predefined Pd(PCy3)2 catalyst, 
in presence of a mixture of carbonates and pivalic acid. Shortly after, Baudoin and co-workers 
developed specific conditions to generate an array of 1-indanoles and 1-indanamines (Scheme 
13).[55] In their case, exclusive formation of the indane was observed with selectivity towards 
the trans isomer. The method was used to synthesize the synthetic precursor 59 of the herbicide 
indaziflam. After removal of the phtalimide group with treatment with hydrazine, the 
indanamine 60 was obtained.  
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Scheme 13: Application of C(sp3)-H activation for natural product scaffold or valuable intermediate synthesis 
In 2012, starting from cycloalkenyl bromides 61, the Baudoin’s group built the 
hexahydroindoles core of Aeruginosins through Pd(0)-catalysed intramolecular C(sp3)-H 
alkenylation in a really efficient manner (Scheme 14).[52] The efficiency of the method was later 
exploited for the synthesis of the natural products Aeruginosin 298A and 98A-C (Scheme 14).[56] 
In this report, 4.8 grams of the common intermediate 63 were obtained using C(sp3)-H 
alkenylation of 62. The synthesis of Aeruginosin 298A was completed on 700 mg scale, with 
an overall yield of 8.2% for 17 steps. This direct application of C(sp3)-H activation showed its 
robustness and applicability for complex molecules synthesis. 
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Scheme 14: Baudoin’s synthesis of hexahydroindoles and application to the synthesis of aeruginosins natural products 
5.6. Enantioselectives C(sp3)-H activation 
In organic synthesis, the selective synthesis of one enantiomer of a product is always 
challenging. During a C(sp3)-H activation reaction, the CMD step can be enantiodetermining 
for the discrimination of two enantiotopics methyl groups or two methylene C-H bonds. 
According to the plausible transition state, enantioselectivities can be reached with the use of a 
chiral base or a chiral ligand. 
The first example of enantioselective Pd-catalysed C(sp3)-H activation has been reported by 
Kündig and co-workers in 2011 (Scheme 15).[57] While using a C2-symmetric NHC, they were 
able to achieve very high enantioselectivities for the enantiodiscrimination of two methylene 
C-H bonds despite the need of high reaction temperatures (140-160°C) in their synthesis of 
trans-fused indolines 65 (Scheme 15). The enantiodiscrimination of two methyl groups was later 
reported by Kagan for the synthesis of enantioenriched indolines 68 introducing a new type of 
bidentate-type ligand (Scheme 15).[58] Finally, the group of Cramer introduced the monodentate 
TADDOL-derived phosphoramidites and phosphonites ligands for the direct C(sp3)-H 
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activation of a cyclopropyl moiety (Scheme 15).[59] Good yield, as well as good 
enantioselectivities can be achieved for the synthesis of tetrahydroquinolines 71. 
 
Scheme 15: Relevant examples of enantioselectives C(sp3)-H activation 
According to the increasing interest from chemists and biologist for enantioselective synthesis, 
the field of C(sp3)-H activation using chiral ligand or chiral base is in intensive development to 
reach high enantioselectivities in the discrimination of both methyl groups or secondary C-H 
bonds.[60] 
6. Research developments and projects covered in this thesis 
All along this thesis, we tried to develop new systems based on intramolecular C(sp3)-H 
activation to access medium-sized rings. With the growing concurrence in this field, we tried 
to reach a high degree or originality, applicability and scalability for these new processes. 
This manuscript is divided into two parts: the first part will cover the direct C(sp3)-H activation 
reactions. First, the efficient synthesis of lycorine alkaloids using a double palladium-catalysed 
C(sp2)/C(sp3)-H activation reaction. Then, a new approach for the synthesis of -lactams from 
carbamoyl chlorides will be covered. Finally, the last chapter will cover the synthesis of 
benzoxazines through benzazetidines rearrangement.  
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The second part of this thesis will cover the remote (or distal) C(sp3)-H activation, notably using 
1,4-Pd shift. The first chapter will deal with the synthesis of -lactams and indanones via C(sp2)-
C(sp3) coupling. The second chapter will focus on the formation of C(sp3)-C(sp3) bonds for the 
synthesis of benzofurans, indolines, chromanones and benzofuranols. 
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Part 1: Direct C(sp3)-H activation 
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Chapter 1.1: 
Synthesis of lycorine alkaloids using Pd-catalysed C-H 
arylation 
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1. Lycorine alkaloids and derivatives:  
In this first chapter of this manuscript, we focus our attention on the synthesis of lycorine 
alkaloids.  
More than ten congeners of the lycorine alkaloids have been extracted and characterized from 
the plants belonging to Amaryllidaceae species by Wildman and co-workers in 1955.  Pratosine, 
hippadine, assoanine, lycorine and its degradation product ()-lycorane are representative of 
this family of molecules (Figure 8).[61]  Today, about 30 congeners of this family have been 
identified.[62] [63] 
  
Figure 8: some relevant Lycorine alkaloids family members 
To understand the relations between Amaryllidaceae  alkaloids, their biosynthesis, including 
lycorines, have been elucidated( Figure 9).[64] These molecules are derived from the amino acids 
L-phenylalanine and L-tyrosine, which can provide protocatechuic aldehyde and tyramine 
respectively. Imine formation, followed by reduction and methylation leads to the common 
precursor o-methylnorbelladine. Alternative ways of oxidative phenol coupling produce three 
main skeleton which offer diversity in the Amaryllidaceae alkaloids. A complex process of 
enzymatic steps is occurring on the different alkaloids which gives a spectrum of compounds 
that differs between species and cultivars, and even between the different tissues of the same 
plant.[64] Each Amaryllidaceae species produces a mixture of alkaloids, often with a few major 
compounds and a larger number of compounds at low concentrations. 
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Figure 9: Overview of lycorine alkaloids biosynthesis 
The pharmacological activities of pyrrolophenanthridine derivatives, or lycorine alkaloids, have 
been widely studied in the past decades. Their biological activities, including cancer cell growth 
inhibition, anti-Alzheimer (acetylcholinesterase inhibition), but also anti-tripanosomal and anti-
fungal activities have consequently received attention from both chemists and biologists.[65] 
According to the diverse biological activites of theses molecules, chemists focused their 
attention on the development of new libraries of non-natural lycorines derivatives for medical 
uses. For instance, Evidente and co-workers could identify a lycorine analogue which was 100 
times more potent against an U373 human glioblastoma model in vitro.[66] This recent example 
highlights the interest of developing a general method to access diverse lycorine alkaloids 
derivatives, in a simple and efficient manner. 
2. Previous synthesis: 
A variety of total synthesis of natural lycorine alkaloids have been reported, after the initial 
work of Kotera in 1958.[67] Today, more than 30 synthesis of these compounds have been 
described in the literature. 
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2.1. Previous synthesis involving Pd-catalysis 
According to the numerous reports relative to lycorine alkaloids synthesis, this part will be 
dedicated to relevant synthesis of such molecules. 
Palladium catalysis, involving cross-coupling reactions has been largely used for the 
construction of the polycyclic core of lycorine alkaloids. Most of the synthetic strategies are 
relying on the use of an indole derivative for the construction of the polycyclic core of the 
pyrrolophenanthridine. The main disconnections for the lycorine core are described figure 10. 
 
Figure 10: Previous disconnections for lycorine core synthesis 
To illustrate this and in complement to metal-catalysed cross-coupling reactions, Kerr reported 
the formation of isoquinoline structure using an oxidative aryl-aryl coupling from 1.1 using 
hypervalent iodine (Scheme 16). Further DDQ oxidation to indole underwent facile and rapid 
access to hippadine.[68]  
 
Scheme 16: Synthesis of Hippadine by Kerr  
The shortest synthesis of (±)--lycorane was published in 2017 by the group of Hilton (Scheme 
17).[69] This synthesis is using a sequential intramolecular acylal cyclisation (IAC) from 1.5 
followed by an intramolecular Heck reaction to furnish 1.7. After hydrogenation of the two 
olefins, followed by amide reduction, the product was obtained in 31% overall yield, over 6-7 
steps. This synthesis is to the best of our knowledge, the shortest and most efficient synthesis 
of (±)--lycorane. 
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Scheme 17: Synthetic path for rapid access to (±)--lycorane by Hilton et al. 
In 2014, the group of Takemoto reported the synthesis of pratosine and hippadine using an 
intramolecular C-H functionalization strategy (Scheme 18).[70] The polycyclic core was 
constructed in a stepwise manner including a C(sp3)-H activation between a carbamoyl chloride 
and a benzylic C-H bond. The authors are using Pd(OAc)2 as catalyst, Ad2Pn-Bu as ligand and 
PivNHO- as base for the CMD, under CO atmosphere. The desired intermediate 1.9 was 
obtained in moderate yield, with decarbonylated side product 1.10 as major product. The 
intermediate 1.9 can then be reduced using DIBAL-H, leading to the indole which after further 
oxidation, afforded the pratosine. 
 
Scheme 18: Synthesis of pratosine by Takemoto et al. 
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3. Initial work on Pd-catalysed C-H arylation:  
3.1. Initial work on palladium catalysed C-H arylation of carbonyls compounds 
From 1997, the groups of Buchwald,[71] Hartwig[72] and Miura[73] developed the first 
intermolecular coupling of aryl halides and ketone enolates, for the synthesis of -aryl ketones 
1.12 (Scheme 19).[71] Based on these methodologies, they later explored the arylation of other 
substrates such as carboxylic acid derivatives. In 1998, Hartwig published the first inter and 
intramolecular -arylation of amides, for the synthesis of substituted amides and oxindoles 
1.18.[74] Based on the in situ formation of an enolate with the presence of a strong base (tBuOK), 
followed by palladium-catalysed C-H arylation, this methodology allows the formation of a 
broad range of valuable products.  
 
Scheme 19: General -functionalization of carbonyl compounds and synthesis of oxindoles by Hartwig et al. 
Later, improvements by Zhu showed that the use of carbonate as milder base could generate 
the formation of oxindole 1.20 from 1.19 (Scheme 20).[75]  
 
Scheme 20: Zhu’s -arylation for the synthesis of oxindoles 
3.2. Palladium-catalysed intramolecular double C-H activation methodology:  
 
3.2.1. Intramolecular double C(sp2)-H arylation 
Intramolecular double C-H activation reactions have been widely studied in the past decades, 
notably for the efficient access to polycyclic compounds. First introduced by Echavarren and 
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co-workers in 1996 in a C(sp2)/C(sp2) manner,[76] and later explored by Kamikawa for helicenes 
1.24 synthesis,[77] these methods were later extended from carbocycles to heterocycles (Scheme 
21). Tanaka proposed a new synthesis of fused indolines  1.26 using this approach, starting from 
a bis-halogenated substrate 1.25.[78] Indeed, the fast oxidative addition of palladium into the C-
Br bond of 1.25 allowed the formation of the 5-membered ring. Subsequently, oxidative addition 
of palladium into the C-Cl bond, followed by C-H arylation, afforded the fused indoline 1.26 in 
63% yield. 
 
Scheme 21: Early examples of double C-H arylation by Echavarren, Kamikawa and Tanaka 
3.2.2. Intramolecular double C(sp2)/C(sp3)-H arylation 
More recently, Baudoin developed a new type of double C-H activation reaction for the rapid 
construction of polycyclic molecules, involving a C(sp2)-H-arylation combined with a C(sp3)-
H-arylation in a one-pot manner (Scheme 22).[79] In this case, the choice of leaving group 
(bromide and chloride) is crucial for the formation of the product as a single isomer. Starting 
from 1.27, the fast oxidative addition in the C-Br bond, followed by aryl-aryl coupling affords 
the formation of the 6-membered ring. Then, C(sp3)-H arylation can occur after oxidative 
addition of palladium into the C-Cl bond. Pd(OAc)2, combined with PCy3 generates in situ the 
active Pd(0) species. Inorganic base (K2CO3) and polar solvent (DMF) at 140°C afford the 
heterocyclic product 1.28 in 87% yield. This method is the first report of such double C-H 
activation reaction, involving a C(sp3)-H activation.  
Based on these precedents, we estimated that double C-H arylation methodology could be a 
powerful tool for the rapid construction of lycorine alkaloids. 
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Scheme 22: Double C(sp2)-H-arylation and C(sp3)-H arylation for rapid access to polycyclic molecules  
4. Goal of this project and retrosynthetic analysis:  
With these previous reports in hand, we considered the following retrosynthetic plan for 
lycorine alkaloids synthesis: amide reduction and selective arene hydrogenation of 1.29 would 
lead to the (±)--lycorane (Scheme 23). Additionally, hippadine and pratosine could be obtained 
respectively from the tetracyclic intermediate 1.29 and 1.9. To obtain the 
pyrrolophenanthridinone core, we envisioned disconnecting compounds simultaneously at 
bonds a and b using a Pd0-catalysed double C−X/C−H arylation. Starting from a bis-
halogenated precursors 1.30 and 1.31 with the halogens atoms located either on ring A and C or 
both on ring C, we believed that the polycyclic core of the molecule could be constructed. 
Finally, precursors for C-H arylation could be obtained by simple alkylation of readily available 
starting material 1.32 and 1.33.  
 
Scheme 23: Retrosynthetic plan for lycorine alkaloids synthesis 
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4.1. Double C-H activation investigations for lycorine alkaloids synthesis 
4.1.1.   Substrate design and mecanism  
For the synthesis of lycorine alkaloids using double C-H activation strategy, we started by 
investigating for the most appropriated bis-halogenated substrate to perform this reaction 
(Scheme 24).  
The double C−X/C−H arylation was first conducted with compound 1.30 bearing the two 
bromine atoms on the same aromatic ring. PCy3 was chosen as the ligand, as it was previously 
employed in both individual C(sp2)−H[80] and C(sp3)−H arylations.[81] The well-defined 
Pd(PCy3)2 complex, which was found to provide superior yields in previous C(sp3)−H 
activation reactions,[54] was employed as the catalyst, combined with catalytic PivOK/K2CO3, 
as the basic system.[82] Under these conditions, the double C−Br/C−H arylation took place, but 
isomer 1.34, arising from the electronically favoured activation of the C(sp2)−Hb bond instead 
of the more sterically accessible C(sp2)−Ha bond was isolated as the major product. This 
observation was consistent with initial observations from Harayama and co-workers.[83] 
 
Scheme 24: Formation of pyrrolophenanthridinone isomer 
To solve this regioselectivity issue, we examined the reaction of isomeric dibromide 1.31a, 
bearing bromine atoms on rings A and C (Scheme 25). Under the same conditions, the desired 
product 1.29 was isolated, albeit in low yield (22%) and with byproducts from competitive 
arylation at C−Hb position. A simple solution was found by replacing the bromine atom on ring 
C with a chlorine atom starting from 1.31b. Indeed, in this case the oxidative addition of the 
C−Br bond to Pd0 is faster than that of the C−Cl bond, to give intermediate 1.37. Upon activation 
of the most reactive C(sp2)−Hd bond vs the less reactive C(sp3)−Hc bonds, ring B would be 
formed with the correct regiochemistry via palladacycle 1.38. Then C−Cl oxidative addition, 
would lead to complex 1.40, followed by activation of a C−Hc bond to give palladacycle 1.41, 
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which would allow for the construction of ring D after reductive elimination. Accordingly, 
compound 1.31b furnished the desired product 1.29 in higher yield (37%), and isomers 
byproducts were not detected. 
 
Scheme 25: Synthesis of pyrrolophenanthridinone core 
4.1.2. Reaction optimization 
With this first result in hand, we started the optimization of the reaction for the synthesis of 
1.29. Decreasing the temperature from 140 to 120°C considerably affect the yield (28%) (Table 
1, Entry 2). Switching the base from K2CO3 to Cs2CO3, the yield was increased to 50% (Entry 
3). By reducing the equivalents of base from 4 to 2 equivalents, the desired product 1.29could 
be obtained in 92% isolated yield (Entry 4). Palladium loading could be decreased to 5 mol% 
and afford the product still in good yield (70%) (Entry 5). Moreover, in situ catalyst generation 
from Pd(OAc)2/PCy3 or Pd2dba3/PCy3 could also be employed but provided a lower yield than 
the well defined Pd(PCy3)2 complex (respectively 53% and 50%)(Entries 6-7). When the 
reaction was stopped at incomplete conversion (15 min), the monocyclized intermediate 1.39, 
from C(sp2)−Br/C(sp2)−H arylation, was isolated in 68% yield, thereby validating the initial 
mechanistic hypothesis. 
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Entries Pd/L  Additive  Base (equiv) T°C  1H NMR yield 
(isolated)* 
1 Pd(PCy3)2 (10 
mol%) 
PivOK K2CO3 (4 equiv) 140 37% 
2 Pd(PCy3)2 (10 
mol%) 
PivOK K2CO3 (4 equiv) 120 28% 
3 Pd(PCy3)2 (10 
mol%) 
PivOH Cs2CO3 (4 equiv) 140 50% 
4 Pd(PCy3)2 (10 
mol%) 
PivOH Cs2CO3 (2 equiv) 140 90% (92%) 
5 Pd(PCy3)2 (5 
mol%) 
PivOH Cs2CO3 (2 equiv) 140 70% 
6 Pd(OAc)2/PCy3 
(10 mol%) 
PivOH Cs2CO3 (2 equiv) 140 53% 
7 Pd2dba3/PCy3 
(10 mol%) 
PivOH Cs2CO3 (2 equiv) 140 50% 
*Using trichloroethylene as internal standard 
Table 1: Optimization table for the double C-H arylation 
4.1.3. Scope and limitations 
With this optimized conditions in hand, we next studied the scope of the double C(sp2)/C(sp3)-
H arylation (Scheme 26). We found out that different substituents with electron donating or 
electron withdrawing properties on the aromatic ring were suitable for this reaction. As 
explained before, as far as the oxidative addition is occurring in the C-Br bond first, product 
could be obtained in good yield as a single regioisomer. By increasing the electron density on 
ring A, and decreasing the electron density on ring C the compounds 1.49 and 1.50 were obtained 
in moderate yields (respectively 54% and 27%), as single product. In all other cases, good to 
excellent yields of the polycyclic product were obtained. Functional groups, such as methyl 
ester 1.52, nitriles 1.48, pyridine 1.47 or protected phenols 1.51 were also tolerated in these 
conditions. Substituents in α-position to the amide were also well tolerated (1.53-1.55), 
consistent with previous results on the individual C(sp3)−H arylation reaction.[74]  
52 
 
 
Scheme 26: Scope of double C(sp2)/C(sp3)-H arylation 
4.2. Selective arene hydrogenation of the pyrrolophenanthridinone core 
Gratifingly, the synthesis of 1.29 could be scaled up, without significant decrease in efficacy 
(Scheme 27).  
 
Scheme 27: Synthesis of the pyrrolophenanthridinone core 
Then, we considered directly converting 1.29 to (±)-γ-lycorane through selective arene 
hydrogenation. Selectivity for ring C over ring A might be particularly difficult because, as 
shown with the calculated HOMO of 1.29 (Figure 11), both aromatic rings have almost similar 
electron density and should react at comparable rates. 
However, ring C is more strained than ring A due to the adjacent ring fusions with rings B and 
D and could potentially be reduced more easily by ring strain release. This is shown with the 
more distorted bond angles in ring C (Figure 11).  
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Figure 11: DFT-optimized structure of 1.29 (B97X-D/6-31G**) showing the HOMO and selected bond angles 
Several reports are describing the arene reduction of indoles, indolines and oxindoles, notably 
by using heterogenous catalysts such as PtO2, Pd/C or Rh/C.[84] [85] [86] Fluorinated solvents are 
often used in hydrogenation conditions for there low nucleophilicity toward nucleophilic 
addition on olefins. In homogenous fashion, Zeng and co-workers developed a Rh/NHC catalyst 
for the hydrogenation of aromatic rings.[87]   
However, selective arene reduction is really rare, and has only been reported by Kotera and co-
workers on polycyclic system, for the hemisynthesis of (±)-()-lycorane.[88] 
With those previous reports, we started our investigations for selective arene hydrogenation of 
pyrrolophenanthridinone 1.29 (Table 2). Starting with PtO2 in AcOH did not give any traces of 
product even when the reaction was run under 50 bar of H2 (Entry 1). Then, while changing to 
Pd/C in HFIP with 50 bar of H2, the desired isomer 1.58 was obtained in 41%, with an expected 
cis,cis relationship (d.r. > 95:5) (Entry 2). Increasing the catalyst loading (20 mol%) gave the 
desired product in 55% yield, whereas with a significant amount of the undesired isomer 1.59 
(17 %) (Entry 3). Then, by replacing Pd/C to the more reactive Rh/C with only 6 bar of H2, we 
could achieve the synthesis of 1.58 with 62% yield as a single isomer (Entry 4). Moreover, by 
increasing the pressure to 10 bar showed the apparition of the over reduced product 1.60 in 60% 
yield (Entry 5).  
We also examined different homogenous rhodium catalysts, and notably Rh/NHC complexes 
used by Zheng and co-workers for the hydrogenation of oxindoles.[89] The Rh/NHC complexes 
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were preformed from [Rh(COD)Cl]2, and used directly for the selective arene hydrogenation of 
1.29  under 50 bar H2. In this case, CAAC carbene or SiMes showed good activities, with yield 
for the desired product from 64 to 73% (Entries 6-7). However, the reaction scale-up could not 
be performed with similar yields.  
 
Entry Catalyst Solvent  P(H2) 
(bar) 
1H NMR yield* 
(isolated) for 
1.58  
1 PtO2 (10 mol%) AcOH 50 – 
2a Pd/C (10 mol%) HFIP 50 41 % + 5 % 1.59  
3a Pd/C (20 mol%) HFIP 50 55 % + 17 % 1.59 
4 Rh/C (30 mol%) HFIP 6 66% (62%)  
5 Rh/C (30 mol%) HFIP 10 30% + 60% 1.60 
6 [Rh(COD)Cl]2/CAAC·HCl/ 
t-BuOK (20 mol %) 
TFE 50 64% 
7 [Rh(COD)Cl]2/SiMes·HCl/ 
t-BuOK (20 mol %) 
TFE 50 73% 
*Using trichloroethylene as internal standard 
Table 2: Selected conditions for hydrogenation of 1.29; a: At 50°C;  
 
 
4.3. (±)--lycorane and derivatives synthesis completion 
The arene reduction of 1.29 could be scaled up to 0.5 mmol by using Rh/C with 6 bar H2. After 
amide reduction with LiAlH4 in THF under reflux, the desired (±)--lycorane was obtained (58 
% over two steps) (Scheme 28). Moreover, the intermediate 1.29 can be easily converted to 
hippadine, following Takemoto procedure.[90] 
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Scheme 28: (±)--lycorane and hippadine synthesis completion 
To conclude, (±)--lycorane was obtained in only 4 steps, starting from commercially available 
starting material, with an overall yield of 47%. To our knowledge, this is the shortest and most 
efficient synthesis of this product (Previous shortest synthesis: Hilton, 6-7 steps, 30.6 % overall 
yield).[69]  
In addition to 1.29, dimethoxy-substituted compound 1.45 was converted to (±)-γ-lycorane 
analogue 1.61 through the same reductive sequence (Scheme 29). The pyrrolophenanthridinone 
1.45 is valuable platforms for the synthesis of more oxidized lycorine alkaloids such as pratosine 
which were synthesized as previously reported. 
 
Scheme 29: Synthesis of lycorane analogue and pratosine 
5. Conclusion 
To summarize, we developed a new double C(sp2)/C(sp3)-H arylation methodology for the 
access to lycorine alkaloids derivatives, thanks to a judicious choice of precursor. The double 
C-H arylation methodology was applied to a broad scope of molecules, allowing the easy access 
to lycorine alkaloids products. Furthermore, this methodology has been applied for the first 
time for the synthesis of natural product, herein hippadine and pratosine. The synthesis of the 
racemic metabolite (±)--lycorane was also achieved using this double closing catalysed by 
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palladium, followed by selective arene hydrogenation. To date, this sequence remains the 
shortest and most efficient synthetic pathway for this molecule (Scheme 30).[91]  
 
 
Scheme 30: Overview of the (±)--lycorane synthesis 
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Chapter 1.2: 
Synthesis of -Lactams 
by Palladium(0)-Catalysed C(sp3)-H Carbamoylation 
Work realized with Dr. David Dailler as principal author 
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1. Naturally occurring -lactams, biosynthesis and interests 
lactams heterocycles are one of the most studied heterocycles from the last century, by either 
chemists but also biologists or medical professionals. The history of lactams started with the 
accidental discovery by Sir Alexander Fleming of the natural penicillin, and its ability to 
annihilate pathogenic bacteria.[92] -lactam antibiotics target the penicillin-binding proteins or 
PBPs, a group of enzymes found anchored in the cell membrane, which are involved in the 
cross-linking of the bacterial cell wall. The -lactam ring portion of this group of antibiotics 
binds to these different PBPs, rendering them unable to perform their role in cell wall 
synthesis.  This then leads to death of the bacterial cell due to osmotic instability or autolysis.[93]  
Natural -lactams are subdivided in 4 families: penicillin/cephalosporins, clavams, 
carbapenems and the monocyclic -lactams. (Figure 12) 
 
Figure 12: Representatives structures of the families of -lactams 
 
To date, two distinct methods for the biosynthesis of β-lactams have been described. The first 
pathway discovered was that of the penams and cephems (Figure 13). This path begins with the 
linear tripeptide δ-(L-α-aminoadipyl)-L-cysteine-D-valine (ACV) which cyclizes via 
enzymatic oxidation and gives the bicyclic intermediate isopenicillin N. This intermediate is 
then converted to the penam core structure. Various transamidations lead to the different natural 
penicillins.[94]  
While the ring closure in penams and cephems between positions 1 and 4 of the β-lactam is 
oxidative, the clavams and carbapenems have their rings closed by two-electron processes 
between positions 1 and 2 (Figure 13).[95] A specific enzyme, the -lactam synthetase undergo 
the cyclization of 2.1 to 2.2. 
In contrast, the biosynthesis of monobactams is still today not known in detail. 
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Figure 13: Biosynthesis of cephem, carbapenem and clavam 
2. Interest for -lactams and previous synthesis 
Today, the increasing microbial resistance against the classical antibacterial agents is truly 
problematic and have lead the scientists to elaborate more active -lactams and -lactamase 
inhibitors (-lactamase are a family of enzymes involved in bacterial resistance to antibiotics. 
They act by opening the -lactam ring of the penicillins, thereby shutting down their 
activity).[96]  
Since the first report by Staudinger in 1907 for the synthesis of -lactam scaffold between 
imines and ketenes, many new approaches have been reported in the literature (Scheme 31). 
Modified Staudinger reaction,[97] [98] carbonylation,[99] or umpolung[100] approaches are some 
relevant synthesis which have been widely developed in the last years for the efficient access 
to 2-azetidinone core and provided wide variety of -lactam containing molecules.  
 
Scheme 31: Some relevant synthesis of -lactams 
3. Synthesis of -lactam by C(sp3)-H functionnalization   
Since the early report of Corey[101] using C-H insertion of a diazo intermediate in their synthesis 
of penicillin and with the recent emergence of transition-metal catalysed or transition-metal-
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free C-H insertion methodologies, new approaches have been employed for the synthesis of -
lactam.[102]  
Based on previous reports developed by the group of Daugulis[103] and Chen[104] for the synthesis 
of pyrrolidines and azetidines, the groups of Shi[105] and Wu[106] [107] have employed a pyridine- 
or quinoline-based directing group (DG), respectively, to form the nitrogen-carbon bond of the 
-lactam ring 2.12 (Scheme 32). In these methodologies, a stoichiometric amount of oxidant is 
required to perform the PdII/PdIV catalytic process by regenerating the PdII. Additionally, the 
installation and removal of a directing group is also required. Finally, these methodologies were 
at that time restricted to the activation of methylene C-H bonds. 
Cramer and co-workers published an enantioselective synthesis of -lactam 2.14, by 
intramolecular C(sp3)-H activation of methylene C-H bond, starting from chloroacetamides 
compounds 2.13 (Scheme 32).[108] In this report, the use of a phosphoramidite ligand allows 
direct access to enantioenriched products, with the generation of a new C(sp3)-C(sp3) bond. The 
reaction allows direct C-C coupling but is only applicable for the cleavage of benzylic C-H 
bonds. 
Finally, Gaunt and co-workers published the synthesis of -lactams 2.16 starting directly from 
aliphatic amines 2.15 and through a carbonylative process (Scheme 32).[109] Using PdII-Pd0-PdII 
catalysis, with an oxidative system (CuII as co-catalyst and benzoquinone (BQ) as oxidant) and 
under an atmosphere of CO, they were able to obtain a wide range of -lactams starting directly 
from aliphatic amines.  
 
Scheme 32: Previous synthesis of -lactams by C-H functionalization 
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4. Reactivity of carbamoyl chlorides in transition-metal-catalysis 
4.1.  In intermolecular fashion 
The first report about the use of carbamoyl chloride in palladium catalysis was developed in 
1991 by the group of Jousseaume reacting aryl, vinyl or allyl stannanes 2.17 in a Stille-like 
reaction (Scheme 33).[110] Some years later, a Suzuki-Miyaura cross-coupling was developed 
with carbamoyl chloride by the group of Takemoto and co-workers with in situ formed alkyl 
boron reagents 2.20 as partners.[111] With these pioneer examples, several other palladium cross-
couplings reactions have been developed such as modified Negishi[112] or Corriu-Kumada[113] 
involving carbamoyl chlorides. 
 
Scheme 33: Early examples of palladium catalysis including carbamoyl chloride as partner 
 
4.2. In intramolecular fashion 
With the great interest for oxindoles and -lactams synthesis for biological applications, Grigg, 
Tong and Takemoto developed new accesses to these motifs involving oxidative addition of 
palladium into the C-Cl bond of the carbamoyl chloride (Scheme 34). Grigg proposed a domino 
reaction involving carbopalladation of alkyne from 2.22, followed by intermolecular cross-
coupling with organoborane or organotin reagents to access oxindoles 2.23.[114] In their case, 
exclusive formation of the cis isomer of the product is formed. 
With a similar approach, Takemoto proposed an intramolecular Heck reaction after oxidative 
addition of palladium into a C-Cl, C-CN or C-S bond of 2.24, followed by trapping of the -
allyl palladium intermediate by a soft nucleophile to access oxindoles 2.26 (Scheme 34).[115]  
Finally, Tong used a similar approach for their synthesis of -lactams 2.28, with the trapping or 
the-allyl palladium intermediate with sodium iodide after carbopalladation of 2.27.[116] 
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Scheme 34: Synthesis of oxindoles and -lactams  by Grigg, Takemoto and Tong 
 
Based on the report from Grigg and co-workers, Lautens and Schoenebeck also developed two 
stereoselectives synthesis of oxindoles 2.31 and 2.32, starting from alkyne-tethered carbamoyl 
chloride 2.30,[117] [118] and involving either a trans or cis alkyne chloropalladation (Scheme 35). 
By a slightly change of the reaction conditions, they were able to obtain selectively the trans or 
the cis alkene product. 
 
Scheme 35: Stereoselective synthesis of oxindoles by Lautens and Schoenebeck 
 
Takemoto and co-workers developed an intramolecular C(sp3)-H activation of o-
tolylcarbamoyl chloride 2.33 to afford oxindoles 2.34 (Scheme 36). In their conditions, the use 
of Ad2PnBu as ligand and an atmosphere of carbon monoxide are required to minimize the 
decarbonylation to 2.35. With this optimized conditions, they could access a broad scope of 
oxindoles, possessing different functionalities on the aromatic ring.  
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Takemoto proposed a mechanism for this reaction (Scheme 36). Oxidative addition of the in 
situ formed Pd0 catalyst into the C-Cl bond of 2.33 lead to 2.36. At this point, the 
decarbonylation of 2.36 can occur but can be avoided using an atmosphere of CO. The 
possibility of a CO reinsertion to reform 2.36 after decarbonylation is proposed. Then, the 
ligand exchange and the concerted metalation-deprotonation with PivNHO- lead to 2.39 which 
after reductive elimination, gives 2.34 and regenerate the Pd0 catalyst to ensure the turn-over of 
the reaction. 
 
Scheme 36: Takemoto’s synthesis of oxindoles and proposed mechanism 
 
5. Formation of -lactam by palladium catalysed C(sp3)-H carbamoylation 
5.1. Reaction design and optimization 
Inspired by the work of Takemoto and co-workers, we decided to turn our attention to the 
synthesis of -lactams and use the same reactivity of the carbamoyl chlorides to form the C(O)-
C bond of the four member ring. At the outset of this work, we looked for the most appropriate 
substrate for the optimization (Table 3). Trimethoxybenzyl (TMB) protected isopropylamine 
2.40 was easily accessible and constituted a good substrate for the reaction optimization to 
obtain a non-volatile product 2.41 and after deprotection, the free -lactam. Carbamoyl 
chlorides are easily feasible from secondary amines, by reacting triphosgene in benzene with 
the presence of triethylamine as base.  
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As described earlier, we were aware of the decarbonylation side reaction that could occurs with 
palladium catalysis at high temperature. This side reaction would affect the reaction efficiency 
and to limit it, we started to run the experiments under an atmosphere of carbon monoxide, 
while screening different conditions.  
We started our investigations under classical conditions using Pd(PPh3)4 as catalyst, pivalic acid 
(30 mol%), Cs2CO3 (1.5 equiv) in xylene at 120°C and under an atmosphere of CO (balloon). 
(Table 3, Entry 1) In these conditions, the product 2.41 was formed in 27% 1H NMR yield.  
We next studied the Pd/Ligand catalyst. The use of the bulky and electron rich ligand Ad2P(n-
Bu).HI, previously used by Takemoto and co-workers, combined with a PdII source such as 
Pd(OPiv)2,  Pd(MeCN)2Cl2, or PdMe2(TMEDA) provided the product in good yield (62-66%, 
entries 4-8). The use of PdCl2 as precataylst provided the products 2.41 in 76% (entry 9) and by 
increasing the base from 1.5 equivalent to 3 equivalent in mesitylene, the product was isolated 
in 85% (entry 11).  
We also studied the impact of the temperature on the reaction, but the reaction proceed less 
efficiently at lower (110°C, 57%) and higher temperature (130°C, 58%) (Entries 12-13). 
Replacing the Ad2P(n-Bu) ligand by more classical alkyl or aryl phosphines, the yield dropped 
significantly to less than 50% (Entries 14-19). 
The bench stable PAd2(n-Bu)-Pd-G3 or the well defined palladium catalyst Pd[PAd2(n-Bu)]2 
were also tested, giving comparable yield than the catalyst formed in situ (80 % and 85% 
isolated yield respectively). 
While starting directly from the secondary amine 2.40r, no traces of desired product 2.41 were 
detected (entry 22). 
The yield could be increased significantly by using the double-chamber system developed by 
the group of Skrydstrup, with the in situ generation of CO from decarbonylation of COgen 
precursor (Figure 14).[119] Equivalents of CO can be controlled, and the COgen provides a safe, 
versatile and convenient solid source of CO. While using 3 equivalents of CO from COgen, the 
desired product 2.41 could be isolated in 92% yield.  
Control experiments were tested without atmosphere of CO to provide the product in 75% NMR 
yield or by using technical grade solvent under non-inert conditions (75% isolated) (Entries 24 
and 26). 
66 
 
Finally, the reaction was scaled up to 1.26 mmol and provides the desired -lactam 2.41 over 
330 mg scale.  
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Entry [Pd] Ligand n Solvent 
CO source Temp 
[°C] 
Yield 
2a [%][c] 
balloon COgen[b] 
(equiv) 
  
1 Pd(PPh3)4 – 1.5 Xylene   120 27% 
2 Pd(OAc)2 PPh3 1.5 Xylene   120 10% 
3 Pd(OAc)2 Ad2P(n-Bu)•HI 1.5 Xylene   120 45% 
4 Pd(OPiv)2 Ad2P(n-Bu)•HI 1.5 Xylene   120 62% 
5 Pd2(dba)3 Ad2P(n-Bu)•HI 1.5 Xylene   120 42% 
6 Pd(MeCN)4HBF4 Ad2P(n-Bu)•HI 1.5 Xylene   120 35% 
7 Pd(MeCN)2Cl2 Ad2P(n-Bu)•HI 1.5 Xylene   120 64% 
8 PdMe2(TMEDA) Ad2P(n-Bu)•HI 1.5 Xylene   120 66% 
9 PdCl2 Ad2P(n-Bu)•HI 1.5 Xylene   120 76% 
10 PdCl2 Ad2P(n-Bu)•HI 3 Xylene   120 82% 
11 PdCl2 Ad2P(n-Bu)•HI 3 Mesitylene   120 92% (85%) 
12 PdCl2 Ad2P(n-Bu)•HI 3 Mesitylene   110 57% 
13 PdCl2 Ad2P(n-Bu)•HI 3 Mesitylene   130 58% 
14 PdCl2 P(o-tol)3 3 Mesitylene   120 15% 
15 PdCl2 PPh3 3 Mesitylene   120 24% 
16 PdCl2 PCy2Ph 3 Mesitylene   120 41% 
17 PdCl2 PAd2Bn 3 Mesitylene   120 18% 
18 PdCl2 PtBu3HBF4 3 Mesitylene   120 21% 
19 PdCl2 PCy3HBF4 3 Mesitylene   120 28% 
20 PAd2(n-Bu)-Pd-
G3 
– 3 Mesitylene   120 80% 
21 Pd[PAd2(n-Bu)]2 – 3 Mesitylene   120 88% (85%) 
22[d] PdCl2 PAd2(n-Bu)•HI 3 Mesitylene   120 0% 
23 PdCl2 PAd2(n-Bu)•HI 3 Mesitylene – – 120 70% 
24 PdCl2 PAd2(n-Bu)•HI 3 Mesitylene   (1.5) 120 75% 
25 PdCl2 PAd2(n-Bu)•HI 3 Mesitylene   (3) 120 94% (92%) 
26[e] PdCl2 PAd2(n-Bu)•HI 3 Mesitylene   (3) 120 (95%) (75%)[f] 
Table 3: Optimization table for -lactam synthesis; [a] Performed using 0.133 mmol of 1a unless otherwise stated. [b] 9-
Methylfluorene-9-carbonyl chloride (COgen), Pd(OAc)2/P(t-Bu)3•HBF4 cat., Cy2NMe, mesitylene, two-chamber system (COware), 
both reaction chambers were placed at the same temperature. [c] Determined by NMR analysis using trichloroethylene as internal 
standard. Yield of isolated product 2a is given within parentheses. [d] Using amine 3a instead of 1a. [e] Performed using 1.33 mmol 
(400 mg) of 1a. [f] Performed using technical-grade mesitylene under non-inert conditions. TMB = 2,4,6-trimethoxybenzyl.  
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Figure 14: Double-chamber system 
5.2. Mechanistic studies 
For the synthesis ofthe-lactam 2.41 using carbamoylation reaction, mechanistic studies were 
performed. 
First, we wanted to confirm the formation of the oxidative addition complex, and its reactivity 
toward C(sp3)-H activation conditions. For this, we simplified the system, and used 
diisopropylamine carbamoyl chloride 2.42 (Scheme 37). The formation of the palladium 
complex 2.43 was performed using stoichiometric Pd(PPh3)4 in toluene, at 80°C. The desired 
complex was recrystallized and reacted in the presence of pivalic acid (30 mol%), Cs2CO3 (3 
equiv), in mesitylene at 120°C to afford the desired -lactam 2.44 in 26% yield. In parallele, 
2.42 was reacted in the standard conditions to afford the -lactam 2.44 in similar yield (35%).  
 
Scheme 37: Mechanistic studies starting from precomplex 2.43 and direct C(sp3)-H activation from 2.42 
Furthermore, we studied the reversibility of the decarbonylation/reinsertion of CO (Scheme 38). 
When the reaction was run under 13CO source (3 equivalents) with 2.40, a slight insertion (2.5%) 
of 13C was observed for the -lactam 2.41. This suggested that the CO is rather important to 
avoid decarbonylation by saturating the reaction atmosphere, and thereby, validating the 
mechanism below (Figure 15).  
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Scheme 38: 13CO incorporation in standard conditions 
With these observations, we proposed the following mechanism (Figure 15). Oxidative addition 
of Pd0 occurs in the C-Cl bond to provide the palladium intermediate 2.46. At this point, 
irreversible decarbonylation can occur to led to the amine 2.48 as a side product. After ligand 
exchange and C-H cleavage, the palladacycle 2.49 is formed. Finally, the reductive elimination, 
gives the desired product 2.50.  
 
Figure 15: Proposed mechanism 
5.3. Scope of the reaction 
After optimizing the conditions for the -lactam 2.41 synthesis, we next studied the scope and 
limitations starting from different carbamoyl chlorides. For this, we started with several 
commercially available primary amines which were converted to secondary amines 2.52a and 
2.52b after 1,4 Michael addition and reductive amination (Scheme 39). Amines were then 
converted to carbamoyl chlorides 2.51a and 2.51b using triphosgene in benzene in the presence 
of Et3N.  
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Scheme 39: Synthesis of carbamoyl chlorides from secondary amines 
The reactions were carried out using either a CO ballon or CO from COgen precursor. In all 
cases, the use of COgen furnishes similar or better yield than the use of CO balloon. A possible 
explanation could be the poisoning of the palladium catalyst by a too high CO concentration in 
the reaction, thereby reducing the efficiency of the catalytic system. In most cases, 
decarbonylation product, as well as ureas resulting from nucleophilic addition of amine on the 
carbamoyl chlorides are observed as side products. 
We first tried to activate primary C-H bonds by changing the moiety at R2 and by using a 
removable TMB (2,4,6-trimethoxybenzyle) protecting group on the nitrogen (Scheme 40). The 
reaction proceeds efficiently, providing in most cases the desired -lactams. The yield 
decreased significantly while using an ethyl substituent 2.53, which could probably be 
explained by less effective Thorpe-Ingold effect. Enantiopures -lactams (2.57-2.60) were 
obtained from enantiopures commercially available amines. Interestingly, competitive C(sp3) 
vs. C(sp2)- H activation was tested, furnishing a mixture of 2.61/2.62 with the -lactam 2.61 as 
major product (ratio [7:3]).  Indeed, this result shows the most favoured formation of 5-
membered palladacycle vs. 6-membered palladacycle. 
We also modified the substituent at R1. Alkyl 2.63, long-chain substituted aryl (2.64, 2.66-2.67), 
ester 2.68 and phtalimide 2.69 provided the desired -lactams in good to excellent yield, 
without observation of undesired isomers or degradation of the functional groups (43-81%). 
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Scheme 40: Scope of Palladium catalysed C(sp3)-H carbamoylation: first part 
Next, the activation of primary C-H bonds with tetrasubsituted C were tested (Scheme 41). 
Despite the fact that 2.55 and 2.56 could not be obtain in our conditions, several other 
tetrasubstituted C were obtained in good to excellent yields (2.70-2.71). Moreover, substituents 
bearing intracyclic insaturation did not provide any traces of competitive Heck product (2.72-
2.74). The applicability of the reaction was also demonstrated while forming the fused bicycle 
2.75 in 70% yield.  
Activation of activated secondary and tertiary C-H bonds were tested, thereby furnishing the 
carbamoylation product in good yield (2.76-2.79). Benzylic as well as methine from 
cyclopropane C-H bonds were tolerated, providing original structures such as spiro 2.77 or 
fused -lactams 2.79.  
Finally, to complete the scope of this transformation, the reaction was run on unactivated 
methylene C-H bonds. The reaction was efficient to provide different sized bicyclic systems 
(2.80-2.83) after activation of an inert methylene C-H bond, albeit with variable yields. The 
latter was maximal for 2.80 using COgen whereas the CO-balloons conditions were much less 
efficient (40%). Such reaction on unactivated C-H bonds with a Pd0/PdII catalytic system 
remained underdeveloped, and these results could open the way to new applications. 
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Scheme 41: Scope of Palladium catalysed C(sp3)-H carbamoylation: second part 
5.4. Enantioselective synthesis of -lactams: scope and limitations 
An interesting feature for the synthesis of -lactams through carbamoylation reaction could be 
the enantiotopic differentiation of methyl groups toward the synthesis of highly enantioenriched 
products. Several previous reports shows enantiotopic discrimination of two methyls group by 
using a chiral base[120] or a chiral ligand[121] [122] [123] [124] in the synthesis of indanes, indolines 
etc. With these previous reports in hand, we tried to develop a new enantioselective synthesis 
of -lactams.  
While starting from the substrate 2.40 bearing two enantiotopic methyl groups, intensives 
investigations were made using chiral bases and different families of chiral ligands, including 
NHCs, binepines, binol-derived phosphonites and phosphoramidites, and we found out that 
TADDOL-phosphonites ligands showed the best reactivity and gave the best enantiomeric 
ratios for the product. After further optimization of the reaction by synthesizing new TADDOL-
phosphonites ligands but also by screening all the reaction parameters (T°C, concentration, 
base, equivalents…), we finally obtained the desired N-protected -lactam 2.85 with 92:8 
enantiomeric ratio (Scheme 42).[125] In this case, 20 mol% of the TADDOL-phosphonite ligand 
2.84 is required, under an atmosphere of CO. The use of COgen gives a better yield for the 
product than with CO balloon, but with a slight decrease of the enantiomeric ratio. Furthermore, 
the TMB group was removed under oxidative conditions, to give the free enantioenriched -
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lactam 2.86 in 76% yield. The absolute configuration of 2.86 was determined based on a 
previous report.[126] 
 
Scheme 42: Enantioselective synthesis of 2.85 and deprotection of the TMB group 
With this optimized conditions in hand, we then try to apply it to different substrates bearing 
two enantiotopics methyls (Scheme 43). Similar N-substituted carbamoyl chlorides were tested, 
showing comparable enantiomeric ratios in the selected conditions (2.88-2.91). However, 
turning the system to quaternary center 2.92 shows a drop in the enantiomeric ratio (e.r. 37.63). 
Higher steric hindrance could be an explanation for the drop of selectivity in the 
enantiodetermining step.  
The conditions were also tested on enantiotopics methylenes or methyne C-H bonds (2.93-
2.94). In this case, low yield and enantiomeric ratio were obtained, showing the limits of the 
developed method.  
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Scheme 43: Scope and limitations of the enantioselective synthesis of -lactams 
5.5. Synthesis of enantiopure -amino acid 
Finally, the applicability of the palladium catalysed C(sp3)-H carbamoylation was used for the 
synthesis of the compound 2.98 (Scheme 44). This -amino acid is accessible through 
enzymatic process in 4 steps with an overall yield of 29%,[127] and used as a building block for 
bioactives molecules synthesis.[128] 
Starting from commercially available enantiopure amine 2.95, we first introduce the TMB 
under reductive amination conditions. The secondary amine intermediate was reacted with 
triphosgene to give the substrate 2.96. Standard conditions for C-H carbamoylation gave the 
desired -lactam in 82%, which was deprotected under oxidative conditions and give the free 
-lactam 2.97 in 91%. Finally, hydrolysis of the amide in acidic conditions (6M HCl) provided 
the enantiopure -amino acid 2.98, in a 5 steps sequence and with an overall yield of 65%, 
including only 2 purifications. 
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Scheme 44: Synthesis of enantiopure -amino acid 
6. Conclusion 
In this project, we developed a new method to access valuable -lactams using palladium-
catalysed C(sp3)-H carbamoylation. The applicability of the reaction was studied and applied 
to a broad scope of -lactams bearing different moieties. This reaction is suitable with primary, 
secondary and tertiary C-H bond, as well as unactivated C-H bonds. Then, an enantioselective 
version was demonstrated and successfully applied for methyl discrimination. Finally, the 
applicability of the reaction was demonstrated through the synthesis of valuable enantiopure -
amino acid for bioactive molecule synthesis (Scheme 45).[129] 
 
Scheme 45: Overview of the palladium catalysed C(sp3)-H carbamoylation 
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Chapter 1.3: 
Domino Pd0-Catalysed C(sp3)–H Arylation/Electrocyclic 
Reactions via Benzazetidine Intermediates 
In collaboration with Spirochem and Dr. E. Clot  
78 
 
1. Toward the synthesis of benzazetidines 
1.1. Interest for nitrogen-containing heterocycles 
As presented in the previous chapter entitled “Synthesis of -Lactams by Palladium(0)-
Catalysed C(sp3)-H Carbamoylation”, small sized nitrogen heterocycles are very important 
scaffolds in organic and medicinal chemistry.[130] In 2014, among 1994 FDA (Food and Drug 
Administration) approved drugs, including 1086 single small molecule drug, 640 small 
molecules were including nitrogen heterocycles (Figure 23). With the context of drug 
discovery, new access to well-known heterocycles as well as access to new motifs are really 
important for pharmaceuticals companies or academic research labs.  
 
Figure 16: Nitrogen-heterocyles among FDA approved drugs 
Recent organic synthesis reports show a lack of diversity and accessibility in term of fused 4-
membered N-heterocycles. Small and strained nitrogen heterocycles are of particular interest 
for organic chemists to elucidate new chemical reactivities and investigate new chemical spaces 
for biomedical research. This is particularly true with the non-natural occurring benzazetidines, 
with almost no general method to access them. 
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1.2. Benzazetidines synthesis: early reports 
Benzazetidines contains a highly rigid benzo-fused 4-membered azetidine core. It has been 
shown that the strained structure of N-H free benzazetidine 3.1 easily undergo electrocyclic 
opening to generate the reactive aza-ortho-xylylene 3.2 which can further react in pericyclics 
or electrocyclics reactions (Figure 24).[131] [132] 
 
Figure 17: Equilibrium between benzazetidine and aza-ortho-xylylene  
In the literature, several reports are describing the synthesis of benzazetidines after reaction in 
harsch conditions, but few providing a general access to them. 
 In 1966, Burgess described the first example of benzazetidine synthesis by N2 extrusion of 
substituted triazine 3.3 (Scheme 46).[133] 
35 years later, the synthesis of benzazetidine has been more widely studied by Singal and co-
workers (Scheme 46).[134] Through a [2+2] cycloaddition between in situ generated benzyne and 
imine 3.5, they could provide a method for the access of 1,2-diaryl benzazetidines 3.6. Different 
electron-donating or electon-withdrawing groups could be introduced on the aryl, thereby 
providing 17 examples of benzazetidines albeit in moderate yields.  
Few years later, Kobayashi proposed a different approach for their synthesis (Scheme 46).[135] 
Using a intramolecular iodoamination of o-(acylamino)styrene 3.7, they could afford N-acyl 
benzazetidines products 3.8. Unfortunately, the scope of the reaction was really limited. 
The most relevant and general synthesis of benzazetidines was developed in 2016 by the group 
of Chen, employing a palladium-catalysed C(sp2)-H amination strategy (Scheme 46).[136] The 
efficiency of this reaction is inherent with the use of picolinamide directing group, previously 
developed by Daugulis[28] and an oligomeric iodine (III) oxidant PhI(DMM) (dimethyl 
malonate). Good yields were achieved but the reaction was limited to benzazetidines 3.10 
bearing ortho substituents. Furthermore, competitive C-O coupling from dimethyl malonate 
was observed in most cases. 
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Scheme 46: Precedent methods to access benzazetidines  
2. Recent reports and attempts for benzazetidine synthesis 
2.1. Previous reports 
With our understanding in the field of Pd0-catalysed C(sp3)-H activation and according to the 
literature precedents, we considered a new approach to access benzazetidines. 
On one hand, the synthesis of 5-membered rings indolines 3.12 is known since the report from 
Ohno and co-workers through a Pd0-catalysed C(sp3)-activation (Scheme 47a).[51]  
On another hand, the C-H activation of a N-Me as been reported by Fagnou and co-workers for 
the synthesis of isoxindoles 3.14 (Scheme 47b).[46]  
Finally, other strained 4-membered rings benzocyclobutenes 36 [41] or -lactams[125] have been 
efficiently constructed through this approach (Scheme 47c).  
With these precedents, we hypothesized that benzazetidine 3.16 could be obtained through 
intramolecular C(sp3)-H activation, starting from easily accessible aniline precursors 3.15 
(Scheme 47d). 
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Scheme 47: Previous syntheses of indolines and benzocyclobutenes and our strategy for the synthesis of 
benzazetidines 
However, if the structure similarities of benzazetidine with indolines, -lactams or 
benzocyclobutenes are obvious, their synthesis seems to be much more challenging (Figure 25):  
- First, the high energy barrier for the C-C reductive elimination leading to the highly 
strained benzazetidine in comparison with indolines might be difficult to achieve. 
         - In comparison to the synthesis of benzocyclobutenes that benefited from Thorpe–Ingold 
effects due to the presence of a quaternary carbon, the C-H activation step might be more 
difficult. 
 - Finally, the instability of the benzazetidine ring system under the high temperatures 
that are usually required in such reactions should also be considered.  
 
Figure 18: Structure similarity between -lactam, indoline, benzocyclobutene and benzazetidines 
3. Attempts for benzazetidine synthesis 
We started our investigations toward the synthesis of benzazetidines.The initial idea was to use 
N-methyl-o-bromoaniline 3.15 as precursor and perform an intramolecular C(sp3)-H arylation 
using standard conditions (Scheme 48). We first studied the influence of the substituents on the 
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nitrogen. We hypothesized that the choice of substituent should be crucial to overcome the 
challenges mentioned above. 
We started from N,N-dimethylaniline 3.15a, and by using Pd(PCy3)2 (10 mol%),  CsOPiv (30 
mol%) and Cs2CO3 (3 equiv) in mesitylene at 160°C as standard conditions, this furnished the 
demethylation product 3.17 (Scheme 48). This indicates that the C-H activation occurs but the 
reductive elimination is difficult compared to the possible demethylation.  
Electron-withdrawing groups were introduced on the nitrogen to increase the bulk of the 
substrate or decrease the donor effect of the nitrogen. Boc-protected anilines 3.15b only leads 
to degradation. Other protecting-groups such as methyloxycarbonyl 3.15c, 
trifluomethanesulfonyl 3.15d, and trifluoroacetyl 3.15e were also tested, but only the former 
gave traces of product (< 5%).  
The use of a cyclobutanamide derivative 3.15f provided the spiro product 3.19 resulting from -
arylation.[137] To suppress this -arylation reaction, a pivalamide group was introduced. 
Unfortunately, exclusive C(sp3)-H arylation on the tert-butyl group was observed, furnishing 
the 3,4-dihydroquinolone 3.20 in 80% yield.[53]   
To disfavour this competing C(sp3)-H arylation, we proposed to introduce a bulky and 
unactivated adamantamide group 3.15h. Surprisingly, this substrates furnished the unexpected 
benzoxazine 3.21 in 54% yield.  
 
Scheme 48: Influence of the nitrogen substituent. [a] yield determined by 1H NMR. [b] Based on GCMS analysis [c]Yield of 
the isolated product 
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4. Synthesis of 4H-benzoxazines via Domino Pd0-Catalysed C(sp3)–H 
Arylation/Electrocyclic Reaction 
4.1.  Initial result, mechanism, and DFT calculations 
With the unexpected formation of the benzoxazine 3.21 starting from o-bromo-N-
methyladamantamide 3.15h, we tried to find a plausible mechanism.  
After the classical steps for C(sp3)-H activation reaction and reductive elimination, we 
postulated that the benzazetidine 3.22 was formed (Scheme 49). This benzazetidine 
intermediate, in the harsh reaction conditions could presumably undergo a 4 electrocyclic ring 
opening, to afford the really unstable aza-ortho-xylylene 3.23 (relative calculated energy: G = 
12.0 kcal mol–1) (Gibbs free energies relative to 3.23 [DFT, B97X-D/6–311G**]). This second 
intermediate 3.23 could rearrange in a 6 electrocyclic reaction to afford the more 
thermodynamically stable product 3.21. Relatives calculated energies indicates that the reaction 
tends to the more stable benzoxazine 3.21 (relative calculated energy: G = - 14.4 kcal mol–1), 
thereby leading exclusively to this product. This observation is to the best of our knowledge, 
the first example of domino Pd-catalysed C(sp3)-H activation/electrocyclic rearrangement. 
 
Scheme 49: Initial observation of benzoxazine and plausible mechanism pathway 
To try to understand the role of the adamantamide substituent, additional calculations have been 
performed By Dr. E. Clot on the system (Figure 26). The idea was to compare the activation 
barriers (G) for reductive elimination of several nitrogen substituted substrates. DFT 
calculations were done for the reductive elimination step with different substituents on the 
nitrogen (3.24 R=Me, 3.25 R= CO2Me and 3.26 R= CO(Ad)) The results showed a lower 
activation barrier for R = C(O)Ad (21.7 kcal.mol-1) compared to R= Me or R = CO2Me (27.6 
kcal.mol-1 and 26.8 kcal.mol-1 respectively) which is in agreement with the observed result. 
Moreover, stabilizing dispersive interactions shown by non-covalent interaction map between 
the adamantyl and the tricyclohexylphosphine could also be a reason for a lower energy 
activation barrier. Theses interactions are inexistent for R = Me or R = CO2Me. 
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Figure 19: Non-covalent interaction map for R = Me, CO2Me, Ad; [PBE0-D3(BJ)/def2-QZVP*+SMD, 433 K]. 
4.2. Synthesis of 4H-benzoxazines: reaction optimization and deuteration experiments 
With this initial result in hand, further optimizations for the synthesis of 3.21 were investigated.  
We started the reaction development by changing the solvent (Table 4). With mesitylene as a 
first result (54%), we realized that this reaction was really solvent dependant. Common polar 
and apolar high boiling point solvents were tested with the same catalytic system. While 
changing with the isomer 1,2,4-trimethylbenzene, the yield dropped to 17% (Entry 2). More 
polar solvents such as anisole gave similar result (48%) whereas switching to benzonitrile did 
not give any trace of product (Entries 3-5). Mixture of xylenes was then employed and the 
desired benzoxazine was obtained in 70% yield (Entry 6). After testing all the isomers of xylene 
separately, the 4H-benzoxazine 3.21 was obtained in 84% isolated yield with o-xylene (Entry 
9). 
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Entries Solvent 1H NMR yield* (isolated) 
1 mesitylene 54 % (54%) 
2 1,2,4-trimethylbenzene 17 % 
3 anisole 48 % 
4 benzonitrile 0 % 
5 p-cymene 36 % 
6 xylenes (mixture) 70 % 
7 p-xylene 77 % 
8 m-xylene 79 % 
9 o-xylene 84% (84%) 
*Using trichloroethylene as internal standard 
Table 4: Solvent screening for 4H-benzoxazine synthesis  
According to the proposed mechanism, further investigations have been done to observe and 
isolate the benzazetidine intermediate 3.22 (Scheme 50). Reduction of the temperature, as well 
as reduction of the reaction time did not give satisfying results. In the first case, a slight decrease 
of the temperature showed only protodebrominated product. In the second case, starting 
material with small amount of benzoxazine 3.21 was recovered after 1, 2  or 3 hours.  
 
Scheme 50: Attempts for benzazetidine synthesis 
From previous observation, we postulated that the C-H activation step might be the rate 
limiting. However, the absence of isotopic effect in intermolecular competition experiments 
between protiated and deuterated substrates 3.15h and 3.15h-d3 showed that the C-H activation 
step is not rate-determining for the synthesis of benzoxazines (Scheme 51).   
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Scheme 51: Absence of isotopic effect in intermolecular competition experiment 
4.3. Scope of the domino reaction 
We next investigated the scope of the C(sp3)-H activation/electrocyclic rearrangement (Scheme 
53). The different substrates were synthesized from commercially available o-bromo anilines 
3.23, with freshly synthesized acid chlorides (Scheme 52). Further alkylation with 
corresponding iodoalkyles afforded the desired substrates 3.24. 
 
Scheme 52: General access to substrates for C(sp3)-H activation/Electrocyclic reaarangement 
First, we introduced different functionalities on the para position to the amide on the aromatic 
ring (Scheme 53). Electron withdrawing groups such as methyl ester 3.28, fluoride 3.29, 
trifluoromethyl 3.30 or nitrile 3.31 were successfully introduced with formation of 4H-
benzoxazine in good yields (55-81%). Electron donating group such as methoxy 3.32 or methyl 
3.33 were also introduced, without significant decrease of the yield (63-86%). The trends 
showed the moderate influence of a substituent on the yield. An X-Ray analysis from 3.30 
confirmed the structure of the final product. Moreover, a scale-up of the reaction using the 
bench stable Pd-G4-PCy3 catalyst could afford the desired benzoxazine 3.21 over gram scale.  
The reaction was next run with subsituent on the meta position to the amide on the aromatic 
ring. In this case, mixture of isomers from palladacycle reopening are obtained (Scheme 53) 
(3.34-3.37). This observation correlates with previous observations for benzocyclobutenes 
synthesis. After C-H activation, a proton transfer can undergo palladacycle opening, which after 
rotation, C(sp2)-H arylation and reductive elimination, afford an isomer of the directly coupled-
product (Scheme 54).[41] The ratio between the two isomers tends to undergo the formation of 
less hindered products, by replacing PivO- with AdCO2- as the CMD base. Acidity is also 
determining to understand the isomers ratio. When R = F (3.36), the isomeric mixture for m/m’ 
reaches [2.7:1]. The acidic C(sp2)-H bond adjacent to the –F, combined with moderates 
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hindrance afford the undesired isomer in important quantity. As far as the steric hindrance is 
increased (3.37), the undesired isomer is obtained as traces (m/m’ [6.7:1]).  
 
Scheme 53: Scope of 4H-benzoxazines. [a] using AdCO2H instead of PivOCs;[b] parenthesis showed the isolated yield of 
major isomer; [c] X-ray structure (ellipsoids set at 50% probability) 
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Scheme 54: Mechanism hypothesis for isomers formation 
Next, we investigated the substituents for R1 (Scheme 55). We focused on bulky and unactivated 
moieties toward C-H activation conditions (3.44-3.47 and 3.50-3.51). These groupment enabled 
the reaction, in particular compound 3.45 bearing a modified cyclohexyl moiety. Other bridged 
bicyclic substrates from commercially available from Spirochem were also affording the 
desired product in moderate to good yield (36-50%, 3.46-3.47 and 3.50-3.51), thereby providing 
original benzoxazine structures. These bioisoesters of a p-substituted benzene ring showed 
more moderate yield than while using adamantayl group, presumably because of thermal 
stability.  
Finally, reactivity investigations were performed while changing subsitutent R3. While 
replacing the N-methyl with an N-ethyl substituent 3.48r, exclusive formation of indoline 3.49 
was observed (80%). This can be explained by the more reactive methyl vs. methylene toward 
C(sp3)-H activation conditions, furnishing exclusively the latter mentioned  product. 
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Scheme 55: Scope of benzazetidines. [a] using AdCO2H instead of PivOCs;[b] parenthesis showed the isolated yield of major 
isomer; [c] X-ray structure (ellipsoids set at 50% probability) 
4.4. 4H-Benzoxazines derivatizations:  
4H-benzoxazines are interesting scaffold for drug discovery[138]  but they can also be synthetic 
intermediates for the synthesis of more elaborated nitrogen heterocycles. For example, 3.36 can 
be easily reduced to the fully saturated NH-benzoxazines 3.52 using sodium borohydride 
(Scheme 56). 
 
Scheme 56: Reduction of benzoxazine 
More interestingly, the electrophilic benzylic position of the benzoxazine 3.29 allows an HCl-
mediated ring opening of the heterocycle to afford the intermediate 3.53 in quantitative yield 
(Scheme 57). This intermediate can further react in an annulation reaction following a procedure 
described by Garg and co-workers.[139] After reacting with N-methylskatole 3.54 and Cs2CO3, 
the tetracyclic product 3.55 can be afforded in 50% yield. Finally, hydrolysis of the 
adamantamide can be performed, providing tetrahydroindoloquinoline 3.56 which possesses 
the tetracyclic core of the communesin family derivatives.[140] 
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Scheme 57: Toward the tetracyclic core of the communesin alkaloids family 
According to the proposed reaction mechanism for benzoxazines synthesis, we hypothesized 
that the aza-ortho-xylylene intermediate 3.23 could potentially react in intermolecular 
cyclisation reaction (Scheme 58).  
Based on the formation of the tetracyclic product 3.55, we believed that N-methylskatole 3.54 
could directly undergo formation of 3.55, starting from N-methyl-o-bromoanilide 3.15h, 
through nucleophilic annelation or electrocyclisation. Unfortunatly, exclusive formation of 4H-
benzoxazine 3.21, resulting from the most favored intramolecular electrocyclic ring formation 
was observed (75%). Similar investigations were done to try to react 3.15h in intermolecular 
pericyclic reactions. However, while running the reaction in the presence of different 
dienophiles, exclusive formation of the benzoxazine was observed 3.21. 
 
Scheme 58: Attempts for intermolecular cyclisation via aza-ortho-xylylene formation 
5. Conclusion: 
In conclusion, we reported the unexpected synthesis of 4H-benzoxazines after an unprecedented 
domino C(sp3)-H activation/electrocyclic rearrangement of unstable benzazetidines 
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intermediates. 20 different benzoxazines could be afforded while using a bulky and unactivated 
amide substituent. 4H-benzoxazines products can then be converted to polycyclic products that 
can be find in natural products such as communesin alkaloids (Scheme 59).[141] 
 
Scheme 59: Synthesis of 4H-benzoxazines by Pd0-catalysed C(sp3)-H activation/electrocyclic rearrangement of benzazetidine 
intermediates 
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Part 2 : Remote C(sp3)-H activation 
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Chapter 2.1: 
1,4-Palladium Shift/C(sp3)-H Activation Strategy for the 
Construction of 5-Membered Rings 
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1. Introduction to 1,4-Pd shift 
Over the past decades, reports on C-H activation have increased exponentially. Many transition 
metals have been discovered to catalyze C-H activation. However, palladium is the most 
powerful and most widely used transition metal in organic chemistry, and has been found to be 
capable of catalyzing various C-H activation in recent years. This is particularly true for the 
activation of “parafins” C-H bonds. An interesting feature of palladium-catalyzed C-H 
activation is that palladium, in most cases, only activates C-H bonds that are in close vicinity 
to a chelation-directing group. While such directing group affords selective C-H activation, it 
also significantly limit the synthetic utility of the functionalization (Figure 27).  
Therefore, methods have been developed to functionalize remote C-H bonds.  
 
Figure 20: Direct C-H functionalization limitations 
The distal functionalization of C-H bonds can be achieved via a two-steps process, also called 
through-space palladium migration (Figure 60). In this approach, the palladium is first 
introduced after oxidative addition or carbopalladation to an initial position. In the second step, 
the proximity of the palladium species with a C-H bond can lead to the cleavage of this C-H 
bond and form a palladacycle. Then, a proton mediated palladacycle opening can undergo the 
relocation of the palladium to a remote carbone. The resulting effect is a palladium migration. 
This migration introduces a palladium moiety to a remote position, where its direct introduction 
might be difficult and thereby, can allow the functionalization of distal positions than the one 
where the palladium was initially installed.[142] 
 
Scheme 60: 1,n-Pd shift 
In the literature, several 1,n-palladium migrations have been reported, notably for the formation 
of carbo- or heterocyclic products (Scheme 61).[143] [144] [145] [146] [147] [148] Such migrations have 
received special attention from computational chemists, who have conducted studies on the 
mechanism and transition state.[149] [150] Additional to palladium, rhodium,[142] platinium[151] and 
iridium[152] are also known to undergo similar migrations. 
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Scheme 61: A rare example of 1,5-Pd shift by Suffert and co-workers [153] 
Among all palladium migrations, the 1,4-Pd migration is the most commonly observed (Figure 
28). The 1,4-Pd shift is facilitated by the formation of a relatively strain-free 5-membered ring 
palladacycle. In this case, the shift mostly relies on the unability of palladium to undergo 
reductive elimination, and form strained products.  
It has been reported in the literature that palladium can migrates from a wide range of C(sp2) or 
C(sp3)-hybridized positions to C(sp2)/C(sp3) remote positions.[154] [144]  
 
Figure 21: General principle for 1,4-Pd shift 
2. Early examples of 1,4-Palladium shift/cross-couplings reactions 
The initial observation of 1,4-Pd shift has been reported by Heck in 1972 (Scheme 62).[155] After 
transmetallation of palladium with an alkyl-mercury moiety 4.3, a mixture of coupled product 
4.4 and 4.5 resulting from direct functionalization and product from 1,4-Pd shift/Heck coupling 
was observed.  This early alkyl-to-aryl palladium shift was later extended in the reverse order 
in a Suzuki-Miyaura cross-coupling by Buchwald (Scheme 62).[156] Starting from 4.6, after 
initial oxidative addition of palladium into the C-Br bond, a 1,4-Pd shift from aryl-to-alkyl can 
occur, followed by the trapping of the palladium intermediate in a Suzuki-Miyaura reaction. 
The presence of two ortho substituents on the arylbromide is in this case necessary to avoid 
direct aryl-aryl coupling. Further extansions were proposed later.[157]  
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Scheme 62: Early examples of 1,4-Pd shift by Heck and Buchwald 
In the early 2000’s, Larock proposed a new aryl-to-aryl palladium shift, combined with an 
olefin coupling, directly inspired from the pioneer work from Heck (Scheme 63).[158] Ethyl 
acrylate was choosen as partner. In this report, the ratio between the olefin isomers 4.9 and 4.10 
could be modulated by changing the reaction parameters: by reacting 4.8 while using PivOCs 
as base in a diluted reaction, a 1:1 mixture of the two isomers can be obtained; the use of 
NaHCO3 in the presence of TBAC and high concentration afforded exclusively the direct 
coupling product 4.10 (100%). 
More recently, Lin developed the first aryl-to-vinyl palladium shift starting from 4.11 (Scheme 
63). Here, the shifted palladium species can react in a borylation[159] or Heck reaction[160] to form 
functionalized olefins 4.12 and 4.13 with good yields and selectivities.  
 
Scheme 63: Larock and Lin precedents in 1,4-Pd shift 
Several other reports are also using 1,4-Pd shift to access olefins 4.15 after -hydride 
elimination[161] [162] [39] [40]  or C-O coupling products 4.17 (Scheme 64).[161]  
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Scheme 64: report from Larock for olefin and C-O coupling products formation 
3. 1,4-Pd migration/ C-H functionalizations 
After a 1,4-Pd shift, the shifted organopalladium species can further react in any kind of 
palladium-catalyzed reaction. Initiated by the pionner work of Larock, the shifted palladium 
species can react for example in a C-H activation reaction.  
In 2000, Larock developed a new annulation process, involving iodobenzene 4.18 and 
diphenylacetylene, using palladium-catalysed C-H arylation conditions to afford 9-
benzylidene-9H-fluorene 4.21 (Scheme 65).[154] In this process, an oxidative 
addition/carbopalladation sequence occurs to form 4.19, followed by a 1,4-Pd migration from 
vinyl-to-aryl position to lead to 4.20. Then, the shifted organopalladium species 4.20 reacted in 
a C(sp2)-H arylation reaction to afford the desired tricyclic product 4.21. 
 
Scheme 65: 1,4-Pd shift/ C-H arylation from Larock 
This first example of 1,4-Pd shift/C-H activation reaction was further extended by Larock in 
another similar C(sp2)-H arylation methodology (Scheme 66). In this report, o-iodobiaryl 
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substrates 4.22 were used. Oxidative addition of palladium into the C-I bond, followed by 1,4-
aryl-to-aryl palladium shift gives a palladium intermediate 4.24 which can easily react in a C-
H arylation reaction, and afford complex tricyclics compounds such as dibenzofurans or 
fluorenes 4.25.  
In a different fashion, Larock also developed an alkyl-to-aryl 1,4-Pd shift/ C-H arylation 
sequence to access another range of fused products 4.29 in an efficient way (Scheme 66). This 
transformation starts with an oxidative addition of palladium followed by carbopalladation on 
4.26 to generate an alkyl palladium species 4.27. This intermediate could undergo 1,4-migration 
to aryl, followed by C-H arylation step to afford the desired product.  
 
Scheme 66: 1,4-Pd shift/ C-H functionalization from Larock in a C-H arylation manner 
4. 1,4-Pd migration/C(sp3)-H activation 
In the middle of the 2000’s, the 1,4-Pd shift has been used in combination with C(sp3)-H bonds 
activation to functionalize less reactive positions (Scheme 67).  
First introduced by Larock to generate fused cyclopropanes, a 1,4-Pd 
migration/carbopalladation/C(sp3)-H activation sequence starting from 4.30 lead to the 
formation of 4.36 in 67% yield.[163] Surpisingly, the authors observed exclusively the product 
resulting from C-H activation of methylene vs. methyle group in this case. The product 4.34 
resulting from C-H arylation was observed as traces. This example is to the best of our 
knowledge, the first example of 1,4-Pd migration/C(sp3)-H activation sequence. 
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Scheme 67: First example of 1,4-Pd shift/C(sp3)-H activation sequence 
A few years later, Zhu described a method to access fused oxindoles 4.41 through a 
carbopalladation/1,4-Pd shift/C(sp3)-H activation of methylene C-H bonds after ingenious 
substrate design (Scheme 68).[164] This method afforded a broad range of products bearing 
different moieties in moderate to excellent yields.   
 
Scheme 68: Zhu’s synthesis of oxindoles 
As shown with these examples, the 1,4-Pd shift is a well-established process. However, there is 
no example in the literature of 1,4-Pd-shift/C(sp3)-H activation. Moreover, as discussed earlier, 
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the aryl-to-vinyl palladium shift is a well-known process, there is no report suggesting an aryl-
to-,-unsaturated carbonyl palladium migration (Scheme 69).  
 
Scheme 69: Lack of report for simple 1,4-Pd shift/C(sp3)-H activation and aryl to -insaturated carbonyl Pd shift 
5. 1,4-Pd shift/C(sp3)-H activation to access 5-membered rings 
5.1. Reaction design 
In 2016, Baudoin reported the synthesis of strained-lactams 4.45 from akenyl bromides 4.42 
(Scheme 70a).[165] After initial oxidative addition of palladium into the C-Br bond, direct C(sp3)-
H activation occured to form the desired -lactams 4.45. With this report in hand, we believe 
that the organopalladium intermediate arising from direct oxidative addition (4.43), could also 
be generated after a 1,4-Pd shift from a remote C-Br bond on an aromatic ring (4.43’) starting 
from 4.46 (Scheme 70b). This strategy could allow the access to a variety of 5-membered ring 
products. 
 
Scheme 70: Synthesis of -lactams from “direct” C-H activation and by combining with a 1,4-shift 
5.2. Reaction design and optimization 
As a starting point, we selected the substrate 4.48 to investigate the 1,4-Pd shift/C(sp3)-H 
activation sequence and afford the-lactam 4.49 (Table 5). The reaction was conducted at 
160°C to avoid proto-debromination and favour the reductive elimination of the relatively 
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strained -lactam. Pd(PPh3)4 was selected as initial catalyst (10 mol%), combined with pivalic 
acid (30 mol%) and rubidium carbonate (1.5 equiv) in mesitylene at 160°C. Traces of product 
4.49 were observed in this case (8%), with proto-debrominated product as the major product 
(Entry 1). Changing the catalyst to Pd(Pt-Bu3)2 did not give any traces of product, whereas the 
use of Pd2dba3/PCy3 afforded the desired product in 31% NMR yield (Entry 3). Turning our 
attention to the most reactive Pd(PCy3)2 could increased the yield to 65% (Entry 4). Finally, the 
desired -lactam 4.49 could be afforded in 94% isolated yield while reducing the concentration 
to [0.025M] (Entry 5).  
 
Entries Pd source Additive (30 
mol%) 
Base Solvent NMR yield 
(Isolated) 
1 Pd(PPh3)4 (10 mol%) PivOH Rb2CO3 (1.5 equiv.) Mesitylene [0.05M] 8% 
2 Pd(Pt-Bu3)2 (10 mol%) PivOH Rb2CO3 (1.5 equiv.) Mesitylene [0.05M] 0% 
3 Pd2dba3/PCy3 (10 mol%) PivOH Rb2CO3 (1.5 equiv.) Mesitylene [0.05M] 31% 
4 Pd(PCy3)2 (10 mol%) PivOH Rb2CO3 (1.5 equiv.) Mesitylene [0.05M] 65% 
5 Pd(PCy3)2 (10 mol%) PivOH Rb2CO3 (1.5 equiv.) Mesitylene [0.025M] 100% (94%) 
Table 5: Optimization table for 1,4-Pd shift/C-H activation 
5.3. Mechanism and deuteration experiment 
The proposed mechanism for the developed reaction is depicted scheme 71. After oxidative 
addition of palladium into the C-Br bond of 4.56, ligand exchange with the pivalate can afford 
the intermediate 4.50. This intermediate can undergo a carboxylate mediated C(sp2)-H 
activation with H1 to afford the palladacycle 4.51. This palladium moiety is then too strained to 
undergo reductive elimination, and can open by proton transfer with the pivalic acid to afford 
4.52. The palladium is then in the ideal position to undergo C(sp3)-H activation from H2, 
affording the palladacycle 4.53, which after reductive elimination give the desired 5-membered 
ring -lactam 4.54.  
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Scheme 71: 1,4-Pd shift/C(sp3)-H activation mechanism hypothesis 
To test the proposed mechanism, deuteration experiments were run in the standard conditions 
(Scheme 72). Starting from 4.48-d7, no deuterium incorporation was observed on the aromatic 
ring. Proton incorporation on the -lactam brings evidence for the reversibility of the C(sp3)-H 
activation step. This H/D exchange can be assigned to an external proton source (presumably 
from mesitylene or traces of water) exchanging with the deuterium atom on the Pd-bounded 
pivalate, consistent with previous observations. Similar H/D exchanges were observed from 
partially deuterated substrates 4.48-d6 and 4.48-d1.These experiments are underlining on one 
hand the non-reversibility of the 1,4-Pd shift. On another hand, the reversibility of the C(sp3)-H 
activation reaction seems to be confirmed. 
 
Scheme 72: Deuteration experiments for 1,4-Pd shift/C(sp3)-H activation 
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5.4. Scope of the 1,4-Pd shift/C(sp3)-H activation: access to -lactams 
With the optimized conditions in hand, we next studied the scope of the reaction for the 
synthesis of -arylidene -lactams (Scheme 74). Substrates were synthesised from primary 
amines using aza-Michael additions or reductive amination on ketones or aldehydes (Scheme 
73). These secondary amines 4.56a and 4.56b could then be reacted with 2-bromocinnamic 
acids derivatives 4.58, previously obtained from Knoevenagel reaction with commercial 
feedstocks. 
 
Scheme 73: Substrates synthesis 
We first tested the reactivity of the arylchloride compared to the arylbromide (Scheme 74). 
Starting from 2-chlorocinnamic acid derivative gave lower yield than with the model substrate 
4.49 (55%). Modifications at R2 were then performed while keeping the TMB-protected 
nitrogen. Average to good yield were obtained for t-Bu 4.62, cyclopropyl 4.63 and ethyl 4.61. 
The former was in this case challenging because of the lack of Thorpe-Ingold effect. 
Comparison between C(sp3) and C(sp2)-H activation clearly appears to be in favour of the latter 
with exclusive formation of the oxindoles 4.64 and 4.65 in average to good yield, thereby 
providing an alternative access to these scaffolds. 
Modifications on the nitrogen with R1 = diethyl (4.67) and diisopropyl (4.66) furnished the 
product in low to excellent yield respectively. As a comparison, 4.67 was obtained in only 31%, 
whereas 4.61 was obtained in 45%. This can maybe be explain by the presence of the more 
bulky TMB group compared to ethyl, which could favour the reductive elimination process. 
Then, substrates 4.68 to 4.70 gave exclusive formation of the desired -lactams as a single 
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isomer. Furthermore, sensitive moieties such as nitrile 4.71, sulfone 4.72 and ester 4.73 remained 
untouched.  In some cases, the use of 10% PCy3 is necessary to prevent from the catalyst 
degradation. 
 
Scheme 74: Scope for -lactams with modifications at R2 and at the nitrogen; [a]: Using additional PCy3 (10 mol%) 
In the second part of the scope, we made some modifications on the aryl moiety R3 (Scheme 
75) (4.74-4.80). Substituents at the meta or para position to the bromine were well tolerated, 
giving the products in good to excellent yields (4.74-4.78). These scaffolds are of particular 
interest, according to similar products showing antiparasitic activities toward Colletotrichum 
orbiculare.[166] 
We finally turned our attention to the synthesis of bicyclic -lactams. Fused pyrrolidine 4.81 
and azepane 4.83, relevant to the synthesis of pyrrolizidine[167] and Stemona alkaloids[168] were 
obtained in acceptable yield (51% and 40% respectively) with proto-debrominated side product. 
This method represent an interesting alternative for the obtention of these patterns. As a 
comparison, the fused 5,6 -lactam 4.82 was obtained with almost quantitative yield (98%). The 
trend was confirmed with the obtention of several 5,6-fused -lactams bearing heteroatoms such 
as oxaninanes 4.84 and 4.85 and the enantiopure N-Boc protected piperazine 4.86.  
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Scheme 75: Scope for the -lactams with variation on the aromatic and bicyclic products; [a]: Using additional PCy3 
(10 mol%) 
5.5. Attempts for the synthesis of anantine and derivatives 
-lactams are of particular interest for their biological activities[166] and can be found in 
numerous natural products. [169] Their synthesis has been largely studied for drug discovery,[170] 
and extended for -lactams-containing natural product. 
The -arylidene--lactam motif can be found in natural products anantine, isoanantine and 
cynometrine (Figure 30).[171] These three imidazole alkaloids were isolated from the leaves of 
Cynometra species which have been used as a traditional medicine in Africa and which 
possesses antitussive and analgesic activities.[172] 
 
Figure 22: Anantine, isoanantine and cynometrine structures 
First synthesized by Naito and co-workers in 1993 through a radical cyclization,[171] we 
suggested a new approach for the synthesis of (±)-anantine and (±)-cynometrine using a 1,4-Pd 
shift/C(sp3)-H activation sequence (Scheme 76). For this, we proposed the following 
retrosynthetic plan: anantine and cynometrine could be formed from the intermediates 4.87a 
and 4.87b. These -lactams could be synthesized respectively from 4.88a and 4.88b using the 
1,4-Pd shift/C(sp3)-H activation. Precursors 4.88a and 4.88b could be obtained after nitrogen 
protection of 1-methylhistamine 4.91 and amide coupling with 4.90.  
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Before starting our investigations for the synthesis of anantine and cynometrine, we were aware 
that the 1,4-Pd shift/C(sp3)-H activation sequence might be difficult according to the following 
considerations: 1) The absence of a Thorpe-Ingold effect to favour the reaction on substrates 
4.88a and 4.88b; 2) The possibility of 4.88a and 4.88b to undergo-hydride elimination after 
the C-H cleavage; 3) Finally, the strongly coordinating propensity of imidazole to chelate 
palladium which could undergo catalyst deactivation. 
 
Scheme 76: Retrosynthetic plan for anantine and cynometrine synthesis 
The precursors for C-H activation were synthesized starting from commercially available 1-
methylhistamine 4.91 (Scheme 77). Reductive amination were used for the introduction of a 
methyl or TMB on the primary amine. Then, amide couplings with the 2-bromocinnamic acid 
chloride 4.94 were performed to afford 4.88a and 4.88b. 
 
Scheme 77: Synthesis of 4.88a and 4.88b 
With these substrates in hand, we tried to react in the optimized conditions for 1,4-Pd 
shift/C(sp3)-H activation (Scheme 78). Starting from 4.88a, only starting material was 
recovered. In the case of 4.88b, the reaction undergo complete degradation. Further 
optimizations for these reactions were made (T°C, base, ligand, concentration…) but the 
desired products could not be observed, probably for the reasons outlined before.  
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Scheme 78: Attempts for synthesis of 4.95 and 4.96 
5.6. Formal synthesis of (-)-pyrrolam-A 
After the attempt to apply a 1,4-Pd shift/C(sp3)-H activation strategy to afford anantine and 
cynometrine, we focused our attention  on the synthesis of the enantiopure 5,5-fused -lactam 
4.99, relevant to the synthesis of (-)-pyrrolam A, an alkaloid extracted from Streptomyces 
olivaceus (Scheme 79).[173]  
Starting from commercially available (S)-2-methylpyrrolidine 4.97 and 2-bromocinnamic acid 
4.90, classical amide coupling was performed. Then, the substrate 4.98 was reacted in the 
standard conditions to afford the desired -lactam 4.99 in 50% yield. 4.99 can finally be 
converted to (-)-pyrrolam A according to previous report, after ozonolysis, triflation, and proto-
detriflation. This 1,4-Pd shift/C(sp3)-H process provides a new formal synthesis to the latter in 
only 5 steps (previously described in 7 steps from D-proline).[174]  
 
Scheme 79: Formal synthesis of (-)-pyrrolam A 
5.7. Scope of the 1,4-Pd shift/C(sp3)-H activation: access to indanones 
In the next part of the scope, we try to investigate 1,4-Pd shift/C(sp3)-H activation conditions 
on other ,-insaturated carbonyl substrates. We examined the reactivity of chalcone 4.102 
bearing activable benzylic C(sp3)-H bonds. The substrates were easily accessible after 
aldolisation of the corresponding acetophenone 4.100 and o-bromo-benzaldehyde 4.101 
(Scheme 80). 
 
Scheme 80: Synthesis of chalcone derivatives 
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Using the same conditions for C-H activation, the reaction proceeded remarkably well, 
furnishing several arylidene indanones derivatives (Scheme 81). Electron-rich (4.105-4.108) and 
electron-deficient subsitutents (4.109) could be introduced, as well as free aniline (4.110). Of 
note, these compounds found interesting biological properties for Alzeihmer disease, breast 
cancer, leukemia or as inhibitor of tubulin assembly.[175] 
 
Scheme 81: Scope of indanones; [a]: Using additional PCy3 (10 mol%)  
6. Conclusion 
In conclusion, we reported an unprecedented 1,4-Pd shift followed by C(sp3)-H activation on 
unactivated and benzylic positions to afford a broad range of -arylidene -lactams and 
indanones through C(sp2)-C(sp3) bond formation.[176] The applicability of the method was 
demonstrated with the formal synthesis of (-)-pyrrolam. This report represents a new domino 
reaction and open the way to the development of new C(sp3)-H functionalization reactions that 
are difficult to achieve through direct methods (Scheme 82).  
 
Scheme 82: 1,4-Pd shift/C(sp3)-H activation for the construction of  5-membered rings 
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Chapter 2.2: 
Redox-neutral Coupling between Two C(sp3)–H Bonds 
Enabled by 1,4-Palladium Shift for the Synthesis of Fused 
Heterocycles 
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1. Introduction to C(sp3)-C(sp3) couplings through palladium-catalyzed single C-H 
bond cleavage 
The formation of carbon-carbon bonds using transition-metal catalysis has been widely 
developed in the past decades. Cross-coupling reactions as well as C-H activations reactions 
showed their robustness for the formation of C(sp2)-C(sp2) or C(sp2)-C(sp3) bonds to afford 
valuable products in a straightforward manner.[177] In these methodologies, the new C-C bond 
are generally selectively formed at positions which bear the leaving group (Scheme 83a). 
In the field of C-H activation, direct and remote functionalization using palladium catalysis 
usually undergo C(sp2)-C(sp2) or C(sp2)-C(sp3) bonds formation (Scheme 83b). However, if 
this method has shown its ability to undergo such bond formation, the formation of C(sp3)-
C(sp3) bonds is still very limited.[178]  
 
Scheme 83: C(sp2)-C(sp3) and C(sp3)-C(sp3) bonds formation via single C-H activation 
Among the few reports describing such C(sp3)-C(sp3) coupling, reactions are facilitated by the 
formation of an alkylpalladium species (Scheme 84). This alkylpalladium intermediate then 
undergo a C(sp3)-H activation reaction to afford the C(sp3)-C(sp3) coupled products. The 
alkylpalladium species are formed after carbopalladation or oxidative addition. Additionally, 
the presence of a quaternary carbone in the -position to the Pd avoid the -hydride elimination 
and ensure the viability of the alkylpalladium species. 
 
Scheme 84: C(sp3)-C(sp3) bonds formation from alkylpalladium species 
In 2009, Larock and co-workers reported the formation of fused cyclopropanes through C(sp3)-
C(sp3) bond formation (Scheme 85). The alkylpalladium intermediate 5.2 is formed after 
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carbopalladation of 5.1. This alkylpalladium intermediate 5.2 can further reacts in a C(sp3)-H 
activation on a methylene C-H bond to form the fused cyclopropane 5.3.[163]  
Similarly, Loh described the formation of pyrroloisoindolone 5.6 after reaction of 
alkylpalladium species in a C(sp3)-H activation reaction (Scheme 85).[179] In this case, the 
alkylpalladium species is also generated after carbopalladation. 
In a different fashion, Cramer reported in 2015 the enantioselective synthesis of -lactam 5.8 
(Scheme 85). In this report, the oxidative addition of palladium into a C(sp3)-Cl bond can yield 
an alkylpalladium species that further react in a C(sp3)-H activation.[180]  
Finally, Lee and co-workers described a palladium-catalysed divergent cyclopropanation after 
C(sp3)-H activation of methyl or methylene C-H bonds (Scheme 85).[181] With a fine tuning of 
the reaction conditions, spiro- 5.10 or fused-cyclopropanes 5.11 can be formed via C(sp3)-C(sp3) 
coupling. In this case, the alkylpalladium species are also generated from carbopalladation of 
5.9. 
 
Scheme 85: Precedents for C(sp3)-C(sp3) coupling using C(sp3)-H activation 
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2. Early report from Dyker and alkylpalladium species in cross-couplings 
In addition to oxidative addition and carbopalladation, alkylpalladium species can also be 
generated after 1,4-Pd shift from a C(sp2) to a C(sp3).  
In the 90’s, Dyker reported an interesting result while generating an alkylpalladium 
intermediate from C(sp3)-H activation at a methoxy group (Scheme 86).[182] While reacting 1-
iodo-2-methoxy-3-methylbenzene 5.12 with catalytic Pd(OAc)2, the alkylpalladium 
intermediate could undergo the formation of C(sp2)-C(sp3) bond (5.13) as well as C(sp3)-C(sp3) 
bond (5.14). 
 
Scheme 86: Early work from Dyker for C(sp3)-C(sp3) bonds generation 
Mechanistically, the oxidative addition of palladium is occurring into the C-I bond of 5.12, 
followed by base mediated C(sp3)-H activation of the methoxy group to generate the 
palladacycle 5.15 (Scheme 87). With the absence of ligand, 5.15 can undergo a second oxidative 
addition of 5.12 to generate the palladium (IV) intermediate 5.16. After reductive elimination 
and formation of the biaryl moiety, the alkylpalladium intermediate 5.17 is formed. At this point, 
C(sp2)-H activation followed by reductive elimination can occur to furnish the benzopyran 5.13; 
C(sp3)-H activation of the ortho methyl group can occur to form the dihydrobenzofuran 5.14. 
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Scheme 87: Mecanistic hypothesis for the formation of benzopyran and dihydrobenzofuran 
In a synthetic point of view, this reaction seems to be limited and lead to mixtures of 
polyarylated products. The absence of a ligand promotes the second undesired oxidative 
addition. However, with the formation of benzofurans, Dyker described herein a potentially 
valuable method to generate C(sp3)-C(sp3) bonds. 
Recent developments showed that unproductive oxidative addition can be shut down with 
ancillary ligands.[39] [183] Moreover, it was shown that aryl bromide can generate alkylpalladium 
species after 1,4-Pd shift. Buchwald[156] [157] and Romo[184] generated alkylpalladium species 
from aryl bromide, and reacted them in Buchwald-Hartwig or Suzuki-Miyaura cross-coupling. 
As shown in scheme 88, in the case of Buchwald, the alkylpalladium is generated on a ter-butyl 
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group, whereas in Romo’s synthesis of Hypercalin C, the alkylpalladium species is generated 
on a methoxy group.  
 
Scheme 88: Precedent trapping of alkylpalladium species in Buchwald-Hartwig or Suzuki-Miyaura couplings 
3. Redox-neutral coupling between two C(sp3)-H bonds enabled by 1,4-Pd shift for the 
synthesis of fused heterocycles 
3.1. 1,4-Pd shift as a tool for the construction of C(sp3)-C(sp3) bonds: toward the synthesis of 
dihydrobenzofurans 
Inspired from Dyker and Larock, we investigated a new approach to generate C(sp3)-C(sp3) 
bonds after 1,4-Pd shift (Scheme 89).  
Starting from 5.24, we envisaged to synthesize the dihydrobenzofuran 5.28. After an initial 
oxidative addition of palladium into the C-Br bond, followed by C(sp3)-H activation, the 
intermediate 5.25 could be obtained. We hypothesized that if the intermediate 5.25 could 
undergo a proton mediated palladacycle opening to form 5.26, this alkylpalladium moiety could 
directly undergo C(sp3)-H activation of a methyl at the ortho position followed by reductive 
elimination and generate simple dihydrobenzofurans 5.28.[176] The proton mediated 
palladacycle opening could be favoured toward reductive elimination of 5.25. Indeed, the highly 
strained benzoxetane 5.27 formation would be disfavoured.  
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Scheme 89: 1,4-Pd shift/C(sp3)-H activation hypothesis 
3.1.1. Interest for dihydrobenzofurans 
The 2,3-dihydrobenzofurans (DHB) are present in a large number of natural products, such as 
(-)-linderol A, (+)-conocarpan or (+)-lithospermic acid (Figure 31).[185] These natural products 
display various biological activities, and chemists focused their attention on the development 
of new libraries of non-natural DHB derivatives for medical uses.[186] As a consequence, a broad 
catalogues of reactions using traditional or modern synthetic methods for accessing DHB 
skeleton have been developed. 
 
Figure 23: Representative DHB examples in natural products 
The major strategies for  DHB 5.29 synthesis are depicted scheme 90.[185] These methodologies 
mostly relies on oxygen-carbon or C2-C3 bonds formation. However, the formation of C1-C2 
bond is under-represented, with C-H insertion of carbene 5.37 via transition-metal-catalysis as 
one of the only example.[187]  
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Scheme 90: Main strategies for the synthesis of DHB core 
3.1.2. Synthesis of dihydrobenzofurans 
For the synthesis of DHB through C(sp3)-C(sp3) coupling, we started our investigations using 
5.39. The substrate was chosen to afford a non-volatile product after C-H activation reaction. 
We used classical conditions as starting point to afford 5.40 (Table 6). Pd(PCy3)2 was selected 
as the catalyst, combined with a stoichiometric base in toluene. According to Dyker and our 
previous results, a high dilution was necessary to undergo a 1,4-Pd migration.[176] Combination 
of catalytic cesium pivalate and Cs2CO3 (1 equiv) at 120°C showed traces of product 5.40  (Entry 
1). By replacing Cs2CO3 to Rb2CO3 or stoichiometric cesium pivalate (1-3 equiv), significant 
amount of DHB 5.40 was observed by 1H NMR (20-25%) (Entries 2-4). Finally, higher 
temperature (140°C) was required to form 5.40 in good yield after purification (92%) (Entry 5).  
 
Entries Additive (equiv.) Base (equiv.) T°C NMR yield * (isolated) 
1 CsOPiv (30 mol%) Cs2CO3 (1 equiv) 120°C Traces 
2 CsOPiv (30 mol%) Rb2CO3 (1 equiv) 120°C 20% 
3 CsOPiv (1 equiv) - 120°C 25% 
4 CsOPiv (3 equiv) - 120°C 25% 
5 CsOPiv (1 equiv) - 140°C 88% (92%) 
*Using trichloroethylene as internal standard 
Table 6: optimization table for dihydrobenzofuran synthesis 
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3.1.3. Scope and limitations for DHB synthesis 
With the optimized conditions in hand for the synthesis of DHB 5.40, we studied the scope and 
limitations of the C(sp3)-H/C(sp3)-H coupling reaction (Scheme 92). Substrates were prepared 
according to known procedure, starting from commercially available phenol 5.41 (Scheme 91). 
Selective ortho-bromation, followed by alkylation gave the desired substrates 5.42. 
 
Scheme 91: Synthesis of reaction substrate for dihydrobenzofurans 
We first studied the influence of the substituents on the aromatic ring (R3) toward DHB 
synthesis (Scheme 92). Aldehyde was tolerated, furnishing the desired product 5.45 in good 
yield (91%). Lower yield were obtained for 5.46 and 5.47, presumably because of their high 
volatility. Additionally, ortho-substituent was tolerated (5.48, 79%).  
We then turned our attention to subtrates bearing carbonyl susbtituents at R2. Reactions 
proceeded with good yield for R2 = CO2Me (5.49-5.50) or R2 = CO2NR2 (5.51-5.52, 53-88%). 
Modification at R1 = –CO2Me 5.53 also lead to the product, thereby allowing possible 
functionalization at C2 (73%).[188] Of note, these products are obtained through an unprecedented 
1,4-Pd shift on activated methylene position, possibly occurring through enolate formation and 
palladation.  Additionally, methyl ester 5.54 at R1 and R2 provided the desired product in 41%, 
as a single trans diastereoisomer. We also investigated the formation of DHB 5.55 starting from 
modified Bisphenol C as precursor. In this case, the double C(sp3)-H/C(sp3)-H coupling 
furnished the desired product in 68% with 20 mol% catalyst, and the activation of four C(sp3)-
H bonds. Finally, for R2 = Me (5.56), only traces of product were observed, indicating that the 
current reaction is limited to primary or acidic secondary C(sp3)-H bonds. 
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Scheme 92: Scope and limitations for dihydrobenzofurans synthesis. a: performed at 160°C; b: using 20 mol% Pd(PCy3)2.  
3.2. Extension to the synthesis of indolines 
To extend our method for C(sp3)-H/C(sp3)-H coupling, we next considered the synthesis of 
indolines (Scheme 93).  
According to previous reports, C(sp3)-H activation of N-methyl aniline derivative is occurring, 
furnishing demethylation product after iminium formation or direct coupling products.[141] In a 
similar fashion, we hypothesized that if the C(sp3)-H activation would occur on N-methyl 
aniline derivative 5.62, the generated alkylpalladium 5.64 could react with an ortho-methyl 
subsitutents in a C(sp3)-H activation reaction to furnish indolines 5.66 (Scheme 93). 
 
Scheme 93: C(sp3)-H activation on N-methyl anilines: hypothesis for indoline synthesis 
3.2.1. Interest for indolines 
The indoline scaffold is present in numerous naturally bioactive alkaloids such as (-)-
physostigmine or (+)-aspidospermidine and is also a structural component of several 
pharmaceutically active compounds (Pentopril) (Figure 32).  
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Figure 24: Some relevant indoline-containing natural products and biologically active compound 
Nowadays, a large spectra of reactions have been designed for the synthesis of indolines 5.67. 
The main disconnections for indoline synthesis are depicted scheme 94.[189] Most of the 
approaches relies on the formation of the N-aryl bond, through copper-catalyzed Ullmann-
Goldberg reaction[190] or Buchwald-Hartwig coupling.[191] However, only few reports described 
the direct formation of C1-C2 bond. Carbene insertion from 5.76[192] or copper-catalyzed radical 
cyclisation from 5.75 are representative examples for such bond formation.[193]  
 
Scheme 94: Main disconnections for indoline synthesis 
3.2.2. Reaction optimization 
For the synthesis of indolines through C(sp3)-C(sp3) coupling, we started our investigations 
with N-methyl aniline bearing trifluoroacetyl substituent 5.77 to access 5.78 (Table 7). The 
protecting group was selected to reduce de demethylation side reaction. 
Using the predefined Pd(PCy3)2 catalyst, combinations of additives/bases were tested in toluene 
[0.025M] at 160°C (Table 7). Starting from cesium pivalate as stoichiometric base gave us as 
initial result the desired indoline 5.78 in 10% yield (Entry 1). Surprisingly, combination of 
PivOH/Cs2CO3 did not give any product (Entry 2). Finally, using Rb2CO3 (1.5 equiv) in 
combination with adamantoic acid as CMD base, 5.78 was isolated in 74% (Entry 4).  
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Entries Additive (equiv.) Base (equiv.) NMR yield* (isolated) 
1 CsOPiv (1 equiv) - 10% 
2 PivOH (30 mol%) Cs2CO3 (1.5 equiv) 0% 
3 PivOH (30 mol%) Rb2CO3 (1.5 equiv) 23% 
4 AdCO2H (30 mol%) Rb2CO3 (1.5 equiv) 72% (74%) 
                 *Using trichloroethylene as internal standard 
Table 7: Optimization table for indoline synthesis 
3.2.3. Scope and limitations for indolines synthesis 
With the optimized conditions in hand, we next studied the scope for indolines synthesis 
(Scheme 96). Reaction substates 5.80 were obtained after o-bromination of commercially 
available anilines 5.79, followed by trifluoroacetylation and methylation (Scheme 95).  
 
Scheme 95: Synthesis of substrates for indolines 
Different substituents on the aromatic ring (R3) were well tolerated, furnishing the desired 
indolines in moderate to good yield (Scheme 96, 5.77-5.85, 38-62%).  However, attempts to 
introduce a methyl ester moiety at R1 (5.87) or R2 (5.86) did not give any trace of the desired 
product. In these cases, only degradation was observed by 1H NMR. Changing the 
trifluoroacetyl protecting group to other protecting groups such as methyl carbamate did not 
furnish the desired product 5.88. With these observations, it seems that the acidity of the C-H 
bond of the N-methyl is determining for the reaction to occur. Nevertheless, diverse indolines 
were successfully isolated and this method provides an alternative synthesis to this scaffold.  
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Scheme 96: Scope and limitations for indolines synthesis 
3.3. Extensions on o-methoxyphenylketones 
3.3.1. Synthesis of chroman-4-ones 
After the synthesis of 5-membered heterocycles DHB and indolines, we next investigated the 
formation of 6-membered rings via 1,4-Pd shift. As discussed earlier, it appears that only 
activated C(sp3)-H bonds are suitable for this transformation. We turned our attention to o-
methoxyphenylketones 5.89 bearing enolisable subsituent to access chroman-4-ones 5.90 
(Scheme 97).[194] 
 
 
Scheme 97: Hypothesis for the synthesis of chroman-4-ones 
For this, we investigated the reactivity of 5.91 toward C(sp3)-H/C(sp3)-H coupling conditions 
to access 5.92 (Table 8). First, Pd(PCy3)2 was selected as catalyst, in combination with 
PivOH/Rb2CO3 in toluene [0.025M] at 120°C. In this case, the desired product was formed in 
35% NMR yield (Entry 1). Further optimizations were made, notably by changing the 
additive/base system, increasing the yield for the chroman-4-one 5.92 to 72% yield with a 
mixture of adamantoic acid and Cs2CO3 (Entry 4). 
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Entries Additive (equiv.) Base (equiv.) NMR yield* (isolated) 
1 PivOH (30 mol%) Rb2CO3 (1.5 equiv) 35% 
2 PivOH (30 mol%) Rb2CO3 (1 equiv) 45% 
3 AdCO2H (30 mol%) Rb2CO3 (1 equiv) 60% 
4 AdCO2H (30 mol%) Cs2CO3 (1 equiv) 71% (72%) 
       *Using trichloroethylene as internal standard 
Table 8: Optimization table for chroman-4-one synthesis 
3.3.2. Scope of chroman-4-ones 
With the optimized conditions in hand, we investigated the scope of the reaction for the 
chroman-4-ones synthesis (Scheme 98). Starting materials 5.93 were obtained from 
commercially available phenol, after electrophilic bromination and methylation reactions.  
For the synthesis of chroman-4-ones, subsitutents on the aromatic ring (R2) furnished the 
desired products with good yields (5.92-5.97, 52-68%). Moreover, alkyl subsitutents can be 
introduced at R1, providing C3-subsituted chroman-4-ones (5.98-5.99, 55-82%). 
 
Scheme 98: Scope of chroman-4-ones 
3.3.3. Deuteration experiments 
In order to rationalize the plausible reaction mechanism, deuteration experiments were 
conducted for the synthesis of chroman-4-one (Scheme 99). Initially, we tried to perform the 
reaction on the deuterated compound 5.96r-d3 using our standard conditions. Surprisingly, no 
trace of desired product was observed after different reaction time. This result might suggest a 
really high kinetic isotope effect (KIE) (similar results were obtained while using deuterated 
indolines precursor). Then, an equimolar mixture of 5.96r and 5.96r-d3-2were reacted under 
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the same conditions. 1H NMR analysis of the crude showed 50% deuterium incorporation in 
5.96d-2. These two results tends to show that the first C(sp3)-H activation might be the rate 
limiting step in this transformation. 
 
Scheme 99: Deuteration experiments for chroman-4-one synthesis 
3.3.4. Nucleophilic addition of alkylpalladium intermediate on arylketones 
In the previous parts of this chapter, the in situ generated alkylpalladium species were reacted 
in a C(sp3)-H activation reaction, affording dihydrobenzofurans, indolines and chromanones. 
Precedents reports from Yamamoto,[195] [196] Muir,[197] Shibasaki[198] or Ley[199] showed that 
arylpalladium or alkylpalladium species can also react as nucleophiles, with electrophilic 
ketones or imines (Scheme 100). While using 5.100, the absence of enolizable position in alpha 
to a ketone could undergo nucleophilic addition to generate a tertiary alcohol 5.102 and access 
another class of functionalized products.  
 
Scheme 100: Hypothesis for alkylpalladium reactivity in nucleophilic addition 
To confirm our hypothesis, investigations were made starting with biarylketone derivative 5.103 
(Table 9). We started using Pd(PCy3)2 as catalyst, in combinations with additive/base under 
higher temperature (160°C) in toluene [0.025M]. As initial result, pivalic acid (30 mol%), 
combined with cesium carbonate (1.5 equiv) provided the desired tertiary alcohol 5.104 in 10% 
yield (Entry 1). Replacing Cs2CO3 by Rb2CO3 did not affect the reaction whereas the use of 
stoichiometric pivalic acid and cesium carbonate furnished 5.104 in 50% yield (Entries 2-3). In 
126 
 
the presence of cesium pivalate (3 equiv), the desired product was isolated in 69% yield (Entry 
5).  
 
Entries Additive (equiv.) Base (equiv.) NMR yield* (isolated) 
1 PivOH (30 mol%) Cs2CO3 (1.5 equiv) 10% 
2 PivOH (30 mol%) Rb2CO3 (1.5 equiv) 18% 
3 PivOH (3 equiv) Cs2CO3 (3 equiv) 50% 
4 CsOPiv (1.5 equiv) - 40% 
5 CsOPiv (3 equiv) - 77% (69%) 
        *Using trichloroethylene as internal standard 
Table 9: Optimization table for nucleophilic addition 
In a mechanistic point of view, this reaction is supposed to require a stoichiometric reductant 
to regenerate the Pd0 catalyst after nucleophilic addition. In the reaction mixture, the only 
stoichiometric reagent is the cesium pivalate. We postulated that the generated palladium 
pivalate would decompose to Pd0 particles, thereby allowing the turn over of the reaction. 
Indeed, while heating Pd(OPiv)2 in toluene at 160°C, particles of Pd0 were observed.[200] 
According to previous studies, the decomposition of Pd(OAc)2 showed that Pd0 metal particles 
were observed while heating the catalyst at T°C > 47°C.  
3.3.5. Scope of 2,3-dihydrobenzofuran-3-ol 
With our optimized conditions, we next studied the scope for the 2,3-dihydrobenzofuran-3-ol 
synthesis (Scheme 102). Starting from commercially available 2-hydroxybenzaldehyde 
derivatives 5.105, ortho bromination followed by methylation of the phenol were performed to 
generate 5.106 (Scheme 101). The substrates were then reacted with aryl Grignard reagents, 
followed by PCC oxidation, to afford the desired substrates 5.107. 
 
Scheme 101: Synthesis of substrates for nucleophilic addition 
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For the synthesis of 2,3-dihydrobenzofuran-3-ol, electron-withdrawing or electron-donating 
groups could be introduced on both aromatic rings, furnishing tertiary alcohols in moderate to 
good yields (Scheme 102) (5.104-5.114, 50-78%). The reaction seems to occur with higher 
efficiency while using an electron-withdrawing group on the aromatic ring (5.110 and 5.114). 
Additionally, attempts to react imines derivatives in these conditions afforded the desired 
amines, albeit in low yields (5.115-5.117).  
 
Scheme 102: Scope for 2,3-dihydrobenzofuran-3-ol synthesis 
Finally, the moderate stability of 2,3-dihydrobenzofuran-3-ol 5.113 and 5.114 can undergo water 
elimination to afford benzofurans 5.118 and 5.119 when reacted in CDCl3 at room temperature 
(Scheme 103).  
 
Scheme 103: Dehydration of 2,3-dihydrobenzofuran-3-ol to form benzofurans derivatives 
4. Perspectives 
With these results in hand, we are now pursuing our investigations for 1,4-Pd shift/C-H 
activation reaction on new substrates (Scheme 104). For example, using 5.120 as substrate, 
benzofuran-3-one 5.121 arising from C(sp2)-C(sp3) coupling can be observed in 49% 1H NMR 
yield after C(sp2)-H activation of the aldehyde moiety. This initial result can open new 
perspectives to access such building blocks.  
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Scheme 104: Initial result for benzofuran-3-one synthesis 
Furthermore, alternatives to methoxy or N-methyl anilines were tested as suitable groupments 
for 1,4-Pd shift (Scheme 105). Notably, acetyl moiety seemed to be promising while running 
reactions with 5.122. Indeed, the desired C(sp3)-C(sp3) coupling indanone 5.123 was observed 
in 23% 1H NMR yield. This cascade process involving 1,4-Pd shift afford a new method to 
synthesize such bicyclic product.  
 
Scheme 105: Initial result using acetyl for 1,4-Pd shift  
5. Conclusion 
After taking advantage of the 1,4-Pd shift to form C(sp2)-C(sp3) coupling products, we 
developed here a new method to afford different valuable heterocycles through C(sp3)-C(sp3) 
coupling. Complementary to CDC (cross-dehydrogenative-coupling) methods, our conditions 
have the advantage to be redox-neutral, with the C-Br bond acting as an internal oxidant. We 
described the synthesis of functionalized DHB, indolines and chroman-4-ones by double 
C(sp3)-H activation. Furthermore, the in situ generation of an alkylpalladium species can 
undergo nucleophilic addition on keto-substrates to afford 2,3-dihydrobenzofuran-3-ol, which 
can easily be converted to functionalized benzofurans (Scheme 106).[201]  
 
Scheme 106: 1,4-Pd shift/C(sp3)-C(sp3) coupling 
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General conclusion 
Over the past decade, the transition metal-catalysed intramolecular activation of unactivated C-
H bonds has emerged as a powerful tool for organic chemists according to their abundance. 
Selective functionalizations of C-H bonds provide a rapid access to molecular complexity in an 
atom- and step-economical fashion. Within this field, my Ph.D. thesis was focused on the 
development of new methodologies involving Pd0/PdII catalysed C(sp3)-H activation to access 
valuable building blocks or natural products. My thesis is divided into two distinct parts, namely 
“direct C(sp3)-H functionalization” and “remote C(sp3)-H functionalization”. 
First, we developed a double C(sp2)/C(sp3)-H arylation method to access lycorine alkaloids 
derivatives, according to a fine design of reaction substrate. The scope of the double C-H 
arylation was studied, allowing the access to lycorines derivatives in an efficient manner. 
Moreover, this methodology has been applied for the first time for the synthesis of natural 
products hippadine and pratosine as well as the metabolite (±)--lycorane, involving a selective 
arene hydrogenation. The sequence remains, the shortest and most efficient synthetic path for 
this molecule (Scheme 107). 
 
Scheme 107: Synthesis of (±)--lycorane using double C(sp2)/C(sp3)-H arylation 
Then, we developed a new method to access -lactams using palladium catalysed C(sp3)-H 
carbamoylation under carbon monoxide atmosphere. The applicability of the reaction was 
studied and applied to a broad scope of -lactams bearing different functionalities. This reaction 
is suitable with primary, secondary and tertiary C-H bond, as well as unactivated C-H bonds. 
Additionally, an enantioselective version was developed to afford enantioenriched -lactams. 
Finally, the applicability of the reaction was demonstrated through the synthesis of enantiopure 
-amino acid for bioactive molecule synthesis (Scheme 108). 
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Scheme 108: Synthesis of -lactams  
With our synthesis of -lactams, we investigated the synthesis of other nitrogen-containing 4-
membered ring benzazetidines. However, the low stability of these compounds gave us the 
unexpected benzoxazines through an unprecedented domino C(sp3)-H activation/electrocyclic 
rearrangement of the benzazetidines intermediates. 20 examples of benzoxazine could be 
afforded while using a bulky and unactivated nitrogen substituent, to favour reductive 
elimination during the process. Benzoxazines can then be converted to the polycyclic core of 
natural product alkaloids (Scheme 109).  
 
Scheme 109: Synthesis of 4H-benzoxazines with benzazetidine rearrangement 
In addition to direct C(sp3)-H functionalization, remote functionalization of C(sp3)-H bonds 
using a 1,4-Pd migration was investigated. We reported an unprecedented 1,4-Pd shift followed 
by C(sp3)-H activation on unactivated positions to afford a broad range of -arylidene -lactams 
and indanones through C(sp2)-C(sp3) bonds formation. The applicability of the method was 
demonstrated with the formal synthesis of (-)-pyrrolam (Scheme110).  
 
Scheme 110: 1,4-Pd shift/C(sp3)-H activation for -lactams and indanones synthesis 
 
After taking advantage of the 1,4-Pd shift to form C(sp2)-C(sp3) coupling products, we extended 
the method to create C(sp3)-C(sp3) bonds. Here, the ability of palladium to undergo a 1,4-shift 
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generates an alkylpalladium species, which can react in a second C(sp3)-H activation reaction 
or in a nucleophilic addition.We described the synthesis of functionalized dihydrobenzofurans, 
indolines and chroman-4-ones by double C(sp3)-H activation and 2,3-dihydrobenzofuran-3-ol 
through nucleophilic addition. Our method presents the advantage to be redox-neutral (Scheme 
111). 
 
Scheme 111: 1,4-Shift/C(sp3)-H activation for the access to various heterocycles 
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Experimental part: 
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Part 1 : Direct C(sp3)-H activation 
Chapter 1.1: Synthesis of lycorine alkaloids using Pd-
catalysed CH-arylation:  
General information 
Techniques: All reactions involving air-sensitive material were carried out in pre-dried 
glassware under an argon atmosphere by using Schlenk techniques employing double-line 
argon-vacuum lines and working in an argon-filled glove box. Analytical thin layer 
chromatography (TLC) was performed using pre-coated Merck silica gel 60 F254 plates (0.25 
mm). Visualization of the developed chromatogram was performed by UV absorbance (254 
nm) or TLC stains (KMnO4 and Phosphomolybdic acid). Flash chromatography was performed 
using Silicycle SiliaFlash P60 (230-400 mesh) with the indicated solvent system, using 
gradients of increasing polarity in most cases. 
Chemicals: 
Anhydrous solvents were obtained by distillation over calcium hydride (xylenes) or by 
distillation over sodium (mesitylene, toluene). Anhydrous THF, DME, DMF, DMSO, were 
purchased from Acros Organics. The solvents were degassed by three cycles of freeze-pump-
thaw and storing in single-necked flasks equipped with a J-Young PTFE valve when necessary. 
Pd(PCy3)2, PdCl2, Pd(OAc)2, Pd(PPh3)4 were purchased from Strem. All other chemical 
reagents were purchased from Sigma-Aldrich, Acros Organics, Fisher, Solvias and Fluorochem 
and used as received without further purification unless otherwise stated. CO gas was purchased 
from PanGas in 3.8 quality. 
Instrumentation: 
HPLC analyses were performed using a Shimadzu Prominence system with SIL-20A auto 
sample, CTO-20AC column oven, LC-20AD pump system, DGU-20A3 degasser and SPD 
M20A Diode Array or UV/VIS detector. The following chiral columns from Daicel Chemical 
Industries were used: OD-H (chiralcel), OJ-H (chiralcel) or IA (chiralpak) in 4.6 x 250 mm 
size. Infrared spectra were taken on a Bruker ALPHA FT-IR spectrometer and are reported in 
reciprocal centimeters (cm–1). Nuclear magnetic resonance spectra were recorded on a Bruker 
Advance 250 (250 MHz), Bruker Advance 400 (400 MHz), Bruker Advance 500 (500 MHz) 
in deuterated chloroform (residual peaks 1H δ = 7.26 ppm, 13C δ = 77.16 ppm) unless otherwise 
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noted. 31P NMR spectra were on a Bruker Advance 400 (400 MHz). 19F spectra were referenced 
to external CFCl3. 31P spectra were referenced to external 95% solution of H3PO4. Data are 
reported in parts per million (ppm) as follows: chemical shift, multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, quint = quintuplet, sept = septuplet, m = multiplet and br s = 
broad signal), coupling constant in Hz and integration. High resolution mass spectra were 
recorded by Dr. H. Nadig (Department of Chemistry, University of Basel) and Dr. M. Pfeffer 
on a Bruker maXis 4G QTOF ESI mass spectrometer. Optical rotations were measured on a 
Perkin Elmer 341 Polarimeter in a 1 mL micro cuvette (cell length 100mm) with NaD-Line (λ = 
589 nm) at 20 °C. 
Synthesis of anilines: 
GENERAL PROCEDURE A FOR ACYLATION OF ANILINES: 
Anilines (1 equiv) were dissolved in DCM (0.1 M) in presence of Et3N (2 equiv) and cooled to 
0°C. Acid chlorides (1.2 equiv) were carefully added and the mixture was allowed to reach room 
temperature. After completion, the reaction was quenched with HCl 1M, and extracted with 
DCM. The crude was washed with NaOH 1M , dried over Na2SO4, filtered and purified by 
chromatography on silica gel using cyclohexane/AcOEt as solvent.  
GENERAL PROCEDURE B FOR ACYLATION OF ANILINES: 
Anilines (1 equiv) were dissolved in DCM (0.1 M) in presence DMAP (0.05 equiv) and cooled 
to 0°C. Acetic anhydride (1.1 equiv) was carefully added and the mixture was allowed to reach 
room temperature. After completion, the reaction was quenched with HCl 1M, and extracted 
with DCM. The crude was washed with NaOH 1M, dried over Na2SO4, filtered and purified by 
chromatography on silica gel using cyclohexane/AcOEt as solvent.  
GENERAL PROCEDURE FOR ALKYLATION OF AMIDES:  
 
Amides (1 equiv) were dissolved in dry THF (0.1 M) and cooled to 0°C with an ice bath. The 
solution was placed under argon, and NaH (60 % dispersion in oil, 3 equiv) was carefully added. 
The mixture was stirred for 10 minutes, followed by addition of the bromobenzyle partners (or 
chlorobenzyle as specified) (1.1 equiv) dissolved in dry THF (0.1 M). The mixture was then 
stirred overnight under reflux, cooled to room temperature and carefully quenched with water. 
The crude was extracted with AcOEt, dried over Na2SO4, filtered, evaporated and purified over 
silica gel using cyclohexane/AcOEt to afford the pure compounds. 
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GENERAL PROCEDURE FOR THE DOUBLE C(SP2)-H/C(SP3)-H 
ARYLATION UNDER OPTIMIZED CONDITIONS: 
In a 10 mL screw-cap vial, previously charged with substrate (0.15 mmol, 1 equiv) and stirring 
bar, was weighted in a glovebox Cs2CO3 (98 mg, 0.30 mmol, 2 equiv), pivalic acid (4.6 mg, 
0.045 mmol, 0.3 equiv) and Pd(PCy3)2 (10 mg, 0.015 mmol, 0.1 equiv). The vial was removed  
from the glovebox and mesitylene (3 mL) was added. The sealed vial was stirred in a pre-heated 
heating block at 140 °C for 16 h. Then, the mixture was cooled to room temperature and directly 
charged on silica for chromatography on gel. The mesitylene was flushed using cyclohexane 
and the mixture was purified using cyclohexane /AcOEt to afford the desired compounds. 
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N-(2,6-Dibromophenyl)acetamide 1.33a:  
 
Following general procedure A for acylation of anilines, 2,6-dibromoaniline (2 g, 7.97 mmol, 1 equiv), 
Et3N (2.3 mL, 15.9 mmol, 2 equiv)  and acetyl chloride (0.68 mL, 9.56 mmol, 1.2 equiv) were reacted in 
DCM. N-(2,6-dibromophenyl)acetamide was obtained after chromatography on silica gel as a 
yellowish solid (1 g, 3.41 mnmol, 43 %). 1 
1H NMR (400 MHz, Methanol-d4) δ = 7.69 – 7.66 (m, 2H), 7.16 – 7.12 (m, 1H), 2.17 (s, 3H) 
13C NMR (101 MHz, Methanol-d4) δ= 172.1, 136.7, 133.5, 131.3, 125.5, 22.4. 
N-(2-Bromophenyl)acetamide 1.31sa: 
 
Following general procedure A for acylation of anilines, 2-bromoaniline (3 g, 17.1 mmol, 1 equiv), Et3N 
(4.80 mL, 34.2 mmol, 2 equiv) and acetyl chloride (1.46 mL, 20.5 mmol, 1.2 equiv) were reacted in DCM. 
N-(2-bromophenyl)acetamide was obtained after chromatography on silica gel as a yellowish solid 
(2.36 g, 11.0 mnmol, 64 %). 2 
1H NMR (400 MHz, Methanol-d4) δ = 7.67 – 7.58 (m, 2H), 7.36 – 7.34 (m, 1H), 7.11 (td, J = 
7.8, 1.6 Hz, 1H), 2.18 (s, 3H). 
13C NMR (101 MHz, Methanol-d4) δ = 172.0, 137.2, 133.9, 129.0, 128.4, 128.1, 119.2, 23.2. 
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N-(2-Chloro-4-fluorophenyl)acetamide 1.49sa:  
 
Following general procedure B for acylation of anilines, 2-chloro-4-fluoroaniline (1 g, 6.87 mmol, 1 equiv), 
DMAP (42 mg, 0.34 mmol, 0.05 equiv) and acetic anhydride (0.71 mL, 7.56 mmol, 1.1 equiv) were reacted 
in DCM. N-(2-chloro-4-fluorophenyl)acetamide was obtained after chromatography on silica gel as a 
white solid (940 mg, 5.0 mmol, 73 %).3 
1H NMR (400 MHz, Chloroform-d) δ = 8.35 -8.27 (m, 1H), 7.49 (s, 1H), 7.17 – 7.09 (m, 1H), 
7.03 - 6.97 (m, 1H), 2.23 (s, 3H). 
13C NMR (101 MHz, Chloroform-d) δ = 168.3, 158.5 (d, J = 250 Hz), 131.2, 123.5, 123.1 (d, J = 
6.6 Hz), 116.3 (d, J = 27 Hz), 114.7(d, J = 22 Hz), 24.9. 
N-(3,4,5-Trimethoxyphenyl)acetamide 1.51ssa:  
 
 
 
 
 
 
 
 
Following general procedure B for acylation of anilines, 3,4,5-trimethoxyaniline (1.5 g, 8.19 mmol, 1 
equiv), DMAP (50 mg, 0.41 mmol, 0.05 equiv) and acetic anhydride (0.84 mL, 9.0 mmol, 1.1 equiv) were 
reacted in DCM. N-(3,4,5-trimethoxyphenyl)acetamide was obtained after chromatography on silica 
gel as a yellowish solid (1.54 g, 6.9 mnmol, 83 %). 4 
1H NMR (400 MHz, Chloroform-d) δ = 7.97 (s, 1H), 6.81 (s, 2H), 3.78 (s, 3H), 3.74 (m, 6H), 
2.12 (s, 3H). 
13C NMR (101 MHz, Chloroform-d) δ = 168.8, 153.2, 135.0, 134.4, 97.7, 61.0, 56.0, 24.5. 
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N-(2-Chloro-3,4,5-trimethoxyphenyl)acetamide 1.51sa:  
 
 
 
 
 
 
 
N-Chlorosuccinimide (593 mg, 4.5 mmol, 1 equiv) was added to a solution of 1.51ssa (1.0 g, 4.5 
mmol, 1 equiv) in acetonitrile (20 mL). The reaction mixture was heated at 65 °C overnight, 
cooled to room temperature and quenched with saturated aqueous NaHCO3 solution (140 mL). 
The aqueous layer was extracted with ethyl acetate (3 x 20 mL). The combined organic were 
washed wit NaOH 10 % (2 x 20 mL), dried over Na2SO4, filtered, and concentrated. The product 
was purified by chromatography on silica gel using cyclohexane/AcOEt as solvent (568 mg, 
2.2 mmol, 50 % yield). 5 
1H NMR (400 MHz, Chloroform-d) δ = 7.90 (s, 1H), 7.56 (s, 1H), 3.91 (s, 3H), 3.87 (s, 3H), 
3.85 (s, 3H), 2.23 (s, 3H). 
13C NMR (101 MHz, Chloroform-d) δ = 168.5, 152.4, 149.7, 139.4, 131.0, 108.6, 101.0, 61.4, 
56.3, 25.1. 
HRMS (ESI): Calculated for C11H15ClNO4 ([M+H]+): 260.0690; found 260.0684 
IR (neat) : ν =1660, 1457 cm-1 
N-(4-(Benzyloxy)-3-methylphenyl)acetamide 1.52ssa:  
 
 
4-Amino-2-methylphenol (79.3 mmol, 9.76 g, 1 equiv) was dissolved in 160 mL of ethyl acetate 
and placed under argon atmosphere. Ac2O (79.3 mmol, 7.43 mL, 1 equiv) was slowly added to 
the turning solution, which was then stirred for 2 h. The reaction was quenched with water (50 
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mL), and the organic phase was back extracted with AcOEt (2 x 30 mL). The combined organic 
mixture were washed with brine, dried over Na2SO4 and evaporated under vacuum. The product 
was obtained as a brownish solid (12.1 g, 73.3 mmol, 92 %) and directly engaged in the next 
step. 
K2CO3 (90.9 mmol, 12.6 g, 3 equiv), and N-(4-hydroxy-3-methylphenyl)acetamide (30.3 mmol, 
5 g, 1 equiv) were stirred at room temperature in 300 mL of acetone. Benzyle bromide (32.8 
mmol, 3.92 mL, 1.08 equiv) was slowly added to the mixture, which was then heated at reflux 
for 16 h. The brownish mixture was cooled to room temperature and acetone was evaporated 
under vacuum. The remaining solid was dissolved in AcOEt (120 mL) and water (120 mL). The 
crude was extracted with AcOEt (3 x 40 mL) and the combined organic layers were dried over 
Na2SO4, filtered and evaporated under vacuum. N-(4-(benzyloxy)-3-methylphenyl)acetamide 
was obtained without any further purification (7.74 g, 100 %).  
1H NMR (400 MHz, Chloroform-d) δ = 7.45 – 7.36 (m, 4H), 7.34 – 7.31 (m, 1H), 7.28 – 7.27 
(m, 1H), 7.25 – 7.23 (m, 1H), 6.81 (d, J = 8.5 Hz, 1H), 5.05 (s, 2H), 2.26 (s, 3H), 2.13 (s, 3H). 
13C NMR (101 MHz, Chloroform-d) δ = 168.4, 153.9, 137.5, 130.9, 128.6, 127.9, 127.9, 127.2, 
123.5, 119.1, 112.0, 70.3, 24.5, 16.6. 
HRMS (ESI): Calculated for C16H18NO4 ([M+H]+): 256.1338; found 256.1341 
IR (neat) : ν =1640, 1455 cm-1 
N-(4-(Benzyloxy)-2-chloro-5-methylphenyl)acetamide 1.52sa:  
 
N-Chlorosuccinimide (3.65 g, 27.3 mmol, 1 equiv) was added to a solution of 1.52ssa (7.0 g, 
27.3 mmol, 1 equiv) in acetonitrile (140 mL). The reaction mixture was heated at 65 °C 
overnight, cooled to room temperature and quenched with saturated aqueous NaHCO3 solution 
(140 mL). The aqueous layer was extracted with ethyl acetate (3 x 60 mL). The combined 
organic were washed wit NaOH 10 % (2 x 50 mL), dried over Na2SO4, filtered, and 
concentrated. The product was obtained as a brownish solid (7.5 g, 25.9 mmol, 95 % yield).6 
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1H NMR (400 MHz, Chloroform-d) δ = 8.03 (s, 1H), 7.44 – 7.33 (m, 5H), 6.88 (s, 1H), 5.03 
(s, 2H), 2.25 (s, 3H), 2.21 (s, 3H).  
13C NMR (101 MHz, Chloroform-d) δ = 168.1, 153.6, 136.7, 128.6, 128.0, 127.6, 127.1, 126.9, 
124.6, 120.8, 112.2, 70.4, 24.6, 16.3. 
HRMS (ESI): Calculated for C16H17ClNO2 ([M+H]+): 290.0948; found 290.0944 
IR (neat) : ν =1637, 1569 cm-1 
mp: 160-162°C 
N-(2-Chlorophenyl)propionamide 1.53sa:  
 
Following general procedure A for acylation of anilines, 2-chloroaniline (1 g, 7.84 mmol, 1 equiv), Et3N 
(2.2 mL, 15.7 mmol, 2 equiv) and propionyl chloride (0.75 mL, 8.62 mmol, 1.1 equiv) were reacted in 
DCM. N-(2-chlorophenyl)propionamide  was obtained after chromatography on silica gel as a white 
solid (1.44 g, 7.84 mnmol, 100 %). 7 
1H NMR (400 MHz, Chloroform-d) δ = 8.43 – 8.37 (m, 1H), 7.65 (s, 1H), 7.39 – 7.31 (m, 1H), 
7.31 – 7.22 (m, 1H), 7.03 (td, J = 7.8, 1.5 Hz, 1H), 2.47 (q, J = 7.6 Hz, 2H), 1.28 (t, J = 7.6 Hz, 
3H). 
13C NMR (101 MHz, Chloroform-d) δ = 171.9, 134.6, 128.9, 127.8, 124.4, 122.5, 121.5, 31.0, 
9.6. 
N-(2-Chlorophenyl)-2-phenylacetamide 1.54sa:  
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Following general procedure A for acylation of anilines, 2-chloroaniline (1 g, 7.84 mmol, 1 equiv), Et3N 
(2.2 mL, 15.7 mmol, 2 equiv)  and phenylacetyl chloride (1.25 mL, 9.41 mmol, 1.2 equiv) were reacted in 
DCM. N-(2-chlorophenyl)-2-phenylacetamide was obtained after chromatography on silica gel as a 
yellowish solid (1.8 g, 7.33 mnmol, 94 %). 8 
1H NMR (500 MHz, Chloroform-d) δ = 8.41 – 8.35 (m, 1H), 7.66 (s, 1H), 7.46 – 7.40 (m, 2H), 
7.40 – 7.34 (m, 3H), 7.29 – 7.21 (m, 1H), 7.27 – 7.22 (m, 1H), 7.00 (td, J = 7.7, 1.5 Hz, 1H), 3.80 
(s, 2H). 
13C NMR (126 MHz, Chloroform-d) δ = 169.2, 134.6, 134.1, 129.8, 129.5, 129.0, 128.0, 127.8, 
124.8, 122.8, 121.3, 45.3. 
N-(2-Chlorophenyl)isobutyramide 1.55sa:  
 
Following general procedure A for acylation of anilines, 2-chloroaniline (638 mg, 5 mmol, 1 equiv), Et3N 
(1.41 mL, 10 mmol, 2 equiv)  and isobutyryl chloride (0.63 mL, 6.0 mmol, 1.2 equiv) were reacted in DCM. 
N-(2-chlorophenyl)isobutyramide was obtained after chromatography on silica gel as a white solid 
(780 mg, 3.95 mnmol, 79 %). 9 
1H NMR (400 MHz, Chloroform-d) δ = 8.40 (m, 1H), 7.70 (s, 1H), 7.39 – 7.31 (m, 1H), 7.30 – 
7.23 (m, 1H), 7.07 -7.01 (m, 1H), 2.66 – 2.54 (sep, J = 7.1 Hz, 1H), 1.30 (d, J = 6.9 Hz, 6H). 
13C NMR (101 MHz, Chloroform-d) δ = 175.3, 134.9, 129.1, 127.9, 124.6, 121.7, 37.2, 19.7. 
 
N-(Benzo[d][1,3]dioxol-5-ylmethyl)-N-(2,6-dibromophenyl)acetamide 1.30: 
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Following general procedure for alkylation of amides, aniline (1.5 mmol, 439 mg, 1 equiv) was 
reacted with NaH (4.5 mmol, 180 mg, 3 equiv) and 5-(bromomethyl)benzo[d][1,3]dioxole (1.65 
mmol, 355 mg, 1.1 equiv). 1.30 was obtained after purification as a yellowish solid (620 mg, 
1.45 mmol, 96 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.59 (s, 1H), 7.57 (s, 1H), 7.09 -7.01 (m, 1H), 6.83 – 
6.78 (m, 1H), 6.63 – 6.57 (m, 2H), 5.90 (s, 2H), 4.75 (s, 2H), 1.83 (s, 3H). 
13C NMR (101 MHz, Chloroform-d) δ = 170.1, 147.4, 147.3, 140.3, 133.2, 130.6, 129.8, 126.2, 
124.1, 111.3, 107.9, 101.0, 51.1, 22.5. 
 HRMS (ESI): Calculated for C16H14Br2NO3 ([M+H]+): 425.9340; found 425.9344 
IR (neat) : ν =1640, 1555 cm-1 
mp: 240-243°C 
N-((6-Bromobenzo[d][1,3]dioxol-5-yl)methyl)-N-(2-bromophenyl)acetamide 1.31a:  
 
Following general procedure for alkylation of amides, 2-bromoacetanilide (7.1 mmol, 1.5 g, 1 
equiv) was reacted with NaH (21.3 mmol, 850 mg, 3 equiv) and 5-bromo-6 
(bromomethyl)benzo[d][1,3]dioxole (7.8 mmol, 2.3 g, 1.1 equiv). 1.31a was obtained after 
purification as a yellowish solid (3.03 g, 7.1 mmol, 99 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.69 – 7.62 (m, 1H), 7.24 – 7.17 (m, 2H), 7.00 (s, 1H), 
6.88 – 6.84 (m, 2H), 5.95 (m, 2H), 5.47 (d, J = 14.6 Hz, 1H), 4.39 (d, J = 14.6 Hz, 1H), 1.84 (s, 
3H). 
13C NMR (101 MHz, Chloroform-d) δ = 170.5, 148.0, 147.7, 140.8, 133.9, 131.2, 130.0, 129.5, 
128.6, 124.2, 115.4, 112.4, 111.2, 101.9, 50.2, 22.5. 
 HRMS (ESI): Calculated for C16H14Br2NO3 ([M+H]+): 425.9340; found 425.9339 
IR (neat) : ν =1648, 1575 cm-1 
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mp: 268-270°C 
N-((6-Bromobenzo[d][1,3]dioxol-5-yl)methyl)-N-(2-chlorophenyl)acetamide 1.31b: 
 
Following general procedure for alkylation of amides, 2-chloroacetanilide (59.6 mmol, 10.1 g, 
1 equiv) was reacted with NaH (177 mmol, 7.1 g, 3 equiv) and 5-bromo-6 
(bromomethyl)benzo[d][1,3]dioxole (65.0 mmol, 19.1 g, 1.1 equiv). 1.31b was obtained after 
purification as a brownish solid (22.1 g, 59.6 mmol, 100 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.50 -7.45 (m, 1H), 7.30 -7.24 (m, 1H), 7.20 – 7.15 (m, 
1H), 6.99 (s, 1H), 6.92 -6.85 (m, 1H), 6.86 (s, 1H), 5.98 – 5.90 (m, 2H), 5.43 (d, J = 14.6 Hz, 1H), 
4.44 (d, J = 14.6 Hz, 1H), 1.84 (s, 3H). 
13C NMR (101 MHz, Chloroform-d) δ = 170.7, 148.0, 147.7, 139.4, 133.6, 131.1, 130.7, 129.8, 
129.5, 128.0, 115.2, 112.4, 111.1, 101.9, 50.3, 22.3. 
  HRMS (ESI): Calculated for C16H13BrClNaNO3 ([M+Na]+): 403.9665; found 403.9666 
IR (neat) : ν =1660, 1555 cm-1 
mp: 248-250°C 
N-(2-Bromobenzyl)-N-(2-chlorophenyl)acetamide 1.44r:  
 
Following general procedure for alkylation of amides 2-chloroacetanilide (2 mmol, 340 mg, 1 
equiv) was reacted with NaH (6 mmol, 240 mg, 3 equiv) and 2-bromobenzyle bromide (2.2 
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mmol, 550 mg, 1.1 equiv). 1.44r was obtained after purification as a yellowish oil (590 mg, 1.74 
mmol, 87 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.48 – 7.40 (m, 3H), 7.28 – 7.20 (m, 2H), 7.16 – 7.05 
(m, 2H), 6.91 -6.87 (m, 1H), 5.56 (d, J = 14.7 Hz, 1H), 4.50 (d, J = 14.7 Hz, 1H), 1.86 (s, 3H). 
13C NMR (101 MHz, Chloroform-d) δ = 170.6, 139.5, 136.3, 133.6, 132.8, 131.6, 131.0, 130.7, 
129.8, 129.2, 127.9, 127.7, 124.6, 50.6, 22.3. 
HRMS (ESI): Calculated for C15H14BrClNO ([M+H]+): 337.9947; found 337.9942 
IR (neat) : ν =1640, 1558 cm-1 
N-(2-Bromo-4,5-dimethoxybenzyl)-N-(2-chlorophenyl)acetamide 1.45r:  
 
Following general procedure for alkylation of amides, 2-chloroacetanilide (0.98 mmol, 166 mg, 
1 equiv) was reacted with NaH (2.94 mmol, 118 mg, 3 equiv) and 1-bromo-2-(bromomethyl)-
4,5-dimethoxybenzene (1.08 mmol, 334 mg, 1.1 equiv). 1.45r was obtained after purification as 
a brownish oil (345 mg, 0.87 mmol, 88 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.49 – 7.43 (m, 1H), 7.29 -7.22 (m 1H), 7.17 – 7.11 (m, 
1H), 6.99 (s, 1H), 6.86 – 6.81 (m, 2H), 5.43 (d, J = 14.3 Hz, 1H), 4.51 (d, J = 14.3 Hz, 1H), 3.82 
(s, 3H), 3.81 (s, 3H), 1.83 (s, 3H). 
13C NMR (101 MHz, Chloroform-d) δ = 170.6, 149.1, 148.6, 139.2, 133.7, 131.1, 130.6, 129.7, 
128.4, 127.9, 115.0, 114.9, 114.2, 56.2, 56.2, 50.0, 22.4 
HRMS (ESI): Calculated for C17H17BrClNaNO3 ([M+Na]+): 419.9978; found 419.997 
IR (neat) : ν =1630, 1548 cm-1 
N-(2-Bromo-5-fluorobenzyl)-N-(2-chlorophenyl)acetamide 1.46r: 
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Following general procedure for alkylation of amides, 2-chloroacetanilide (4.13 mmol, 700 mg, 
1 equiv) was reacted with NaH (12.4 mmol, 496 mg, 3 equiv) and 1-bromo-2-(bromomethyl)-4-
fluorobenzene (4.54 mmol, 1.2 g, 1.1 equiv). 1.46r was obtained after purification as a brownish 
solid (1.4 g, 3.9 mmol, 95 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.52 – 7.47 (m, 1H), 7.42 -7.39 (m, 1H), 7.30 -7.26 
(m, 1H), 7.24 – 7.15 (m, 2H), 6.99 – 6.92 (m, 1H), 6.86 – 6.82 (m, 1H), 5.47 (d, J = 15.0 Hz, 1H), 
4.47 (d, J = 15.1 Hz, 1H), 1.87 (s, 3H). 
13C NMR (101 MHz, Chloroform-d) δ = 170.8, 162.1 (d, J = 247.2 Hz), 139.5, 138.5 (d, J = 7.3 
Hz), 133.9 (d, J = 7.9 Hz), 133.5, 130.9, 130.8, 130.0, 128.1, 118.3 (d, J = 3.3 Hz), 118.1 (d, J = 23.2 
Hz), 116.4 (d, J = 22.4 Hz), 50.9 (d, J = 1.3 Hz), 22.3. 
19F NMR (376 MHz, Chloroform-d) δ = -110.0. 
HRMS (ESI): Calculated for C15H13BrClNO ([M+H]+): 355.9853; found 355.9848 
IR (neat) : ν =1630, 1458 cm-1 
N-(2-Chlorophenyl)-N-((2-chloropyridin-3-yl)methyl)acetamide 1.47r:  
 
Following general procedure for alkylation of amides, 2-chloroacetanilide (2.95 mmol, 500 mg, 
1 equiv) was reacted with NaH (8.85 mmol, 354 mg, 3 equiv) and 2-chloro-3-
(chloromethyl)pyridine (3.25 mmol, 526 mg, 1.1 equiv). 1.47r was obtained after purification as 
a white solid (595 mg, 2.02 mmol, 68 %). 
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1H NMR (400 MHz, Chloroform-d) δ = 8.29 – 8.21 (m, 1H), 7.88 – 7.81 (m, 1H), 7.50 – 7.43 
(m, 1H), 7.31 – 7.27 (m, 1H), 7.23 – 7.15 (m, 2H), 7.03 – 6.97 (m, 1H), 5.37 (d, J = 15.0 Hz, 1H), 
4.59 (d, J = 15.1 Hz, 1H), 1.86 (s, 3H). 
 
13C NMR (101 MHz, Chloroform-d) δ =171.0, 151.1, 148.8, 140.2, 139.6, 133.3, 131.4, 130.9, 
130.6, 130.1, 128.2, 122.8, 48.6, 22.2. 
HRMS (ESI): Calculated for C14H13Cl2N2O ([M+H]+): 295.0405; found 295.0399 
IR (neat) : ν =1640, 1498 cm-1 
mp: 226-228°C 
N-(2-Bromobenzyl)-N-(2-chloro-4-cyanophenyl)acetamide 1.44r: 
 
Following general procedure A for acylation of anilines, 4-amino-3-chlorobenzonitrile (392 mg, 2.57 
mmol, 1 equiv), Et3N (0.72 mL, 5.14 mmol, 2 equiv) and acetyl chloride (0.22 mL, 3.1 mmol, 1.2 equiv) 
were reacted in DCM. N-(2-chloro-4-cyanophenyl)acetamide was obtained after extraction and used 
directly for next step without further purification (500 mg, 2.57 mmol, 100 %). 
Following general procedure for alkylation of amides, N-(2-chloro-4-cyanophenyl)acetamide 
(2.57 mmol, 500 mg, 1 equiv) was reacted with NaH (7.71 mmol, 308 mg, 3 equiv) and 2-
bromobenzyle bromide (2.83 mmol, 707 mg, 1.1 equiv). 1.44r was obtained after purification as 
a yellowish oil (280 mg, 0.77 mmol, 30 %). 
1H NMR (250 MHz, Chloroform-d) δ = 7.80 – 7.75 (m, 1H), 7.43 (m, 3H), 7.29 – 7.20 (m, 
1H), 7.16 – 7.07 (m, 1H), 7.03 – 6.97 (m, 1H), 5.57 (d, J = 14.6 Hz, 1H), 4.54 (d, J = 14.6 Hz, 1H), 
1.85 (s, 3H). 
13C NMR (101 MHz, Chloroform-d) δ = 169.5, 143.7, 135.6, 135.2, 134.1, 132.9, 132.1, 131.9, 
131.6, 129.8, 128.0, 124.7, 116.7, 114.0, 50.2, 22.4. 
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HRMS (ESI): Calculated for C16H13BrClN2O ([M+H]+): 362.9900; found 362.9894 
IR (neat) : ν =2220, 1640, 1557 cm-1 
 
 
 
N-((6-Bromobenzo[d][1,3]dioxol-5-yl)methyl)-N-(2-chloro-4-fluorophenyl)acetamide 
1.49r:  
 
Following general procedure for alkylation of amides, N-(2-chloro-4-fluorophenyl)acetamide 
(2.13 mmol, 400 mg, 1 equiv) was reacted with NaH (6.39 mmol, 260 mg, 3 equiv) and 5-bromo-
6-(bromomethyl)benzo[d][1,3]dioxole (2.34 mmol, 690 mg, 1.1 equiv). 1.49r was obtained after 
purification as a white solid (710 mg, 1.77 mmol, 83 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.22 (dd, J = 8.0, 2.7 Hz, 1H), 6.97 (s, 1H), 6.92 – 
6.82 (m, 3H), 5.98 – 5.93 (m, 2H), 5.42 (d, J = 14.5 Hz, 1H), 4.40 (d, J = 14.5 Hz, 1H), 1.83 (s, 
3H). 
13C NMR (101 MHz, Chloroform-d) δ = 170.6, 162.0 (d, J = 252.3 Hz), 148.1, 147.7, 135.6 (d, 
J = 3.9 Hz), 134.7 (d, J = 10.9 Hz), 132.1 (d, J = 9.2 Hz), 129.3, 118.0 (d, J = 25.6 Hz), 115.3 (d, J 
= 8.7 Hz), 115.1, 112.5, 111.2, 102.0, 50.2, 22.3. 
19F NMR (376 MHz, Chloroform-d) δ = -114.3. 
HRMS (ESI): Calculated for C16H13BrClNO3 ([M+H]+): 399.9751; found 399.9746 
IR (neat) : ν =1670, 1585 cm-1 
mp: 248-250°C 
N-(2-Bromobenzyl)-N-(2-chloropyridin-3-yl)acetamide 1.50r:  
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Following general procedure A for acylation of anilines, 2-chloropyridin-3-amine (330 mg, 2.57 mmol, 1 
equiv), Et3N (0.72 mL, 5.14 mmol, 2 equiv)  and acetyl chloride (0.22 mL, 3.1 mmol, 1.2 equiv) were 
reacted in DCM. N-(2-chloropyridin-3-yl)acetamide was obtained after extraction and used directly for 
next step without further purification (438 mg, 2.57 mmol, 100 %). 
Following general procedure for alkylation of amides, N-(2-chloropyridin-3-yl)acetamide (2.57 
mmol, 438 mg, 1 equiv) was reacted with NaH (7.71 mmol, 308 mg, 3 equiv) and 2-
bromobenzyle bromide (2.83 mmol, 707 mg, 1.1 equiv). 1.50r was obtained after purification as 
a yellowish solid (270 mg, 0.80 mmol, 31 %). 
1H NMR (400 MHz, Chloroform-d) δ = 8.39 – 8.33 (m, 1H), 7.48 – 7.41 (m, 2H), 7.26 – 7.22 
(m, 1H), 7.20 – 7.07 (m, 3H), 5.62 (d, J = 14.5 Hz, 1H), 4.50 (d, J = 14.5 Hz, 1H), 1.88 (s, 3H). 
13C NMR (101 MHz, Chloroform-d) δ = 170.0, 151.1, 149.4, 139.6, 136.1, 135.8, 133.0, 132.0, 
129.7, 128.0, 124.7, 123.2, 50.1, 22.5. 
HRMS (ESI): Calculated for C14H13BrClN2O ([M+H]+): 338.9900; found 338.9904 
IR (neat) : ν =1660, 1602 cm-1 
mp: 222-225°C 
N-((6-Bromobenzo[d][1,3]dioxol-5-yl)methyl)-N-(2-chloro-3,4,5-
trimethoxyphenyl)acetamide 1.51r:  
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Following general procedure for alkylation of amides, 1.51sa (1.16 mmol, 301 mg, 1 equiv) was 
reacted with NaH (3.48 mmol, 140 mg, 3 equiv) and 5-bromo-6-
(bromomethyl)benzo[d][1,3]dioxole (1.22 mmol, 360 mg, 1.1 equiv). 1.51r was obtained after 
purification as a yellowish oil (507 mg, 1.16 mmol, 100 %). 
1H NMR (400 MHz, Chloroform-d) δ = 6.94 (s, 1H), 6.83 (s, 1H), 6.15 (s, 1H), 5.94 – 5.89 (m, 
2H), 5.33 (d, J = 14.4 Hz, 1H), 4.36 (d, J = 14.4 Hz, 1H), 3.86 (s, 3H), 3.84 (s, 3H), 3.60 (s, 3H), 
1.83 (s, 3H). 
13C NMR (101 MHz, Chloroform-d) δ = 170.5, 152.1, 150.7, 147.9, 147.5, 143.5, 134.6, 129.5, 
120.0, 115.4, 112.2, 111.2, 109.5, 101.9, 61.3, 61.3, 56.2, 50.2, 22.1. 
HRMS (ESI): Calculated for C19H20BrClNO6 ([M+H]+): 472.0163; found 472.0157 
IR (neat) : ν =1648, 1555 cm-1 
Methyl 4-((N-(4-(benzyloxy)-2-chloro-5-methylphenyl)acetamido)methyl)-3-
bromobenzoate 1.52r: 
To methyl 3-bromo-4-methylbenzoate (26.2 mmol, 6 g, 1 equiv) in dry CCl4 (198 mL) was 
added NBS (26.2 mmol, 4.68 g, 1 equiv) and the reaction mixture was irradiated with a 250-W 
lamp for 16 h with a cooling system to keep the temperature at 20 °C. The reaction mixture was 
quenched with aqueous NaHCO3 (100 mL) and the crude was extracted with DCM (3 x 30 mL). 
The combined organic layers were further washed with 10 % NaOH, brine, dried over Na2SO4, 
filtered and evaporated under vacuum. The mixture is then used without further purification. 1H 
NMR: Desired product (73 %) + dibromobenzyle (15 %) + starting material (12 %). 
Under argon, 1.52sa (11.2 mmol, 3.25 g, 1 equiv) was dissolved in 150 mL of dry THF. Then, 
LiHMDS (17.9 mmol, 3 g, 1.6 equiv) was carrefully added at room temperature to the turning 
solution, which was stirred for 10 minutes. A solution of mixture of benzylbromide (4.5 g) in 
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dry THF (100 mL) was added and the reaction was heated at 65 °C for 3 h.  The 
solution was cooled to room temperature, and quenched with water (100 mL). The aqueous 
phase was extracted with AcOEt (3 x 40 mL), dried over Na2SO4, filtered and evaporated. The 
crude was purified by chromatography on silicagel, using cyclohexane/AcOEt [8 :2] as eluent. 
The desired product was obtained as an orange oil (5.22 g, 10.2 mmol, 91 % yield). 
1H NMR (400 MHz, Chloroform-d) δ = 8.17 – 8.11 (m, 1H), 7.93 – 7.89 (m, 1H), 7.55 – 7.50 
(m, 1H), 7.43 – 7.32 (m, 5H), 6.95 (s, 1H), 6.77 – 6.70 (m, 1H), 5.42 (d, J = 15.1 Hz, 1H), 5.05 (s, 
2H), 4.57 (d, J = 15.1 Hz, 1H), 3.91 (s, 3H), 2.11 (s, 3H), 1.89 (s, 3H). 
13C NMR (101 MHz, Chloroform-d) δ = 171.6, 165.9, 157.3, 141.6, 136.4, 134.0, 132.1, 131.8, 
131.1, 131.0, 130.9, 128.9, 128.7, 128.4, 127.6, 127.5, 124.3, 113.2, 70.7, 52.6, 51.4, 22.3, 16.2. 
HRMS (ESI): Calculated for C25H24BrClNO4 ([M+H]+): 516.0577; found 516.0572 
IR (neat) : ν =1735, 1640, 1485 cm-1 
N-((6-Bromobenzo[d][1,3]dioxol-5-yl)methyl)-N-(2-chlorophenyl)propionamide 1.53r: 
 
Following general procedure for alkylation of amides N-(2-chlorophenyl)propionamide (1.5 
mmol, 275 mg, 1 equiv) was reacted with NaH (4.5 mmol, 180 mg, 3 equiv) and 5-bromo-6 
(bromomethyl)benzo[d][1,3]dioxole (1.65 mmol, 485 mg, 1.1 equiv). 1.53r was obtained after 
purification as a brownish solid (505 mg, 1.26 mmol, 85 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.51 – 7.44 (m, 1H), 7.29 – 7.24 (m, 1H), 7.20 – 7.15 
(m, 1H), 7.00 (s, 1H), 6.91 – 6.84 (m, 1H), 6.86 (s, 1H), 5.98 – 5.89 (m, 2H), 5.46 (d, J = 14.6 Hz, 
1H), 4.43 (d, J = 14.6 Hz, 1H), 2.03 – 1.97 (m, 2H), 1.09 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, Chloroform-d) δ = 173.9, 147.9, 147.7, 139.1, 133.7, 131.3, 130.7, 129.8, 
129.7, 127.9, 115.3, 112.4, 111.1, 101.9, 50.4, 27.5, 9.5. 
HRMS (ESI): Calculated for C17H15BrClNO3 ([M+H]+): 396.0002; found 396.0005 
IR (neat) : ν =1641, 1587 cm-1 
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mp: 268-270°C 
N-((6-Bromobenzo[d][1,3]dioxol-5-yl)methyl)-N-(2-chlorophenyl)-2-phenylacetamide 
1.54r:  
 
Under argon, amide 1.54sa (0.407 mmol, 100 mg, 1 equiv) was dissolved in 3 mL of dry THF. 
Then, LiHMDS (0.650 mmol, 106 mg, 1.6 equiv) was carrefully added at room temperature to 
the turning solution, which was stirred for 10 minutes. A solution of 5-bromo-6-
(bromomethyl)benzo[d][1,3]dioxole (0.448 mmol, 132 mg, 1.1 equiv) in dry THF (3 mL) was 
then added and the reaction was heated at 65 °C for 3 h.  The solution was cooled to room 
temperature, and quenched with water (6 mL). The aqueous phase was extracted with AcOEt 
(3 x 3 mL), dried over Na2SO4, filtered and evaporated. The crude was purified by 
chromatography on silicagel, using cyclohexane/AcOEt [8 :2] as eluent. The desired product 
was obtained as a yellowish solid (142 mg, 0.31 mmol, 76 % yield). 
1H NMR (250 MHz, Chloroform-d) δ = 7.53 – 7.45 (m, 1H), 7.33 – 7.26 (m, 1H), 7.25 – 7.19 
(m, 3H), 7.17 – 7.11 (m, 1H), 7.07 – 7.02 (m, 2H), 6.97 (s, 1H), 6.85 (s, 1H), 6.80 – 6.72 (m, 1H), 
5.97 – 5.91 (m, 2H), 5.45 (d, J = 14.5 Hz, 1H), 4.45 (d, J = 14.5 Hz, 1H), 3.45 (d, J = 15.0 Hz, 
1H), 3.33 (d, J = 15.0 Hz, 1H). 
13C NMR (126 MHz, Chloroform-d) δ = 171.1, 148.0, 147.6, 138.7, 134.9, 133.8, 131.7, 130.7, 
129.9, 129.5, 129.4, 128.5, 127.8, 126.9, 115.3, 112.4, 111.2, 101.9, 50.6, 41.3. 
HRMS (ESI): Calculated for C22H18BrClNO3 ([M+H]+): 458.0159; found 458.0153 
IR (neat) : ν =1682, 1587 cm-1 
mp: 277-280°C 
N-((6-Bromobenzo[d][1,3]dioxol-5-yl)methyl)-N-(2-chlorophenyl)isobutyramide 1.55r:  
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Following general procedure for alkylation of amides, 2-chloroacetanilide (2.02 mmol, 400 mg, 
1 equiv) was reacted with NaH (6.06 mmol, 242 mg, 3 equiv) and 5-bromo-6-
(bromomethyl)benzo[d][1,3]dioxole (2.22 mmol, 650 mg, 1.1 equiv). 1.55r was obtained after 
purification as a brownish oil (525 mg, 1.40 mmol, 69 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.53 – 7.46 (m, 1H), 7.30 – 7.22 (m, 1H), 7.20 – 7.11 
(m, 1H), 6.95 (s, 1H), 6.91 – 6.86  (m, 2H), 5.99 – 5.92 (m, 2H), 5.49 (d, J = 14.6 Hz, 1H), 4.38 
(d, J = 14.6 Hz, 1H), 2.27 (sept, J = 6.7 Hz, 1H), 1.10 (d, J = 6.6 Hz, 3H), 1.04 (d, J = 6.8 Hz, 
3H). 
13C NMR (101 MHz, Chloroform-d) δ = 177.6, 147.9, 147.7, 139.1, 133.8, 131.1, 130.7, 129.8, 
129.7, 127.8, 115.3, 112.5, 111.0, 101.9, 50.3, 31.9, 20.2, 19.4. 
HRMS (ESI): Calculated for C18H18BrClNO3 ([M+H]+): 410.0159; found 410.0153 
IR (neat) : ν =1647, 1565 cm-1 
Double C(sp2)-H/C(sp3)-H arylation:  
6H-[1,3]Dioxolo[4,5-k]pyrrolo[3,2,1-de]phenanthridin-8(9H)-one 1.34:  
 
In a 10 mL srew-cap vial, previously charged with 1.34r (0.15 mmol, 64 mg, 1 equiv) and stirring 
bar, was weighted in a glovebox K2CO3 (83 mg, 0.60 mmol, 4 equiv), potassium pivalate (6.3 
mg, 0.045 mmol, 0.3 equiv) and Pd(PCy3)2 (10 mg, 0.015 mmol, 0.1 equiv). The vial was 
removed from the glovebox and mesitylene (3 mL) was added. The sealed vial was stirred in a 
pre-heated heating block at 140 °C for 16 h. Then, the mixture was cooled to room temperature 
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and directly charged on silica for chromatography. The mesitylene was flushed using 
cyclohexane and the mixture was purified using cyclohexane /AcOEt to afford 1.34 as a 
yellowish solid. (0.09 mmol, 24 mg, 60 %).  
1H NMR (400 MHz, Chloroform-d) δ = 7.93 – 7.89 (m, 1H), 7.15 – 7.11 (m, 1H), 7.06 – 7.00 
(m, 2H), 6.72 (d, J = 8.0 Hz, 1H), 6.68 – 6.63 (m, 1H), 6.10 (s, 2H), 4.94 (d, J = 1.1 Hz, 2H), 3.55 
– 3.52 (m, 2H) + Cyclohexane. 
13C NMR (101 MHz, Chloroform-d) δ = 174.8, 147.5, 144.8, 140.0, 124.9, 124.1, 123.0, 122.7, 
122.6, 120.6, 114.9, 113.1, 108.0, 101.6, 42.9, 36.5. 
7H-[1,3]Dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridin-5(4H)-one 1.29: 
 
In a 10 mL srew-cap vial, previously charged with 1.31a (0.15 mmol, 64 mg, 1 equiv) and stirring 
bar, was weighted in a glovebox K2CO3 (83 mg, 0.60 mmol, 4 equiv), potassium pivalate (6.3 
mg, 0.045 mmol, 0.3 equiv) and Pd(PCy3)2 (10 mg, 0.015 mmol, 0.1 equiv). The vial was 
removed from the glovebox and mesitylene (3 mL) was added. The sealed vial was stirred in a 
pre-heated heating block at 140 °C for 16 h. Then, the mixture was cooled to room temperature, 
filtered through celite, and evaporated under vacuum. 1H NMR of the crude, using C2HCl3 (13.6 
uL, 0.15 mmol, 1equiv) as internal standard shows the presence of the desired product 1.29 (22 
%) and numerous side products. 
 
In a 10 mL srew-cap vial, previously charged with 1.31b (0.15 mmol, 57 mg, 1 equiv) and stirring 
bar, was weighted in a glovebox K2CO3 (83 mg, 0.60 mmol, 4 equiv), potassium pivalate (6.3 
mg, 0.045 mmol, 0.3 equiv) and Pd(PCy3)2 (10 mg, 0.015 mmol, 0.1 equiv). The vial was 
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removed from the glovebox and mesitylene (3 mL) was added. The sealed vial was stirred in a 
pre-heated heating block at 140 °C for 16 h. Then, the mixture was cooled to room temperature 
and directly charged on silica for chromatography on gel. The mesitylene was flushed using 
cyclohexane and the mixture was purified using cyclohexane /AcOEt to afford 1.29 as a 
yellowish solid. (0.057 mmol, 15 mg, 37 %).  
1H NMR (400 MHz, Chloroform-d) δ = 7.40 (dd, J = 7.9, 1.0 Hz, 1H), 7.20 (s, 1H), 7.07 (dd, 
J = 7.4, 1.0 Hz, 1H), 6.98 (t, J = 7.6 Hz, 1H), 6.61 (s, 1H), 6.00 (s, 2H), 4.95 (s, 2H), 3.52 (s, 2H). 
13C NMR (101 MHz, Chloroform-d) δ = 174.7, 148.1, 148.0, 139.7, 123.5, 123.2, 122.9, 122.9, 
122.8, 120.0, 117.2, 107.7, 102.8, 101.7, 43.5, 36.50. 
Optimization of the reaction - selected conditions:  
 
 [a] Performed with 0.1 mmol of substrate. 1HNMR yield performed using trichloroethylene as 
internal standard. 
  
Pd source Ligand Additive 
(30 mol %) 
Base Solvent (0.05 
M) 
Temperature 
(°C) 
NMR yield 
(isolated) 
Pd(PCy3)2 (10 mol%) - PivOK K2CO3 (4 equiv) Mesitylene 140 37 % 
Pd(PCy3)2 (10 mol%) - PivOK K2CO3 (2 equiv) Mesitylene 140 45 % 
Pd(PCy3)2 (10 mol%) - PivOK K2CO3 (2 equiv) Mesitylene 120 28 % 
Pd(PCy3)2 (10 mol%) - - K2CO3 (2 equiv) DMF 140 0 % 
Pd(PCy3)2 (10 mol%) - PivOK Cs2CO3 (2 
equiv) 
Mesitylene 140 75 % 
Pd(PCy3)2 (10 mol%) - PivOH Cs2CO3 (2 
equiv) 
Mesitylene 140 90 % (92 %)  
Pd(PCy3)2 (5 mol%) - PivOH Cs2CO3 (2 
equiv) 
Mesitylene 140 70 % 
Pd(OAc)2 (10 mol%) PCy3 (20 mol%) PivOH Cs2CO3 (2 
equiv) 
Mesitylene 140 53 % 
Pd2(dba)3 (5 mol%) PCy3 (10 mol%) PivOH Cs2CO3 (2 
equiv) 
Mesitylene 140 50 % 
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1-(4-Chloro-[1,3]dioxolo[4,5-j]phenanthridin-5(6H)-yl)ethan-1-one 1.39:  
 
Following general procedure, 1.31b (57 mg, 0.15 mmol, 1 equiv) was reacted with Cs2CO3 (98 mg, 0.30 
mmol, 2 equiv), pivalic acid (4.6 mg, 0.045 mmol, 0.3 equiv) and Pd(PCy3)2 (10 mg, 0.015 
mmol, 0.1 equiv) in mesitylene (3 mL) at 140°C for 15 min. The mixture was purified by 
chromatography on silicagel using cyclohexane/AcOEt as solvent to afford 1.39  as a yellowish 
oil (31 mg, 0.103 mmol, 68 %) 
1H NMR (400 MHz, Chloroform-d) δ = 7.53 (dd, J = 7.8, 1.5 Hz, 1H), 7.35 (dd, J = 8.1, 1.4 Hz, 
1H), 7.29 – 7.24 (m, 1H), 7.21 (s, 1H), 6.79 (s, 1H), 5.98 (s, 2H), 5.65 (d, J = 15.0 Hz, 1H), 3.86 
(d, J = 15.0 Hz, 1H), 2.00 (s, 3H). 
13C NMR (101 MHz, Chloroform-d) δ = 171.4, 148.1, 147.9, 135.5, 133.2, 131.2, 130.5, 128.7, 
127.7, 125.4, 122.7, 107.0, 104.4, 101.5, 45.8, 21.8. 
HRMS (ESI): Calculated for C16H13ClNO3 ([M+H]+): 302.0584; found 302.0578 
IR (neat) : ν =1698, 1640, 1555 cm-1 
 
7H-Pyrrolo[3,2,1-de]phenanthridin-5(4H)-one 1.44: 
 
Following general procedure, 1.44r (0.15 mmol, 51 mg, 1 equiv) was reacted with Cs2CO3 (98 mg, 0.30 
mmol, 2 equiv), pivalic acid (4.6 mg, 0.045 mmol, 0.3 equiv) and Pd(PCy3)2 (10 mg, 0.015 
mmol, 0.1 equiv) in mesitylene (3 mL) at 140°C for 16 h. The mixture was purified by 
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chromatography on silicagel using cyclohexane/AcOEt as solvent to afford 1.44 as a yellowish 
solid (0.15 mmol, 33 mg, 100%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.77 – 7.71 (m, 1H), 7.59 – 7.54 (m, 1H), 7.34 – 7.29 
(m, 1H), 7.28 – 7.23 (m, 1H), 7.18 – 7.10 (m, 1H), 7.12 – 7.08 (m, 1H), 7.05 - 6.97 (m, 1H), 5.01 
(s, 2H), 3.50 (d, J = 1.2 Hz, 2H). 
13C NMR (101 MHz, Chloroform-d) δ = 174.7, 140.3, 129.0, 128.8, 128.4, 128.1, 127.8, 124.2, 
123.5, 122.8, 122.5, 120.5, 117.0, 43.3, 36.3. 
HRMS (ESI): Calculated for C15H12NO ([M+H]+): 222.0919; found 222.0913 
IR (neat) : ν =1693, 1630, 1560 cm-1 
mp: 206-208°C 
7H-[1,3]Dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridin-5(4H)-one 1.29: 
 
Following general procedure, 1.31b (0.15 mmol, 57 mg, 1 equiv) was reacted with Cs2CO3 (98 mg, 0.30 
mmol, 2 equiv), pivalic acid (4.6 mg, 0.045 mmol, 0.3 equiv) and Pd(PCy3)2 (10 mg, 0.015 
mmol, 0.1 equiv) in mesitylene (3 mL) at 140°C for 16 h. The mixture was purified by 
chromatography on silicagel using cyclohexane/AcOEt as solvent to afford 1.29 as a brownish 
solid (0.139 mmol, 37 mg, 92 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.40 (dd, J = 7.9, 1.0 Hz, 1H), 7.20 (s, 1H), 7.07 (dd, 
J = 7.4, 1.0 Hz, 1H), 6.98 (t, J = 7.6 Hz, 1H), 6.61 (s, 1H), 6.00 (s, 2H), 4.95 (s, 2H), 3.52 (s, 2H). 
13C NMR (101 MHz, Chloroform-d) δ = 174.7, 148.1, 148.0, 139.7, 123.5, 123.2, 122.9, 122.9, 
122.8, 120.0, 117.2, 107.7, 102.8, 101.7, 43.5, 36.50. 
9,10-Dimethoxy-7H-pyrrolo[3,2,1-de]phenanthridin-5(4H)-one 5e: 
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Following general procedure, 1.31b (0.15 mmol, 60 mg, 1equiv) was reacted with Cs2CO3 (98 mg, 0.30 
mmol, 2 equiv), pivalic acid (4.6 mg, 0.045 mmol, 0.3 equiv) and Pd(PCy3)2 (10 mg, 0.015 
mmol, 0.1 equiv) in mesitylene (3 mL) at 140°C for 16 h. The mixture was purified by 
chromatography on silicagel using cyclohexane/AcOEt as solvent to afford 1.29 as a yellowish 
solid (0.130 mmol, 37 mg, 89 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.48 (dd, J = 7.9, 1.0 Hz, 1H), 7.23 (s, 1H), 7.11 – 7.06 
(m, 1H), 7.01 (t, J = 7.6 Hz, 1H), 6.63 (s, 1H), 5.00 (s, 2H), 3.97 (s, 3H), 3.91 (s, 3H), 3.57 – 3.51 
(m, 2H). 
13C NMR (126 MHz, Chloroform-d) δ = 174.7, 149.4, 148.8, 139.6, 123.2, 123.1, 122.6, 121.4, 
121.3, 119.6, 117.2, 110.2, 105.3, 56.1, 56.1, 43.0, 36.3. 
9-Fluoro-7H-pyrrolo[3,2,1-de]phenanthridin-5(4H)-one 1.46:  
 
Following general procedure, 1.46r (54 mg, 0.15 mmol, 1 equiv) was reacted with Cs2CO3 (98 mg, 
0.30 mmol, 2 equiv), pivalic acid (4.6 mg, 0.045 mmol, 0.3 equiv) and Pd(PCy3)2 (10 mg, 0.015 
mmol, 0.1 equiv) in mesitylene (3 mL) at 140°C for 16 h. The mixture was purified by 
chromatography on silicagel using cyclohexane/AcOEt as solvent to afford 1.46 as a grey solid 
(36 mg, 0.15 mmol, 100 %) 
1H NMR (400 MHz, Chloroform-d) δ = 7.73 – 7.69 (m, 1H), 7.52 – 7.48 (m, 1H), 7.14 – 7.08 
(m, 1H), 7.02 – 6.98 (m, 2H), 6.88 – 6.82 (m, 1H), 4.98 (s, 2H), 3.50 (s, 2H). 
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13C NMR (101 MHz, Chloroform-d) δ = 174.6, 162.7 (d, J = 250.3 Hz), 139.8, 131.3 (d, J = 8.3 
Hz), 125.1 (d, J = 3 Hz), 124.4 (d, J = 8.5 Hz), 124.1, 123.5, 122.9, 120.3, 116.2, 115.3 (d, J = 22.1 
Hz), 114.7 (d, J = 22.6 Hz), 43.2 (d, J = 2.1 Hz), 36.4. 
19F NMR (376 MHz, Chloroform-d) δ = -113.0. 
HRMS (ESI): Calculated for C15H11FNO ([M+H]+): 240.0825; found 240.0819 
IR (neat) : ν =1685, 1622, 1545, 1105 cm-1 
mp: 225-227°C 
7H-Indolo[1,7-gh][1,6]naphthyridin-5(4H)-one 1.47:  
 
Following general procedure, 1.47r (51 mg, 0.15 mmol, 1 equiv) was reacted with Cs2CO3 (98 mg, 0.30 
mmol, 2 equiv), pivalic acid (4.6 mg, 0.045 mmol, 0.3 equiv) and Pd(PCy3)2 (10 mg, 0.015 
mmol, 0.1 equiv) in mesitylene (3 mL) at 140°C for 16 h. The mixture was purified by 
chromatography on silicagel using cyclohexane/AcOEt as solvent to afford 1.47 as a white solid 
(32 mg, 0.144 mmol, 96 %). 
1H NMR (400 MHz, Chloroform-d) δ = 8.55 – 8.52 (m, 1H), 8.03 – 7.98 (m, 1H), 7.47 – 7.44 
(m, 1H), 7.24 – 7.16 (m, 1H), 7.20 – 7.13 (m, 1H), 7.10 – 7.01 (m, 1H), 5.10 (s, 2H), 3.55 (s, 2H). 
13C NMR (101 MHz, Chloroform-d) δ = 174.5, 149.2, 148.0, 142.3, 135.2, 125.9, 124.7, 123.1, 
123.0, 122.8, 122.4, 117.7, 43.1, 36.3. 
HRMS (ESI): Calculated for C14H11N2O ([M+H]+): 223.0871; found 223.0866 
IR (neat) : ν =1697, 1638, 1565 cm-1 
mp: 214-217°C 
5-Oxo-4,5-dihydro-7H-pyrrolo[3,2,1-de]phenanthridine-2-carbonitrile 1.48 : 
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Following general procedure, 1.48r (55 mg, 0.15 mmol, 1 equiv) was reacted with Cs2CO3 (98 mg, 
0.30 mmol, 2 equiv), pivalic acid (4.6 mg, 0.045 mmol, 0.3 equiv) and Pd(PCy3)2 (10 mg, 0.015 
mmol, 0.1 equiv) in mesitylene (3 mL) at 140°C for 16 h. The mixture was purified by 
chromatography on silicagel using cyclohexane/AcOEt as solvent to afford 1.48 as a white solid 
(32 mg, 0.13 mmol, 86 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.89 (d, J = 1.2 Hz, 1H), 7.79 – 7.71 (m, 1H), 7.41 – 
7.32 (m, 3H), 7.23 – 7.19 (m, 1H), 5.08 (s, 2H), 3.59 (s, 2H). 
13C NMR (101 MHz, Chloroform-d) δ = 174.3, 144.2, 129.9, 128.9, 128.8, 128.2, 127.6, 126.9, 
125.8, 124.3, 123.0, 119.7, 118.0, 106.1, 43.4, 35.9. 
HRMS (ESI): Calculated for C16H11N2O ([M+H]+): 247.0871; found 247.0866 
IR (neat) : ν =2247, 1694, 1627, 1589 cm-1 
mp: 235-237°C 
2-Fluoro-7H-[1,3]dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridin-5(4H)-one 1.49:  
 
Following general procedure, 1.49r (60 mg, 0.15 mmol, 1 equiv) was reacted with Cs2CO3 (98 mg, 
0.30 mmol, 2 equiv), pivalic acid (4.6 mg, 0.045 mmol, 0.3 equiv) and Pd(PCy3)2 (10 mg, 0.015 
mmol, 0.1 equiv) in mesitylene (3 mL) at 140°C for 16 h. The mixture was purified by 
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chromatography on silicagel using cyclohexane/AcOEt as solvent to afford 1.49  as a yellow oil 
(23 mg, 0.081 mmol, 54 %). 
1H NMR (500 MHz, DMSO-d6) δ = 7.56 – 7.52 (m, 2H), 6.99 – 6.96 (m, 1H), 6.89 (s, 1H), 
6.06 (s, 2H), 4.84 (s, 2H), 3.54 (s, 2H). 
13C NMR (126 MHz, DMSO-d6) δ = 173.6, 159.2 (d, J = 237.2 Hz), 147.9, 147.5 135.5, 124.7 
(d, J = 9.5 Hz), 123.6, 121.5 (d, J = 2.1 Hz), 117.3 (d, J = 9.1 Hz), 110.9 (d, J = 26.6 Hz), 107.8, 
106.8 (d, J = 25.3), 103.3, 101.6, 42.8, 35.9. 
19F NMR (376 MHz, Chloroform-d) δ = -111.4. 
HRMS (ESI): Calculated for C16H11FNO3 ([M+H]+): 284.0723; found 284.0718 
IR (neat) : ν =1697, 1638, 1565, 1221 cm-1 
7H-Benzo[c]pyrrolo[3,2,1-ij][1,7]naphthyridin-5(4H)-one 1.50 :  
 
Following general procedure, 1.50r (51 mg, 0.15 mmol, 1 equiv) was reacted with Cs2CO3 (98 mg, 0.30 
mmol, 2 equiv), pivalic acid (4.6 mg, 0.045 mmol, 0.3 equiv) and Pd(PCy3)2 (10 mg, 0.015 
mmol, 0.1 equiv) in mesitylene (3 mL) at 140°C for 16 h. The mixture was purified by 
chromatography on silicagel using cyclohexane/AcOEt as solvent to afford 1.50 as a yellowish 
oil (9 mg, 0.04 mmol, 27 %) 
1H NMR (400 MHz, Chloroform-d) δ = 8.20 (d, J = 5.5 Hz, 1H), 7.82 – 7.77 (m, 1H), 7.42 – 
7.35 (m, 3H), 7.25 – 7.19 (m, 1H), 5.13 (s, 2H), 3.67 (s, 2H). 
13C NMR (101 MHz, Chloroform-d) δ = 172.5, 146.3, 144.0, 130.4, 130.1, 128.4, 128.1, 126.5, 
125.6, 123.6, 122.7, 114.5, 43.0, 38.0. 
HRMS (ESI): Calculated for C14H11N2O ([M+H]+): 223.0871; found 223.0866 
IR (neat) : ν =1691, 1671, 1545 cm-1 
1,2,3-Trimethoxy-7H-[1,3]dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridin-5(4H)-one 1.51:  
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Following general procedure, 1.51r (71 mg, 0.15 mmol, 1 equiv) was reacted with Cs2CO3 (98 mg, 0.30 
mmol, 2 equiv), pivalic acid (4.6 mg, 0.045 mmol, 0.3 equiv) and Pd(PCy3)2 (10 mg, 0.015 
mmol, 0.1 equiv) in mesitylene (3 mL) at 140°C for 16 h. The mixture was purified by 
chromatography on silicagel using cyclohexane/AcOEt as solvent to afford 1.51 as a brownish 
solid (43 mg, 0.121 mmol, 81 %). 
1H NMR (400 MHz, Chloroform-d) δ = 8.05 (s, 1H), 6.60 (s, 1H), 5.98 (s, 2H), 4.85 (s, 2H), 
3.99 (s, 3H), 3.92 (s, 3H), 3.85 (s, 3H), 3.58 (s, 2H). 
13C NMR (101 MHz, Chloroform-d) δ = 174.3, 151.8, 149.7, 147.8, 147.1, 141.6, 136.6, 122.4, 
122.4, 107.4, 107.4, 106.6, 106.5, 101.5, 61.5, 60.8, 59.8, 43.5, 35.2. 
HRMS (ESI): Calculated for C19H18NO6 ([M+H]+): 356.1134; found 356.1129 
IR (neat) : ν =1696, 1627, 1521, 1495, 1482, 1359, 1223 cm-1 
mp: 266-269°C 
Methyl 2-(benzyloxy)-1-methyl-5-oxo-4,5-dihydro-7H-pyrrolo[3,2,1-de]phenanthridine-
10-carboxylate 1.52:  
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Following general procedure, 1.52r (78 mg, 0.15 mmol, 1 equiv) was reacted with Cs2CO3 (98 mg, 
0.30 mmol, 2 equiv), pivalic acid (4.6 mg, 0.045 mmol, 0.3 equiv) and Pd(PCy3)2 (10 mg, 0.015 
mmol, 0.1 equiv) in mesitylene (3 mL) at 140°C for 16 h. The mixture was purified by 
chromatography on silicagel using cyclohexane/AcOEt as solvent to afford 1.52 as a yellowish 
solid (33 mg, 0.083 mmol, 55 %). 
1H NMR (400 MHz, Chloroform-d) δ = 8.75 – 8.67 (m, 1H), 7.96 – 7.89 (m, 1H), 7.48 – 7.31 
(m, 5H), 7.33 – 7.26 (m, 1H), 6.89 (s, 1H), 5.06 (s, 2H), 4.96 (s, 2H), 3.95 (s, 3H), 3.52 (s, 2H), 
2.72 (s, 3H). 
13C NMR (101 MHz, Chloroform-d) δ = 175.0, 166.8, 154.1, 137.4, 135.9, 135.8, 131.5, 129.8, 
128.8, 128.7, 128.2, 128.2, 128.1, 127.4, 124.2, 121.0, 117.7, 111.5, 72.3, 52.5, 43.9, 36.7, 15.4. 
HRMS (ESI): Calculated for C25H21NaNO4 ([M+Na]+): 422.1368; found 422.1360 
IR (neat) : ν =1740, 1688, 1637 cm-1 
mp: 254-256°C 
4-Methyl-7H-[1,3]dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridin-5(4H)-one 1.53:  
 
Following general procedure, 1.53r (60 mg, 0.15 mmol, 1 equiv) was reacted with Cs2CO3 (98 mg, 
0.30 mmol, 2 equiv), pivalic acid (4.6 mg, 0.045 mmol, 0.3 equiv) and Pd(PCy3)2 (10 mg, 0.015 
mmol, 0.1 equiv) in mesitylene (3 mL) at 140°C for 16 h. The mixture was purified by 
chromatography on silicagel using cyclohexane/AcOEt as solvent to afford 1.53 as a yellowish 
oil (31 mg, 0.11 mmol, 74 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.45 – 7.38 (m, 1H), 7.21 (s, 1H), 7.09 – 7.05 (m, 1H), 
7.05 – 6.97 (m, 1H), 6.65 – 6.58 (m, 1H), 6.00 (s, 2H), 5.04 – 4.90 (m, 2H), 3.47 (q, J = 7.5 Hz, 
1H), 1.50 (d, J = 7.7 Hz, 3H). 
13C NMR (101 MHz, Chloroform-d) δ = 178.3, 148.1, 148.0, 138.4, 129.2, 123.1, 123.0, 122.8, 
122.7, 120.0, 117.2, 107.8, 102.8, 101.7, 43.5, 41.7, 15.2. 
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HRMS (ESI): Calculated for C17H14NO3 ([M+H]+): 280.0974; found 280.0971 
IR (neat) : ν = 1699, 1642, 1513, 1472 cm-1 
4-Phenyl-7H-[1,3]dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridin-5(4H)-one 1.54:  
 
Following general procedure, 1.54r (69 mg, 0.15 mmol, 1 equiv) was reacted with Cs2CO3 (98 mg, 
0.30 mmol, 2 equiv), pivalic acid (4.6 mg, 0.045 mmol, 0.3 equiv) and Pd(PCy3)2 (10 mg, 0.015 
mmol, 0.1 equiv) in mesitylene (3 mL) at 140°C for 16 h. The mixture was purified by 
chromatography on silicagel using cyclohexane/AcOEt as solvent to afford 1.54 as a white solid 
(17 mg, 0.048 mmol, 32 %).  
1H NMR (400 MHz, Chloroform-d) δ = 7.49 – 7.45 (m, 1H), 7.37 – 7.29 (m, 4H), 7.28 – 7.25 
(m, 2H), 7.25 (s, 1H), 7.04 – 7.00 (m, 2H), 6.64 (s, 1H), 6.01 (s, 2H), 5.06 – 4.91 (m, 2H), 4.64 
(s, 1H). 
13C NMR (101 MHz, Chloroform-d) δ = 175.6, 148.2, 148.1, 138.9, 136.2, 129.1, 128.6, 127.8, 
127.4, 124.1, 123.2, 123.0, 123.0, 120.5, 117.4, 107.8, 102.8, 101.7, 53.0, 43.7. 
HRMS (ESI): Calculated for C22H16NO3 ([M+H]+): 342.1130; found 342.1128 
IR (neat) : ν = 1689, 1632, 1517, 1471 cm-1 
mp: 252-254°C 
4,4-Dimethyl-7H-[1,3]dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridin-5(4H)-one 1.55:  
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Following general procedure, 1.55r (62 mg, 0.15 mmol, 1 equiv) was reacted with Cs2CO3 (98 mg, 
0.30 mmol, 2 equiv), pivalic acid (4.6 mg, 0.045 mmol, 0.3 equiv) and Pd(PCy3)2 (10 mg, 0.015 
mmol, 0.1 equiv) in mesitylene (3 mL) at 140°C for 16 h. The mixture was purified by 
chromatography on silicagel using cyclohexane/AcOEt as solvent to afford 1.55 as a white solid 
(39 mg, 0.133 mmol, 88 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.44 – 7.38 (m, 1H), 7.22 (s, 1H), 7.06 – 6.97 (m, 2H), 
6.67 – 6.60 (m, 1H), 6.00 (s, 2H), 4.98 (s, 2H), 1.40 (s, 6H). 
13C NMR (101 MHz, Chloroform-d) δ = 181.0, 148.0, 148.0, 137.0, 134.3, 123.2, 123.1, 123.0, 
121.4, 119.8, 117.2, 107.8, 102.8, 101.6, 45.6, 43.5, 24.2. 
HRMS (ESI): Calculated for C18H16NO3 ([M+H]+): 294.1130; found 294.1121 
IR (neat) : ν = 1695, 1635, 1537, 1475 cm-1 
mp: 238-240°C 
Synthesis of (±)-()-lycorane and analogues 
7H-[1,3]Dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridin-5(4H)-one 1.29 (gram-scale 
reaction): 
 
 
In a 250 mL Schlenck tube equipped with stirring bar and charged with substrate 1.31b (6.5 
mmol, 2.49 g, 1 equiv) was weighted in a glovebox Cs2CO3 (4.24 g, 13 mmol, 2 equiv), pivalic 
acid (200 mg, 1.95 mmol, 0.3 equiv) and Pd(PCy3)2 (434 mg, 0.65 mmol, 0.1 equiv). The 
Schlenk was removed from glovebox and mesitylene (130 mL) was added. The mixture was 
then stirred in a previously heated oil bath at 140 °C for 16 h. The mixture was cooled to room 
temperature, and directly charged on chromatography on silica gel. Mesitylene was flushed 
using cyclohexane and the crude was purified using cyclohexane/AcOEt [5:5] to give 1.29 as a 
brown solid (1.4 g, 5.28 mmol, 81 %). 
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1H NMR (400 MHz, Chloroform-d) δ = 7.40 (dd, J = 7.9, 1.0 Hz, 1H), 7.20 (s, 1H), 7.07 (dd, 
J = 7.4, 1.0 Hz, 1H), 6.98 (t, J = 7.6 Hz, 1H), 6.61 (s, 1H), 6.00 (s, 2H), 4.95 (s, 2H), 3.52 (s, 2H). 
13C NMR (101 MHz, Chloroform-d) δ = 174.7, 148.1, 148.0, 139.7, 123.5, 123.2, 122.9, 122.9, 
122.8, 120.0, 117.2, 107.7, 102.8, 101.7, 43.5, 36.50. 
2,3,3a,4,7,12b-Hexahydro-1H-[1,3]dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridin-5(3a1H)-
one 1.58: 
 
In an autoclave, equipped with stirring bar and charged with 1.29 (289 mg, 1.1 mmol, 1 equiv) and HFIP 
(20 mL) was added under an argon atmosphere Rh/C (5 % wt, 673 mg, 0.327 mmol, 30 mol%). The 
autoclave was sealed and purged three times with H2. The mixture was stirred at room temperature under 
6 bar H2 for 30 h (followed by TLC). The mixture was then filtered through celite, evaporated and purified 
by chromatography on silica gel (Cyclohexane/AcOEt). The product was obtained as a yellowish oil (180 
mg, 0.664 mmol, 61 %).  
1H NMR (400 MHz, Chloroform-d) δ = 6.61 (s, 1H), 6.59 (s, 1H), 5.95 – 5.90 (m, 2H), 4.54 
(d, J = 17.3 Hz, 1H), 4.32 (d, J = 17.3 Hz, 1H), 3.76 (t, J = 4.6 Hz, 1H), 2.75 (dt, J = 12.7, 4.4 Hz, 
1H), 2.57 (ddt, J = 16.1, 6.9, 1.1 Hz, 1H), 2.47 – 2.36 (m, 1H), 2.09 (d, J = 16.1 Hz, 1H), 1.79 – 
1.66 (m, 3H), 1.40 – 1.29 (m, 1H), 1.27 – 1.09 (m, 2H). 
13C NMR (101 MHz, Chloroform-d) δ = 175.8, 146.9, 146.8, 131.8, 123.5, 108.6, 106.8, 101.2, 
55.9, 42.9, 40.5, 40.0, 33.1, 30.4, 28.0, 23.8. 
7a,8,8a,11a,12,12a-Hexahydro-7H-[1,3]dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridin-
5(4H)-one 1.59:   
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In an autoclave, equipped with stirring bar and charged with 1.29 (28.1 mg, 0.1 mmol, 1 equiv) and HFIP 
(1.8 mL) was added under an argon atmosphere Pd/C (10 % wt, 21.3 mg, 0.02 mmol).The autoclave was 
sealed and purged three times with H2. The mixture was stirred at 50 °C under 50 bar H2 for 48 h (followed 
by TLC). The mixture was then filtered through celite, evaporated and purified by chromatography on 
silica gel (Cyclohexane/AcOEt), to give 1.59 (5 mg, 0.017 mmol, 17 %) and 1.58 (14.5 mg, 0.05 mmol, 51 
%) as oils. 
1H NMR (400 MHz, Chloroform-d) δ = 7.10 – 7.07 (m, 1H), 7.06 – 7.03 (m, 1H), 6.97 – 6.92 
(m, 1H), 5.05 (d, J = 1.0 Hz, 1H), 4.88 (d, J = 0.9 Hz, 1H), 4.23 (ddd, J = 9.3, 6.3, 4.7 Hz, 1H), 
4.04 (td, J = 4.5, 3.2 Hz, 1H), 3.87 (dd, J = 13.4, 4.4 Hz, 1H), 3.74 (dd, J = 13.4, 10.9 Hz, 1H), 
3.51 (s, 2H), 2.82 (dt, J = 12.4, 3.9 Hz, 1H), 2.24 – 2.07 (m, 2H), 2.02 – 1.95 (m, 1H), 1.76 – 1.66 
(m, 2H). 
13C NMR (101 MHz, Chloroform-d) δ = 174.1, 140.4, 126.0, 123.4, 123.3, 122.5, 122.1, 94.1, 
73.5, 73.3, 40.5, 36.8, 33.9, 31.3, 29.5, 28.6. 
HRMS (ESI): Calculated for C17H14NO3 ([M+H]+): 272.1287; found 272.1279 
IR (neat) : ν = 1688, 1631 cm-1 
(±)--lycorane :  
 
Compound 1.58 (141 mg, 0.52 mmol, 1 equiv) was dissolved in THF (14 mL) and placed under 
argon atmosphere. LiAlH4 (79 mg, 2.1 mmol, 4 equiv) was added portionwise to the turning 
solution at room temperature. The mixture was heated at reflux for 15 h, cooled to room 
temperature, and the solution was poured over sodium sulfate. The crude was extracted with 
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dichloromethane (3 x 10 mL), filtered, and evaporated under vacuum. The crude was filtered 
on a silica plug, using AcOEt as solvent. (±)--lycorane  was obtained as a yellowish solid (126 
mg, 0.49 mmol, 95 %). 
1H NMR (400 MHz, Chloroform-d) δ = 6.61 (s, 1H), 6.49 (s, 1H), 5.90 – 5.86 (m, 2H), 4.01 
(d, J = 14.4 Hz, 1H), 3.38 (td, J = 9.2, 3.9 Hz, 1H), 3.21 (d, J = 14.3 Hz, 1H), 2.74 (dt, J = 12.0, 
4.7 Hz, 1H), 2.38 (t, J = 4.9 Hz, 1H), 2.24 – 2.11 (m, 2H), 2.02 (dddd, J = 12.3, 10.9, 8.2, 3.9 Hz, 
1H), 1.81 – 1.67 (m, 2H), 1.67 – 1.60 (m, 1H), 1.53 – 1.42 (m, 2H), 1.37 – 1.25 (m, 2H). 
13C NMR (101 MHz, Chloroform-d) δ = 146.2, 145.8, 133.3, 127.4, 108.5, 106.4, 100.8, 63.1, 
57.3, 53.9, 39.6, 37.5, 31.9, 30.6, 29.4, 25.4. 
1H NMR (400 MHz, Chloroform-d) δ = 
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13C NMR (101 MHz, Chloroform-d) δ =  
Litterature  (ppm) Observed (ppm) 
6.61 (s) 6.61 (s) 
6.49 (s) 6.49 (s) 
5.89 (d, J = 1.3 
Hz); 5.88 (d, J = 1.3 
Hz) 
5.90 – 5.86 (m) 
4.02 (d, J = 14.3 Hz) 4.01 (d, J = 14.4 Hz) 
3.38 (td, J = 9.2, 3.9 
Hz) 
3.38 (td, J = 9.2, 3.9 
Hz) 
3.21 (d, J = 
14.3 Hz) 
3.21 (d, J = 14.3 Hz) 
2.74 (dt, J = 9.8, 4.7 
Hz) 
2.74 (dt, J = 12.0, 4.7 
Hz) 
2.38 (t, J = 4.7 Hz) 2.38 (t, J = 4.9 Hz) 
2.18 (m, 2H) 2.24 – 2.11 (m) 
2.07 – 1.99 (m) 2.02 (dddd, J = 12.3, 
10.9, 8.2, 3.9 Hz) 
1.78 – 1.67 (m) 1.81 – 1.67 (m) 
1.66 – 1.60 (m) 1.67 – 1.60 (m) 
1.53 – 1.42 (m) 1.53 – 1.42 (m) 
1.39 – 1.29 (m) 1.37 – 1.25 (m) 
Litterature (ppm) Observed (ppm) 
146.06 146.2 
145.66 145.8 
133.18 133.3 
127.31 127.4 
108.33 108.5 
106.26 106.4 
100.65 100.8 
62.91 63.1 
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57.11 57.3 
53.72 53.9 
39.48 39.6 
37.37 37.5 
31.69 31.9 
30.39 30.6 
29.30 29.4 
25.20 25.4 
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9,10-Dimethoxy-2,3,3a,4,7,11b-hexahydro-1H-pyrrolo[3,2,1-de]phenanthridin-5(3a1H)-one 
1.45p:  
 
In an autoclave, equipped with stirring bar and charged with 1.45 (33 mg, 0.116 mmol, 1 equiv) and HFIP 
(2.1 mL) was added under an argon atmosphere Rh/C (5 % wt, 72 mg, 0.035 mmol, 30 mol%). The 
autoclave was sealed and purged three times with H2. The mixture was stirred at room temperature under 
6 bar H2 for 30h (followed by TLC). The mixture was then filtered through celite, evaporated and purified 
by chromatography on silica gel (Cyclohexane/AcOEt). The product was obtained as a yellowish solid (17 
mg, 0.059 mmol, 51 %).  
1H NMR (400 MHz, Chloroform-d) δ = 6.64 (s, 1H), 6.61 (s, 1H), 4.58 (d, J = 17.2 Hz, 1H), 
4.34 (d, J = 17.3 Hz, 1H), 3.87 (s, 3H), 3.85 (s, 3H), 3.78 (t, J = 4.7 Hz, 1H), 2.78 (dt, J = 12.8, 
4.4 Hz, 1H), 2.58 (dd, J = 16.1, 6.9 Hz, 1H), 2.44 (dt, J = 11.9, 5.9 Hz, 1H), 2.10 (d, J = 16.1 Hz, 
1H), 1.80 – 1.70 (m, 3H), 1.43 – 1.31 (m, 1H), 1.26 – 1.13 (m, 2H). 
13C NMR (101 MHz, Chloroform-d) δ = 175.9, 148.3, 148.2, 130.5, 122.3, 111.6, 109.6, 56.1, 
56.0, 42.5, 40.1, 39.9, 33.1, 30.5, 28.1, 23.8.   
HRMS (ESI): Calculated for C17H22NO3 ([M+H]+): 288.1600; found 288.1604 
IR (neat) : ν = 1698, 1622 cm-1 
mp: 224-226°C 
9,10-Dimethoxy-2,3,3a,3a1,4,5,7,11b-octahydro-1H-pyrrolo[3,2,1-de]phenanthridine 1.61:  
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Compound 1.45p (14.5 mg, 0.0505 mmol, 1 equiv) was dissolved in THF (1.5 mL) and placed 
under argon atmosphere. LiAlH4 (8 mg, 0.202 mmol, 4 equiv) was added portionwise to the 
turning solution at room temperature. The mixture was heated at reflux for 15 h, cooled to room 
temperature, and the solution was poured over sodium sulfate. The crude was extracted with 
dichloromethane (3 x 3 mL), filtered, and evaporated under vacuum. The crude was filtered on 
a silica plug, using AcOEt as solvent. Compound 1.61 was obtained as a yellowish oil (12.7 mg, 
0.046 mmol, 92 %). 
1H NMR (400 MHz, Chloroform-d) δ = 6.65 (s, 1H), 6.53 (s, 1H), 4.06 (d, J = 14.1 Hz 1H), 
3.86 (s, 3H), 3.84 (s, 3H), 3.43 – 3.35 (m, 1H), 3.25 (d, J = 14.2 Hz, 1H), 2.81 – 2.74 (m, 1H), 
2.42 – 2.36 (m, 1H), 2.25 – 2.14 (m, 2H), 2.08 – 1.97 (m, 1H), 1.84 – 1.76 (m, 1H), 1.73 – 1.61 (m, 
2H), 1.54 – 1.39 (m, 2H), 1.39 – 1.22 (m, 2H). 
13C NMR (126 MHz, Chloroform-d) δ = 147.7, 147.3, 132.2, 126.4, 111.4, 109.4, 63.1, 56.9, 
56.1, 56.0, 54.0, 39.3, 37.5, 31.8, 30.6, 29.4, 25.4. 
HRMS (ESI): Calculated for C17H24NO2 ([M+H]+): 274.1807; found 274.1809 
IR (neat) : ν = 1634 cm-1 
Hippadine:  
 
Hippadine was synthesized from 1.29 according to a reported literature procedure. 
1H NMR (500 MHz, Chloroform-d) δ = 8.04 (dd, J = 3.6, 0.4 Hz, 1H), 7.98 (s, 1H), 7.92 (dd, 
J = 7.7, 0.6 Hz, 1H), 7.75 (dd, J = 7.7, 0.7 Hz, 1H), 7.65 (s, 1H), 7.47 (t, J = 7.7 Hz, 1H), 6.90 (d, 
J = 3.6 Hz, 1H), 6.17 (s, 2H). 
13C NMR (126 MHz, Chloroform-d) δ = 158.3, 152.7, 148.7, 131.8, 131.1, 128.6, 124.1, 123.7, 
122.8, 122.7, 118.5, 116.8, 110.9, 108.2, 102.4, 101.9. 
  
183 
 
Pratosine: 
 
Pratosine was synthesized from 1.45 according to a reported literature procedure. 
1H NMR (400 MHz, Chloroform-d) δ = 8.03 (d, J = 3.6 Hz, 1H), 7.96 (s, 1H), 7.93 (d, J = 7.7 
Hz, 1H), 7.73 (dd, J = 7.7, 0.8 Hz, 1H), 7.60 (s, 1H), 7.46 (t, J = 7.7 Hz, 1H), 6.88 (d, J = 3.6 Hz, 
1H), 4.10 (s, 3H), 4.05 (s, 3H). 
13C NMR (101 MHz, , Chloroform-d) δ = 158.5, 153.7, 149.7, 131.2, 129.5, 128.6, 124.0, 
123.6, 122.5, 120.8, 118.1, 116.8, 110.8, 110.1, 103.8, 56.4, 56.4. 
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Computational details  
Geometry optimizations were performed with the B97X-D functional/6-31G** basis set in 
vacuum, using the Spartan '16 software (Wavefunction, Inc.). 
Compound 1.29 
E = -562552.85344 kcal = -2353721.13877 kJ 
H               -1.6957     -2.3756      0.0000 
C               -1.7452     -1.2863      0.0000 
C               -1.9415      1.5647      0.0000 
C               -0.5612     -0.4878      0.0000 
C               -2.9706     -0.6409      0.0000 
C               -3.0719      0.7581      0.0000 
C               -0.6705      0.9336      0.0000 
H               -2.0288      2.6541      0.0000 
C                0.7824     -1.1159      0.0000 
C                3.5058     -2.0559      0.0000 
C                1.0859     -2.5011      0.0000 
C                1.8948     -0.2592      0.0000 
C                3.2372     -0.6834      0.0000 
C                2.4162     -2.9585      0.0000 
H                0.2783     -3.2376      0.0000 
H                2.6091     -4.0349      0.0000 
H                4.5340     -2.4300      0.0000 
N                1.8127      1.1399      0.0000 
C                0.5431      1.8725      0.0000 
H                0.5173      2.5394     -0.8831 
H                0.5173      2.5394      0.8831 
C                3.0811      1.7340      0.0000 
O                3.2919      2.9456      0.0000 
C                4.1093      0.5613      0.0000 
H                4.7622      0.6499     -0.8860 
H                4.7622      0.6499      0.8860 
O               -4.2383     -1.2088      0.0000 
C               -5.1676     -0.0942      0.0000 
H               -5.7913     -0.1364      0.9105 
H               -5.7913     -0.1364     -0.9105 
O               -4.4036      1.1425      0.0000 
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Chapter 1.2: Synthesis of -Lactams by Palladium(0)-
Catalysed C(sp3)-H Carbamoylation 
General information:  
Techniques: All reactions involving air-sensitive material were carried out in pre-dried 
glassware under an argon atmosphere by using Schlenk techniques employing double-line 
argon-vacuum lines and working in an argon-filled glove box. Analytical thin layer 
chromatography (TLC) was performed using pre-coated Merck silica gel 60 F254 plates (0.25 
mm). Visualization of the developed chromatogram was performed by UV absorbance (254 
nm) or TLC stains (KMnO4 and Phosphomolybdic acid). Flash chromatography was performed 
using Silicycle SiliaFlash P60 (230-400 mesh) with the indicated solvent system, using 
gradients of increasing polarity in most cases. 
Chemicals: 
Anhydrous solvents were obtained by distillation over calcium hydride (xylenes) or by 
distillation over sodium (mesitylene, toluene). Anhydrous THF, DME, DMF, DMSO, were 
purchased from Acros Organics. The solvents were degassed by three cycles of freeze-pump-
thaw and storing in single-necked flasks equipped with a J-Young PTFE valve when necessary. 
PdCl2, Pd(OAc)2, Pd(PPh3)4 were purchased from Strem. All other chemical reagents were 
purchased from Sigma-Aldrich, Acros Organics, Fisher, Solvias and Fluorochem and used as 
received without further purification unless otherwise stated. CO gas was purchased from 
PanGas in 3.8 quality. 
Instrumentation: 
HPLC analyses were performed using a Shimadzu Prominence system with SIL-20A auto 
sample, CTO-20AC column oven, LC-20AD pump system, DGU-20A3 degasser and SPD 
M20A Diode Array or UV/VIS detector. The following chiral columns from Daicel Chemical 
Industries were used: OD-H (chiralcel), OJ-H (chiralcel) or IA (chiralpak) in 4.6 x 250 mm 
size. Infrared spectra were taken on a Bruker ALPHA FT-IR spectrometer and are reported in 
reciprocal centimeters (cm–1). Nuclear magnetic resonance spectra were recorded on a Bruker 
Advance 250 (250 MHz), Bruker Advance 400 (400 MHz), Bruker Advance 500 (500 MHz) 
in deuterated chloroform (residual peaks 1H δ = 7.26 ppm, 13C δ = 77.16 ppm) unless otherwise 
noted. 31 P NMR spectra were on a Bruker Advance 400 (400 MHz). 19F spectra were referenced 
to external CFCl3. 31P spectra were referenced to external 95% solution of H3PO4. Data are 
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reported in parts per million (ppm) as follows: chemical shift, multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, quint = quintuplet, sept = septuplet, m = multiplet and br s = 
broad signal), coupling constant in Hz and integration. High resolution mass spectra were 
recorded by Dr. H. Nadig (Department of Chemistry, University of Basel) on a Bruker maXis 
4G QTOF ESI mass spectrometer. Optical rotations were measured on a Perkin Elmer 341 
Polarimeter in a 1 mL micro cuvette (cell length 100mm) with NaD-Line (λ = 589 nm) at 20 °C. 
Optimization of the racemic conditions: selected conditions: 
 
 
Entry [Pd] Ligand n Solvent 
CO source Temp 
[°C] 
Yield 
2a [%][c] 
balloon COgen[b] 
(equiv) 
  
1 Pd(PPh3)4 – 1.5 THF - - 120 45% 
2 Pd(PPh3)4 – 1.5 DME - - 120 37% 
3 Pd(PPh3)4 – 1.5 DMF - - 120 0% 
4 Pd(PPh3)4 – 1.5 DMSO - - 120 0% 
5 Pd(PPh3)4 – 1.5 Toluene - - 120 45% 
6 Pd(PPh3)4 – 1.5 Xylene - - 120 47% 
7 Pd(PPh3)4 – 1.5 Xylene   120 27% 
8 Pd(OAc)2 PPh3 1.5 Xylene   120 10% 
9 Pd(OAc)2 PAd2(n-Bu)•HI 1.5 Xylene   120 45% 
10 Pd(OPiv)2 PAd2(n-Bu)•HI 1.5 Xylene   120 62% 
11 Pd2(dba)3 PAd2(n-Bu)•HI 1.5 Xylene   120 42% 
12 Pd(MeCN)4HBF4 PAd2(n-Bu)•HI 1.5 Xylene   120 35% 
13 Pd(MeCN)2Cl2 PAd2(n-Bu)•HI 1.5 Xylene   120 64% 
14 PdMe2(TMEDA) PAd2(n-Bu)•HI 1.5 Xylene   120 66% 
15 PdCl2 PAd2(n-Bu)•HI 1.5 Xylene   120 76% 
16 PdCl2 PAd2(n-Bu)•HI 3 Xylene   120 82% 
17 PdCl2 PAd2(n-Bu)•HI 3 Mesitylene   120 92% (85%) 
18 PdCl2 PAd2(n-Bu)•HI 3 Mesitylene   110 57% 
19 PdCl2 PAd2(n-Bu)•HI 3 Mesitylene   130 58% 
20 PdCl2 P(o-tol)3 3 Mesitylene   120 15% 
21 PdCl2 PPh3 3 Mesitylene   120 24% 
22 PdCl2 PCy2Ph 3 Mesitylene   120 41% 
23 PdCl2 PAd2Bn 3 Mesitylene   120 18% 
24 PdCl2 PtBu3HBF4 3 Mesitylene   120 21% 
25 PdCl2 PCy3HBF4 3 Mesitylene   120 28% 
26 PAd2(n-Bu)-Pd-G3 – 3 Mesitylene   120 80% 
27 Pd[PAd2(n-Bu)]2 – 3 Mesitylene   120 88% (85%) 
28[d] PdCl2 PAd2(n-Bu)•HI 3 Mesitylene   120 0% 
29 PdCl2 PAd2(n-Bu)•HI 3 Mesitylene – – 120 70% 
30 PdCl2 PAd2(n-Bu)•HI 3 Mesitylene   (1.5) 120 75% 
31 PdCl2 PAd2(n-Bu)•HI 3 Mesitylene   (3) 120 94% (92%) 
32[e] PdCl2 PAd2(n-Bu)•HI 3 Mesitylene   (3) 120 (95%) (75%)[f] 
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[a] Performed using 0.133 mmol of 1a unless otherwise stated. [b] 9-Methylfluorene-9-carbonyl chloride (COgen), 
Pd(OAc)2/P(t-Bu)3•HBF4 cat., Cy2NMe, mesitylene, two-chamber system (COware), both reaction chambers were placed 
at the same temperature. [c] Determined by NMR analysis using trichloroethylene as internal standard. Yield of isolated 
product 2a is given within parentheses. [d] Using amine 3a instead of 1a. [e] Performed using 1.33 mmol (400 mg) of 1a. 
[f] Performed using technical-grade mesitylene under non-inert conditions. TMB = 2,4,6-trimethoxybenzyl.  
 
 
With alternative sources of CO: 
Ru3CO12 (1equiv) instead of CO balloon: 0% 
Paraformaldehyde (3 equiv) instead of CO balloon : 45%  
Pivalic-formic (3 equiv) instead of CO balloon : 36% 
Mechanistic studies 
Synthesis of complex 2.43 
 
 
 
To a solution of tetrakistriphenylphosphine palladium(0) (500 mg, 0.433 mmol, 1 equiv) in 
toluene (9 mL) was added N,N-diisopropylcarbamoyl chloride (106 mg, 0.648 mmol, 1.5 equiv) 
and stirred at 80 °C overnight. The solution was cooled to ambient temperature and 
concentrated in vacuo. The residue was washed with diethyl ether and dried in vacuo to give 
the complex 2.43 as a yellow powder (300 mg, 0.378 mmol, 87%). 
1H NMR (500 MHz, Chloroform-d) δ = 7.81 – 7.76 (m, 12H), 7.40 – 7.32 (m, 18H), 6.26 (hept, 
J = 6.7 Hz, 1H), 2.72 (hept, J = 6.7 Hz, 1H), 0.91 (d, J = 6.7 Hz, 6H), 0.29 (d, J = 6.8 Hz, 6H). 
31P NMR (202 MHz, CDCl3) δ = 19.5. 
The physical and spectroscopic properties matched those described in the literature. 
Formation of -lactam from 2.43 
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In a vial was charged complex 2.43 (103 mg, 0.133 mmol, 1 equiv) with pivalic acid (4.7 mg, 
0.04 mmol, 0.3 equiv) and cesium carbonate (130 mg, 0.399 mmol, 3.0 equiv) in mesitylene 
(2.6 mL). The mixture was heated to 120°C overnight. The reaction mixture was cooled to 
ambient temperature, filtered through celite pad, washed with Et2O and the filtrated was 
concentrated in vacuo. Trichloroethylene (12.1 L, 0.133 mmol, 1.0 equiv) was added to the 
crude mixture and the NMR yield of the -lactam was determined (26%). 
Formation of -lactam from corresponding carbamoyl chloride 
 
 
In a vial charged with N,N-diisopropylcarbamoyl chloride (21.8 mg, 0.133 mmol, 1 equiv) was 
reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI (12 mg , 0.0266 mmol, 
20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 
3.0 equiv) in mesitylene (2.62 mL). The mixture was heated to 120°C overnight. The reaction 
mixture was cooled to ambient temperature, filtered through celite pad, washed with Et2O and 
the filtrated was concentrated in vacuo. Trichloroethylene (12.1 L, 0.133 mmol, 1.0 equiv) was 
added to the crude mixture and the NMR yield of the -lactam was determined (35%). 
Synthesis of Taddol Phosphine 
TADDOL 
In a two-neck-flask equipped with a magnetic stirring bar and reflux condenser were placed 
active magnesium turnings (53 mmol, 5.3 equiv) and THF (30 mL) was added. To this 
suspension, a solution of the aryl halide (50 mmol, 5.0 equiv) in THF (10 mL) was added. If the 
exothermic reaction did not start after 5 min, iodine was added and the reaction mixture was 
warmed using an oil bath. After the start of the exothermic reaction, the reaction mixture was 
refluxed for 30 min and then cooled down to rt. A solution of chiral diester (10 mmol, 1.0 equiv) 
in THF or ether (40 mL) was added slowly, keeping the internal temperature below the boiling 
NO
PdCl2 (10 mol%)
PdAd2(n-Bu) HI (20 mol%)
PivOH (0.3 equiv)
Cs2CO3 (3 equiv)
Mesitylene, 120 Â°C,  18 h
N
O
NMR yield : 35%
Cl
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point of the solvent. After complete addition, the reaction mixture was refluxed for 8-14 h and 
then cooled down to rt. Saturated ammonium chloride solution (40 mL), hydrochloric acid (1.0 
M, 10 mL) and water (50 mL) were added carefully. The resulting biphasic mixture was extracted 
with ether (4x 50 mL). The combined organic extracts were washed with brine (30 mL) and dried 
over sodium sulfate. All volatiles were removed under reduced pressure. The crude mixture was 
purified by column chromatography (SiO2, Pentane:Et2O). 
Dichloroarylphosphine 
To a solution of chlorobis(diethylamino)phosphine (1.1 equiv) in dry Et2O (1 mL/mmol) at –
78°C was added a freshly prepared solution of a Grignard or an organolithium reagent (1.0 to 
1.5 equiv, 0.5 to 2 M in Et2O) slowly via cannula. After complete addition, the reaction mixture 
was allowed to warm up to rt and stirred for an additional hour. In case an organolithium reagent 
was used, the reaction mixture was used as such for the next step. When a Grignard reagent was 
used, the reaction mixture was filtered using a Schlenk-frit and the residue was washed with 
additional Et2O (~0.5 mL/mmol). The filtrate was concentrated with a rotary evaporator under 
N2-atmosphere and the obtained oil was redissolved in Et2O (~0.5 mL/mmol). The reaction 
mixture was cooled to 0 °C and a solution of hydrogen chloride (4.4 to 5 equiv equiv, 2M in 
Et2O) was added dropwise. After complete addition, the reaction mixture was allowed to warm 
up to rt and stirred for an additional hour. The formed white precipitate was filtered off 
(Schlenk-frit). The residue was washed with additional Et2O (~0.5 mL/mmol) and the filtrate 
was concentrated with a rotary evaporator under N2-atmosphere. The crude mixture was 
purified by distillation under high vacuum. 
Phosphonite 
To a mixture of TADDOL of (0.3 mmol, 1 equiv) and 4Å MS (75 mg) in THF (1.2 mL) at 0°C 
was added triethylamine (0.70 mmol, 2.34 equiv). Next, the dichloroarylphosphine (0.33 mmol, 
1.1 equiv) was added dropwise. The reaction was allowed to warm to rt and stirred for 2 h. The 
reaction was diluted with Et2O, filtered through celite, and concentrated under reduced pressure. 
Purification by column chromatography (SiO2, Pentane:Et2O) afforded the phosphonite ligand 
as a white solid. 
Diethyl (2R,3R)-2,3-dimethoxysuccinate 2.84a 
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Diethyl tartrate (3.41 mL, 20.0 mmol) and dimethyl sulfate (3.89 mL, 41.0 mmol) were added 
sequentially to a cooled (0°C) suspension of NaH (960 mg, 40.0 mmol) in diethyl ether (200 
mL) and the resulting mixture was stirred overnight at rt. The reaction was quenched with sat. 
NaHCO3 (100 mL), the aqueous phase extracted with diethyl ether (3 x 50 mL), the combined 
organic layers were washed with NH4OH (50 mL, 10% in H2O), dried over MgSO4, filtered and 
the solvent was removed under reduced pressure to provide oil the title compound in 
quantitative yield as a colorless liquid.  
1H NMR (400 MHz, Chloroform-d) : δ = 4.33-4.19 (m, 4H), 4.21 (s, 2H,), 3.45 (s, 6H), 1.30 (t, 
J = 7.2 Hz, 6 H) 
 
13C NMR (101 MHz, Chloroform-d) : δ = 169.2, 81.2, 61.3, 59.6, 14.2 
 
IR (neat): ν = 2985, 2933, 2833, 1754, 1730, 1465, 1447, 1390, 1369, 1348, 1267, 1218, 1185, 
1149, 1108, 1026, 926, 858, 810 cm-1. 
 
The physical and spectroscopic properties matched those described in the literature.10 
 
(2R,3R)-1,1,4,4-Tetrakis(3,5-bis(trifluoromethyl)phenyl)-2,3-dimethoxybutane-1,4-diol 
2.84b 
 
  
 
Following general procedure “TADDOL”, the Grignard reagent generated from 3,5- 
bis(trifluoromethyl)bromobenzene (12.5 g, 42.7 mmol, 5.0 equiv) and magnesium (1.1 g, 45.3 
mmol, 5.3 equiv) in THF was reacted with diethyl (2R,3R)-2,3-dimethoxysuccinate (2 g, 8.54 
mmol, 1.0 equiv).The crude mixture was purified by flash chromatography affording 6.3 g (6.31 
mmol, 74%) of a yellow oil which solidified under vacuum. 
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1H NMR (400 MHz, Chloroform-d) : δ = 8.11 – 8.06 (m, 4H), 7.95 – 7.91 (m, 4H), 7.92 – 7.90 
(m, 2H), 7.86 – 7.84 (m, 5H), 4.42 (s, 2H), 4.23 (s, 2H), 2.46 (s, 6H). 
13C NMR (101 MHz, Chloroform-d) : δ = 146.72, 144.93, 132.71 (q, JC,F = 33.7 Hz), 132.07 (q, 
JC,F = 33.6 Hz), 127.39 – 127.16 (m), 126.77 – 126.46 (m), 123.2 (q, JC,F = 273 Hz), 123.1 (q, JC,F = 
273 Hz), 122.47 (m), 122.42 – 122.21 (m), 84.21, 78.77, 60.66. 
19F NMR (376 MHz, Chloroform-d) : δ = -63.12, -63.24. 
IR (neat): ν = 3290, 2884, 1625, 1460, 1365, 1005, 762 cm-1. 
HRMS (ESI): Calculated for C38H22F24O4 ([M-H]-): 997.1077; found: 997.1062 
Optical rotation : []D20 = -1° (c = 1.0, CHCl3) 
(5R,6R)-4,4,7,7-Tetrakis(3,5-bis(trifluoromethyl)phenyl)-2-(3,5-di-tert-butyl-4-
methoxyphenyl)-5,6-dimethoxy-1,3,2-dioxaphosphepane 2.84 
 
 
 
Following general procedure “Phosphonite”, 2.84 was obtained as a yellow solid (310 mg, 0.249 
mmol, 83 %). 
1H NMR (400 MHz, Chloroform-d) : δ = 8.29 – 8.25 (m, 2H), 8.10 – 8.05 (m, 2H), 7.94 – 7.91 
(m, 1H), 7.81 – 7.80 (m, 1H), 7.79 – 7.77 (m, 2H), 7.75 – 7.73 (m, 1H), 7.72 – 7.67 (m, 3H), 7.19 
(s, 2H), 4.64 (dd, J = 7.9, 5.6 Hz, 1H), 3.71 (s, 3H), 3.68 (s, 3H), 3.65 – 3.61 (m, 1H), 2.47 (s, 
3H), 1.42 (s,9H), 1.34 (s, 9H). 
13C NMR (101 MHz, Chloroform-d) : Many signals due to C-P and C-F coupling 
31P NMR (162 MHz, Chloroform-d) : δ = 161.3. 
19F NMR (376 MHz, Chloroform-d) : δ = -63.01, -63.05, -63.12. 
Optical rotation : []D20 = -20.3° (c = 1.06, CHCl3) 
HRMS (ESI): Calculated for C53H44F24O5P ([M+H]+): 1247.2538; found: 1247.2523 
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Synthesis of secondary amines 
 
N-(2,4,6-Trimethoxybenzyl)propan-2-amine 2.40r: 
  
N-(2,4,6-trimethoxybenzyl)propan-2-amine was obtained according to a known procedure. 
The physical and spectroscopic properties matched those described in the literature. 11 
N-(2,4,6-trimethoxybenzyl)ethanamine 2.53a:  
 
Following general procedure A, ethylamine (70 % in MeOH, 25.5 mmol, 5 equiv), 2,4,6-
trimethoxybenzaldehyde (1 g, 5.1 mmol, 1 equiv), were reacted in THF (10 mL)  for 4h with 4Å 
MS (2.5 g, 6.5 mmol.). NaBH4 (580 mg, 15.3 mmol, 3 equiv) in EtOH (6 mL) was carefully 
added and the mixture was stirred overnight.  The crude mixture was filtered through celite, 
acidified using a solution of HCl (0.1M) and stirred for 30 min. The mixture was then basified 
using NaOH solution (0.1M) and extracted three times using AcOEt. The combined organic 
layers were dried over sodium sulfate, filtered and evaporated under vacuum. The excess of 
starting material was removed under high vacuum. The crude mixture was purified by 
chromatography on silica gel using DCM/MeOH as eluent to provide oil N-(2,4,6-
trimethoxybenzyl)ethanamine as a yellowish oil (1.1 g, 4.90 mmol, 96 %). 
1H NMR (400 MHz, Chloroform-d) : δ =  6.11 (s, 2H), 3.79 (s, 3H), 3.78 (s, 6H), 3.76 (s, 2H), 
2.59 (q, J = 7.2 Hz, 2H), 1.65 (br s, 1H), 1.08 (t, J = 7.1 Hz, 3H). 
13C NMR (Chloroform-d, 101 MHz) :  δ = 160.3, 159.4, 109.5, 90.4, 55.7, 55.4, 43.2, 41.2, 
15.5. 
IR (neat): ν = 2953, 1581, 1473 cm-1. 
HRMS (ESI): Calculated for C12H20NO3 ([M+H]+): 226.1438; found: 226.1440 
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2-Methyl-N-(2,4,6-trimethoxybenzyl)propan-2-amine 2.55a: 
 
Following general procedure B, 2,4,6-trimethoxybenzaldehyde (1 g, 5.1 mmol, 1 equiv), tert-
butylamine (0.541 mL, 5.1 mmol, 1 equiv), AcOH (0.583 mL, 10.2 mmol, 2 equiv) and 
NaBH(OAc)3 (2.16 g, 10.2 mmol, 2equiv) were reacted in DCE (25 mL) overnight. Then, the 
mixture was quenched using a solution of NaOH (1M) and the crude mixture was stirred for 
further 30 min. The crude mixture was extracted twice with DCM, dried over sodium sulfate, 
filtered, evaporated under vacuum and purified by chromatography on silica gel using 
DCM/MeOH as eluent, yielding slighly yellow oil Sc (1.25 g, 5.0 mmol, 97 %). 
1H NMR (400 MHz, Chloroform-d): δ = 6.10 (s, 2H), 3.79 (s, 6H), 3.78 (s, 3H), 3.70 (s, 2H), 
1.43 (br.ns, 1H), 1.16 (s, 9H). 
 
13C NMR (Chloroform-d, 101 MHz) : δ = 160.2, 159.2, 110.3, 90.7, 55.7, 55.4, 50.6, 35.1, 29.2. 
IR (neat): ν = 2960, 1598, 1463, 1205 cm-1. 
HRMS (ESI): Calculated for C14H24NO3 ([M+H]+): 254.1751; found: 254.1753 
 
2-Phenyl-N-(2,4,6-trimethoxybenzyl)propan-2-amine 2.56a:  
 
Following general procedure B, 2,4,6-trimethoxybenzaldehyde (700 mg, 3.57 mmol, 1 equiv), 
cumylamine (483 mg, 3.57 mmol, 1 equiv), AcOH (0.408 mL, 7.14 mmol, 2 equiv) and 
NaBH(OAc)3 (1.51 g, 7.14 mmol, 2equiv) were reacted in DCE (15 mL) overnight. Then, the 
mixture was quenched using a solution of NaOH (1M) and the crude mixture was stirred for 
further 30 min. The crude mixture was extracted twice with DCM, dried over sodium sulfate, 
filtered, evaporated under vacuum and purified by chromatography on silica gel using 
DCM/MeOH as eluent, yielding slighly yellow oil Sd (1.02 g, 3.2 mmol, 90 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.57 – 7.47 (m, 2H), 7.33 (dd, J = 8.5, 7.0 Hz, 2H), 
7.24 – 7.17 (m, 1H), 6.07 (s, 2H), 3.75 (s, 3H), 3.75 (s, 6H), 3.45 (s, 2H), 1.52 (s, 6H). 
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13C NMR (101 MHz, Chloroform-d) δ = 160.2, 159.1, 148.0, 127.8, 126.1, 125.9, 109.8, 90.6, 
55.9, 55.6, 55.3, 35.5, 29.8. 
IR (neat): ν = 2961, 1596, 1460, 1127 cm-1. 
HRMS (ESI): Calculated for C19H26NO3 ([M+H]+): 316.1913; found: 316.1917 
 
(R)-3,3-Dimethyl-N-(2,4,6-trimethoxybenzyl)butan-2-amine 2.57a:  
 
Following general procedure B, 2,4,6-trimethoxybenzaldehyde (1 g, 5.1 mmol, 1 equiv), (R)-3,3-
dimethylbutan-2-amine (0.7 mL, 5.1 mmol, 1 equiv), AcOH (0.583 mL, 10.2 mmol, 2 equiv) and 
NaBH(OAc)3 (2.16 g, 10.2 mmol, 2equiv) were reacted in DCE (25 mL) overnight. Then, the 
mixture was quenched using a solution of NaOH (1M) and the crude mixture was stirred for 
further 30 min. The crude mixture was extracted twice with DCM, dried over sodium sulfate, 
filtered, evaporated under vacuum and purified by chromatography on silica gel using 
DCM/MeOH as eluent, yielding slighly yellow oil (1.4 g, 5.0 mmol, 98 %). 
1H NMR (400 MHz, Chloroform-d ) : δ = 6.11 (s, 2H), 3.88 – 3.71 (m, 11H), 2.09 (q, J = 6.4 
Hz, 1H), 1.83 (br s, 1H), 0.97 (d, J = 6.3 Hz, 3H), 0.81 (s, 9H). 
 
13C NMR (Chloroform-d, 101 MHz) :  δ =  = 160.1, 159.6, 109.6, 90.5, 60.4, 55.7, 55.4, 40.1, 
34.1, 26.6, 14.8. 
IR (neat): ν = 2954, 1607, 1140, 1204 cm-1. 
HRMS (ESI): Calculated for C16H28NO3 ([M+H]+): 282.2064; found: 282.2062 
 
(S)-N-(2,4,6-Trimethoxybenzyl)octan-2-amine 2.58a:  
 
Following general procedure B, 2,4,6-trimethoxybenzaldehyde (1.38  g, 7.03 mmol, 1 equiv), (S)-
octan-2-amine (1 g, 7.03 mmol, 1 equiv), AcOH (0.804 mL, 14.06 mmol, 2 equiv) and 
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NaBH(OAc)3 (2.98 g, 14.06 mmol, 2equiv) were reacted in DCE (14 mL) overnight. Then, the 
mixture was quenched using a solution of NaOH (1M) and the crude mixture was stirred for 
further 30 min. The crude mixture was extracted twice with DCM, dried over sodium sulfate, 
filtered, evaporated under vacuum and purified by chromatography on silica gel using 
DCM/MeOH as eluent, yielding slighly yellow oil  (1.8 g, 5.8 mmol, 83 %). 
1H NMR (400 MHz, Chloroform-d ) : δ =  6.08 (s, 2H), 3.84 – 3.72 (m, 11H), 2.71 – 2.62 (m, 
1H), 2.55 – 2.46 (m, 1H), 1.52 – 1.38 (m, 1H), 1.32 – 1.17 (m, 10H), 1.04 (d, J = 6.3 Hz, 3H), 
0.84 (t, J = 6.6 Hz, 3H). 
 
13C NMR (Chloroform-d, 101 MHz) :  δ =  = 160.3, 159.4, 108.8, 90.4, 55.6, 55.3, 51.7, 38.7, 
36.8, 32.0, 29.5, 26.0, 22.7, 20.2, 14.2. 
IR (neat): ν = 2933, 2820, 1623, 1156 cm-1. 
HRMS (ESI): Calculated for C18H32NO3 ([M+H]+): 310.2382; found: 310.2387 
 
(R)-1-Cyclohexyl-N-(2,4,6-trimethoxybenzyl)ethan-1-amine 2.59a:  
 
Following general procedure B, 2,4,6-trimethoxybenzaldehyde (1.38  g, 7.03 mmol, 1 equiv), R-
(-)-Cyclohexylethylamine (0.95 mL, 7.03 mmol, 1 equiv), AcOH (0.804 mL, 14.06 mmol, 2 
equiv) and NaBH(OAc)3 (2.98 g, 14.06 mmol, 2equiv) were reacted in DCE (14 mL) overnight. 
Then, the mixture was quenched using a solution of NaOH (1M) and the crude mixture was stirred 
for further 30 min. The crude mixture was extracted twice with DCM, dried over sodium sulfate, 
filtered, evaporated under vacuum and purified by chromatography on silica gel using 
DCM/MeOH as eluent, yielding slighly yellow oil  (1.95 g, 6.33 mmol, 90 %). 
1H NMR (400 MHz, Chloroform-d ) : δ =  6.11 (s, 2H), 3.83 – 3.72 (m, 11H), 2.37 – 2.29 (m, 
1H), 1.76 – 1.61 (m, 5H), 1.40 – 1.29 (m, 1H), 1.27 – 1.07 (m, 3H), 1.00 (d, J = 6.4 Hz, 3H), 
0.97 – 0.84 (m, 2H). 
13C NMR (Chloroform-d, 101 MHz) :  δ =  = 160.3, 159.5, 90.5, 56.5, 55.8, 55.4, 42.7, 39.1, 
29.9, 28.3, 26.9, 26.8, 26.7, 16.7. 
IR (neat): ν = 2923, 2850, 1603, 1149 cm-1. 
HRMS (ESI): Calculated for C18H30NO3 ([M+H]+): 308.2220; found: 308.2222 
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(R)-2-((2,4,6-Trimethoxybenzyl)amino)propan-1-ol 2.60aa:  
 
Following general procedure C, 2,4,6-trimethoxybenzaldehyde (1.5 g, 7.63 mmol, 1 equiv), L-
alaninol (573 mg, 7.63 mmol, 1 equiv) and Pd/C (812 mg, 10% w/w, 10 mol%) were reacted in 
MeOH (11 mL) and stirred overnight under H2 atmosphere. The crude mixture was then filtered 
through celite,  the solvent evaporated and the crude mixture purified by chromatography on 
silica gel to provide oil N-isopropyl-2,3-dihydro-1H-inden-2-amine (686 mg, 2.67 mmol, 35 %). 
1H NMR (400 MHz, Chloroform-d) δ = 6.10 (s, 2H), 3.81 (d, J = 12.5 Hz, 1H + NH), 3.78 – 3.77  
(m, 9H), 3.73 (d, J = 12.6 Hz, 1H), 3.59 (dd, J = 10.7, 4.0 Hz, 1H), 3.24 (dd, J = 10.7, 6.3 Hz, 1H), 
2.70 (td, J = 6.4, 4.0 Hz, 1H + OH), 1.02 (d, J = 6.5 Hz, 3H). 
 
13C NMR (101 MHz, Chloroform-d) δ = 160.4, 159.4, 108.9, 90.5, 65.1, 55.7, 55.4, 53.0, 38.5, 
17.4. 
IR (neat): ν = 3132, 2925, 2840, 1608, 1139 cm-1. 
HRMS (ESI): Calculated for C13H22NO4 ([M+H]+): 256.1543; found: 256.1544 
 
(R)-2-((2,4,6-Trimethoxybenzyl)amino)propyl pivalate 2.60a:  
 
(R)-2-((2,4,6-Trimethoxybenzyl)amino)propan-1-ol (300 mg, 1.18 mmol, 1 equiv) was dissolved 
in dichloromethane (6 mL) and cooled to 0 °C. Triethylamine (0.201 mL, 1.43 mmol, 1.2 equiv) 
and DMAP (7.2 mg, 0.06 mmol, 5 mol%) were added, followed by dropwise addition of pivaloyl 
chloride (0.163 mL, 1.3 mmol, 1.1 equiv). The reaction mixture was allowed to warm slowly to 
ambient temperature and stirred for 16 h. The reaction mixture was quenched with water (10 mL) 
and extracted with dichloromethane (2 x 10 mL).  The combined organic layers were dried over 
sodium sulfate, filtered and evaporated under vacuum. The residue was purified by 
chromatography on silica gel using DCM/MeOH as eluent to afford (R)-2-((2,4,6-
trimethoxybenzyl)amino)propyl pivalate as yellowish oil (200 mg, 0.58 mmol, 50 %). 
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1H NMR (400 MHz, Chloroform-d ) δ = 6.11 (s, 2H), 4.05 – 4.00 (m, 1H), 3.92 – 3.86 (m, 1H), 
3.82 (d, J = 5.5 Hz, 2H), 3.80 (s, 3H), 3.78 (s, 6H), 3.33 (br s, 1H), 2.90 – 2.80 (m, 1H), 1.17 (s, 
9H), 1.09 (d, J = 6.4 Hz, 3H). 
 
13C NMR (101 MHz, Chloroform-d) δ = 178.2, 160.4, 159.3, 108.6, 90.3, 68.3, 55.6, 55.3, 50.5, 
38.8, 38.5, 27.1, 16.9. 
IR (neat): ν = 2957, 1729, 1608, 1150 cm-1. 
HRMS (ESI): Calculated for C18H30NO5 ([M+H]+): 340.2118; found: 340.2119 
 
(S)-1-Phenyl-N-(2,4,6-trimethoxybenzyl)ethan-1-amine 2.61a:  
 
Following general procedure B, 2,4,6-trimethoxybenzaldehyde (1.38  g, 7.03 mmol, 1 equiv), (S)-
1-phenylethan-1-amine (900 mg, 7.03 mmol, 1 equiv), AcOH (0.804 mL, 14.06 mmol, 2 equiv) 
and NaBH(OAc)3 (2.98 g, 14.06 mmol, 2 equiv) were reacted in DCE (14 mL) overnight. Then, 
the mixture was quenched using a solution of NaOH (1M) and the crude mixture was stirred for 
further 30 min. The crude mixture was extracted twice with DCM, dried over sodium sulfate, 
filtered, evaporated under vacuum and purified by chromatography on silica gel using 
DCM/MeOH as eluent, yielding slighly yellow oil  (1.75 g, 5.8 mmol, 82 %). 
1H NMR (400 MHz, Chloroform-d ) : δ =  7.40 – 7.27 (m, 4H), 7.27 – 7.17 (m, 1H), 6.10 (s, 
2H), 3.79 (s, 3H), 3.75 (s, 6H), 3.66 (s, 2H), 2.15 (s, 1H), 1.33 (d, J = 6.6 Hz, 3H). 
 
13C NMR (Chloroform-d, 101 MHz) :  δ =  = 160.4, 159.5, 146.3, 128.2, 127.0, 126.7, 109.3, 
90.5, 57.3, 55.6, 55.4, 39.5, 24.5. 
IR (neat): ν = 2923, 2857, 1613 cm-1. 
HRMS (ESI): Calculated for C18H24NO3 ([M+H]+): 302.1756; found: 302.1758 
 
N-(Cyclopentylmethyl)propan-2-amine 2.63a:  
 
Following general procedure C, cyclopentanecarboxaldehyde (1 g, 10.2 mmol, 1 equiv), 
isopropylamine (0.874 mL, 10.2 mmol, 1 equiv) and Pd/C (1.09 g, 10% w/w, 10 mol%) were 
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reacted in MeOH (25 mL) and stirred overnight under H2 atmosphere. The crude mixture was 
then filtered through celite, and the solvent evaporated to provide oil N-
(cyclopentylmethyl)propan-2-amine as a yellowish oil (1.30 g, 9.18 mmol, 90 %). 
1H NMR (400 MHz, Chloroform-d ) : δ = 2.78 (hept, J = 6.2 Hz, 1H), 2.52 (d, J = 7.1 Hz, 2H), 
2.08 – 1.89 (m, 1H), 1.85 – 1.68 (m, 3H), 1.65 – 1.48 (m, 4H), 1.22 – 1.09 (m, 2H), 1.06 (d, J = 
6.2 Hz, 6H). 
 
13C NMR (Chloroform-d, 101 MHz):  δ = 53.3, 48.9, 40.1, 30.9, 25.2, 22.8. 
IR (neat): ν = 2953, 2867, 1452, 730 cm-1. 
HRMS (ESI): Calculated for C9H20N ([M+H]+): 142.1590; found: 142.1592 
 
N-(2,4,6-Trimethylbenzyl)propan-2-amine 2.64a:  
 
Following general procedure B, mesitaldehyde (500 mg, 3.37 mmol, 1 equiv), isopropylamine 
(0.577 mL, 6.74 mmol, 2 equiv), AcOH (0.385 mL, 6.74 mmol, 2 equiv) and NaBH(OAc)3 (1.58 
g, 6.74 mmol, 2equiv) were reacted in DCE (10 mL) overnight. Then, the mixture was quenched 
using a solution of NaOH (1M) and the crude mixture was stirred for further 30 min. The crude 
mixture was extracted twice with DCM, dried over sodium sulfate, filtered, evaporated under 
vacuum and purified by chromatography on silica gel using DCM/MeOH as eluent, yielding 
slighly yellow oil  (505 mg, 2.64 mmol, 78 %). 
1H NMR (400 MHz, Chloroform-d ): δ = 6.85 (s, 2H), 4.48 (d, J = 14.7 Hz, 1H), 4.34 (d, J = 
14.7 Hz, 1H), 3.47 – 3.40 (m, 1H), 3.01 (dd, J = 14.4, 5.0 Hz, 1H), 2.48 – 2.42 (m, 1H), 2.33 (s, 
6H), 2.26 (s, 3H), 1.06 (d, J = 6.1 Hz, 3H). 
 
13C NMR (Chloroform-d, 101 MHz):  δ = 166.8, 137.6, 137.4, 129.4, 128.5, 47.6, 44.1, 38.9, 
21.0, 20.1, 19.4. 
IR (neat): ν = 2965, 2361 cm-1. 
HRMS (ESI): Calculated for C13H22N ([M+H]+): 192.1747; found: 192.1749 
 
N-Benzylpropan-2-amine 2.65a:  
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Following general procedure A, isopropylamine (3.62 mL, 42.3 mmol, 3equiv), benzaldehyde 
(1.5 g, 14.1 mmol, 1 equiv) , were reacted in THF (10 mL)  for 4h with 4Å MS (5 g, 14 mmol). 
NaBH4 (1.6 g, 42.3 mmol, 3 equiv)in EtOH (10 mL) was carefully added and the mixture was 
stirred overnight.  The crude mixture was filtered through celite, acidified using a solution of 
HCl (0.1M) and stirred for 30 min. The mixture was then basified using NaOH solution (0.1M) 
and extracted three times using AcOEt. The combined organic layers were dried over sodium 
sulfate, filtered and evaporated under vacuum. The excess of starting material was removed under 
high vacuum. The crude mixture was purified by chromatography on silica gel using 
DCM/MeOH as eluent to provide oil N-benzylpropan-2-amine as a yellowish oil (400 mg, 2.68 
mmol, 19 %). 
1H NMR (400 MHz, Chloroform-d ): δ = 7.36 – 7.20 (m, 5H), 3.78 (s, 2H), 2.86 (hept, 1H), 1.46 
(br s, 1H), 1.10 (d, J = 6.3 Hz, 6H). 
 
13C NMR (Chloroform-d, 101 MHz):  δ =  = 140.9, 128.5, 128.2, 127.0, 51.8, 48.2, 23.0 
IR (neat): ν = 2964, 2362, 1453, 1171 cm-1. 
HRMS (ESI): Calculated for C10H16N ([M+H]+): 150.1283; found: 150.1284 
 
N-Phenethylpropan-2-amine 2.66a: 
 
Following general procedure C, acetone (1.17 mL, 15.9 mmol, 1 equiv), 2-phenylethan-1-amine (2 
mL, 15.9 mmol, 1 equiv) and Pd/C (1.69 g, 10% w/w, 10 mol%) were reacted in MeOH (15 mL) 
and stirred overnight under H2 atmosphere. The crude mixture was then filtered through celite, 
and the solvent evaporated to provide oil N-phenethylpropan-2-amine (2.4 g, 14.6 mmol, 92 %). 
1H NMR (400 MHz, Chloroform-d ): δ = 7.36 – 7.11 (m, 5H), 2.93 – 2.68 (m, 5H), 1.10 (br s, 
1H), 1.03 (d, J = 6.3 Hz, 6H). 
 
13C NMR (Chloroform-d, 101 MHz):  δ = 140.0, 128.6, 128.4, 126.0, 48.7, 48.5, 36.5, 22.9. 
IR (neat): ν = 2962, 2825, 1473, 1173, 697 cm-1. 
HRMS (ESI): Calculated for C11H18N ([M+H]+): 164.1434; found: 164.1437 
The physical and spectroscopic properties matched those described in the literature.12 
N-Isopropyl-3-phenylpropan-1-amine 2.67a:  
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Following general procedure B, 3-phenylpropionaldehyde (2 g, 14.9 mmol, 1 equiv),  
isopropylamine (3.83 mL, 44.7 mmol, 3 equiv), AcOH (1.7 mL, 29.8 mmol, 2 equiv) and 
NaBH(OAc)3 (6.32 g, 29.8 mmol, 2equiv) were reacted in DCE (75 mL) overnight. Then, the 
mixture was quenched using a solution of NaOH (1M) and the crude mixture was stirred for 
further 30 min. The crude mixture was extracted twice with DCM, dried over sodium sulfate, 
filtered, evaporated under vacuum and purified by chromatography on silica gel using 
DCM/MeOH as eluent, yielding slighly yellow oil  (2 g, 11.3 mmol, 76 %). 
1H NMR (400 MHz, Chloroform-d ): δ = 7.34 – 7.26 (m, 2H), 7.21 (d, J = 7.3 Hz, 3H), 2.80 
(hept, J = 6.3 Hz, 1H), 2.72 – 2.62 (m, 4H), 1.90 – 1.79 (m, 2H), 1.20 (br s, 1H), 1.07 (d, J = 6.3 
Hz, 6H). 
 
13C NMR (Chloroform-d, 101 MHz):  δ = 142.3, 128.5, 128.4, 125.9, 48.8, 47.3, 34.0, 32.2, 23.1. 
IR (neat): ν = 2964, 2861, 1473, 699 cm-1. 
HRMS (ESI): Calculated for C12H20N ([M+H]+): 178.1590; found: 178.1592 
 
The physical and spectroscopic properties matched those described in the literature. 13 
 
Ethyl 3-(isopropylamino)propanoate 2.68a:  
 
To a solution of isopropylamine (20 mmol, 1.18 g, 2.0 equiv) in ethanol (13 mL) at 0°C was 
added, via addition funnel, a solution of ethyl acrylate (10 mmol, 1 g, 1.0 equiv) in ethanol (7 
mL). The reaction mixture was allowed to warm to ambient temperature then stirred at ambient 
temperature for 24 h, and concentrated under vacuum. The excess of amine was removed under 
high vacuum to provide oil the pure desired compound (1.59 g, 10 mmol, 100 %).  
1H NMR (400 MHz, Chloroform-d ) : δ = 4.14 (q, J = 7.1 Hz, 2H), 2.92 – 2.72 (m, 3H), 2.49 
(t, J = 6.6 Hz, 2H), 1.33 – 1.21 (m, 4H), 1.05 (d, J = 6.2 Hz, 6H). 
13C NMR (Chloroform-d, 101 MHz):  δ = 172.8, 60.3, 48.4, 42.5, 35.0, 22.9, 14.2. 
IR (neat): ν = 1732 1191 cm-1. 
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HRMS (ESI): Calculated for C8H18NO2 ([M+H]+): 160.1332; found: 160.1331 
The physical and spectroscopic properties matched those described in the literature. 14 
2-(3-(Isopropylamino)propyl)isoindoline-1,3-dione 2.69a:  
 
 
3-Phthalimidopropionaldehyde was prepared following an analogous procedure described by 
Livinghouse and co-worker. Acroleine (561 mg, 10 mmol, 1equiv) and phthalimide (1.47 g, 10 
mmol, 1equiv) were suspended in AcOEt (6.5 mL) and stirred at 65 °C for 10 min. Then, Triton 
B (40 % solution of benzyltrimethylammonium hydroxide in MeOH, 90 μL, 0.2 mmol, 2 mol%) 
was added to the solution, which was further stirred for 20 min. The mixture was then cooled 
to rt, the solvent removed under vacuum and the resulting yellowish solid triturated with Et2O. 
The resulting solid was then filtered to provide oil 3-phthalimidopropionaldehyde (2.02 g, 10 
mmol, 100 %). Then, following general procedure C, 3-phthalimidopropionaldehyde (2.02 g, 
10 mmol, 1 equiv), isopropylamine (0.852 mL, 10 mmol, 1 equiv) and Pd/C (1.06 g, 10% w/w, 
10 mol%) were reacted in MeOH (25 mL) and stirred overnight under H2 atmosphere. The crude 
mixture was then filtered through celite, and the solvent evaporated to provide oil 2-(3-
(isopropylamino)propyl)isoindoline-1,3-dione as a yellowish oil (1.84 g, 7.5 mmol, 75 %). 
1H NMR (400 MHz, Chloroform-d ) : δ = 7.88 – 7.81 (m, 2H), 7.76 – 7.66 (m, 2H), 3.76 (t, J 
= 6.8 Hz, 2H), 2.75 (hept, J = 6.2 Hz, 1H), 2.62 (t, J = 7.0 Hz, 2H), 1.94 – 1.79 (m, 3H), 1.03 (d, 
J = 6.2 Hz, 6H). 
13C NMR (Chloroform-d, 101 MHz) :  δ =   168.5, 133.9, 132.2, 123.2, 48.7, 44.3, 36.0, 29.2, 
22.9. 
IR (neat): ν = 1773, 1705, 1468, 1442 cm-1. 
HRMS (ESI): Calculated for C14H19N2O2 ([M+H]+): 247.1441; found: 247.1442 
The physical and spectroscopic properties matched those described in the literature. 15 
2-Methyl-N-(3-phenylpropyl)butan-2-amine 2.70a:  
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Following general procedure B, 3-phenylpropionaldehyde (1 g, 7.45 mmol, 1 equiv), tert-
amylamine (2.61 mL, 22.4 mmol, 3 equiv), AcOH (0.852 mL, 14.9 mmol, 2 equiv) and 
NaBH(OAc)3 (3.16 g, 14.9 mmol, 2equiv) were reacted in DCE (37 mL) overnight. Then, the 
mixture was quenched using a solution of NaOH (1M) and the crude mixture was stirred for 
further 30 min. The crude mixture was extracted twice with DCM, dried over sodium sulfate, 
filtered, evaporated under vacuum and purified by chromatography on silica gel using 
DCM/MeOH as eluent, yielding slighly yellow oil  (1.35 g, 6.57 mmol, 88 %). 
1H NMR (400 MHz, Chloroform-d): δ = 7.34 – 7.13 (m, 5H), 3.73 (s, 1H), 2.72 – 2.62 (m, 2H), 
2.60 – 2.47 (m, 2H), 1.86 – 1.69 (m, 2H), 1.47 – 1.32 (m, 2H), 1.01 (s, 6H), 0.82 (t, J = 7.5 Hz, 
3H). 
 
13C NMR (Chloroform-d, 101 MHz) :  δ =  = 142.2, 128.3, 128.2, 125.6, 52.3, 41.5, 33.8, 33.0, 
32.6, 26.5, 8.2. 
IR (neat): ν = 3028, 2935, 1475, 1442 cm-1. 
HRMS (ESI): Calculated for C14H24N ([M+H]+): 206.1903; found: 206.1902 
 
3-Phenyl-N-(2-phenylpropan-2-yl)propan-1-amine 2.71a:  
 
Following general procedure B, phenylpropionaldehyde (500 mg, 3.73 mmol, 1 equiv), 
cumylamine (504 mg, 3.73 mmol, 1 equiv), AcOH (0.427 mL, 7.46 mmol, 2 equiv) and 
NaBH(OAc)3 (1.58 g, 7.1 mmol, 2equiv) were reacted in DCE (19 mL) overnight. Then, the 
mixture was quenched using a solution of NaOH (1M) and the crude mixture was stirred for 
further 30 min. The crude mixture was extracted twice with DCM, dried over sodium sulfate, 
filtered, evaporated under vacuum and purified by chromatography on silica gel using 
DCM/MeOH as eluent, yielding slighly yellow oil  (832 mg, 3.28 mmol, 88 %). 
1H NMR (400 MHz, Chloroform-d ) : δ =  7.46 – 7.41 (m, 2H), 7.36 – 7.30 (m, 2H), 7.27 – 
7.19 (m, 3H), 7.18 – 7.10 (m, 3H), 2.62 – 2.55 (m, 2H), 2.38 (t, J = 7.1 Hz, 2H), 1.82 – 1.70 (m, 
2H), 1.47 (s, 6H). 
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13C NMR (Chloroform-d, 101 MHz) :  δ  = 142.3, 128.5, 128.4, 128.3, 126.4, 125.9, 125.8, 56.2, 
42.8, 33.8, 32.5, 29.6. 
IR (neat): ν = 3026, 2928, 1495, 1452, 699 cm-1. 
HRMS (ESI): Calculated for C18H24N ([M+H]+): 254.1903; found: 254.1908 
 
N-(tert-Butyl)-3,7-dimethyloct-6-en-1-amine 2.72a: 
 
Following general procedure B, (±)-citronellal (1.66 g, 10 mmol, 1 equiv), tert-butylamine (1.06 
mL, 10 mmol, 1 equiv), AcOH (1.14 mL, 20 mmol, 2 equiv) and NaBH(OAc)3 (4.23 g, 20 mmol, 
2equiv) were reacted in DCE (25 mL) overnight. Then, the mixture was quenched using a 
solution of NaOH (1M) and the crude mixture was stirred for further 30 min. The crude mixture 
was extracted twice with DCM, dried over sodium sulfate, filtered, evaporated under vacuum 
and purified by chromatography on silica gel using DCM/MeOH as eluent, yielding slighly 
yellow oil  (1.77 g, 8.4 mmol, 84 %). 
1H NMR (400 MHz, Chloroform-d ) : δ = 5.08 – 4.99 (m, 1H), 2.59 – 2.38 (m, 2H), 1.99 – 1.85 
(m, 2H), 1.62 (d, J = 1.3 Hz, 3H), 1.53 (s, 3H), 1.48 – 1.07 (m, 6H), 1.04 (s, 9H), 0.83 (d, J = 6.3 
Hz, 3H). 
 
13C NMR (Chloroform-d, 101 MHz) :  δ =   131.1, 124.9, 50.3, 40.4, 38.3, 37.3, 30.8, 29.1, 25.8, 
25.5, 19.7, 17.7. 
IR (neat): ν = 2964, 2917, 2362, 1449, 731 cm-1. 
HRMS (ESI): Calculated for C14H30N ([M+H]+): 212.2378; found: 212.2379 
 
N-(((1S,5R)-6,6-dimethylbicyclo[3.1.1]hept-2-en-3-yl)methyl)-2-methylpropan-2-amine 
2.73a:  
 
Following general procedure B, (-)-myrtenal (800 mg, 5.33 mmol, 1 equiv), tert-butylamine 
(0.565 mL, 5.33 mmol, 1 equiv), AcOH (0.610 mL, 10.7 mmol, 2 equiv) and NaBH(OAc)3 (2.26 
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g, 10.7 mmol, 2equiv) were reacted in DCE (25 mL) overnight. Then, the mixture was quenched 
using a solution of NaOH (1M) and the crude mixture was stirred for further 30 min. The crude 
mixture was extracted twice with DCM, dried over sodium sulfate, filtered, evaporated under 
vacuum and purified by chromatography on silica gel using DCM/MeOH as eluent, yielding 
slighly yellow oil  (970 mg, 4.69 mmol, 88 %). 
1H NMR (400 MHz, Chloroform-d ): δ = 5.41 – 5.35 (m, 1H), 3.12 – 3.02 (m, 2H), 2.36 (dt, J = 
8.5, 5.6 Hz, 1H), 2.30 – 2.15 (m, 2H), 2.06 (dd, J = 5.7, 1.6 Hz, 2H), 1.26 (s, 3H), 1.18 (d, J = 8.6 
Hz, 1H), 1.12 (s, 9H), 0.81 (s, 3H). 
 
13C NMR (Chloroform-d, 101 MHz):  δ = 146.6, 117.1, 50.9, 47.9, 45.1, 41.0, 38.2, 31.7, 31.3, 
28.9, 26.4, 21.2. 
 
IR (neat): ν = 2960, 2913, 1483, 733 cm-1. 
HRMS (ESI): Calculated for C14H26N ([M+H]+): 208.2060; found: 208.2061 
 
(S)-2-Methyl-N-((4-(prop-1-en-2-yl)cyclohex-1-en-1-yl)methyl)propan-2-amine 2.74a: 
 
Following general procedure B, (-)-perillaldehyde (1.5 g, 10 mmol, 1 equiv), tert-butylamine (1.06 
mL, 10 mmol, 1 equiv), AcOH (1.15 mL, 20 mmol, 2 equiv) and NaBH(OAc)3 (4.23 g, 20 mmol, 
2equiv) were reacted in DCE (25 mL) overnight. Then, the mixture was quenched using a 
solution of NaOH (1M) and the crude mixture was stirred for further 30 min. The crude mixture 
was extracted twice with DCM, dried over sodium sulfate, filtered, evaporated under vacuum 
and purified by chromatography on silica gel using DCM/MeOH as eluent, yielding slighly 
yellow oil  (1.84 g, 8.9 mmol, 89 %). 
1H NMR (400 MHz, Chloroform-d ): δ = 5.64 – 5.57 (m, 1H), 4.73 – 4.64 (m, 2H), 3.13 – 3.00 
(m, 2H), 2.19 – 2.04 (m, 4H), 2.00 – 1.89 (m, 1H), 1.87 – 1.76 (m, 1H), 1.75 – 1.70 (m, 3H), 1.59 – 
1.35 (m, 2H), 1.11 (s, 9H). 
 
13C NMR (Chloroform-d, 101 MHz) :  δ =   150.2, 136.7, 121.5, 108.6, 50.6, 48.8, 41.4, 30.8, 
29.1, 28.1, 20.9. 
IR (neat): ν = 2960, 2922, 1463, 790 cm-1. 
HRMS (ESI): Calculated for C14H26NO ([M+H]+): 208.2060; found: 208.2062 
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1-Cyclopropyl-N-(2,4,6-trimethoxybenzyl)methanamine 2.76a:  
 
Following general procedure B, 2,4,6-trimethoxybenzaldehyde (1 g, 5.1 mmol, 1 equiv), 
cyclopropylmethanamine (0.445 mL, 5.1 mmol, 1 equiv), AcOH (0.583 mL, 10.2 mmol, 2 equiv) 
and NaBH(OAc)3 (2.16 g, 10.2 mmol, 2equiv) were reacted in DCE (25 mL) overnight. Then, the 
mixture was quenched using a solution of NaOH (1M) and the crude mixture was stirred for 
further 30 min. The crude mixture was extracted twice with DCM, dried over sodium sulfate, 
filtered, evaporated under vacuum and purified by chromatography on silica gel using 
DCM/MeOH as eluent, yielding slighly yellow oil  (1.25 g, 5.0 mmol, 98 %). 
1H NMR (400 MHz, Chloroform-d ): δ = 6.10 (s, 2H), 3.81 – 3.75 (m, 11H), 2.44 (br s, 1H), 2.41 
(d, J = 7.0 Hz, 2H), 1.03 – 0.92 (m, 1H), 0.47 – 0.39 (m, 2H), 0.10 – 0.02 (m, 2H). 
 
13C NMR (Chloroform-d, 101 MHz) :  δ =   160.4, 159.4, 109.0, 90.5, 55.7, 55.4, 54.1, 41.3, 
11.4, 3.5. 
IR (neat): ν = 3000, 2362, 1604, 1459, 1130 cm-1. 
HRMS (ESI): Calculated for C14H22NO3 ([M+H]+): 252.1594; found: 252.1597 
 
1,1-Dicyclopropyl-N-(2,4,6-trimethoxybenzyl)methanamine 2.77a: 
 
Following general procedure B, 2,4,6-trimethoxybenzaldehyde (697 mg, 3.55 mmol, 1 equiv), 
dicyclopropylmethanamine (395 mg, 3.55 mmol, 1 equiv), AcOH (0.406 mL, 7.1 mmol, 2 equiv) 
and NaBH(OAc)3 (1.5 g, 7.1 mmol, 2equiv) were reacted in DCE (18 mL) overnight. Then, the 
mixture was quenched using a solution of NaOH (1M) and the crude mixture was stirred for 
further 30 min. The crude mixture was extracted twice with DCM, dried over sodium sulfate, 
filtered, evaporated under vacuum and purified by chromatography on silica gel using 
DCM/MeOH as eluent, yielding slighly yellow oil  (847 mg, 2.91 mmol, 82 %). 
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1H NMR (400 MHz, Chloroform-d ) : δ =  6.08 (s, 2H), 3.86 (s, 2H), 3.81 – 3.75 (m, 9H), 1.04 
(t, J = 8.6 Hz, 1H), 0.96 – 0.85 (m, 2H), 0.48 – 0.37 (m, 4H), 0.20 – 0.07 (m, 4H). 
 
13C NMR (Chloroform-d, 101 MHz) :  δ = 160.3, 159.3, 109.0, 90.4, 67.0, 55.6, 55.4, 40.2, 16.2, 
2.8, 2.2 . 
IR (neat): ν = 3001, 2939, 1604, 1459, 1149 cm-1. 
HRMS (ESI): Calculated for C17H26NO3 ([M+H]+): 292.1907; found: 292.1911 
 
N-Isopropyl-2,3-dihydro-1H-inden-2-amine S2.78a:  
 
Following general procedure C, acetone (0.276 mL, 3.75 mmol, 1 equiv), 2,3-dihydro-1H-inden-
2-amine (500 mg, 3.75 mmol, 1 equiv) and Pd/C (400 mg, 10% w/w, 10 mol%) were reacted in 
MeOH (7 mL) and stirred overnight under H2 atmosphere. The crude mixture was then filtered 
through celite, and the solvent evaporated to provide oil N-isopropyl-2,3-dihydro-1H-inden-2-
amine (526 mg, 3 mmol, 80 %). 
1H NMR (400 MHz, Chloroform-d ): δ = 7.22 – 7.17 (m, 2H), 7.17 – 7.11 (m, 3H), 3.74 (p, J = 
7.1 Hz, 1H), 3.18 (dd, J = 15.4, 7.1 Hz, 2H), 2.98 (hept, J = 6.2 Hz, 1H), 2.72 (dd, J = 15.4, 7.1 Hz, 
2H), 1.27 (br s, 1H), 1.10 (d, J = 6.3 Hz, 6H). 
 
13C NMR (Chloroform-d, 101 MHz) :  δ = 141.9, 126.5, 124.8, 57.1, 46.6, 40.5, 23.3. 
IR (neat): ν = 2962, 1475, 1175, 741 cm-1. 
HRMS (ESI): Calculated for C12H18N ([M+H]+): 176.1434; found: 176.1437 
 
N-(2,4,6-Trimethoxybenzyl)-2,3-dihydro-1H-inden-2-amine 2.79a:  
 
Following general procedure C, 2,4,6-trimethoxybenzaldehyde (447 mg, 2.28 mmol, 1 equiv), 
2,3-dihydro-1H-inden-2-amine (304 mg, 2.28 mmol, 1 equiv) and Pd/C (243 mg, 10% w/w, 10 
mol%) were reacted in MeOH (10 mL) and stirred overnight under H2 atmosphere. The crude 
mixture was then filtered through celite, the solvent evaporated and purified by chromatography 
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on silica gel to provide oil N-(2,4,6-trimethoxybenzyl)-2,3-dihydro-1H-inden-2-amine (215 mg, 
0.684 mmol, 30 %). 
1H NMR (400 MHz, Chloroform-d ): δ = 7.21 – 7.07 (m, 4H), 6.12 (s, 2H), 3.84 (s, 2H), 3.81 (s, 
9H), 3.60 (p, J = 6.9 Hz, 1H), 3.15 (dd, J = 15.6, 7.1 Hz, 2H), 2.79 (dd, J = 15.6, 6.8 Hz, 2H), 1.73 
(br s, 1H). 
 
13C NMR (Chloroform-d, 101 MHz) :  δ =  160.4, 159.4, 142.4, 126.3, 124.7, 109.4, 90.5, 58.8, 
55.8, 55.5, 40.4, 39.9. 
IR (neat): ν = 2937, 2361, 1597, 1131cm-1. 
HRMS (ESI): Calculated for C19H24NO3 ([M+H]+): 314.1751; found: 314.1754 
 
N-(2,4,6-Trimethoxybenzyl)-1,2,3,4-tetrahydronaphthalen-1-amine 2.80a:  
 
Following general procedure B, 2,4,6-trimethoxybenzaldehyde (691 mg, 3.52 mmol, 1 equiv), 
1,2,3,4-tetrahydronaphthalen-1-amine (518 mg, 3.52 mmol, 1 equiv), AcOH (0.403 mL, 7.04 
mmol, 2 equiv) and NaBH(OAc)3 (1.49 g, 7.04 mmol, 2 equiv) were reacted in DCE (10 mL) 
overnight. Then, the mixture was quenched using a solution of NaOH (1M) and the crude mixture 
was stirred for further 30 min. The crude mixture was extracted twice with DCM, dried over 
sodium sulfate, filtered, evaporated under vacuum, yielding slighly yellow oil  (950 mg, 2.9 
mmol, 83 %). 
1H NMR (250 MHz, Chloroform-d) δ = 7.11 – 7.02 (m, 4H), 6.15 (s, 2H), 3.88 (d, J = 1.8 Hz, 
2H), 3.82 (s, 9H), 3.72 – 3.66 (m, 1H), 2.90 – 2.61 (m, 2H), 2.12 – 1.95 (m, 3H), 1.87 – 1.61 (m, 
2H). 
 
13C NMR (63 MHz, Chloroform-d) δ = 160.4, 159.6, 140.0, 137.8, 129.0, 128.8, 126.4, 125.7, 
109.7, 90.7, 55.8, 55.5, 54.2, 39.4, 29.7, 28.0, 19.0. 
IR (neat): ν = 2936, 2361, 1607, 1131 cm-1. 
HRMS (ESI): Calculated for C20H26NO3 ([M+H]+): 328.1907; found: 328.1912 
 
(R)-N-(2,4,6-Trimethoxybenzyl)-1,2,3,4-tetrahydronaphthalen-1-amine 2.98a:  
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Following general procedure B, 2,4,6-trimethoxybenzaldehyde (2.67 g, 13.6 mmol, 1 equiv), (R)-
1,2,3,4-tetrahydronaphthalen-1-amine (2 g, 13.6 mmol, 1 equiv), AcOH (1.56 mL, 27.2 mmol, 2 
equiv) and NaBH(OAc)3 (5.76 g, 27.2 mmol, 2 equiv) were reacted in DCE (30 mL) overnight. 
Then, the mixture was quenched using a solution of NaOH (1M) and the crude mixture was stirred 
for further 30 min. The crude mixture was extracted twice with DCM, dried over sodium sulfate, 
filtered, evaporated under vacuum, yielding slighly yellow oil (4.45 g, 13.6 mmol, 100 %). 
1H NMR (250 MHz, Chloroform-d) δ = 7.13 – 7.00 (m, 4H), 6.15 (s, 2H), 3.88 (d, J = 1.8 Hz, 
2H), 3.82 (s, 9H), 3.72 – 3.65 (m, 1H), 2.94 – 2.59 (m, 2H), 2.22 – 1.93 (m, 3H), 1.88 – 1.51 (m, 
2H). 
13C NMR (63 MHz, Chloroform-d) δ = 160.4, 159.6, 140.0, 137.8, 129.0, 128.8, 126.4, 125.7, 
109.7, 90.7, 55.8, 55.5, 54.2, 39.4, 29.7, 28.0, 19.0. 
 
IR (neat): ν = 2938, 2355, 1635, 1115 cm-1. 
HRMS (ESI): Calculated for C20H26NO3 ([M+H]+): 328.1907; found: 328.1912 
 
N-(2,4,6-trimethoxybenzyl)pentan-3-amine 2.83a:  
 
 
 
Following general procedure B, 2,4,6-trimethoxybenzaldehyde (1 g, 5.1 mmol, 1 equiv), Pentan-
3-amine (0.88 g, 10.2 mmol, 2 equiv), AcOH (0.58 mL, 10.2 mmol, 2 equiv) and NaBH(OAc)3 
(2.16 g, 10.2 mmol, 2 equiv) were reacted in DCE (25 mL) overnight. Then, the mixture was 
quenched using a solution of NaOH (1M) and the crude mixture was stirred for further 30 min. 
The crude mixture was extracted twice with DCM, dried over sodium sulfate, filtered, evaporated 
under vacuum, yielding slighly yellow oil  (1.02 g, 3.8 mmol, 75 %). 
1H NMR (400 MHz, Chloroform-d) δ = 6.07 (s, 2H), 3.76 (s, 3H), 3.76 (s, 6H), 3.71 (s, 2H), 2.20 (p, J = 
6.0 Hz, 1H), 1.91 (s, 1H), 1.46 – 1.26 (m, 4H), 0.81 (t, J = 7.5 Hz, 6H). 
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13C NMR (101 MHz, Chloroform-d) δ = 160.2, 159.4, 109.7, 90.5, 59.3, 55.7, 55.4, 38.8, 26.1, 10.2. 
  
IR (neat): ν = 2928, 2840, 1623, 1139 cm-1. 
HRMS (ESI): Calculated for C20H26NO3 ([M+H]+): 269.1913; found: 269.1917 
 
Synthesis of carbamoyl chlorides 
The carbamoyl chlorides were not submitted to heating. The carbamoyl chlorides were 
freshly used and stored in a freezer (–30 °C). The yield of the reaction did not show any loss 
of efficiency after storing in the freezer for several days. 
Isopropyl(2,4,6-trimethoxybenzyl)carbamoyl chloride 2.54c: 
 
Following general procedure for the synthesis of carbamoyl chlorides, N-(2,4,6-
trimethoxybenzyl)propan-2-amine (800 mg, 3.34 mmol 1 equiv) dissolved in dry benzene (8 mL, 
0.4M) and Et3N (0.560 mL, 4.01 mmol, 1.2 equiv) were slowly added to a stirred solution of 
triphosgene (337 mg, 1.14 mmol, 0.34 equiv) in dry benzene (8 mL, 0.4M) at 0 °C . The mixture 
was then slowly allowed to reach rt and was stirred overnight. The crude mixture was then 
quenched with HCl solution (1M) and extracted twice with DCM. The combined organic layers 
were dried over sodium sulfate, filtered and evaporated under vacuum. The excess of benzene 
was removed by coevaporation with CHCl3.  The desired carbamoyl chloride was obtained as a 
grey solid (792 mg, 2.74 mmol, 82 %) and used without further purification. 
1H NMR (400 MHz, Chloroform-d) δ = 6.11 (s, 2H), 4.72 (s, 2H), 3.83 – 3.82 (m, 9H), 3.57 
(sept, J = 6.8 Hz, 1H), 1.11 (d, J = 6.8 Hz, 6H). 
 
Ethyl(2,4,6-trimethoxybenzyl)carbamoyl chloride 2.53c: 
  
Following general procedure for the synthesis of carbamoyl chlorides, N-(2,4,6-
trimethoxybenzyl)ethanamine (401 mg, 1.78 mmol, 1 equiv) dissolved in dry benzene (4.5 mL, 
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0.4M) and Et3N (0.301 mL, 2.14 mmol, 1.2 equiv) were slowly added to a stirred solution of 
triphosgene (180 mg, 0.60 mmol, 0.34 equiv) in dry benzene (4.5 mL, 0.4M) at 0 °C . The mixture 
was then slowly allowed to reach rt and was stirred overnight. The crude mixture was then 
quenched with HCl solution (1M) and extracted twice with DCM. The combined organic layers 
were dried over sodium sulfate, filtered and evaporated under vacuum. The excess of benzene 
was removed by coevaporation with CHCl3.  The desired carbamoyl chloride was obtained as a 
white solid (472 mg, 1.64 mmol, 92 %) and used without further purification. 
1H NMR (400 MHz, Chloroform-d) δ = 6.11 (s, 2H), 4.69 – 4.66 (m, 2H), 3.82 (s, 3H), 3.81 (s, 
6H), 3.31 – 3.17 (m, 2H), 1.06 – 1.01 (m, 3H). 
Tert-butyl(2,4,6-trimethoxybenzyl)carbamoyl chloride 2.55c: 
  
Following general procedure for the synthesis of carbamoyl chlorides, 2-methyl-N-(2,4,6-
trimethoxybenzyl)propan-2-amine (400 mg, 1.58 mmol, 1 equiv) dissolved in dry benzene (4 
mL, 0.4M) and Et3N (0.267 mL, 1.90 mmol, 1.2 equiv) were slowly added to a stirred solution 
of triphosgene (159 mg, 0.537 mmol, 0.34 equiv) in dry benzene (4 mL, 0.4M) at 0 °C . The 
mixture was then slowly allowed to reach rt and was stirred overnight. The crude mixture was 
then quenched with HCl solution (1M) and extracted twice with DCM. The combined organic 
layers were dried over sodium sulfate, filtered and evaporated under vacuum. The excess of 
benzene was removed by coevaporation with CHCl3.  The desired carbamoyl chloride was 
obtained as a yellowish oil (229 mg, 0.73 mmol, 46 %) and used without further purification. 
1H NMR (250 MHz, Chloroform-d) δ = 6.07 (s, 2H), 4.12 – 4.04 (m, 2H), 3.87 (s, 6H), 3.78 
(s, 3H), 1.33 (s, 9H). 
(2-Phenylpropan-2-yl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 2.56c: 
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Following general procedure for the synthesis of carbamoyl chlorides, 2-phenyl-N-(2,4,6-
trimethoxybenzyl)propan-2-amine (400 mg, 1.27 mmol, 1 equiv) dissolved in dry benzene (3.8 
mL, 0.4M) and Et3N (0.214 mL, 1.52 mmol, 1.2 equiv) were slowly added to a stirred solution 
of triphosgene (128 mg, 0.432 mmol, 0.34 equiv) in dry benzene (3.8 mL, 0.4M) at 0 °C . The 
mixture was then slowly allowed to reach rt and was stirred overnight. The crude mixture was 
then quenched with HCl solution (1M) and extracted twice with DCM. The combined organic 
layers were dried over sodium sulfate, filtered and evaporated under vacuum. The excess of 
benzene was removed by coevaporation with CHCl3.  The desired carbamoyl chloride was 
obtained as an orange oil (341 mg, 0.9 mmol, 71 %) and used without further purification. 
1H NMR (400 MHz, Chloroform-d) δ = 7.70 – 7.61 (m, 2H), 7.41 – 7.36 (m, 3H), 5.93 (s, 2H), 
3.81 (s, 6H), 3.70 (s, 3H), 1.83 (s, 6H). 
(S)-(3,3-Dimethylbutan-2-yl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 2.57c: 
 
Following general procedure for the synthesis of carbamoyl chlorides, (S)-3,3-dimethyl-N-
(2,4,6-trimethoxybenzyl)butan-2-amine (300 mg, 1.07 mmol, 1 equiv) dissolved in dry benzene 
(2.7 mL, 0.4M) and Et3N (0.180 mL, 1.28 mmol, 1.2 equiv) were slowly added to a stirred 
solution of triphosgene (108 mg, 0.367 mmol, 0.34 equiv) in dry benzene (2.7 mL, 0.4M) at 0 
°C . The mixture was then slowly allowed to reach rt and was stirred overnight. The crude 
mixture was then quenched with HCl solution (1M) and extracted twice with DCM. The 
combined organic layers were dried over sodium sulfate, filtered and evaporated under vacuum. 
The excess of benzene was removed by coevaporation with CHCl3.  The desired carbamoyl 
chloride was obtained as a greenish solid (304 mg, 0.89 mmol, 84 %) and used without further 
purification. 
1H NMR (400 MHz, Chloroform-d) δ = 6.16 – 6.10 (m, 2H), 5.04 – 4.45 (m, 2H), 3.87 – 3.78 
(m, 9H), 3.16 – 2.35 (m, 1H), 1.42 – 1.02 (m, 3H), 0.99 – 0.90 (m, 9H). 
(cyclopropylmethyl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 2.76c: 
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Following general procedure for the synthesis of carbamoyl chlorides, 1-cyclopropyl-N-(2,4,6-
trimethoxybenzyl)methanamine (400 mg, 1.59 mmol 1 equiv) dissolved in dry benzene (4 mL, 
0.4M) and Et3N (0.268 mL, 1.91 mmol, 1.2 equiv) were slowly added to a stirred solution of 
triphosgene (161 mg, 0.541 mmol, 0.34 equiv) in dry benzene (4 mL, 0.4M) at 0 °C. The mixture 
was then slowly allowed to reach rt and was stirred overnight. The crude mixture was then 
quenched with HCl solution (1M) and extracted twice with DCM. The combined organic layers 
were dried over sodium sulfate, filtered and evaporated under vacuum. The excess of benzene 
was removed by coevaporation with CHCl3.  The desired carbamoyl chloride was obtained as a 
yellow oil (428 mg, 1.36 mmol, 86 %) and used without further purification. 
1H NMR (250 MHz, Chloroform-d) δ = 6.10 (s, 2H), 4.77 – 4.71 (m, 2H), 3.80 (s, 3H), 3.79 (s, 
9H), 3.09 – 3.01 (m, 2H), 1.21 (m, 1H), 0.51 – 0.35 (m, 2H), 0.27 – 0.10 (m, 2H). 
 
(S)-Octan-2-yl(2,4,6-trimethoxybenzyl)carbamoyl chloride 2.58c: 
 
Following general procedure for the synthesis of carbamoyl chlorides, (S)-N-(2,4,6-
trimethoxybenzyl)octan-2-amine (400 mg, 2.45 mmol, 1 equiv) dissolved in dry benzene (7.5 
mL, 0.4M) and Et3N (0.413 mL, 2.94 mmol, 1.2 equiv) were slowly added to a stirred solution 
of triphosgene (247 mg, 0.833 mmol, 0.34 equiv) in dry benzene (7.5 mL, 0.4M) at 0 °C . The 
mixture was then slowly allowed to reach rt and was stirred overnight. The crude mixture was 
then quenched with HCl solution (1M) and extracted twice with DCM. The combined organic 
layers were dried over sodium sulfate, filtered and evaporated under vacuum. The excess of 
benzene was removed by coevaporation with CHCl3.  The desired carbamoyl chloride was 
obtained as a yellowish solid (515 mg, 2.28 mmol, 93 %) and used without further purification. 
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1H NMR (400 MHz, Chloroform-d) δ = 6.12 – 6.10 (m, 2H), 4.78 – 4.64 (m, 2H), 3.82 (s, 3H), 
3.82 (s, 6H), 3.32 (dt, J = 8.1, 6.4 Hz, 1H), 1.84 – 1.72 (m, 1H), 1.46 – 1.33 (m, 1H), 1.30 – 1.10 
(m, 8H), 1.05 (d, J = 6.7 Hz, 3H), 0.86 (t, J = 7.0 Hz, 3H). 
 
 
(R)-(1-Cyclohexylethyl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 2.59c: 
 
Following general procedure for the synthesis of carbamoyl chlorides, (R)-1-cyclohexyl-N-
(2,4,6-trimethoxybenzyl)ethan-1-amine (600 mg, 1.95 mmol, 1 equiv) dissolved in dry benzene 
(5.0 mL, 0.4M) and Et3N (0.329 mL, 2.34 mmol, 1.2 equiv) were slowly added to a stirred 
solution of triphosgene (197 mg, 0.663 mmol, 0.34 equiv) in dry benzene (5.0 mL, 0.4M) at 0 
°C . The mixture was then slowly allowed to reach rt and was stirred overnight. The crude 
mixture was then quenched with HCl solution (1M) and extracted twice with DCM. The 
combined organic layers were dried over sodium sulfate, filtered and evaporated under vacuum. 
The excess of benzene was removed by coevaporation with CHCl3.  The desired carbamoyl 
chloride was obtained as a red oil (528 mg, 1.42 mmol, 73 %) and used without further 
purification. 
1H NMR (400 MHz, Chloroform-d) δ = 6.11 (s, 2H), 4.82 (d, J = 14.2 Hz, 1H), 4.57 (d, J = 14.1 
Hz, 1H), 3.82 (s, 3H), 3.81 (s, 6H), 2.89 (dq, J = 10.2, 6.7 Hz, 1H), 1.96 – 1.85 (m, 1H), 1.78 – 
1.60 (m, 4H), 1.26 – 1.04 (m, 4H), 1.00 (d, J = 6.8 Hz, 3H), 0.75 – 0.52 (m, 2H). 
(R)-2-((Chlorocarbonyl)(2,4,6-trimethoxybenzyl)amino)propyl pivalate 2.60c: 
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Following general procedure for the synthesis of carbamoyl chlorides, (R)-2-((2,4,6-
trimethoxybenzyl)amino)propyl pivalate (188 mg, 0.553 mmol, 1 equiv) dissolved in dry 
benzene (1.4 mL, 0.4M) and Et3N (0.093 mL, 0.66 mmol, 1.2 equiv) were slowly added to a 
stirred solution of triphosgene (56 mg, 0.188 mmol, 0.34 equiv) in dry benzene (1.4 mL, 0.4M) 
at 0 °C . The mixture was then slowly allowed to reach rt and was stirred overnight. The crude 
mixture was then quenched with HCl solution (1M) and extracted twice with DCM. The 
combined organic layers were dried over sodium sulfate, filtered and evaporated under vacuum. 
The excess of benzene was removed by coevaporation with CHCl3.  The desired carbamoyl 
chloride was obtained as a brownish solid (190 mg, 0.47 mmol, 85 %) and used without further 
purification. 
1H NMR (250 MHz, Chloroform-d) δ = 6.11 (s, 2H), 4.90 (d, J = 14.3 Hz, 1H), 4.62 (d, J = 
14.3 Hz, 1H), 4.33 (dd, J = 11.2, 9.1 Hz, 1H), 4.07 (dd, J = 11.2, 5.3 Hz, 1H), 3.82 (s, 3H), 3.81 (s, 
6H), 3.73 – 3.59 (m, 1H), 1.21 (s, 9H), 0.99 (d, J = 6.9 Hz, 3H). 
(S)-(1-Phenylethyl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 2.61c: 
 
Following general procedure for the synthesis of carbamoyl chlorides, (S)-1-phenyl-N-(2,4,6-
trimethoxybenzyl)ethan-1-amine (300 mg, 0.995 mmol, 1 equiv) dissolved in dry benzene (3.9 
mL, 0.4M) and Et3N (0.167 mL, 1.19 mmol, 1.2 equiv) were slowly added to a stirred solution 
of triphosgene (100 mg, 0.338 mmol, 0.34 equiv) in dry benzene (3.9 mL, 0.4M) at 0 °C . The 
mixture was then slowly allowed to reach rt and was stirred overnight. The crude mixture was 
then quenched with HCl solution (1M) and extracted twice with DCM. The combined organic 
layers were dried over sodium sulfate, filtered and evaporated under vacuum. The excess of 
benzene was removed by coevaporation with CHCl3.  The desired carbamoyl chloride was 
obtained as a brownish solid (325 mg, 0.9 mmol, 90 %) and used without further purification. 
1H NMR (400 MHz, Chloroform-d) δ = 7.24 – 7.16 (m, 5H), 6.09 – 5.98 (m, 2H), 4.89 – 4.80 
(m, 2H), 4.74 – 4.64 (m, 1H), 3.81 (s, 3H), 3.78 (s, 6H), 1.50 (d, J = 7.1 Hz, 3H). 
(Cyclopentylmethyl)(isopropyl)carbamoyl chloride 2.63c: 
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Following general procedure for the synthesis of carbamoyl chlorides, N-
(cyclopentylmethyl)propan-2-amine (400 mg, 2.83 mmol, 1 equiv) dissolved in dry benzene 
(8.5 mL, 0.4M) and Et3N (0.477 mL, 3.40 mmol, 1.2 equiv) were slowly added to a stirred 
solution of triphosgene (286 mg, 0.962 mmol, 0.34 equiv) in dry benzene (8.5 mL, 0.4M) at 0 
°C . The mixture was then slowly allowed to reach rt and was stirred overnight. The crude 
mixture was then quenched with HCl solution (1M) and extracted twice with DCM. The 
combined organic layers were dried over sodium sulfate, filtered and evaporated under vacuum. 
The excess of benzene was removed by coevaporation with CHCl3.  The desired carbamoyl 
chloride was obtained as a yellowish oil (507 mg, 2.49 mmol, 88 %) and used without further 
purification. 
1H NMR (400 MHz, Chloroform-d) δ = 4.55 – 3.77 (m, 1H), 3.40 – 3.20 (m, 2H), 2.28 – 2.15 
(m, 1H), 1.82 – 1.50 (m, 8H), 1.37 – 1.19 (m, 6H). 
Isopropyl(2,4, 6-trimethylbenzyl)carbamoyl chloride 2.64c:  
  
Following general procedure for the synthesis of carbamoyl chlorides, N-isopropyl-3-
phenylpropan-1-amine (400 mg, 2.09 mmol, 1 equiv) dissolved in dry benzene (5.2 mL, 0.4M) 
and Et3N (0.352 mL, 2.51 mmol, 1.2 equiv) were slowly added to a stirred solution of 
triphosgene (211 mg, 0.711 mmol, 0.34 equiv) in dry benzene (5.2 mL, 0.4M) at 0 °C . The 
mixture was then slowly allowed to reach rt and was stirred overnight. The crude mixture was 
then quenched with HCl solution (1M) and extracted twice with DCM. The combined organic 
layers were dried over sodium sulfate, filtered and evaporated under vacuum. The excess of 
benzene was removed by coevaporation with CHCl3.  The desired carbamoyl chloride was 
obtained as a brownish solid (418 mg, 1.65 mmol, 79 %) and used without further purification. 
1H NMR (400 MHz, Chloroform-d) δ = 6.87 (s, 2H), 4.76 (s, 2H), 3.23 – 3.10 (m, 1H), 2.33 
(s, 6H), 2.28 (s, 3H), 1.20 (d, J = 6.8 Hz, 6H). 
Isopropyl(phenyl)carbamoyl chloride 2.65c: 
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Following general procedure A, aniline (130 mg, 1.4 mmol, 1 equiv), acetone (0.103 mL, 1.4 
mmol, 1 equiv) and 4Å MS (200 mg) were stirred for 4h in THF (14 mL). Then, a solution of 
NaBH4 (106 mg, 2.8 mmol, 2 equiv) in EtOH (5 mL) was carefully added to the mixture. The 
reaction was stirred at room temperature overnight, and was then filtered through celite. The 
crude mixture was then acidified using a solution of HCl (0.1M) and stirred for 30 min. The 
mixture was then basified using NaOH solution (0.1M) and extracted three times using AcOEt. 
The combined organic layers were dried over sodium sulfate, filtered and evaporated under 
vacuum. 
Following general procedure for the synthesis of carbamoyl chlorides, N-isopropylaniline (189 
mg, 1.4 mmol, 1 equiv) dissolved in dry benzene (3.5 mL, 0.4M) and Et3N (0.236 mL, 1.36 mmol, 
1.2 equiv) were slowly added to a stirred solution of triphosgene (141 mg, 2.01 mmol, 0.34 equiv) 
in dry benzene (3.5 mL, 0.4M) at 0 °C . The mixture was then slowly allowed to reach rt and was 
stirred overnight. The crude mixture was then quenched with HCl solution (1M) and extracted 
twice with DCM. The combined organic layers were dried over sodium sulfate, filtered and 
evaporated under vacuum. The excess of benzene was removed by coevaporation with CHCl3.  
The desired carbamoyl chloride was obtained as a yellowish solid (218 mg, 1.1 mmol, 79 %) and 
used without further purification. 
1H NMR (400 MHz, Chloroform-d) δ = 7.45 – 7.39 (m, 2H), 7.18 – 7.14 (m, 2H), 4.68 (sept, 
J = 6.8 Hz, 1H), 1.17 (d, J = 6.8 Hz, 6H). 
Benzyl(isopropyl)carbamoyl chloride 2.65c’: 
  
Following general procedure for the synthesis of carbamoyl chlorides, N-benzylpropan-2-
amine (150 mg, 1.1 mmol, 1 equiv) dissolved in dry benzene (2.5 mL, 0.4M) and Et3N (0.170 
mL, 1.21 mmol, 1.2 equiv) were slowly added to a stirred solution of triphosgene (102 mg, 0.343 
mmol, 0.34 equiv) in dry benzene (2.5 mL, 0.4M) at 0 °C . The mixture was then slowly allowed 
to reach rt and was stirred overnight. The crude mixture was then quenched with HCl solution 
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(1M) and extracted twice with DCM. The combined organic layers were dried over sodium 
sulfate, filtered and evaporated under vacuum. The excess of benzene was removed by 
coevaporation with CHCl3.  The desired carbamoyl chloride was obtained as a yellowish solid 
(64 mg, 0.33 mmol, 30 %) and used without further purification. 
1H NMR (400 MHz, Chloroform-d) δ = 7.39 – 7.27 (m, 5H), 4.67 (s, 2H), 4.30 – 4.20 (m, 1H), 
1.20 (d, J = 6.8 Hz, 6H). 
Isopropyl(phenethyl)carbamoyl chloride 2.66c: 
 
Following general procedure for the synthesis of carbamoyl chlorides, N-phenethylpropan-2-
amine (400 mg, 2.45 mmol, 1 equiv) dissolved in dry benzene (7.5 mL, 0.4M) and Et3N (0.413 
mL, 2.94 mmol, 1.2 equiv) were slowly added to a stirred solution of triphosgene (247 mg, 0.833 
mmol, 0.34 equiv) in dry benzene (7.5 mL, 0.4M) at 0 °C . The mixture was then slowly allowed 
to reach rt and was stirred overnight. The crude mixture was then quenched with HCl solution 
(1M) and extracted twice with DCM. The combined organic layers were dried over sodium 
sulfate, filtered and evaporated under vacuum. The excess of benzene was removed by 
coevaporation with CHCl3.  The desired carbamoyl chloride was obtained as a yellowish solid 
(515 mg, 2.28 mmol, 93 %) and used without further purification. 
1H NMR (400 MHz, Chloroform-d) δ = 7.37 – 7.18 (m, 5H), 4.61 – 4.27 (m, 1H), 3.55 – 3.37 
(m, 2H), 3.02 – 2.89 (m, 2H), 1.29 – 1.18 (m, 6H). 
Isopropyl(3-phenylpropyl)carbamoyl chloride 2.67c: 
 
Following general procedure for the synthesis of carbamoyl chlorides, N-isopropyl-3-
phenylpropan-1-amine (302 mg, 0.916 mmol, 1 equiv) dissolved in dry benzene (2.4 mL, 0.4M) 
and Et3N (0.154 mL, 1.1 mmol, 1.2 equiv) were slowly added to a stirred solution of triphosgene 
(96 mg, 0.311 mmol, 0.34 equiv) in dry benzene (2.4 mL, 0.4M) at 0 °C . The mixture was then 
slowly allowed to reach rt and was stirred overnight. The crude mixture was then quenched 
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with HCl solution (1M) and extracted twice with DCM. The combined organic layers were dried 
over sodium sulfate, filtered and evaporated under vacuum. The excess of benzene was 
removed by coevaporation with CHCl3.  The desired carbamoyl chloride was obtained as a 
brownish solid (298 mg, 0.76 mmol, 83 %) and used without further purification. 
1H NMR (400 MHz, Chloroform-d) δ = 7.33 – 7.27 (m, 2H), 7.25 – 7.16 (m, 3H), 4.56 – 4.16 
(m 1H), 3.35 – 3.09 (m, 2H), 2.71 – 2.49 (m, 2H), 2.08 – 1.87 (m, 2H), 1.22 – 1.14 (m, 6H). 
Ethyl 3-((chlorocarbonyl)(isopropyl)amino)propanoate 2.68c:  
  
Following general procedure for the synthesis of carbamoyl chlorides, ethyl 3-
(isopropylamino)propanoate (400 mg, 2.52 mmol, 1 equiv) dissolved in dry benzene (7.5 mL, 
0.4M) and Et3N (0.425 mL, 3.02 mmol, 1.2 equiv) were slowly added to a stirred solution of 
triphosgene (254 mg, 0.857 mmol, 0.34 equiv) in dry benzene (7.5 mL, 0.4M) at 0 °C . The 
mixture was then slowly allowed to reach rt and was stirred overnight. The crude mixture was 
then quenched with HCl solution (1M) and extracted twice with DCM. The combined organic 
layers were dried over sodium sulfate, filtered and evaporated under vacuum. The excess of 
benzene was removed by coevaporation with CHCl3.  The desired carbamoyl chloride was 
obtained as an orange oil (465 mg, 2.09 mmol, 83 %) and used without further purification. 
1H NMR (400 MHz, Chloroform-d) δ = 4.60 – 4.26 (m, 1H), 4.21 – 4.11 (m, 2H), 3.67 – 3.49 
(m, 2H), 2.74 – 2.62 (m, 2H), 1.32 – 1.21 (m, 9H). 
(3-(1,3-Dioxoisoindolin-2-yl)propyl)(isopropyl)carbamoyl chloride 2.69c: 
 
Following general procedure for the synthesis of carbamoyl chlorides, 2-(3-
(isopropylamino)propyl)isoindoline-1,3-dione (300 mg, 1.22 mmol 1 equiv) dissolved in dry 
benzene (3.1 mL, 0.4M) and Et3N (0.206 mL, 1.46 mmol, 1.2 equiv) were slowly added to a 
stirred solution of triphosgene (123 mg, 0.415 mmol, 0.34 equiv) in dry benzene (3.1 mL, 0.4M) 
at 0 °C . The mixture was then slowly allowed to reach rt and was stirred overnight. The crude 
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mixture was then quenched with HCl solution (1M) and extracted twice with DCM. The 
combined organic layers were dried over sodium sulfate, filtered and evaporated under vacuum. 
The excess of benzene was removed by coevaporation with CHCl3.  The desired carbamoyl 
chloride was obtained as a yellowish solid (302 mg, 1.0 mmol, 82 %) and used without further 
purification. 
1H NMR (400 MHz, Chloroform-d) δ = 8.08 – 7.67 (m, 4H), 4.57 – 4.17 (m, 1H), 3.77 – 3.69 
(m, 2H), 3.54 – 3.26 (m, 2H), 2.08 – 2.00 (m, 2H), 1.28 – 1.22 (m, 6H). 
Tert-pentyl(3-phenylpropyl)carbamoyl chloride 2.70c: 
  
Following general procedure for the synthesis of carbamoyl chlorides, 2-methyl-N-(3-
phenylpropyl)butan-2-amine (400 mg, 1.95 mmol, 1 equiv) dissolved in dry benzene (5 mL, 
0.4M) and Et3N (0.329 mL, 2.34 mmol, 1.2 equiv) were slowly added to a stirred solution of 
triphosgene (197 mg, 0.663 mmol, 0.34 equiv) in dry benzene (5 mL, 0.4M) at 0 °C . The 
mixture was then slowly allowed to reach rt and was stirred overnight. The crude mixture was 
then quenched with HCl solution (1M) and extracted twice with DCM. The combined organic 
layers were dried over sodium sulfate, filtered and evaporated under vacuum. The excess of 
benzene was removed by coevaporation with CHCl3.  The desired carbamoyl chloride was 
obtained as a yellowish oil (400 mg, 1.53 mmol, 77 %) and used without further purification. 
1H NMR (400 MHz, Chloroform-d) δ = 7.33 – 7.17 (m, 5H), 3.45 (t, J = 8.4 Hz, 2H), 2.61 (t, 
J = 7.6 Hz, 2H), 2.03 – 1.93 (m, 2H), 1.83 (q, J = 7.5 Hz, 2H), 1.34 (s, 6H), 0.80 (t, J = 7.5 Hz, 
3H). 
(2-Phenylpropan-2-yl)(3-phenylpropyl)carbamoyl chloride 2.71c: 
 
  
Following general procedure for the synthesis of carbamoyl chlorides, 3-phenyl-N-(2-
phenylpropan-2-yl)propan-1-amine (250 mg, 0.987 mmol 1 equiv) dissolved in dry benzene 
220 
 
(2.5mL, 0.4M) and Et3N (0.166 mL, 1.18 mmol, 1.2 equiv) were slowly added to a stirred 
solution of triphosgene (100 mg, 0.336 mmol, 0.34 equiv) in dry benzene (2.5 mL, 0.4M) at 0 
°C . The mixture was then slowly allowed to reach rt and was stirred overnight. The crude 
mixture was then quenched with HCl solution (1M) and extracted twice with DCM. The 
combined organic layers were dried over sodium sulfate, filtered and evaporated under vacuum. 
The excess of benzene was removed by coevaporation with CHCl3.  The desired carbamoyl 
chloride was obtained as a white solid  (290 mg, 0.91 mmol, 92 %) and used without further 
purification. 
1H NMR (400 MHz, Chloroform-d) δ = 7.34 – 7.26 (m, 5H), 7.25 – 7.18 (m, 5H), 3.65 – 3.58 
(m, 1H), 2.65 (t, J = 7.6 Hz, 2H), 2.19 – 2.11 (m, 2H), 1.68 (s, 6H).  
Tert-butyl(3,7-dimethyloct-6-en-1-yl)carbamoyl chloride 2.72c: 
  
Following general procedure for the synthesis of carbamoyl chlorides, N-(tert-butyl)-3,7-
dimethyloct-6-en-1-amine (400 mg, 1.89 mmol, 1 equiv) dissolved in dry benzene (5.6 mL, 
0.4M) and Et3N (0.319 mL, 2.27 mmol, 1.2 equiv) were slowly added to a stirred solution of 
triphosgene (191 mg, 0.643 mmol, 0.34 equiv) in dry benzene (5.6 mL, 0.4M) at 0 °C . The 
mixture was then slowly allowed to reach rt and was stirred overnight. The crude mixture was 
then quenched with HCl solution (1M) and extracted twice with DCM. The combined organic 
layers were dried over sodium sulfate, filtered and evaporated under vacuum. The excess of 
benzene was removed by coevaporation with CHCl3.  The desired carbamoyl chloride was 
obtained as a yellowish solid (404 mg, 1.47 mmol, 78 %) and used without further purification. 
1H NMR (400 MHz, Chloroform-d) δ = 5.07 (dtd, J = 7.1, 3.5, 2.7, 1.4 Hz, 1H), 3.59 – 3.40 
(m, 2H), 1.99 (dq, J = 14.3, 7.3 Hz, 2H), 1.68 (d, J = 1.4 Hz, 3H), 1.71 – 1.62 (m, 1H), 1.60 (s, 
3H), 1.45 (s, 9H), 1.38 – 1.13 (m, 3H) 0.92 (d, J = 6.4 Hz, 3H). 
Tert-butyl(((1S,5R)-6,6-dimethylbicyclo[3.1.1]hept-2-en-3-yl)methyl)carbamoyl chloride 
2.73c: 
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Following general procedure for the synthesis of carbamoyl chloride, 
dimethylbicyclo[3.1.1]hept-2-en-2-yl)methyl)-2-methylpropan-2-amine (280 mg, 1.35 mmol, 1 
equiv) dissolved in dry benzene (3.5 mL, 0.4M) and Et3N (0.228 mL, 1.62 mmol, 1.2 equiv) 
were slowly added to a stirred solution of triphosgene (136 mg, 0.459 mmol, 0.34 equiv) in dry 
benzene (3.5 mL, 0.4M) at 0 °C. The mixture was then slowly allowed to reach rt and was 
stirred overnight. The crude mixture was then quenched with HCl solution (1M) and extracted 
twice with DCM. The combined organic layers were dried over sodium sulfate, filtered and 
evaporated under vacuum. The excess of benzene was removed by coevaporation with CHCl3.  
The desired carbamoyl chloride was obtained as a yellowish solid (270 mg, 1.0 mmol, 74 %) 
and used without further purification 
1H NMR (400 MHz, Chloroform-d) δ = 5.39 – 5.35 (m, 1H), 4.12 – 3.92 (m, 2H), 2.44 – 2.21 
(m, 4H), 2.13 (dtd, J = 5.8, 2.9, 1.3 Hz, 1H), 1.95 (td, J = 5.6, 1.6 Hz, 1H), 1.46 (s, 9H), 1.29 (s, 
3H), 0.86 (s, 3H). 
(S)-Tert-butyl((4-(prop-1-en-2-yl)cyclohex-1-en-1-yl)methyl)carbamoyl chloride 2.74c: 
  
Following general procedure for the synthesis of carbamoyl chlorides, (S)-2-methyl-N-((4-(prop-
1-en-2-yl)cyclohex-1-en-1-yl)methyl)propan-2-amine (259 mg, 1.25 mmol 1 equiv) dissolved in 
dry benzene  (3.8 mL, 0.4M) and Et3N (0.211 mL, 1.5 mmol, 1.2 equiv) were slowly added to a 
stirred solution of triphosgene (126 mg, 0.425 mmol, 0.34 equiv) in dry benzene (3.8 mL, 0.4M) 
at 0 °C . The mixture was then slowly allowed to reach rt and was stirred overnight. The crude 
mixture was then quenched with HCl solution (1M) and extracted twice with DCM. The 
combined organic layers were dried over sodium sulfate, filtered and evaporated under vacuum. 
The excess of benzene was removed by coevaporation with CHCl3.  The desired carbamoyl 
chloride was obtained as a reddish oil (300 mg, 1.11 mol, 89 %) and used without further 
purification. 
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1H NMR (400 MHz, Chloroform-d) δ = 5.61 – 5.58 (m, 1H), 4.76 – 4.65 (m, 2H), 4.15 – 3.94 
(m, 2H), 2.23 – 2.11 (m, 2H), 2.07 – 1.81 (m, 2H), 1.74 (s, 3H), 1.44 (s, 9H). 
 
3,3-Dimethyl-1-oxa-4-azaspiro[4.5]decane-4-carbamoyl chloride 2.75c: 
 
Following general procedure for the synthesis of carbamoyl chlorides, 3,3-dimethyl-1-oxa-4-
azaspiro[4.5]decane (1 g, 5.91 mmol, 1 equiv) dissolved in dry benzene (15 mL, 0.4M) and Et3N 
(0.997 mL, 7.10 mmol, 1.2 equiv) were slowly added to a stirred solution of triphosgene (596 
mg, 2.01 mmol, 0.34 equiv) in dry benzene (15 mL, 0.4M) at 0 °C . The mixture was then slowly 
allowed to reach rt and was stirred overnight. The crude mixture was then quenched with HCl 
solution (1M) and extracted twice with DCM. The combined organic layers were dried over 
sodium sulfate, filtered and evaporated under vacuum. The excess of benzene was removed by 
coevaporation with CHCl3.  The desired carbamoyl chloride was obtained as a yellowish solid 
(1.29 g, 5.55 mmol, 94 %) and used without further purification. 
1H NMR (400 MHz, Chloroform-d) δ = 3.79 – 3.71 (m, 2H), 2.57 – 2.29 (m, 2H), 1.73 – 1.55 
(m, 7H), 1.53 – 1.44 (m, 6H), 1.27 – 1.15 (m, 1H). 
(Cyclopropylmethyl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 2.76c:  
 
 
Following general procedure for the synthesis of carbamoyl chlorides, 1-cyclopropyl-N-(2,4,6-
trimethoxybenzyl)methanamine (400 mg, 1.59 mmol, 1 equiv) dissolved in dry benzene (4 mL, 
0.4M) and Et3N (0.268 mL, 1.91 mmol, 1.2 equiv) were slowly added to a stirred solution of 
triphosgene (161 mg, 0.541 mmol, 0.34 equiv) in dry benzene (4 mL, 0.4M) at 0 °C . The mixture 
was then slowly allowed to reach rt and was stirred overnight. The crude mixture was then 
quenched with HCl solution (1M) and extracted twice with DCM. The combined organic layers 
were dried over sodium sulfate, filtered and evaporated under vacuum. The excess of benzene 
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was removed by coevaporation with CHCl3.  The desired carbamoyl chloride was obtained as 
a yellowish solid (428 mg, 1.36 mmol, 83 %) and used without further purification. 
1H NMR (250 MHz, Chloroform-d) δ = 6.10 (s, 2H), 4.78 (s, 1H), 4.69 (s, 1H), 3.81 – 3.78 (m, 
9H), 3.05 (dd, J = 18.5, 7.2 Hz, 2H), 1.26 – 1.16 (m, 1H), 0.55 – 0.32 (m, 2H), 0.29 – 0.12 (m, 
2H). 
(Dicyclopropylmethyl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 2.77c: 
  
Following general procedure for the synthesis of carbamoyl chlorides, 1,1-dicyclopropyl-N-
(2,4,6-trimethoxybenzyl)methanamine (300 mg, 1.03 mmol, 1 equiv) dissolved in dry benzene 
(3 mL, 0.4M) and Et3N (0.174 mL, 1.24 mmol, 1.2 equiv) were slowly added to a stirred solution 
of triphosgene (104 mg, 0.350 mmol, 0.34 equiv) in dry benzene (3 mL, 0.4M) at 0 °C . The 
mixture was then slowly allowed to reach rt and was stirred overnight. The crude mixture was 
then quenched with HCl solution (1M) and extracted twice with DCM. The combined organic 
layers were dried over sodium sulfate, filtered and evaporated under vacuum. The excess of 
benzene was removed by coevaporation with CHCl3.  The desired carbamoyl chloride was 
obtained as a yellowish solid (287 mg, 0.81mmol, 79 %) and used without further purification. 
1H NMR (400 MHz, Chloroform-d) δ = 6.09 (s, 2H), 4.80 (s, 2H), 3.82 (s, 3H), 3.79 (s, 6H), 
1.31 – 1.18(m, 1H), 0.57 – 0.41 (m, 4H), 0.26 – 0.18 (m, 4H), -0.07 – -0.21 (m, 2H). 
 
(2,3-Dihydro-1H-inden-2-yl)(isopropyl)carbamoyl chloride 2.78c: 
 
Following general procedure for the synthesis of carbamoyl chloride, N-isopropyl-2,3-dihydro-
1H-inden-2-amine (150 mg, 0.856 mmol 1 equiv) dissolved in dry benzene (2.1 mL, 0.4M) and 
Et3N (0.144 mL, 1.03 mmol, 1.2 equiv) were slowly added to a stirred solution of triphosgene 
(86 mg, 0.291 mmol, 0.34 equiv) in dry benzene (2.1 mL, 0.4M) at 0 °C . The mixture was then 
slowly allowed to reach rt and was stirred overnight. The crude mixture was then quenched 
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with HCl solution (1M) and extracted twice with DCM. The combined organic layers were dried 
over sodium sulfate, filtered and evaporated under vacuum. The excess of benzene was 
removed by coevaporation with CHCl3.  The desired carbamoyl chloride was obtained as a 
yellowish oil (160 mg, 0.67 mmol, 78 %) and used without further purification. 
1H NMR (400 MHz, Chloroform-d) δ = 7.23 – 7.14 (m, 4H), 5.23 – 4.60 (m, 1H), 4.22 – 3.71 
(m, 1H), 3.69 – 3.38 (m, 2H), 3.31 – 2.88 (m, 2H), 1.26 – 1.40 (m, 6H). 
 
(2,3-Dihydro-1H-inden-2-yl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 2.79c: 
  
Following general procedure for the synthesis of carbamoyl chlorides, N-(2,4,6-
trimethoxybenzyl)-2,3-dihydro-1H-inden-2-amine (269 mg, 0.858 mmol 1 equiv) dissolved in 
dry benzene (2.1 mL, 0.4M) and Et3N (0.144 mL, 1.03 mmol, 1.2 equiv) were slowly added to a 
stirred solution of triphosgene (86 mg, 0.291 mmol, 0.34 equiv) in dry benzene (2.1 mL, 0.4M) 
at 0 °C . The mixture was then slowly allowed to reach rt and was stirred overnight. The crude 
mixture was then quenched with HCl solution (1M) and extracted twice with DCM. The 
combined organic layers were dried over sodium sulfate, filtered and evaporated under vacuum. 
The excess of benzene was removed by coevaporation with CHCl3.  The desired carbamoyl 
chloride was obtained as a white solid (290 mg, 0.77 mmol, 90 %) and used without further 
purification. 
1H NMR (250 MHz, Chloroform-d) δ = 7.07 (s, 4H), 6.10 (s, 2H), 4.83 (s, 2H), 4.15 – 3.99 (m, 
1H), 3.82 (s, 3H), 3.80 (s, 6H), 3.49 – 3.33 (m, 2H), 2.74 – 2.59 (m, 2H). 
(1,2,3,4-Tetrahydronaphthalen-1-yl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 2.80c: 
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Following general procedure for the synthesis of carbamoyl chlorides, N-(2,4,6-
trimethoxybenzyl)-1,2,3,4-tetrahydronaphthalen-1-amine (490 mg, 1.50 mmol, 1 equiv) 
dissolved in dry benzene (3.7 mL, 0.4M) and Et3N (0.253 mL, 1.80 mmol, 1.2 equiv) were 
slowly added to a stirred solution of triphosgene (151 mg, 0.510 mmol, 0.34 equiv) in dry 
benzene (3.7 mL, 0.4M) at 0 °C . The mixture was then slowly allowed to reach rt and was 
stirred overnight. The crude mixture was then quenched with HCl solution (1M) and extracted 
twice with DCM. The combined organic layers were dried over sodium sulfate, filtered and 
evaporated under vacuum. The excess of benzene was removed by coevaporation with CHCl3.  
The desired carbamoyl chloride was obtained as a yellowish solid (480 mg, 1.23 mmol, 82 %) 
and used without further purification. 
1H NMR (250 MHz, Chloroform-d) δ = 7.09 – 6.97 (m, 4H), 6.10 – 6.03 (m 2H), 5.03 – 4.83 
(m, 2H), 4.71 – 4.50 (m, 1H), 3.81 (s, 3H), 3.80 (s, 6H), 3.80 – 3.73 (m, 2H), 2.86 – 2.50 (m, 
2H), 1.97 – 1.66 (m, 2H). 
 
(R)-(1,2,3,4-Tetrahydronaphthalen-1-yl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 
2.96: 
  
Following general procedure for the synthesis of carbamoyl chlorides, (R)-N-(2,4,6-
trimethoxybenzyl)-1,2,3,4-tetrahydronaphthalen-1-amine (600 mg, 1.83 mmol, 1 equiv) 
dissolved in dry benzene (5 mL, 0.4M) and Et3N (0.308 mL, 2.20 mmol, 1.2 equiv) were slowly 
added to a stirred solution of triphosgene (185 mg, 0.622 mmol, 0.34 equiv) in dry benzene (5 
mL, 0.4M) at 0 °C . The mixture was then slowly allowed to reach rt and was stirred overnight 
at 60°C. The crude mixture was then quenched with HCl solution (1M) and extracted twice with 
DCM. The combined organic layers were dried over sodium sulfate, filtered and evaporated 
under vacuum. The excess of benzene was removed by coevaporation with CHCl3.  The desired 
carbamoyl chloride was obtained as a yellowish solid (613 mg, 1.53 mmol, 86 %) and used 
without further purification. 
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1H NMR (250 MHz, Chloroform-d) δ = 7.09 – 6.95 (m, 4H), 6.10 – 6.03 (m, 2H), 5.03 – 4.82 
(m, 2H), 4.71 – 4.49 (m, 1H), 3.81 (s, 3H), 3.80 (s, 6H), 3.79 – 3.73 (m, 2H), 2.87 – 2.52 (m, 2H), 
1.99 – 1.67 (m, 2H). 
 
(2,3-Dihydro-1H-inden-1-yl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 2.81c: 
 
Following general procedure B for the synthesis of secondary amines, 2,3-dihydro-1H-inden-1-
amine (200 mg, 1.5 mmol, 1 equiv), 2,4,6-trimethoxybenzaldehyde (294 mg, 1.5 mmol, 1 equiv), 
and AcOH (0.172 mL, 3 mmol 2 equiv) were stirred at rt in DCE (15 mL) for 30 min. 
NaBH(OAc)3 (636 mg, 3 mmol, 2 equiv) was then added to the resulting solution, which was 
stirred overnight. Then, the mixture was quenched using a solution of NaOH (1M) and the crude 
mixture was stirred for further 30 min. The crude mixture was extracted twice with DCM, dried 
over sodium sulfate, filtered and evaporated under vacuum.  
Following general procedure for the synthesis of carbamoyl chlorides, N-(2,4,6-
trimethoxybenzyl)-2,3-dihydro-1H-inden-1-amine (470 mg, 1.50 mmol, 1 equiv) dissolved in 
dry benzene (3.8 mL, 0.4M) and Et3N (0.632 mL, 4.50 mmol, 1.2 equiv) were slowly added to 
a stirred solution of triphosgene (151 mg, 0.51 mmol, 0.34 equiv) in dry benzene (3.8 mL, 0.4M) 
at 0 °C . The mixture was then slowly allowed to reach rt and was stirred overnight. The crude 
mixture was then quenched with HCl solution (1M) and extracted twice with DCM. The 
combined organic layers were dried over sodium sulfate, filtered and evaporated under vacuum. 
The excess of benzene was removed by coevaporation with CHCl3.  The desired carbamoyl 
chloride was obtained as a yellowish solid (430 mg, 1.14 mmol, 76 %) and used without further 
purification. 
1H NMR (250 MHz, Chloroform-d) δ = 7.29 – 6.96 (m 4H), 6.11 – 5.93 (m, 2H), 5.07 – 4.75 
(m, 2H), 3.85 – 3.75 (m, 9H), 3.70 – 3.61 (m, 2H), 3.51 – 3.40 (m, 1H), 3.14 – 3.05 (m, 1H), 2.19 
– 2.01 (m, 1H). 
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Dicyclohexylcarbamoyl chloride 2.82c: 
 
Following general procedure for the synthesis of carbamoyl chlorides, dicyclohexylamine (363 
mg, 2.0 mmol 1 equiv) dissolved in dry benzene (5 mL, 0.4M) and Et3N (0.337 mL, 2.24 mmol, 
1.2 equiv) were slowly added to a stirred solution of triphosgene (202 mg, 0.68 mmol, 0.34 
equiv) in dry benzene (5 mL, 0.4M) at 0 °C . The mixture was then slowly allowed to reach rt 
and was stirred overnight. The crude mixture was then quenched with HCl solution (1M) and 
extracted twice with DCM. The combined organic layers were dried over sodium sulfate, 
filtered and evaporated under vacuum. The excess of benzene was removed by coevaporation 
with CHCl3.  The desired carbamoyl chloride was obtained as a yellowish solid (450 mg, 1.84 
mmol, 92 %) and used without further purification. 
1H NMR (400 MHz, Chloroform-d) δ = 4.12 (s, 1H), 3.10 (s, 1H), 2.19 (s, 2H), 1.85 – 1.80 (m, 
6H), 1.65 – 1.54 (m, 2H), 1.54 – 1.04 (m, 10H). 
 
Pentan-3-yl(2,4,6-trimethoxybenzyl)carbamoyl chloride 2.83c:  
 
 
Following general procedure for the synthesis of carbamoyl chlorides, N-(2,4,6-
trimethoxybenzyl)pentan-3-amine (400 mg, 1.5 mmol 1 equiv) dissolved in dry benzene (3.5 
mL, 0.4M) and Et3N (0.250 mL, 1.8 mmol, 1.2 equiv) were slowly added to a stirred solution of 
triphosgene (151 mg, 0.51 mmol, 0.34 equiv) in dry benzene (3.5 mL, 0.4M) at 0 °C . The 
mixture was then slowly allowed to reach rt and was stirred overnight. The crude mixture was 
then quenched with HCl solution (1M) and extracted twice with DCM. The combined organic 
layers were dried over sodium sulfate, filtered and evaporated under vacuum. The excess of 
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benzene was removed by coevaporation with CHCl3.  The desired carbamoyl chloride was 
obtained as a yellowish solid (430 mg, 1.30 mmol, 87 %) and used without further purification. 
 
1H NMR (250 MHz, Chloroform-d) δ = 6.16 – 6.06 (m, 2H), 4.75 – 4.60 (m, 2H), 3.88 – 3.78 (m, 9H), 
3.10 – 2.93 (m, 1H), 1.89 – 1.64 (m, 2H), 1.54 – 1.33 (m, 2H), 0.96 – 0.52 (m, 6H). 
 
Synthesis of -lactams 
4-Methyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-one 2.54:  
 
 
Standard scale synthesis: Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with isopropyl(2,4,6-trimethoxybenzyl)carbamoyl chloride (40 mg, 0.133 mmol, 1 equiv) 
was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI (12 mg , 0.0266 mmol, 
20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 
3.0 equiv) in mesitylene (2.62 mL). The two chambers system was reacted for 18h at 120 °C. The 
crude mixture was purified by flash chromatography using first cyclohexane to elute mesitylene 
and then cyclohexane/EtOAc (75:25 to 0:1) as eluent., to provide oil 2.54 (32.5 mg, 0.122 mmol, 
92 %). 
13C-labeled standard scale synthesis: Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), 13C-COgen (98 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with isopropyl(2,4,6-trimethoxybenzyl)carbamoyl chloride (40 mg, 0.133 mmol, 1 equiv) 
was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI (12 mg , 0.0266 mmol, 
20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 
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3.0 equiv) in mesitylene (2.62 mL). The two chambers system was reacted for 18h at 120 °C. The 
crude mixture was purified by flash chromatography using first cyclohexane to elute mesitylene 
and then cyclohexane/EtOAc (75:25 to 0:1) as eluent., to provide 2.54 (32.5 mg, 0.11 mmol, 89 
%). 
13C-NMR spectra shows a low enrichment of the 13C of the final product (3.1 %). This low 
increasing of 13C compared to the standard procedure, shows the really low incorporation of 13CO 
from COgen during the reaction. 
Standard scale synthesis: Conditions B: CO atmosphere 
Following general procedure B, isopropyl(2,4,6-trimethoxybenzyl)carbamoyl chloride (40 mg, 
0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI 
(12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium 
carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO atmosphere. The 
mixture was stirred for 18h at 120 °C. The crude mixture was purified by flash chromatography 
using first cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, 
to provide oil 2.54 (30.0 mg, 0.064 mmol, 85 %). 
Enantioselective reaction: CO atmosphere 
Following general procedure B, Isopropyl(2,4,6-trimethoxybenzyl)carbamoyl chloride (400 mg, 
1.33 mmol, 1 equiv) was reacted with PdCl2 (24 mg, 0.133 mmol, 10 mol%), L 2.84 (332 mg , 
0.266 mmol, 20 mol%), pivalic acid (41 mg, 0.4 mmol, 30 mol%) and cesium carbonate (650 
mg, 2 mmol, 1.5 equiv) in mesitylene (26.2 mL), under CO atmosphere. The mixture was stirred 
for 18h at 120 °C. The crude mixture was purified by flash chromatography using first 
cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide 
oil 2.85 (266 mg, 1 mmol, 75 %, e.r.: 92:8). 
Optical rotation : []D20 = +71.8° (c = 1.0, CHCl3) 
 
Enantioselective reaction: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with isopropyl(2,4,6-trimethoxybenzyl)carbamoyl chloride (40 mg, 0.133 mmol, 1 equiv) 
was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), L 2.84 (33.2 mg , 0.0266 mmol, 20 
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mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (65 mg, 0.2 mmol, 1.5 
equiv) in mesitylene (2.62 mL). The two chambers system was reacted for 18h at 120 °C. The 
crude mixture was purified by flash chromatography using first cyclohexane to elute mesitylene 
and then cyclohexane/EtOAc (75:25 to 0:1) as eluent., to provide oil 2.85 (30.5 mg, 0.114 mmol, 
86 %, e.r.: 86:14 ). 
Tenfold scale synthesis: 
Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (89 mg, 0.4 mmol,  30 
mol%), P(t-Bu)3.HBF4 (120 mg , 0.4 mmol, 30 mol%), COgen (970 mg, 4 mmol, 3.0 equiv), 
Cy2NMe (1.610 g, 7.98 mmol, 6.0 equiv) and mesitylene (5 mL).  Chamber B, previously charged 
with isopropyl(2,4,6-trimethoxybenzyl)carbamoyl chloride (400 mg, 1.33 mmol, 1 equiv) was 
reacted with PdCl2 (24 mg, 0.133 mmol, 10 mol%), catacXium A.HI (120 mg , 0.266 mmol, 20 
mol%), pivalic acid (41 mg, 0.4 mmol, 30 mol%) and cesium carbonate (1.30 g, 4 mmol, 3.0 
equiv) in mesitylene (26.2 mL). The two chambers system was reacted for 18h at 120 °C. The 
crude mixture was purified by flash chromatography using first cyclohexane to elute mesitylene 
and then cyclohexane/EtOAc (75:25 to 0:1) as eluent., to provide oil 2.54 (337 mg, 1.26 mmol, 
95 %). 
Conditions A: Two-chamber system: Under air atmosphere: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (89 mg, 0.4 mmol,  30 
mol%), P(t-Bu)3.HBF4 (120 mg , 0.4 mmol, 30 mol%), COgen (970 mg, 4 mmol, 3.0 equiv), 
Cy2NMe (1.610 g, 7.98 mmol, 6.0 equiv) and mesitylene (commercial batch under argon 
atmosphere)  (5 mL).  Chamber B, previously charged with isopropyl(2,4,6-
trimethoxybenzyl)carbamoyl chloride (400 mg, 1.33 mmol, 1 equiv) was reacted with PdCl2 (24 
mg, 0.133 mmol, 10 mol%), catacXium A.HI (120 mg , 0.266 mmol, 20 mol%), pivalic acid (41 
mg, 0.4 mmol, 30 mol%) and cesium carbonate (1.30 g, 4 mmol, 3.0 equiv) in mesitylene 
(commercial batch under argon atmosphere)  (26.2 mL). The two chambers system was reacted 
for 18h at 120 °C under air atmosphere. The crude mixture was purified by flash chromatography 
using first cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent., 
to provide oil 2.54 (266 mg, 1.0 mmol, 75 %). 
1H NMR (400 MHz, Chloroform-d ) : δ = 6.11 (s, 2H), 4.57 (d, J = 13.9 Hz, 1H), 4.13 (d, J = 
13.8, 1H), 3.81 (s, 9H), 3.41 – 3.33 (m, 1H), 2.90 (dd, J = 14.2, 4.9 Hz, 1H), 2.38 (dd, J = 14.2, 
2.2, 1H), 1.17 (d, J = 6.0 Hz, 3H). 
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13C NMR (Chloroform-d, 101 MHz) : δ = 166.5, 161.2, 159.7, 104.6, 90.3, 55.8, 55.5, 47.0, 
43.8, 32.4, 18.7. 
IR (neat): ν = 2946, 1739, 1600, 1140cm-1. 
HRMS (ESI): Calculated for C14H19NNaO4 ([M+Na]+): 288.1206; found: 288.1208 
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Large-scale synthesis using a home-made two-chamber system 
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1-(2,4,6-Trimethoxybenzyl)azetidin-2-one 2.53: 
 
Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with ethyl(2,4,6-trimethoxybenzyl)carbamoyl chloride (38.3 mg, 0.133 mmol, 1 equiv) 
was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI (12 mg , 0.0266 mmol, 
20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 
3.0 equiv) in mesitylene (2.62 mL). The two chambers system was reacted for 18h at 120 °C. The 
crude mixture was purified by flash chromatography using first cyclohexane to elute mesitylene 
and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide oil 2.53 (16.0 mg, 0.064 mmol, 
48 %). 
Conditions B: CO atmosphere 
Following general procedure B, ethyl(2,4,6-trimethoxybenzyl)carbamoyl chloride (38.3 mg, 
0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI 
(12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium 
carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO atmosphere. The 
mixture was stirred for 18h at 120 °C. The crude mixture was purified by flash chromatography 
using first cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, 
to provide oil 2.53 (11.4 mg, 0.045 mmol, 34 %). 
1H NMR (400 MHz, Chloroform-d ) : δ = 6.12 (s, 2H), 4.38 (s, 2H), 3.82 (s, 3H), 3.81 (s, 6H), 
3.01 (t, J = 4.0 Hz, 2H), 2.79 (t, J = 4.0 Hz, 2H). 
 
13C NMR (Chloroform-d, 101 MHz) :  δ =  167.2, 161.2, 159.7, 104.2, 90.4, 55.9, 55.5, 38.7, 
36.2, 34.1. 
IR (neat): ν = 2939, 1737, 1596, 1145, 814 cm-1. 
HRMS (ESI): Calculated for C13H17NNaO4 ([M+Na]+): 274.1050; found: 274.1051 
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(S)-4-(Tert-butyl)-1-(2,4,6-trimethoxybenzyl)azetidin-2-one 2.57: 
 
Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with (S)-(3,3-dimethylbutan-2-yl)(2,4,6-trimethoxybenzyl)carbamoyl chloride (47.6 
mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium 
A.HI (12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium 
carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system was 
reacted for 18h at 120 °C. The crude mixture was purified by flash chromatography using first 
cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide 
oil 2.57 (30.7 mg, 0.100 mmol, 75 %). 
Conditions B: CO atmosphere 
Following general procedure B, (S)-(3,3-dimethylbutan-2-yl)(2,4,6-trimethoxybenzyl)carbamoyl 
chloride (47.6 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), 
catacXium A.HI (12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) 
and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO 
atmosphere. The mixture was stirred for 18h at 120 °C, The crude mixture was purified by flash 
chromatography using first cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 
to 0:1) as eluent, to provide oil 2.57 (15.5 mg, 0.051 mmol, 38 %). 
1H NMR (400 MHz, Chloroform-d ): δ = 6.10 (s, 2H), 4.64 (d, J = 14.5 Hz, 1H), 4.21 (dd, J = 
14.5, 1.4 Hz, 1H), 3.82 (s, 3H), 3.78 (s, 6H), 2.97 (dd, J = 5.4, 2.6 Hz, 1H), 2.65 (dd, J = 14.6, 
5.4 Hz, 1H), 2.5 (ddd, J = 14.5, 2.6, 1.4 Hz, 1H), 0.82 (s, 9H). 
 
13C NMR (Chloroform-d, 101 MHz):  δ = 169.0, 161.0, 159.6, 103.8, 90.3, 59.9, 55.7, 55.4, 
37.8, 35.3, 32.4, 25.7. 
IR (neat): ν = 2975, 1739, 743 cm-1. 
HRMS (ESI): Calculated for C17H26NO4 ([M+H]+): 308.1856; found: 308.1859 
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Optical rotation : []D20 = +50.1° (c = 0.7, CHCl3) 
 
(R)-4-Hexyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-one 2.58: 
 
 
Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with (S)-octan-2-yl(2,4,6-trimethoxybenzyl)carbamoyl chloride (49.5 mg, 0.133 mmol, 
1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI (12 mg , 
0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 
mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system was reacted for 
18h at 120 °C. The crude mixture was purified by flash chromatography using first cyclohexane 
to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide oil 2.58 (41 
mg, 0.122 mmol, 92 %). 
Conditions B: CO atmosphere 
Following general procedure B, (S)-octan-2-yl(2,4,6-trimethoxybenzyl)carbamoyl chloride (49.5 
mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium 
A.HI (12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium 
carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO atmosphere. The 
mixture was stirred for 18h at 120 °C, The crude mixture was purified by flash chromatography 
using first cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, 
to provide oil 2.58 (39.3 mg, 0.117 mmol, 88 %). 
1H NMR (400 MHz, Chloroform-d ) : δ = 6.10 (s, 2H), 4.56 (d, J = 14.0 Hz, 1H), 4.13 (d, J = 
14.0 Hz, 1H), 3.81 – 3.78 (m, 9H), 3.26 – 3.20 (m, 1H), 2.81 (dd, J = 14.2, 5.0 Hz, 1H), 2.45 – 
2.39 (m, 1H), 1.80 – 1.69 (m, 1H), 1.28 – 1.18 (m, 9H), 0.86 (t, J = 6.9 Hz, 3H). 
 
13C NMR (Chloroform-d, 101 MHz) :  δ = 166.9, 161.2, 159.6, 104.5, 90.3, 55.8, 55.4, 51.2, 
41.8, 32.7, 32.5, 31.8, 29.3, 25.0, 22.7, 14.2. 
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IR (neat): ν = 2962, 1739, 1608, 1140, 732 cm-1. 
HRMS (ESI): Calculated for C19H30NO4 ([M+H]+): 336.2169; found: 336.2167 
 
Optical rotation : []D20 = +46.6° (c = 1.3, CHCl3) 
 
(S)-4-Cyclohexyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-one 2.59: 
 
Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with (S)-(1-cyclohexylethyl)(2,4,6-trimethoxybenzyl)carbamoyl chloride (49.2 mg, 
0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI 
(12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium 
carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system was 
reacted for 18h at 120 °C. The crude mixture was purified by flash chromatography using first 
cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide 
oil 2.59 (44.4 mg, 0.133 mmol, 100 %). 
Conditions B: CO atmosphere 
Following general procedure B, (S)-(1-cyclohexylethyl)(2,4,6-trimethoxybenzyl)carbamoyl 
chloride  (49.2 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), 
catacXium A.HI (12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) 
and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO 
atmosphere. The mixture was stirred for 18h at 120 °C, The crude mixture was purified by flash 
chromatography using first cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 
to 0:1) as eluent, to provide oil 2.59 (39.1 mg, 0.117 mmol, 88 %). 
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1H NMR (400 MHz, Chloroform-d ) : δ = 6.09 (s, 2H), 4.57 (d, J = 14.0 Hz, 1H), 4.16 (d, J = 
14.0 Hz, 1H), 3.80 (s, 3H), 3.79 (s, 6H), 3.13 – 3.08 (m, 1H), 2.65 (dd, J = 14.3, 5.1 Hz, 1H), 
2.53 (d, J = 14.3 Hz, 1H), 1.70 – 1.46 (m, 5H), 1.19 – 1.04 (m, 4H), 0.91 – 0.72 (m, 2H). 
13C NMR (Chloroform-d, 101 MHz) δ =  167.7, 161.1, 159.6, 104.1, 90.3, 55.7, 55.4, 55.4, 39.2, 
38.0, 33.7, 29.5, 26.5, 26.3, 26.3, 26.0. 
IR (neat): ν = 2972, 1729, 1628, 1120, 734 cm-1. 
HRMS (ESI): Calculated for C19H28NO4 ([M+H]+): 334.2013; found: 334.2013 
 
Optical rotation : []D20 = -38.2° (c = 1.6, CHCl3) 
 
(S)-(4-Oxo-1-(2,4,6-trimethoxybenzyl)azetidin-2-yl)methyl pivalate 2.60:  
 
Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with (S)-2-((chlorocarbonyl)(2,4,6-trimethoxybenzyl)amino)propyl pivalate (53.5 mg, 
0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI 
(12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium 
carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system was 
reacted for 18h at 120 °C. The crude mixture was purified by flash chromatography using first 
cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide 
oil 2.60 (48.6 mg, 0.133 mmol, 100 %). 
Conditions B: CO atmosphere 
Following general procedure B, (S)-2-((chlorocarbonyl)(2,4,6-trimethoxybenzyl)amino)propyl 
pivalate (53.5 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), 
catacXium A.HI (12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) 
and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO 
atmosphere. The mixture was stirred for 18h at 120 °C, The crude mixture was purified by flash 
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chromatography using first cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 
to 0:1) as eluent, to provide oil 2.60 (42.7 mg, 0.117 mmol, 88 %). 
1H NMR (500 MHz, Chloroform-d) δ = 6.10 (s, 2H), 4.60 (d, J = 14.0 Hz, 1H), 4.25 (dd, J = 
11.8, 4.3 Hz, 1H), 4.11 – 4.04 (m, 2H), 3.81 – 3.78 (m, 9H), 3.54 – 3.49 (m, 1H), 2.83 (dd, J = 14.3, 
5.1 Hz, 1H), 2.70 (dd, J = 14.2, 2.4, 1H), 1.18 (s, 9H). 
 
13C NMR (126 MHz, Chloroform-d) δ = 178.3, 166.2, 161.3, 159.5, 104.3, 90.4, 62.0, 55.8, 
55.4, 49.4, 39.3, 39.1, 32.9, 27.2. 
 
IR (neat): ν = 1738, 1598, 904, 723cm-1. 
HRMS (ESI): Calculated for C19H27NNaO6 ([M+Na]+): 388.1731; found: 388.1735 
 
Optical rotation : []D20 = +41.3° (c = 1.2, CHCl3) 
 
(S)-4-phenyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-one 2.61 and  
(S)-3-methyl-2-(2,4,6-trimethoxybenzyl)isoindolin-1-one 2.62:  
 
Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with (S)-(1-phenylethyl)(2,4,6-trimethoxybenzyl)carbamoyl chloride (48.4 mg, 0.133 
mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI (12 mg 
, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 
mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system was reacted for 
18h at 120 °C. The crude mixture was purified by flash chromatography using first cyclohexane 
to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide oil 2.61 and 
2.62 as an inseparable mixture (29.6 mg, 0.09 mmol, 68 %, 7/3). 
Conditions B: CO atmosphere 
Following general procedure B, (S)-(1-phenylethyl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 
(48.4 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), 
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catacXium A.HI (12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) 
and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO 
atmosphere. The mixture was stirred for 18h at 120 °C, The crude mixture was purified by flash 
chromatography using first cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 
to 0:1) as eluent, to provide oil 2.61 and 2.62 as an inseparable mixture (29.6 mg, 0.09 mmol, 68 
%, 7/3). 
(S)-4-phenyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-2.61: Beta-lactam product : 
1H NMR (400 MHz, Chloroform-d ): δ = 7.34 – 7.22 (m, 3H), 7.22 – 7.16 (m, 2H), 5.99 (s, 2H), 
4.67 (d, J = 13.8 Hz, 1H), 4.27 (dd, J = 5.3, 2.4 Hz, 1H), 4.11 (dd, J = 13.8, 1.1 Hz, 1H), 3.79 (s, 3H), 
3.61 (s, 6H), 3.23 (dd, J = 14.4, 5.3 Hz, 1H), 2.72 (ddd, J = 14.4, 2.4, 1.0 Hz, 1H). 
13C NMR (Chloroform-d, 101 MHz) :  δ = 167.2, 161.2, 159.5, 139.8, 130.9, 127.8, 126.2, 
104.0, 90.1, 55.5, 55.4, 54.0, 46.7, 33.1. 
 
IR (neat): ν = 2950, 1737, 1680, 1595, 1150, 907, 727 cm-1. 
HRMS (ESI): Calculated for C19H21NNaO4 ([M+Na]+): 350.1363; found: 350.1365 
 
(S)-3-Methyl-2-(2,4,6-trimethoxybenzyl)isoindolin-1-one 2.62  : Oxindole product : 
1H NMR (400 MHz, Chloroform-d ) : δ = 7.86 (m, 1H), 7.48 (m, 1H), 7.44 – 7.40 (m, 1H), 
7.33 – 7.31 (m, 1H), 6.13 (s, 2H), 5.27 (d, J = 14.2 Hz, 1H), 4.44 (d, J = 14.1 Hz, 1H), 4.19 (q, J 
= 6.7 Hz, 1H), 3.82 (s, 3H), 3.80 (s, 6H), 1.44 (d, J = 6.6 Hz, 3H). 
 
13C NMR (Chloroform-d, 101 MHz) :  δ = 167.3, 161.2, 160.0, 147.6, 132.5, 128.4, 127.7, 
123.6, 121.8, 105.5, 90.4, 55.9, 55.5, 55.0, 32.5, 18.4.  
 
1-(Cyclopentylmethyl)-4-methylazetidin-2-one 2.63: 
 
Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with (cyclopentylmethyl)(isopropyl)carbamoyl chloride (27.1 mg, 0.133 mmol, 1 equiv) 
was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI (12 mg , 0.0266 mmol, 
20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 
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3.0 equiv) in mesitylene (2.62 mL). The two chambers system was reacted for 18h at 120 °C. The 
crude mixture was purified by flash chromatography using first cyclohexane to elute mesitylene 
and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide oil 2.63 (16.7 mg, 0.100 mmol, 
75 %). 
Conditions B: CO atmosphere 
Following general procedure B, (cyclopentylmethyl)(isopropyl)carbamoyl chloride (27.1 mg, 
0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI 
(12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium 
carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO atmosphere. The 
mixture was stirred for 18h at 120 °C, The crude mixture was purified by flash chromatography 
using first cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, 
to provide oil 2.63 (13.0 mg, 0.078 mmol, 59 %). 
1H NMR (400 MHz, Chloroform-d ) : δ = 3.74 – 3.59 (m, 1H), 3.25 (dd, J = 13.9, 7.9 Hz, 1H), 
3.04 (dd, J = 14.4, 4.8 Hz, 1H), 2.87 (dd, J = 14.0, 7.1 Hz, 1H), 2.47 (d, J = 14.4 Hz, 1H), 2.19 
– 2.00 (m, 1H), 1.85 – 1.46 (m, 5H), 1.31 (d, J = 5.9 Hz, 3H), 1.26 – 1.14 (m, 3H). 
 
13C NMR (Chloroform-d, 101 MHz) : δ = 167.1, 47.7, 45.5, 44.0, 38.9, 30.9, 30.8, 25.5, 25.2, 
18.8. 
IR (neat): ν = 2956, 1731, 907, 729 cm-1. 
HRMS (ESI): Calculated for C10H17NNaO ([M+Na]+): 190.1202; found: 190.1202 
 
4-Methyl-1-(2,4,6-trimethylbenzyl)azetidin-2-one 2.64: 
 
Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with isopropyl(2,4,6-trimethylbenzyl)carbamoyl chloride (33.8 mg, 0.133 mmol, 1 equiv) 
was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI (12 mg , 0.0266 mmol, 
20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 
3.0 equiv) in mesitylene (2.62 mL). The two chambers system was reacted for 18h at 120 °C. The 
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crude mixture was purified by flash chromatography using first cyclohexane to elute mesitylene 
and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide oil 2.64 (20.2 mg, 0.093 mmol, 
70 %). 
Conditions B: CO atmosphere 
Following general procedure B, isopropyl(2,4,6-trimethylbenzyl)carbamoyl chloride (33.8 mg, 
0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI 
(12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium 
carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO atmosphere. The 
mixture was stirred for 18h at 120 °C, The crude mixture was purified by flash chromatography 
using first cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, 
to provide oil 2.64 (19.4 mg, 0.078 mmol, 67 %). 
1H NMR (400 MHz, Chloroform-d ) : δ = 6.85 (s, 2H), 4.48 (d, J = 14.7 Hz, 1H), 4.34 (d, J = 
14.7 Hz, 1H), 3.48 – 3.38 (m, 1H), 3.01 (dd, J = 14.4, 5.0 Hz, 1H), 2.48 – 2.40 (m, 1H), 2.33 (s, 
6H), 2.26 (s, 3H), 1.06 (d, J = 6.1 Hz, 3H). 
 
13C NMR (Chloroform-d, 101 MHz) :  δ = 166.8, 137.6, 137.4, 129.4, 128.5, 47.6, 44.1, 38.9, 
21.0, 20.1, 19.4. 
IR (neat): ν = 1733, 907, 731 cm-1. 
HRMS (ESI): Calculated for C14H19NNaO ([M+Na]+): 240.1359; found: 240.1360 
 
4-Methyl-1-phenethylazetidin-2-one 2.66:  
 
Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with isopropyl(phenethyl)carbamoyl chloride (30.0 mg, 0.133 mmol, 1 equiv) was 
reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI (12 mg , 0.0266 mmol, 20 
mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 3.0 
equiv) in mesitylene (2.62 mL). The two chambers system was reacted for 18h at 120 °C. The 
crude mixture was purified by flash chromatography using first cyclohexane to elute mesitylene 
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and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide oil 2.66 (13.5 mg, 0.071 mmol, 
54 %). 
Conditions B: CO atmosphere 
Following general procedure B, isopropyl(phenethyl)carbamoyl chloride (30.0 mg, 0.133 mmol, 
1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI (12 mg , 
0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 
mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO atmosphere. The mixture was 
stirred for 18h at 120 °C, The crude mixture was purified by flash chromatography using first 
cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide 
oil 2.66 (7 mg, 0.037 mmol, 28 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.26 – 7.18 (m, 2H), 7.18 – 7.10 (m, 3H), 3.52 (dt, J = 
14.6, 7.4 Hz, 1H), 3.46 – 3.39 (m, 1H), 3.15 (dt, J = 14.4, 7.4 Hz, 1H), 2.91 (dd, J = 14.4, 4.9 Hz, 
1H), 2.80 (t, J = 7.4 Hz, 2H), 2.36 (dd, J = 14.4, 2.2 Hz, 1H), 1.11 (d, J = 6.2 Hz, 3H). 
 
13C NMR (101 MHz, Chloroform-d) δ = 167.0, 138.8, 128.7, 128.7, 126.7, 47.7, 44.0, 41.8, 
34.7, 18.5. 
IR (neat): ν = 2960, 1740, 1399, 700 cm-1. 
HRMS (ESI): Calculated for C12H15NNaO ([M+Na]+): 212.1246; found: 212.1246 
 
4-Methyl-1-(3-phenylpropyl)azetidin-2-one 2.67:  
 
Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with isopropyl(3-phenylpropyl)carbamoyl chloride (31.9 mg, 0.133 mmol, 1 equiv) was 
reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI (12 mg , 0.0266 mmol, 20 
mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 3.0 
equiv) in mesitylene (2.62 mL). The two chambers system was reacted for 18h at 120 °C. The 
crude mixture was purified by flash chromatography using first cyclohexane to elute mesitylene 
and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide oil 2.67 (21.9 mg, 0.108 mmol, 
81 %). 
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Conditions B: CO atmosphere 
Following general procedure B, isopropyl(3-phenylpropyl)carbamoyl chloride (31.9 mg, 0.133 
mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI (12 mg 
, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 
mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO atmosphere. The mixture was 
stirred for 18h at 120 °C, the excess of mesitylene was removed by flushing cyclohexane on silica 
gel, and the resulting crude mixture was purified by chromatography using cyclohexane/AcOEt 
as eluent, to provide oil 2.67 (16.0 mg, 0.078 mmol, 59 %). 
1H NMR (400 MHz, Chloroform-d ) : δ = 7.26 – 7.17 (m, 2H), 7.15 – 7.07 (m, 3H), 3.60 – 3.52 
(m, 1H), 3.31 – 3.22 (m, 1H), 3.02 – 2.91 (m, 2H), 2.57 (t, J = 7.7 Hz, 2H), 2.40 (dd, J = 14.4, 
2.2 Hz, 1H), 1.84 – 1.74 (m, 2H), 1.23 (d, J = 6.1 Hz, 3H). 
 
13C NMR (Chloroform-d, 101 MHz) : δ = 167.1, 141.3, 128.6, 128.4, 126.1, 47.3, 43.9, 40.0, 
33.5, 29.9, 18.8. 
IR (neat): ν = 2925, 1738, 1400, 701 cm-1. 
HRMS (ESI): Calculated for C13H17NNaO4 ([M+Na]+): 226.1202; found: 226.1203 
 
Methyl 3-(2-methyl-4-oxoazetidin-1-yl)propanoate 2.68: 
 
Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with methyl 3-((chlorocarbonyl)(isopropyl)amino)propanoate (29.5 mg, 0.133 mmol, 1 
equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI (12 mg , 0.0266 
mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 mg, 0.4 
mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system was reacted for 18h at 120 
°C. The crude mixture was purified by flash chromatography using first cyclohexane to elute 
mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide oil 2.68 (12.5 mg, 
0.065 mmol, 50 %). 
Conditions B: CO atmosphere 
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Following general procedure B, methyl 3-((chlorocarbonyl)(isopropyl)amino)propanoate (29.5 
mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium 
A.HI (12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium 
carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO atmosphere. The 
mixture was stirred for 18h at 120 °C, The crude mixture was purified by flash chromatography 
using first cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, 
to provide oil 2.68 (12 mg, 0.060 mmol, 49 %). 
1H NMR (400 MHz, Chloroform-d ) : δ = 4.15 (q, J = 7.1 Hz, 2H), 3.72 – 3.64 (m, 1H), 3.60 
(dt, J = 14.5, 6.5 Hz, 1H), 3.33 – 3.23 (m, 1H), 3.03 (dd, J = 14.5, 4.9 Hz, 1H), 2.66 – 2.50 (m, 
2H), 2.47 (dd, J = 14.5, 2.3 Hz, 1H), 1.32 (d, J = 6.1 Hz, 3H), 1.26 (t, J = 7.1 Hz, 3H). 
 
13C NMR (Chloroform-d, 101 MHz) :  δ = 171.6, 167.1, 60.1, 48.0, 44.2, 36.0, 33.6, 18.7, 14.3. 
 
IR (neat): ν = 2923, 1737, 1396, 1183 cm-1. 
HRMS (ESI): Calculated for C9H15NNaO3 ([M+Na]+): 208.0944; found: 208.0946 
 
2-(3-(2-Methyl-4-oxoazetidin-1-yl)propyl)isoindoline-1,3-dione 2.69 : 
 
Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with (3-(1,3-dioxoisoindolin-2-yl)propyl)(isopropyl)carbamoyl chloride (41.1 mg, 0.133 
mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI (12 mg 
, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 
mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system was reacted for 
18h at 120 °C. The crude mixture was purified by flash chromatography using first cyclohexane 
to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide oil 2.69 (15.6 
mg, 0.057 mmol, 43 %). 
Conditions B: CO atmosphere 
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Following general procedure B, (3-(1,3-dioxoisoindolin-2-yl)propyl)(isopropyl)carbamoyl 
chloride(41.1 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), 
catacXium A.HI (12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) 
and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO 
atmosphere. The mixture was stirred for 18h at 120 °C, The crude mixture was purified by flash 
chromatography using first cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 
to 0:1) as eluent, to provide oil 2.69 (8.0 mg, 0.029 mmol, 22 %). 
1H NMR (400 MHz, Chloroform-d ) : δ = 7.87 – 7.80 (m, 2H), 7.76 – 7.69 (m, 2H), 3.82 – 3.66 
(m, 3H), 3.46 – 3.31 (m, 1H), 3.15 – 3.01 (m, 2H), 2.50 (dd, J = 14.5, 2.3 Hz, 1H), 2.01 – 1.85 
(m, 3H), 1.34 (d, J = 6.1 Hz, 3H). 
 
13C NMR (Chloroform-d, 101 MHz) : δ = 168.4, 167.2, 134.2, 132.2, 123.4, 47.6, 44.1, 38.1, 
35.8, 27.3, 18.9. 
IR (neat): ν = 1711, 1742, 1397, 722 cm-1. 
HRMS (ESI): Calculated for C15H16N2NaO3 ([M+Na]+): 295.1059; found: 295.1057 
 
4-Ethyl-4-methyl-1-(3-phenylpropyl)azetidin-2-one 2.70: 
 
Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with tert-pentyl(3-phenylpropyl)carbamoyl chloride (35.6 mg, 0.133 mmol, 1 equiv) was 
reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI (12 mg , 0.0266 mmol, 20 
mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 3.0 
equiv) in mesitylene (2.62 mL). The two chambers system was reacted for 18h at 120 °C. The 
crude mixture was purified by flash chromatography using first cyclohexane to elute mesitylene 
and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide oil 2.70 (22.5 mg, 0.097 mmol, 
73 %). 
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Conditions B: CO atmosphere 
Following general procedure B, tert-pentyl(3-phenylpropyl)carbamic chloride (35.6 mg, 0.133 
mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI (12 mg 
, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 
mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO atmosphere. The mixture was 
stirred for 18h at 120 °C, The crude mixture was purified by flash chromatography using first 
cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide 
oil 2.70 (22.2 mg, 0.096 mmol, 72 %). 
1H NMR (400 MHz, Chloroform-d ) : δ = 7.30 – 7.17 (m, 5H), 3.21 – 3.03 (m, 2H), 2.75 (d, J 
= 14.3 Hz, 1H), 2.70 – 2.61 (m, 2H), 2.57 (d, J = 14.3 Hz, 1H), 1.95 – 1.85 (m, 2H), 1.76 – 1.67 
(m, 1H), 1.64 – 1.55 (m, 1H), 1.35 (s, 3H), 0.92 (t, J = 7.5 Hz, 3H). 
 
13C NMR (Chloroform-d, 101 MHz) : δ = 167.1, 141.4, 128.5, 128.5, 126.1, 58.8, 47.1, 39.4, 
33.7, 31.0, 30.8, 23.1, 9.1. 
IR (neat): ν = 2924, 1739, 1399, 733 cm-1. 
HRMS (ESI): Calculated for C15H22NO ([M+H]+): 232.1696; found: 232.1699 
 
4-Methyl-4-phenyl-1-(3-phenylpropyl)azetidin-2-one 2.71: 
 
Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with (2-phenylpropan-2-yl)(3-phenylpropyl)carbamoyl chloride (42 mg, 0.133 mmol, 1 
equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI (12 mg , 0.0266 
mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 mg, 0.4 
mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system was reacted for 18h at 120 
°C. The crude mixture was purified by flash chromatography using first cyclohexane to elute 
mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide oil 2.71 (20.8 mg, 
0.074 mmol, 56 %). 
Conditions B: CO atmosphere 
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Following general procedure B, (2-phenylpropan-2-yl)(3-phenylpropyl)carbamoyl chloride (42 
mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium 
A.HI (12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium 
carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO atmosphere. The 
mixture was stirred for 18h at 120 °C, The crude mixture was purified by flash chromatography 
using first cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, 
to provide oil 2.71 (21.2 mg, 0.076 mmol, 57 %). 
1H NMR (400 MHz, Chloroform-d ) : δ = 7.42 – 7.07 (m, 10H), 3.32 – 3.24 (m, 1H), 3.03 (s, 
2H), 3.01 – 2.95 (m, 1H), 2.69 – 2.53 (m, 2H), 1.92 – 1.80 (m, 2H), 1.84 (s, 3H). 
 
13C NMR (Chloroform-d, 101 MHz) : δ = 167.7, 142.1, 141.3, 128.9, 128.5, 128.4, 127.9, 126.1, 
125.6, 59.0, 53.9, 40.5, 33.7, 30.4, 23.4. 
IR (neat): ν = 2926, 1743, 1395, 732 cm-1. 
HRMS (ESI): Calculated for C19H21NNaO ([M+Na]+): 302.1515; found: 302.1517 
 
1-(3,7-Dimethyloct-6-en-1-yl)-4,4-dimethylazetidin-2-one 2.72:  
 
Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with tert-butyl(3,7-dimethyloct-6-en-1-yl)carbamoyl chloride (36.4 mg, 0.133 mmol, 1 
equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI (12 mg , 0.0266 
mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 mg, 0.4 
mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system was reacted for 18h at 120 
°C. The crude mixture was purified by flash chromatography using first cyclohexane to elute 
mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide oil 2.72 (31.6 mg, 
0.133 mmol, 100 %). 
Conditions B: CO atmosphere 
Following general procedure B, tert-butyl(3,7-dimethyloct-6-en-1-yl)carbamoyl chloride (36.4 
mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium 
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A.HI (12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium 
carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO atmosphere. The 
mixture was stirred for 18h at 120 °C, The crude mixture was purified by flash chromatography 
using first cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, 
to provide oil 2.72 (24 mg, 0.101 mmol, 76 %). 
1H NMR (400 MHz, Chloroform-d ): δ = 5.12 – 5.02 (m, 1H), 3.09 (t, J = 7.7 Hz, 2H), 2.68 (s, 
2H), 2.03 – 1.88 (m, 2H), 1.69 – 1.65 (m, 3H), 1.58 (s, 3H), 1.36 (s, 6H), 1.54 – 1.09 (m, 5H), 0.90 
(d, J = 6.3 Hz, 3H). 
 
13C NMR (Chloroform-d, 101 MHz):  δ = 166.5, 131.5, 124.7, 55.4, 50.4, 37.7, 37.0, 36.1, 30.6, 
25.8, 25.5, 25.3, 19.3, 17.8. 
IR (neat): ν = 2925, 1736, 1402, 911, 732cm-1. 
HRMS (ESI): Calculated for C15H27NNaO ([M+Na]+): 260.1985; found: 260.1985 
 
1-(((1R,5S)-6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-yl)methyl)-4,4-dimethylazetidin-2-one 
2.73:  
 
Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with tert-butyl(((1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)methyl)carbamoyl 
chloride (35.9 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), 
catacXium A.HI (12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) 
and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers 
system was reacted for 18h at 120 °C. The crude mixture was purified by flash chromatography 
using first cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, 
to provide oil 2.73 (16.5 mg, 0.07 mmol, 53 %). 
Conditions B: CO atmosphere 
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Following general procedure B, tert-butyl(((1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-
yl)methyl)carbamoyl chloride (35.9 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 
0.0133 mmol, 10 mol%), catacXium A.HI (12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 
0.04 mmol, 30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 
mL), under CO atmosphere. The mixture was stirred for 18h at 120 °C, The crude mixture was 
purified by flash chromatography using first cyclohexane to elute mesitylene and then 
cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide oil 2.73 (15.5 mg, 0.067 mmol, 50 %). 
1H NMR (400 MHz, Chloroform-d ): δ = 5.46 – 5.40 (m, 1H), 3.82 (dq, J = 15.5, 2.2 Hz, 1H), 
3.38 (d, J = 15.5 Hz, 1H), 2.71 (s, 2H), 2.39 (dt, J = 8.6, 5.6 Hz, 1H), 2.29 – 2.18 (m, 2H), 2.17 – 
2.14 (m, 1H), 2.11 – 2.01 (m, 1H), 1.37 (s, 3H), 1.35 (s, 3H), 1.27 (s, 3H), 1.13 (d, J = 8.6 Hz, 1H), 
0.81 (s, 3H). 
 
13C NMR (Chloroform-d, 101 MHz):  δ = 166.9, 144.1, 120.1, 55.7, 50.6, 44.3, 43.8, 40.7, 38.2, 
31.8, 31.4, 26.2, 26.0, 24.6, 21.0. 
IR (neat): ν = 1731, 907, 728 cm-1. 
HRMS (ESI): Calculated for C15H23NNaO ([M+Na]+): 256.1672; found: 256.1672 
 
Optical rotation : []D20 = -59.1° (c = 0.8, CHCl3) 
 
(S)-4,4-Dimethyl-1-((4-(prop-1-en-2-yl)cyclohex-1-en-1-yl)methyl)azetidin-2-one 2.74: 
 
Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with (S)-tert-butyl((4-(prop-1-en-2-yl)cyclohex-1-en-1-yl)methyl)carbamoyl chloride 
(35.9 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), 
catacXium A.HI (12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) 
and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers 
system was reacted for 18h at 120 °C. The crude mixture was purified by flash chromatography 
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using first cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, 
to provide oil 2.74 (18.9 mg, 0.081 mmol, 68 %). 
Conditions B: CO atmosphere 
Following general procedure B, (S)-tert-butyl((4-(prop-1-en-2-yl)cyclohex-1-en-1-
yl)methyl)carbamoyl (35.9 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 
mmol, 10 mol%), catacXium A.HI (12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 
mmol, 30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), 
under CO atmosphere. The mixture was stirred for 18h at 120 °C, The crude mixture was purified 
by flash chromatography using first cyclohexane to elute mesitylene and then 
cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide oil 2.74 (18.3 mg, 0.078 mmol, 59 %). 
1H NMR (400 MHz, Chloroform-d ): δ = 5.66 – 5.60 (m, 1H), 4.74 – 4.67 (m, 2H), 3.70 (d, J = 
15.0 Hz, 1H), 3.57 (d, J = 15.0 Hz, 1H), 2.72 (s, 2H), 2.21 – 1.77 (m, 7H), 1.75 – 1.71 (m, 3H), 1.38 
(s, 3H), 1.35 (s, 3H). 
 
13C NMR (Chloroform-d, 101 MHz):  δ = 166.9, 149.7, 133.5, 124.9, 108.8, 55.9, 50.8, 45.6, 
41.0, 30.8, 27.6, 26.9, 25.2, 24.8, 20.9. 
IR (neat): ν = 2921, 1745, 1392, 732 cm-1. 
HRMS (ESI): Calculated for C15H23NNaO ([M+Na]+): 256.1672 found: 256.1672 
 
Optical rotation : []D20 = -65.5° (c = 1.1, CHCl3) 
 
5-Methyl-3-oxa-1-azaspiro[bicyclo[3.2.0]heptane-2,1'-cyclohexan]-7-one 2.75: 
 
Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with 3,3-dimethyl-1-oxa-4-azaspiro[4.5]decane-4-carbamoyl chloride (30.8 mg, 0.133 
mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI (12 mg 
, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 
mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system was reacted for 
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18h at 120 °C. The crude mixture was purified by flash chromatography using first cyclohexane 
to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide oil 2.75 (18.2 
mg, 0.093 mmol, 70 %). 
Conditions B: CO atmosphere 
Following general procedure B, ethyl(2,4,6-trimethoxybenzyl)carbamoyl chloride (30.8 mg, 
0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI 
(12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium 
carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO atmosphere. The 
mixture was stirred for 18h at 120 °C, The crude mixture was purified by flash chromatography 
using first cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, 
to provide oil 2.75 (18.2 mg, 0.093 mmol, 70 %). 
1H NMR (400 MHz, Chloroform-d) : δ = 3.89 (d, J = 9.0 Hz, 1H), 3.82 (d, J = 9.0 Hz, 1H), 2.91 
(d, J = 15.9 Hz, 1H), 2.86 (d, J = 15.9 Hz, 1H), 2.21 (m, 1H), 1.88 – 1.56 (m, 6H), 1.55 (s, 3H), 1.53 
– 1.39 (m, 3H). 
 
13C NMR (Chloroform-d, 101 MHz):  δ = 175.4, 98.5, 73.9, 59.1, 47.7, 35.9, 32.7, 25.2, 24.5, 
23.9, 23.5. 
IR (neat): ν = 2935, 2859, 1768, 1450, 1264, 913, 731 cm-1. 
HRMS (ESI): Calculated for C11H17NNaO2 ([M+Na]+): 218.1151; found: 218.1150 
 
5-(2,4,6-Trimethoxybenzyl)-5-azaspiro[2.3]hexan-4-one 2.76: 
 
Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with (cyclopropylmethyl)(2,4,6-trimethoxybenzyl)carbamoyl chloride (41.7 mg, 0.133 
mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI (12 mg 
, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 
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mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system was reacted for 
18h at 120 °C. The crude mixture was purified by flash chromatography using first cyclohexane 
to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide oil 2.76 (27.6 
mg, 0.100 mmol, 75 %). 
Conditions B: CO atmosphere 
Following general procedure B, ((cyclopropylmethyl)(2,4,6-trimethoxybenzyl)carbamoyl 
chloride (41.7 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), 
catacXium A.HI (12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) 
and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO 
atmosphere. The mixture was stirred for 18h at 120 °C, The crude mixture was purified by flash 
chromatography using first cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 
to 0:1) as eluent, to provide oil 2.76 (27.7 mg, 0.102 mmol, 76 %). 
1H NMR (400 MHz, Chloroform-d): δ = 6.13 (s, 2H), 4.47 (s, 2H), 3.84 – 3.79 (m, 9H), 3.21 
(s, 2H), 1.14 – 1.06 (m, 2H), 0.86 – 0.79 (m, 2H). 
 
13C NMR (Chloroform-d, 101 MHz):  δ = 172.0, 161.2, 159.7, 104.7, 90.5, 55.9, 55.5, 48.5, 34.4, 
31.6, 7.3. 
IR (neat): ν = 2968, 1745, 1608, 1147, 669 cm-1. 
HRMS (ESI): Calculated for C15H19NNaO4 ([M+Na]+): 300.1206; found: 300.1208 
 
6-Cyclopropyl-5-(2,4,6-trimethoxybenzyl)-5-azaspiro[2.3]hexan-4-one 2.77:  
 
Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with (dicyclopropylmethyl)(2,4,6-trimethoxybenzyl)carbamoyl chloride (47.1 mg, 0.133 
mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI (12 mg 
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, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 
mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system was reacted for 
18h at 120 °C. The crude mixture was purified by flash chromatography using first cyclohexane 
to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide oil 2.77 (34 
mg, 0.107 mmol, 81 %). 
Conditions B: CO atmosphere 
Following general procedure B, (dicyclopropylmethyl)(2,4,6-trimethoxybenzyl)carbamoyl 
chloride (47.1 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), 
catacXium A.HI (12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) 
and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO 
atmosphere. The mixture was stirred for 18h at 120 °C, The crude mixture was purified by flash 
chromatography using first cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 
to 0:1) as eluent, to provide oil 2.77 (34 mg, 0.107 mmol, 81 %). 
1H NMR (400 MHz, Chloroform-d) : δ = 6.10 (s, 2H), 4.59 (d, J = 14.0 Hz, 1H), 4.41 (d, J = 
14.0 Hz, 1H), 3.82 – 3.78 (m, 9H), 2.55 (d, J = 9.3 Hz, 1H), 1.16 – 0.98 (m, 1H), 0.95 – 0.85 (m, 
1H), 0.83 – 0.73 (m, 1H), 0.71 – 0.58 (m, 1H), 0.41 – 0.26 (m, 2H), -0.02 – -0.11 (m, 1H), -0.19 – -
0.28 (m, 1H). 
 
13C NMR (Chloroform-d, 101 MHz):  δ = 172.4, 161.0, 159.7, 104.9, 90.3, 64.1, 55.7, 36.6, 33.5, 
11.6, 7.2, 5.9, 2.4, 0.1. 
IR (neat): ν = 2937, 1736, 1597, 1138, 728 cm-1. 
HRMS (ESI): Calculated for C18H23NNaO4 ([M+Na]+): 340.1519; found: 340.1523 
 
1-Isopropyl-1,2a,7,7a-tetrahydro-2H-indeno[2,1-b]azet-2-one 2.78: 
 
Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with (2,3-dihydro-1H-inden-2-yl)(isopropyl)carbamoyl chloride (31.6 mg, 0.133 mmol, 1 
equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI (12 mg , 0.0266 
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mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 mg, 0.4 
mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system was reacted for 18h at 120 
°C. The crude mixture was purified by flash chromatography using first cyclohexane to elute 
mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide oil 2.78 (20.9 mg, 
0.104 mmol, 78 %). 
Conditions B: CO atmosphere 
Following general procedure B, (2,3-dihydro-1H-inden-2-yl)(isopropyl)carbamoyl chloride (31.6 
mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium 
A.HI (12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium 
carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO atmosphere. The 
mixture was stirred for 18h at 120 °C, The crude mixture was purified by flash chromatography 
using first cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, 
to provide oil 2.78 (20.9 mg, 0.104 mmol, 78 %). 
1H NMR (400 MHz, Chloroform-d): δ = 7.46 – 7.39 (m, 1H), 7.25 – 7.19 (m, 3H), 4.48 (d, J = 
4.0 Hz, 1H), 4.40 (ddd, J = 6.3, 4.0, 1.3 Hz, 1H), 3.83 (hept, J = 6.8 Hz, 1H), 3.24 – 2.99 (m, 
3H), 1.30 (d, J = 6.8 Hz, 3H), 1.23 (d, J = 6.8 Hz, 3H). 
 
13C NMR (Chloroform-d, 101 MHz):  δ = 168.5, 142.1, 137.7, 127.9, 127.4, 126.3, 125.2, 61.5, 
53.6, 44.3, 35.4, 22.1, 20.7. 
IR (neat): ν = 2973, 1742, 672 cm-1. 
HRMS (ESI): Calculated for C13H15NNaO ([M+Na]+): 224.1046; found: 224.1043 
 
1-(2,4,6-Trimethoxybenzyl)-1,2a,7,7a-tetrahydro-2H-indeno[2,1-b]azet-2-one 2.79: 
 
 
 
Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with (2,3-dihydro-1H-inden-2-yl)(2,4,6-trimethoxybenzyl)carbamoyl chloride (52 mg, 
0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI 
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(12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium 
carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system was 
reacted for 18h at 120 °C. The crude mixture was purified by flash chromatography using first 
cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide 
oil 2.79 (42 mg, 0.124mmol, 93 %). 
Conditions B: CO atmosphere 
Following general procedure B, (2,3-dihydro-1H-inden-2-yl)(2,4,6-trimethoxybenzyl)carbamoyl 
chloride (52 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), 
catacXium A.HI (12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) 
and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO 
atmosphere. The mixture was stirred for 18h at 120 °C, The crude mixture was purified by flash 
chromatography using first cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 
to 0:1) as eluent, to provide oil 2.79 (30.6 mg, 0.09 mmol, 68 %). 
1H NMR (400 MHz, Chloroform-d ) : δ = 7.44 – 7.39 (m, 1H), 7.23 – 7.16 (m, 3H), 6.13 (s, 
2H), 4.56 (d, J = 13.9 Hz, 1H), 4.43 (d, J = 3.9 Hz, 1H), 4.20 (d, J = 13.9 Hz, 1H), 4.12 – 4.05 
(m, 1H), 3.83 (s, 3H), 3.80 (s, 6H), 3.06 (d, J = 17.6 Hz, 1H), 2.82 (dd, J = 17.5, 6.8 Hz, 1H). 
 
13C NMR (Chloroform-d, 101 MHz) :  δ = 168.3, 161.3, 159.6, 142.7, 138.1, 127.7, 127.1, 
126.2, 125.2, 104.4, 90.4, 62.0, 55.8, 55.5, 55.1, 33.3, 32.2. 
 
IR (neat): ν = 2939, 1737, 1596, 1459, 1131, 728 cm-1. 
HRMS (ESI): Calculated for C20H21NNaO4 ([M+Na]+): 362.1363; found: 362.1365 
 
1-(2,4,6-Trimethoxybenzyl)-2a,3,4,8b-tetrahydronaphtho[1,2-b]azet-2(1H)-one 2.80: 
 
Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
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charged with (1,2,3,4-tetrahydronaphthalen-1-yl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 
(51.9 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), 
catacXium A.HI (12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) 
and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers 
system was reacted for 18h at 120 °C. The crude mixture was purified by flash chromatography 
using first cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, 
to provide oil 2.80 (47.0 mg, 0.133 mmol, 100 %). 
Conditions B: CO atmosphere 
Following general procedure B, (1,2,3,4-tetrahydronaphthalen-1-yl)(2,4,6-
trimethoxybenzyl)carbamoyl chloride (51.9 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 
mg, 0.0133 mmol, 10 mol%), catacXium A.HI (12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 
mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene 
(2.62 mL), under CO atmosphere. The mixture was stirred for 18h at 120 °C, The crude mixture 
was purified by flash chromatography using first cyclohexane to elute mesitylene and then 
cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide oil 2.80 (22.6 mg, 0.064 mmol, 48 %). 
1H NMR (400 MHz, Chloroform-d): δ = 7.22 – 7.12 (m, 1H), 7.12 – 7.06 (m, 1H), 7.02 (m, 1H), 
6.80 (m, 1H), 6.00 (s, 2H), 4.44 (d, J = 13.9 Hz, 1H), 4.31 (d, J = 4.9 Hz, 1H), 4.04 (d, J = 13.8 Hz, 
1H), 3.80 (s, 3H), 3.73 (s, 6H), 3.55 – 3.47 (m, 1H), 2.86 – 2.56 (m, 2H), 2.37 – 2.24 (m, 1H), 1.57 
– 1.36 (m, 1H). 
13C NMR (Chloroform-d, 101 MHz):  δ = 169.4, 161.2, 159.6, 139.9, 133.2, 130.6, 128.4, 127.8, 
125.6, 103.8, 90.2, 55.6, 55.5, 53.6, 49.7, 33.0, 27.0, 23.0. 
IR (neat): ν = 2935, 1737, 1597, 1133 cm-1. 
HRMS (ESI): Calculated for C21H23NNaO4 ([M+Na]+): 376.1519; found: 376.1521 
 
(–)-2(aR,8bR)-1-(2,4,6-Trimethoxybenzyl)-2a,3,4,8b-tetrahydronaphtho[1,2-b]azet-2(1H)-
one 2.97p:  
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Standard synthesis: 
Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with (1,2,3,4-tetrahydronaphthalen-1-yl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 
(51.9 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), 
catacXium A.HI (12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) 
and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers 
system was reacted for 18h at 120 °C. The crude mixture was purified by flash chromatography 
using first cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, 
to provide oil 2.97p (46.0 mg, 0.130 mmol, 98 %). 
Conditions B: CO atmosphere 
Following general procedure B, (1,2,3,4-tetrahydronaphthalen-1-yl)(2,4,6-
trimethoxybenzyl)carbamoyl chloride (51.9 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 
mg, 0.0133 mmol, 10 mol%), catacXium A.HI (12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 
mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene 
(2.62 mL), under CO atmosphere. The mixture was stirred for 18h at 120 °C, The crude mixture 
was purified by flash chromatography using first cyclohexane to elute mesitylene and then 
cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide oil 2.97p (32 mg, 0.09 mmol, 63 %). 
Tenfold scale synthesis: 
Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (89 mg, 0.4 mmol,  30 
mol%), P(t-Bu)3.HBF4 (120 mg , 0.4 mmol, 30 mol%), COgen (970 mg, 4 mmol, 3.0 equiv), 
Cy2NMe (1.610 g, 7.98 mmol, 6.0 equiv) and mesitylene (5 mL).  Chamber B, previously charged 
with (1,2,3,4-tetrahydronaphthalen-1-yl)(2,4,6-trimethoxybenzyl)carbamoyl chloride (519 mg, 
1.33 mmol, 1 equiv) was reacted with PdCl2 (24 mg, 0.133 mmol, 10 mol%), catacXium A.HI (120 
mg , 0.266 mmol, 20 mol%), pivalic acid (41 mg, 0.4 mmol, 30 mol%) and cesium carbonate 
(1.30 g, 4 mmol, 3.0 equiv) in mesitylene (26.2 mL). The two chambers system was reacted for 
18h at 120 °C. The crude mixture was purified by flash chromatography using first cyclohexane 
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to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide oil 2.97p 
(385 mg, 1.09 mmol, 82 %). 
Optical rotation : []D20 = -38.8° (c = 1.3, CHCl3) 
 
1-(2,4,6-Trimethoxybenzyl)-1,2a,3,7b-tetrahydro-2H-indeno[1,2-b]azet-2-one 2.81:  
 
Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with (2,3-dihydro-1H-inden-1-yl)(2,4,6-trimethoxybenzyl)carbamoyl chloride (50 mg, 
0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI 
(12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium 
carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system was 
reacted for 18h at 120 °C. The crude mixture was purified by flash chromatography using first 
cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide 
oil 2.81 (21 mg, 0.062 mmol, 47 %). 
Conditions B: CO atmosphere 
Following general procedure B, (2,3-dihydro-1H-inden-1-yl)(2,4,6-trimethoxybenzyl)carbamoyl 
chloride (50 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), 
catacXium A.HI (12 mg , 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) 
and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO 
atmosphere. The mixture was stirred for 18h at 120 °C, The crude mixture was purified by flash 
chromatography using first cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 
to 0:1) as eluent, to provide oil 2.81 (11 mg, 0.032 mmol, 25 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.28 – 7.23 (m, 2H), 7.15 – 7.11 (m, 2H), 6.13 (s, 2H), 
4.72 (dd, J = 4.2, 1.0 Hz, 1H), 4.56 (d, J = 14.1 Hz, 1H), 4.04 (d, J = 14.1 Hz, 1H), 3.85 – 3.82 
(m, 1H), 3.36 – 3.27 (m, 1H), 2.97 (dd, J = 17.4, 10.4 Hz, 1H). 
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13C NMR (101 MHz, Chloroform-d) δ = 169.7, 161.3, 159.7, 145.2, 139.6, 128.7, 126.4, 126.4, 
126.0, 104.7, 90.5, 62.0, 55.8, 55.5, 52.3, 33.0, 30.2. 
IR (neat): ν = 1743, 670  cm-1. 
HRMS (ESI): Calculated for C20H21NNaO4 ([M+Na]+): 312.1368; found: 312.1369 
 
7-Cyclohexyl-7-azabicyclo[4.2.0]octan-8-one 2.82:  
 
Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with dicyclohexylcarbamoyl chloride (32.4 mg, 0.133 mmol, 1 equiv) was reacted with 
PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI (12 mg , 0.0266 mmol, 20 mol%), 
pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) 
in mesitylene (2.62 mL). The two chambers system was reacted for 18h at 120 °C. The crude 
mixture was purified by flash chromatography using first cyclohexane to elute mesitylene and 
then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide oil 2.82 (8.5 mg, 0.041 mmol, 29 
%). 
Conditions B: CO atmosphere 
Following general procedure B, dicyclohexylcarbamoyl chloride (32.4 mg, 0.133 mmol, 1 equiv) 
was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI (12 mg , 0.0266 mmol, 
20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 
3.0 equiv) in mesitylene (2.62 mL), under CO atmosphere. The mixture was stirred for 18h at 120 
°C, The crude mixture was purified by flash chromatography using first cyclohexane to elute 
mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide oil 2.82 (7 mg, 0.034 
mmol, 25 %). 
1H NMR (250 MHz, Chloroform-d) δ = 3.78 (dt, J = 5.5, 3.6 Hz, 1H), 3.46 (ddt, J = 11.5, 7.8, 
3.6 Hz, 1H), 3.08 (td, J = 5.5, 4.1 Hz, 1H), 1.89 – 1.20 (m, 22H + H2O). 
 
13C NMR (63 MHz, Chloroform-d) δ = 170.3, 51.5, 49.3, 46.1, 32.0, 30.7, 25.4, 25.3, 24.7, 19.6, 
18.7, 16.9. 
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IR (neat): ν = 2932, 1732 cm-1. 
HRMS (ESI): Calculated for C13H21NNaO ([M+Na]+): 230.1515; found: 230.1513 
 
 
 
 
 
Trans-4-ethyl-3-methyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-one and Cis-4-ethyl-3-
methyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-one 2.83: 
 
 
Conditions A: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with Pentan-3-yl(2,4,6-trimethoxybenzyl)carbamoyl (43.9 mg, 0.133 mmol, 1 equiv) was 
reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI (12 mg , 0.0266 mmol, 20 
mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 3.0 
equiv) in mesitylene (2.62 mL). The two chambers system was reacted for 18h at 120 °C. The 
crude mixture was purified by flash chromatography using first cyclohexane to elute mesitylene 
and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide oil 2.83 (20 mg, 0.068 mmol, 51 
%). 
Conditions B: CO atmosphere 
Following general procedure B, Pentan-3-yl(2,4,6-trimethoxybenzyl)carbamoyl (43.9 mg, 0.133 
mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), catacXium A.HI (12 mg 
, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 
mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO atmosphere. The mixture was 
stirred for 18h at 120 °C, The crude mixture was purified by flash chromatography using first 
cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to provide 
oil 2.83 (16 mg, 0.055 mmol, 41 %). 
 
 
Trans-4-ethyl-3-methyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-one : 
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1H NMR (500 MHz, Chloroform-d) δ = 6.11 (s, 2H), 4.55 (d, J = 13.9 Hz, 1H), 4.16 (dd, J = 
13.9, 1.1 Hz, 1H), 3.82 (s, 3H), 3.80 (s, 6H), 2.78 – 2.74 (m, 1H), 2.66 – 2.61 (m, 1H), 1.71 – 1.63 
(m, 1H), 1.34 – 1.26 (m, 1H), 1.17 (d, J = 7.3 Hz, 3H), 0.81 (t, J = 7.5 Hz, 3H). 
 
13C NMR (126 MHz, Chloroform-d) δ = 170.5, 161.1, 159.7, 104.5, 90.3, 60.9, 55.8, 55.4, 
48.9, 32.7, 25.2, 13.4, 9.4. 
IR (neat): ν = 2952, 1749, 1610, 1140, 740 cm-1 
 
HRMS (ESI): Calculated for C16H23NNaO4 ([M+Na]+): 316.1525; found: 316.1528 
 
 
Cis-4-ethyl-3-methyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-one : 
 
1H NMR (500 MHz, Chloroform-d) δ = 6.11 (s, 2H), 4.58 (d, J = 13.4 Hz, 1H), 4.11 (d, J = 14.0 
Hz, 1H), 3.81 (s, 3H), 3.80 (s, 6H), 3.18 – 3.14 (m, 1H), 3.10 – 3.04 (m, 1H), 1.72 – 1.66 (m, 1H), 
1.43 – 1.35 (m, 1H), 1.16 (d, J = 6.6 Hz, 3H), 0.81 (t, J = 7.5 Hz, 3H). 
 
13C NMR (126 MHz, Chloroform-d) δ = 171.0, 56.3, 55.8, 46.3, 32.6, 21.3, 10.7, 9.0. 
 
 
(R)-4-Methylazetidin-2-one 2.86:  
 
4-methyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-one (135 mg, 0.509 mmol, 1 equiv), K2S2O8 
(275 mg, 1.02 mmol, 2 equiv) and Na2HPO4.7H2O (273 mg, 1.02 mmol, 2equiv) were stirred 
for 3h at 80 °C in MeCN/H2O [2:1] (18 mL). Then, the crude mixture was dried over MgSO4, 
filtered and evaporated. The residue was purified by chromatography on silica gel using 
AcOEt/EtOH [95:5] as eluent to provide (R)-4-methylazetidin-2-one 2.86 (33 mg, 0.388 mmol, 
76 %) as a yellowish oil. 
1H NMR (250 MHz, Chloroform-d) δ = 5.89 (br s, 1H), 3.83 – 3.73 (m, 1H), 3.11 (ddd, J = 14.7, 
5.0, 2.1 Hz, 1H), 2.55 (ddd, J = 14.8, 2.4, 1.5 Hz, 1H), 1.36 (d, J = 6.1 Hz, 3H). 
 
13C NMR (63 MHz, Chloroform-d) δ = 168.2, 45.1, 44.0, 21.3. 
 
IR (neat): ν = 1739, 1381, 908, 728 cm-1. 
[α]D20 = +2.8° (c = 1.14, CHCl3); lit. +3.6 (c = 2.3, CHCl3). 
 
The physical and spectroscopic properties matched those described in the literature.16 
 
(–)-2a,3,4,8b-Tetrahydronaphtho[1,2-b]azet-2(1H)-one 2.97:  
 
263 
 
 
Compound 2.97p (95 mg, 0.269 mmol, 1 equiv), K2S2O8 (145 mg, 0.538 mmol, 2 equiv) and 
Na2HPO4.7H2O (144 mg, 0.538 mmol, 2 equiv) were stirred for 3h at 80 °C in MeCN/H2O [2:1] 
(9.4 mL). Then, the crude mixture was filtered through a pad of MgSO4, and rinsed with MeCN. 
The filtrate was then treated with NBS (52.7 mg, 0.296 mmol, 1.1 equiv) and TMSCl (3.5 mL, 
0.0269 mmol, 0.1 equiv) and stirred for 30 min. The crude mixture was then evaporated and 
purified by chromatography on silica gel using DCM/MeOH 99:1 as eluent to provide oil 
compound 2.97 (42 mg, 0.245 mmol, 91 %).  
 
1H NMR (250 MHz, Chloroform-d) δ = 7.27 – 7.06 (m, 4H), 6.21 (s, 1H), 4.59 (d, J = 5.0 Hz, 
1H), 3.65 – 3.59 (m, 1H), 2.83 – 2.57 (m, 2H), 2.28 – 2.17 (m, 1H), 1.69 – 1.42 (m, 1H). 
 
13C NMR (63 MHz, Chloroform-d) δ = 170.8, 139.4, 134.1, 129.7, 129.1, 128.5, 126.6, 51.5, 
50.6, 26.9, 23.0. 
 
HRMS (ESI): Calculated for C11H11NNaO ([M+Na]+): 196.0733; found: 196.0731 
 
Optical rotation : []D20 = -89.3° (c = 1.0, CHCl3) 
 
The physical and spectroscopic properties matched those described in the literature.17 
 
 
(1R,2R)-1-Amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid hydrochloride 2.98:  
 
 
Following a methodology from F. Fulöp et al., compound 2.97 was refluxed for 3h in an 
aqueous HCl solution (2 mL, 6M). The solvent was removed under vacuum to provide oil 
compound 2.98 as a yellowish solid (32 mg, 0.139 mmol, 100 %).  
1H NMR (250 MHz, D2O) δ = 7.42 – 7.24 (m, 4H), 4.82 (d, J = 3.5 Hz, 1H), 3.19 (dt, J = 12.0, 
3.5 Hz, 1H), 3.10 – 2.91 (m, 2H), 2.37 – 2.23 (m, 1H), 2.15 – 1.95 (m, 1H). 
 
13C NMR (101 MHz, D2O) δ = 176.8, 136.6, 130.0, 129.7, 129.5, 128.8, 126.6, 49.5, 41.3, 27.0, 
20.2. 
The physical and spectroscopic properties matched those described in the literature. 
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Chapter 1.3: Domino Pd0-Catalysed C(sp3)-H 
Arylation/Electrocyclic Reactions via Benzazetidine 
Intermediates 
Supplementary schemes 
Scheme S1. Unified mechanism explaining the formation of the demethylated product and 
benzoxazine isomers. 
 
After oxidative addition of substrate 1 and substitution of the bromide with pivalate, base-
mediated C(sp3)–H activation18 leads to palladacycle B1. Carbonate-mediated decoordination 
of pivalic acid leads to palladacycle C, which furnishes BAZ1 upon reductive elimination. 
Thermal 4/6 electrocyclic reactions lead ultimately to BOX1. Alternatively, complex B1 
undergoes proton transfer to the aromatic ring to give the open Pd complex D.19 The latter can 
undergo pivalate-mediated C(sp2)–H activation to give palladacycle B2, which leads to isomeric 
BOX2 via BAZ2 in a similar way to B1. However, when Z is a methyl group, complex D 
preferentially undergoes elimination to give the iminium E, which hydrolyzes to give the 
observed demethylated product.20 
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Scheme S2. Top: computed reductive elimination leading to benzazetidines with three different 
nitrogen substituents; bottom: Non-Covalent Interaction (NCI) maps21 of the three transition 
states. 
 
See also computational details. 
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General procedures 
GENERAL PROCEDURE FOR ACID CHLORIDE SYNTHESIS: 
Carboxylic acids (1 eq) were dissolved in dichloromethane (0.1 M) with DMF (1 drop). Oxalyl 
chloride (2 eq) was added and the reaction was stirred for 2 h. The volatiles were removed under 
vacuum and the acid chlorides were used without further purification. 
GENERAL PROCEDURE FOR AMIDE SYNTHESIS: 
Acid chloride (1.5 eq) were dissolved in dichloromethane (0.1M) or 1,2-dichloroethane (0.1 M) 
(as specified) and o-bromo substituted anilines (1 eq), Et3N (2 eq) in dichloromethane (0.1M) 
or 1,2-dichloroethane (0.1 M) (as specified) were added carefully at room temperature. The 
mixture was stirred at 60°C and followed by TLC (Cyclohexane/AcOEt). After completion, the 
solvent was removed under vacuum and the crude mixture was purified by chromatography 
over silica gel (cyclohexane/AcOEt).  
Amides (1 eq) were dissolved in THF (0.1 M) and sodium hydride (60 % dispersion in oil, 2 eq) 
was carefully added to the turning solution. The mixture was stirred for 10 minutes, followed 
by addition of alkyl Iodide (2 eq). The mixture was stirred at reflux, and the reaction was 
followed by TLC (cyclohexane/AcOEt). After completion, the reaction was carefully quenched 
with water, and extracted 3 times with AcOEt. The combined organic layers were dried over 
sodium sulfate, filtered and evaporated under vacuum. The desired N-methylated amides were 
purified by chromatography on silica gel, using cyclohexane/AcOEt. 
GENERAL PROCEDURE FOR BENZOXAZINE SYNTHESIS: 
In a 10 mL screw-cap tube charged with amide (0.1 mmol, 1 equiv) was weighted in a glovebox 
Pd(PCy3)2 (0.01 mmol, 6.7 mg, 10 mol %), cesium pivalate (0.03 mmol, 7.1 mg, 30 mol %) (or 
Adamantane carboxylic acid (0.03 mmol, 5.4 mg, 30 mol %) as specified) and Cs2CO3 (0.3 
mmol, 98 mg, 3 equiv). The vial was charged with o-xylene (2 mL), sealed and stirred under 
argon in a previously heated heating block at 160 °C for 15 h. The reaction was cooled to room 
temperature, filtered over celite, and evaporated under vacuum. The crude mixture was purified 
by preparative HPLC using gradient of solvent (H2O: MeCN) [90:10] to [10:90]. The collected 
fraction were evaporated under vacuum to afford the desired product. 
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Synthesis of C–H activation substrates 
tert-butyl (2-bromophenyl)(methyl)carbamate 3.15b 22: 
 
2-bromoaniline (1 g, 5.81 mmol, 1 eq), Boc2O (1.9 g, 8.72 mmol, 1.5 eq) and sodium carbonate 
(925 mg, 8.72 mmol, 1.5 eq) were reacted in dioxane/water [1:1] (5 mL) at 80 °C for 6 h. After 
cooling to room temperature, the crude mixture was quenched with water (20 mL) and extracted 
with dichloromethane (3 x 20 mL). The combined organic layers were dried over Na2SO4, 
filtered and evaporated under vacuum. The crude mixture was purified by chromatography on 
silica gel using cyclohexane/AcOEt [9:1]. The desired carbamate was used for next step (1.35 
g, 4.96 mmol, 85 %). 
The intermediate amide (1.35 g, 4.96 mmol, 1 eq) was dissolved in THF (30 mL) and sodium 
hydride (60 % dispersion in oil, 400 mg, 9.92 mmol, 2 eq) was carefully added. The mixture 
was stirred for 10 minutes at room temperature, followed by addition of iodomethane (0.60 mL, 
9.92 mmol, 2 eq). The reaction was then stirred for 2 h, and quenched with water (30 mL). The 
crude mixture was extracted with AcOEt (3 x 20 mL) and the combined organic phases were 
dried over Na2SO4, filtered and evaporated under vacuum. The crude mixture was purified by 
chromatography over silica gel using cylohexane/AcOEt as solvent [9:1] to afford the pure 
compound as a colorless oil (1 g, 3.5 mmol, 71%).  
1H NMR (400 MHz, Chloroform-d) δ = 7.63 – 7.56 (m, 1H), 7.33 – 7.27 (m, 1H), 7.24 – 7.18 
(m, 1H), 7.16 – 7.10 (m, 1H), 3.15 (s, 3H), 1.34 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ = 154.6, 142.7, 133.6, 133.2, 130.1, 129.5, 128.9, 128.6, 128.3, 
123.5, 123.4, 80.7, 80.2, 37.4, 36.4, 28.5, 28.3. 
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methyl (2-bromophenyl)(methyl)carbamate 3.15c 23:  
 
O-bromo-N-methylaniline (150 mg, 0.806 mmol, 1 eq) was stirred in methylchloroformate (3 
mL) at reflux for 14 h. The crude mixture was evaporated under vacuum and purified by 
chromatography on silica gel using cylohexane/AcOEt as solvent [9:1]. The product was 
obtained as a colorless oil (171 mg, 0.7 mmol, 87 %).  
1H NMR (400 MHz, Chloroform-d) δ = 7.64 – 7.59 (m, 1H), 7.36 – 7.31 (m, 1H), 7.27 – 7.23 
(m, 1H), 7.20 – 7.13 (m, 1H), 3.82 – 3.56 (m, 3H), 3.20 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ = 156.0, 142.0, 133.5, 129.5, 129.1, 128.6, 123.4, 53.3, 37.3. 
N-(2-bromophenyl)-1,1,1-trifluoro-N-methylmethanesulfonamide 3.15d:  
 
 
O-bromo-N-methylaniline (150 mg, 0.806 mmol, 1 eq) was dissolved in dichloromethane (5 
mL) and sodium hydride (60 % dispersion in oil, 65 mg, 1.61 mmol, 2 eq) was carefully added. 
The mixture was stirred for 10 minutes at room temperature, followed by addition of Tf2O (0.41 
mL, 2.42 mmol, 3 eq). The reaction was then stirred for 2 h, and quenched with water (5 mL). 
The crude mixture was extracted with dichloromethane (3 x 5 mL) and the combined organic 
phases were dried over Na2SO4, filtered and evaporated under vacuum. The crude mixture was 
purified by chromatography over silica gel using cylohexane/AcOEt as solvent [9:1]. The 
product was obtained as a yellowish solid (170 mg, 0.53 mmol, 66 %).   
1H NMR (400 MHz, Chloroform-d) δ = 7.72 – 7.67 (m, 1H), 7.44 – 7.36 (m, 2H), 7.32 – 7.27 
(m, 1H), 3.41 (s, 3H). 
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13C NMR (101 MHz, CDCl3) δ = 138.4, 134.4, 131.1, 130.8, 129.0, 125.0, 124.6, 121.8, 118.6, 
115.4, 40.1. 
19F NMR (376 MHz, CDCl3) δ = -74.85. 
HRMS (ESI): Calculated for C8H8BrF3NO2S ([M+H]+): 317.9411; found: 317.9413 
m.p.: 70-72°C 
N-(2-bromophenyl)-2,2,2-trifluoro-N-methylacetamide 3.15e:  
 
O-bromo-N-methylaniline (150 mg, 0.806 mmol, 1 eq) was dissolved in dichloromethane (5 
mL) and sodium hydride (60 % dispersion in oil, 65 mg, 1.61 mmol, 2 eq) was carefully added. 
The mixture was stirred for 10 minutes at room temperature, followed by addition of (CF3CO)2O 
(0.34 mL, 2.42 mmol, 3 eq). The reaction was then stirred for 2h, and quenched with water (5 
mL). The crude mixture was extracted with dichloromethane (3 x 5 mL) and the combined 
organic phases were dried over Na2SO4, filtered and evaporated under vacuum. The crude 
mixture was purified by chromatography over silica gel using cylohexane/AcOEt as solvent 
[9:1]. The product was obtained as a yellowish oil (140 mg, 0.49 mmol, 61 %).   
1H NMR (500 MHz, Chloroform-d) δ = 7.70 – 7.66 (m, 1H), 7.43 – 7.37 (m, 1H), 7.33 – 7.28 
(m, 2H), 3.44 – 3.42 (m, 0.3H), 3.31 (s, 2.7H). 
13C NMR (126 MHz, CDCl3) δ = 157.4, 157.2, 156.9, 156.6, 141.0, 139.5, 134.1, 133.9, 130.9, 
130.3, 130.1, 130.1, 130.0, 130.0, 129.2, 128.7, 128.7, 123.3, 121.6, 119.6, 117.3, 115.0, 112.7, 38.1. 
19F NMR (471 MHz, CDCl3) δ = -68.7, -70.2. 
HRMS (ESI): Calculated for C9H8BrF3NO ([M+H]+): 281.9741; found: 281.9743 
IR (neat) : ν = 1662 cm-1 
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N-(2-bromophenyl)-N-methylcyclobutanecarboxamide 3.15f: 
 
Following general procedure for amides synthesis, cyclobutane acid chloride (270 mg, 2.28 
mmol, 2 eq), o-bromoaniline (200 mg, 1.15 mmol, 1 eq), Et3N (0.32 mL, 2.28 mmol, 2 eq) were 
reacted in dichloromethane (12 mL). After purification, the cyclobutane amide (289 mg, 1.15 
mmol, 1 eq) was reacted with sodium hydride (60 % dispersion in oil, 130 mg, 3.2 mmol, 3 eq), 
iodomethane (0.40 mL, 6 mmol, 6 eq) in THF (10 mL). After extraction and purification, the 
desired amide was obtained as a white solid (240 g, 0.89 mmol, 77 %).  
1H NMR (500 MHz, Chloroform-d) δ = 7.68 – 7.65 (m, 1H), 7.38 – 7.34 (m, 1H), 7.26 – 7.23 
(m, 1H), 7.23 – 7.19 (m, 1H), 3.18 (s, 3H), 2.90 – 2.82 (m, 1H), 2.44 – 2.37 (m, 1H), 2.29 – 2.22 
(m, 1H), 1.79 – 1.69 (m, 4H). 
13C NMR (126 MHz, CDCl3) δ = 174.8, 142.7, 133.9, 130.3, 129.7, 128.8, 123.8, 38.2, 36.0, 
26.4, 25.0, 18.1. 
HRMS (ESI): Calculated for C12H15BrNO ([M+H]+): 268.0337; found: 268.0327 
IR (neat) : ν = 2944, 1659 cm-1 
m.p.: 90-92°C 
N-(2-bromophenyl)-N-methylpivalamide 3.15g 24:  
 
Following general procedure for amides synthesis, pivaloyl acid chloride (1.75 mL, 13.9 mmol, 
1.2 eq), o-bromoaniline (2 g, 11.5 mmol, 1 eq), Et3N (3.26 mL, 23.2 mmol, 2 eq) were reacted in 
dichloromethane (50 mL). After purification, the pivaloyl amide (2.7 g, 10.5 mmol, 1 eq) was 
reacted with sodium hydride (60 % dispersion in oil, 630 mg, 15.8 mmol, 1.5 eq), iodomethane 
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(0.98 mL, 15.8 mmol, 1.5 eq) in THF (30 mL). After extraction and purification, the desired 
amide was obtained as a white solid (2.11 g, 7.81 mmol, 68 %).  
1H NMR (400 MHz, Chloroform-d) δ = 7.66 – 7.61 (m, 1H), 7.37 – 7.27 (m, 2H), 7.23 – 7.18 
(m, 1H), 3.17 (s, 3H), 1.07 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ = 178.0, 144.3, 133.9, 130.7, 129.6, 128.4, 124.4, 39.6, 29.1. 
(3r,5r,7r)-N-(2-bromophenyl)-N-methyladamantane-1-carboxamide 3.15h: 
 
 
Following general procedure for amides synthesis, adamantyl acid chloride (2.98 g, 15 mmol, 
1.5 eq), o-bromoaniline (1.7 g, 10 mmol, 1 eq), Et3N (2.77 mL, 20 mmol, 2 eq) were reacted in 
dichloromethane (60 mL). After purification, the adamantyl amide (2.9 g, 8.7 mmol, 1 eq) was 
reacted with sodium hydride (60 % dispersion in oil, 696 mg, 17.4 mmol, 2 eq), iodomethane 
(1.07 mL, 17.4 mmol, 2 eq) in THF (50 mL). After extraction and purification, the desired amide 
was obtained as a white solid (2.3 g, 6.6 mmol, 75 %).  
1H NMR (400 MHz, Chloroform-d) δ = 7.66 – 7.60 (m, 1H), 7.37 – 7.31 (m, 1H), 7.30 – 7.27 
(m, 1H), 7.24 – 7.18 (m, 1H), 3.14 (s, 3H), 1.91 – 1.83 (m, 6H), 1.69 – 1.64 (m, 4H), 1.60 – 1.48 
(m, 5H). 
13C NMR (101 MHz, CDCl3) δ = 183.5, 177.7, 144.2, 133.7, 130.6, 129.4, 128.2, 124.2, 43.8, 
40.4, 39.8, 39.6, 38.6, 36.4, 28.4, 27.8. 
HRMS (ESI): Calculated for C18H22BrNO ([M+H]+): 348.0963; found: 348.0958 
IR (neat) : ν = 2361, 1622, 911 cm-1 
m.p.: 95-97°C 
 
 
(3s)-N-(2-bromophenyl)-N-(methyl-d3)adamantane-1-carboxamide 3.15h-D3: 
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Following general procedure for amides synthesis, adamantyl acid chloride (300 mg, 1.5 mmol, 
1.5 eq), o-bromoaniline (170 mg, 1 mmol, 1 eq), Et3N (0.28 mL, 2 mmol, 2 eq) were reacted in 
dichloromethane (6 mL). After purification, the adamantyl amide (290 mg, 0.87mmol, 1 eq) 
was reacted with sodium hydride (60 % dispersion in oil, 70 mg, 1.74 mmol, 2 eq), iodomethane-
d3(0.11 mL, 0.17 mmol, 2 eq) in THF (5 mL). After extraction and purification, the desired amide 
was obtained as a white solid (210 mg, 0.6 mmol, 69 %).  
1H NMR (400 MHz, Chloroform-d) δ = 7.66 – 7.61 (m, 1H), 7.37 – 7.27 (m, 2H), 7.24 – 7.19 
(m, 1H), 1.92 – 1.82 (m, 6H), 1.70 – 1.64 (m, 3H), 1.61 – 1.48 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ = 177.7, 144.1, 133.7, 130.6, 129.4, 128.2, 124.3, 43.8, 39.6, 
36.4, 28.4. 
HRMS (ESI): Calculated for C18H20D3BrNO ([M+H]+): 351.1151; found: 351.1154 
IR (neat) : ν = 2908, 1629, 1473 cm-1 
m.p.: 97-99°C 
methyl 3-bromo-4-((3s)-N-methyladamantane-1-carboxamido)benzoate 3.28r:  
 
Following general procedure for amides synthesis, adamantyl acid chloride (379 mg, 1.91 mmol, 
1.5 eq), methyl-amino-3-bromobenzoate (291 mg, 1.27 mmol, 1 eq), Et3N (0.35 mL, 2.54 mmol, 
2 eq) were reacted in 1,2-dichloromethane (10 mL) at 60°C. After purification, the adamantyl 
amide (284 mg, 0.724 mmol, 1 eq) was reacted with sodium hydride (60 % dispersion in oil, 58 
mg, 1.48 mmol, 2 eq), iodomethane (0.1 mL, 1.48 mmol, 2 eq) in THF (5 mL) at 65°C. After 
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extraction and purification, the desired amide was obtained as a yellowish solid (208 mg, 0.512 
mmol, 40 %).  
1H NMR (400 MHz, Chloroform-d) δ = 8.33 – 8.31 (m, 1H), 8.02 – 7.99 (m, 1H), 7.38 – 7.33 
(m, 1H), 3.95 (s, 3H), 3.14 (s, 3H), 1.90 – 1.82 (m, 6H), 1.73 – 1.66 (m, 3H), 1.62 – 1.47 (m, 6H). 
13C NMR (126 MHz, CDCl3) δ = 177.7, 165.2, 148.5, 135.1, 131.2, 130.6, 129.6, 124.4, 52.8, 
44.1, 39.9, 39.8, 36.5, 28.4. 
HRMS (ESI): Calculated for C20H25BrNO3 ([M+H]+): 406.1018; found: 406.1012 
IR (neat) : ν = 2361, 1720, 1285 cm-1 
m.p.: 122-124°C 
(3s)-N-(2-bromo-4-(trifluoromethyl)phenyl)-N-methyladamantane-1-carboxamide 3.30r:  
 
Following general procedure for amides synthesis, adamantyl acid chloride (1.57 g, 7.9 mmol, 
1.5 eq), 2-bromo-4-trifluoromethylelaniline (1.26 g, 5.26 mmol, 1 eq), Et3N (1.46 mL, 10.5 mmol, 
2 eq) were reacted in 1,2-dichloroethane (40 mL) at 60 °C. After purification, the adamantyl 
amide (1.39 g, 3.47 mmol, 1 eq) was reacted with sodium hydride (60 % dispersion in oil, 278 
mg, 6.94 mmol, 2 eq), iodomethane (0.45 mL, 6.94 mmol, 2 eq) in THF (30 mL) at 65°C. After 
extraction and purification, the desired amide was obtained as a white solid (940 mg, 2.26 
mmol, 43 %).  
1H NMR (400 MHz, Chloroform-d) δ = 7.93 – 7.90 (m, 1H), 7.64 – 7.59 (m, 1H), 7.42 – 7.38 
(m, 1H), 3.15 (s, 3H), 1.92 – 1.83 (m, 6H), 1.76 – 1.67 (m, 3H), 1.65 – 1.50 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ = 177.6, 147.7, 131.6, 131.3, 131.0, 130.9, 125.3 (q, J = 4.1 Hz), 
124.6, 124.2, 121.5, 43.9, 39.7, 39.7, 36.3, 28.3. 
HRMS (ESI): Calculated for C19H21BrF3NONa ([M+Na]+): 438.0656; found: 438.0654 
IR (neat) : ν = 2909, 1629 cm-1 
m.p.: 115-117°C 
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(3s)-N-(2-bromo-4-fluorophenyl)-N-methyladamantane-1-carboxamide 3.29r:  
 
Following general procedure for amides synthesis, adamantyl acid chloride (257 mg, 1.19 mmol, 
1.5 eq), 2-bromo-4-fluoroaniline (151 mg, 0.80 mmol, 1 eq), Et3N (0.2 mL, 1.59 mmol, 2 eq) 
were reacted in 1,2-dichloroethane (7 mL) at 60°C. After purification, the adamantyl amide (196 
mg, 0.56 mmol, 1 eq) was reacted with sodium hydride (60 % dispersion in oil, 45 mg, 1.11 
mmol, 2 eq), iodomethane (0.07 mL, 1.11 mmol, 2 eq) in THF (5 mL) at 65°C. After extraction 
and purification, the desired amide was obtained as a yellowish solid (120 mg, 0.310 mmol, 39 
%).  
1H NMR (400 MHz, Chloroform-d) δ = 7.40 – 7.36 (m, 1H), 7.29 – 7.24 (m, 1H), 7.09 – 7.04 
(m, 1H), 3.12 (s, 3H), 1.90 – 1.82 (m, 6H), 1.71 – 1.65 (m, 3H), 1.62 – 1.50 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ = 177.94, 161.6 (d, J = 252.1 Hz), 140.8 (d, J = 3.9 Hz), 131.5 (d, 
J = 8.2 Hz), 125.0 (d, J = 9.1 Hz), 121.1 (d, J = 25.5 Hz), 115.5 (d, J = 21.2 Hz), 44.0, 40.1, 39.9, 
36.6, 28.6. 
19F NMR (376 MHz, CDCl3) δ = -111.0. 
HRMS (ESI): Calculated for C18H22BrFNO ([M+H]+): 366.0869; found: 366.0863 
IR (neat) : ν = 1634, 1490 cm-1 
m.p.: 99-101°C 
(3s)-N-(2-bromo-4-cyanophenyl)-N-methyladamantane-1-carboxamide 3.31r:  
 
Following general procedure for amides synthesis, adamantyl acid chloride (414 mg, 2.09 
mmol, 1.5 eq), 4-amino-3-bromobenzonitrile (274 mg, 1.39 mmol, 1 eq), Et3N (0.3 mL, 2.78 
mmol, 2 eq) were reacted in 1,2-dichloroethane (12 mL) at 60°C. After purification, the 
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adamantyl amide (355 mg, 0.987 mmol, 1 eq) was reacted with sodium hydride (60 % dispersion 
in oil, 78 mg, 1.96 mmol, 2 eq), iodomethane (0.13 mL, 1.96 mmol, 2 eq) in THF (7 mL) at 65°C. 
After extraction and purification, the desired amide was obtained as a white solid (212 mg, 
0.568 mmol, 41 %).  
1H NMR (400 MHz, Chloroform-d) δ = 7.95 – 7.93 (m, 1H), 7.67 – 7.63 (m, 1H), 7.41 – 7.37 
(m, 1H), 3.14 (s, 3H), 1.91 – 1.85 (m, 3H), 1.83 – 1.68 (m, 6H), 1.63 – 1.47 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ = 177.5, 148.9, 137.2, 132.1, 131.3, 125.1, 116.8, 113.3, 44.0, 
39.8, 39.6, 39.6, 36.4, 28.3. 
HRMS (ESI): Calculated for C19H21BrN2ONa ([M+Na]+): 395.0735; found: 395.0729 
IR (neat) : ν = 2906, 1640 cm-1 
m.p.: 118-120°C 
(3s)-N-(2-bromo-4-methoxyphenyl)-N-methyladamantane-1-carboxamide 3.32r:  
 
Following general procedure for amides synthesis, adamantyl acid chloride (1.23 g, 6.18 mmol, 
1.5 eq), 2-bromo-4-methoxylaniline (832 mg, 4.12 mmol, 1 eq), Et3N (1.14 mL, 8.24 mmol, 2 eq) 
were reacted in dichloromethane (30 mL). After purification, the adamantyl amide (1.3 g, 3.58 
mmol, 1 eq) was reacted with sodium hydride (60 % dispersion in oil, 287 mg, 7.17 mmol, 2 
eq), iodomethane (0.44 mL, 7.17 mmol, 2 eq) in THF (20 mL) at 65°C. After extraction and 
purification, the desired amide was obtained as a yellow solid (1.15 g, 3.04 mmol, 74 %).  
1H NMR (400 MHz, Chloroform-d) δ = 7.17 – 7.12 (m, 2H), 6.85 – 6.82 (m, 1H), 3.81 (s, 3H), 
3.08 (s, 3H), 1.89 – 1.80 (m, 6H), 1.70 – 1.62 (m, 3H), 1.59 – 1.46 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ = 178.0, 159.4, 137.0, 130.9, 124.7, 118.6, 113.9, 55.8, 43.8, 
40.1, 39.7, 36.5, 28.5, 27.0. 
HRMS (ESI): Calculated for C19H25BrNO2 ([M+H]+): 378.1069; found: 378.1063 
IR (neat) : ν = 1617, 1495 cm-1 
m.p.: 124-126°C 
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(3s)-N-(2-bromo-4-methylphenyl)-N-methyladamantane-1-carboxamide 3.33r: 
 
Following general procedure for amides synthesis, adamantyl acid chloride (447 mg, 2.25 
mmol, 1.5 eq), 2-bromo-4-methylaniline (279 mg, 1.50 mmol, 1 eq), Et3N (0.416 mL, 3 mmol, 2 
eq) were reacted in dichloromethane (15 mL). After purification, the adamantyl amide (475 mg, 
1.37 mmol, 1 eq) was reacted with sodium hydride (60 % dispersion in oil, 109 mg, 2.73 mmol, 
2 eq), iodomethane (0.17 mL, 2.73 mmol, 2 eq) in THF (10 mL) at 65°C. After extraction and 
purification, the desired amide was obtained as a white solid (482 mg, 1.33 mmol, 89 %).  
1H NMR (500 MHz, Chloroform-d) δ = 7.45 – 7.43 (m, 1H), 7.16 – 7.10 (m, 2H), 3.10 (s, 3H), 
2.37 (s, 3H), 1.8 – 1.84 (m, 6H), 1.70 – 1.65 (m, 3H), 1.59 – 1.49 (m, 6H). 
13C NMR (126 MHz, CDCl3) δ = 177.9, 141.6, 139.9, 134.2, 130.2, 129.0, 123.9, 43.9, 40.0, 
39.8, 36.6, 28.5, 21.0. 
HRMS (ESI): Calculated for C19H25BrNO ([M+H]+): 362.1120; found: 362.1119 
IR (neat) : ν = 1623 cm-1 
m.p.: 111-113°C 
(3s)-N-(2-bromo-5-methylphenyl)-N-methyladamantane-1-carboxamide 3.34r:  
 
Following general procedure for amides synthesis, adamantyl acid chloride (1.57 g, 7.9 mmol, 
1.5 eq), 2-bromo-5-methylaniline (980 mg, 5.26 mmol, 1 eq), Et3N (1.46 mL, 10.5 mmol, 2 eq) 
were reacted in dichloromethane (40 mL). After purification, the adamantyl amide (1.45 g, 4.16 
mmol, 1 eq) was reacted with sodium hydride (60 % dispersion in oil, 337 mg, 8.42 mmol, 2 
eq), iodomethane (0.52 mL, 8.42 mmol, 2 eq) in THF (30 mL) at 65°C. After extraction and 
purification, the desired amide was obtained as a yellowish solid (1.35 g, 3.73 mmol, 71 %).  
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1H NMR (400 MHz, Chloroform-d) δ = 7.51 – 7.47 (m, 1H), 7.10 – 7.08 (m, 1H), 7.04 – 7.00 
(m, 1H), 3.12 (s, 3H), 2.33 (s, 3H), 1.92 – 1.82 (m, 6H), 1.71 – 1.65 (m, 3H), 1.61 – 1.49 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ = 177.8, 144.0, 138.6, 133.4, 131.2, 130.3, 120.7, 43.9, 39.9, 
39.8, 36.6, 28.5, 21.0. 
HRMS (ESI): Calculated for C19H25BrNO ([M+H]+): 362.1120; found: 362.1118 
IR (neat) : ν = 1625 cm-1 
m.p.: 120-122°C 
(3s)-N-(2-bromo-5-methoxyphenyl)-N-methyladamantane-1-carboxamide 3.35r: 
 
Following general procedure for amides synthesis, adamantyl acid chloride (441 mg, 2.45 
mmol, 1.5 eq), 2-bromo-5-methoxyaniline (329 mg, 1.63 mmol, 1 eq), Et3N (0.45 mL, 3.26 
mmol, 2 eq) were reacted in dichloromethane (10 mL). After purification, the adamantyl amide 
(481 g, 1.32 mmol, 1 eq) was reacted with sodium hydride (60 % dispersion in oil, 106 mg, 2.64 
mmol, 2 eq), iodomethane (0.16 mL, 2.64 mmol, 2 eq) in THF (10 mL). After extraction and 
purification, the desired amide was obtained as a yellowish solid (354 mg, 0.94 mmol, 57 %).  
1H NMR (400 MHz, Chloroform-d) δ = 7.51 – 7.49 (m, 1H), 6.84 – 6.82 (m, 1H), 6.81 – 6.76 
(m, 1H), 3.81 (s, 3H), 3.13 (s, 3H), 1.94 – 1.84 (m, 6H), 1.74 – 1.68 (m, 3H), 1.62 – 1.51 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ = 177.8, 159.5, 145.0, 134.0, 116.5, 115.2, 114.6, 55.9, 44.1, 
39.9, 39.9, 36.6, 28.5. 
HRMS (ESI): Calculated for C19H25BrNO2 ([M+H]+): 378.1069; found: 378.1062 
IR (neat) : ν = 2908, 1617, 1495 cm-1 
m.p.: 111-113°C 
 
(3s)-N-(2-bromo-5-fluorophenyl)-N-methyladamantane-1-carboxamide 3.36r:  
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Following general procedure for amides synthesis, adamantyl acid chloride (257 mg, 1.19 mmol, 
1.5 eq), 2-bromo-5-fluoroaniline (151 mg, 0.80 mmol, 1 eq), Et3N (0.2 mL, 1.59 mmol, 2 eq) 
were reacted in dichloromethane (7 mL). After purification, the adamantyl amide (196 mg, 0.56 
mmol, 1 eq) was reacted with sodium hydride (60 % dispersion in oil, 45 mg, 1.11 mmol, 2 eq), 
iodomethane (0.07 mL, 1.11 mmol, 2 eq) in THF (5 mL) at 65°C. After extraction and 
purification, the desired amide was obtained as a yellowish solid (108 mg, 0.295 mmol, 37 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.63 – 7.54 (m, 1H), 7.06 – 7.02 (m, 1H), 7.01 – 6.94 
(m, 1H), 3.13 (s, 3H), 1.90 – 1.85 (m, 6H), 1.74 – 1.67 (m, 3H), 1.63 – 1.50 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ = 177.63, 161.9 (d, J = 247.0 Hz), 145.6 (d, J = 9.5 Hz), 134.5 (d, 
J = 8.9 Hz), 118.9 (d, J = 3.9 Hz), 118.1 (d, J = 22.9 Hz), 116.8 (d, J = 23.1 Hz), 44.0, 39.8, 39.8, 
36.5, 28.5. 
19F NMR (376 MHz, CDCl3) δ = -112.5. 
HRMS (ESI): Calculated for C18H22BrFNO ([M+H]+): 366.0869; found: 366.0863 
IR (neat) : ν = 1636, 1490 cm-1 
m.p.: 101-103°C 
 (3s)-N-(2-bromo-5-(trifluoromethoxy)phenyl)-N-methyladamantane-1-carboxamide 
3.37r: 
 
Following general procedure for amides synthesis, adamantyl acid chloride (2.98 g, 15 mmol, 
1.5 eq), 2-bromo-5-(trifluoromethoxy)aniline (2.56 g, 10 mmol, 1 eq), Et3N (2.77 mL, 20 mmol, 
2 eq) were reacted in dichloromethane (120 mL). After purification, the adamantyl amide (3.3 
g, 7.89 mmol, 1 eq) was reacted with sodium hydride (60 % dispersion in oil, 630 mg, 15.8 
mmol, 2 eq), iodomethane (0.97 mL, 15.8 mmol, 2 eq) in THF (100 mL) at reflux. After 
280 
 
extraction and purification, the desired amide was obtained as a white solid (2.2 g, 5.0 mmol, 
51 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.68 – 7.65 (m, 1H), 7.19 – 7.17 (m, 1H), 7.13 – 7.09 
(m, 1H), 3.14 (s, 3H), 1.89 – 1.81 (m, 6H), 1.70 – 1.49 (m, 9H). 
13C NMR (101 MHz, CDCl3) δ = 177.6, 148.5 (q, J = 1.9 Hz), 145.6, 134.7, 123.6, 122.4, 122.2, 
120.3 (q, J = 260.1 Hz), 44.0, 39.8, 39.7, 36.5, 28.5. 
19F NMR (376 MHz, CDCl3) δ = -58.1. 
HRMS (ESI): Calculated for C19H22BrF3NO2 ([M+H]+): 432.0786; found: 432.0788 
IR (neat) : ν = 2906, 1614, 1494 cm-1 
m.p.: 117-119°C 
(3s)-N-(2-bromo-3-fluorophenyl)-N-methyladamantane-1-carboxamide 3.38r:  
 
Following general procedure for amides synthesis, adamantyl acid chloride (257 mg, 1.19 mmol, 
1.5 eq), 2-bromo-3-fluoroaniline (151 mg, 0.80 mmol, 1 eq), Et3N (0.2 mL, 1.59 mmol, 2 eq) 
were reacted in 1,2-dichloroethane (7 mL) at 60°C. After purification, the adamantyl amide (196 
mg, 0.56 mmol, 1 eq) was reacted with sodium hydride (60 % dispersion in oil, 45 mg, 1.11 
mmol, 2 eq), iodomethane (0.07 mL, 1.11 mmol, 2 eq) in THF (5 mL) at 65°C. After extraction 
and purification, the desired amide was obtained as a yellowish solid (110 mg, 0.30 mmol, 32 
%).  
1H NMR (400 MHz, Chloroform-d) δ = 7.35 – 7.29 (m, 1H), 7.17 – 7.09 (m, 2H), 3.14 (s, 3H), 
1.90 – 1.83 (m, 6H), 1.71 – 1.65 (m, 3H), 1.62 – 1.50 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ = 177.9, 160.1 (d, J = 246.1 Hz), 146.30, 128.7 (d, J = 9.2 Hz), 
126.0 (d, J = 3.7 Hz), 116.1 (d, J = 22.7 Hz), 112.0 (d, J = 19.9 Hz), 44.0, 39.9, 39.8, 36.5, 28.5. 
19F NMR (376 MHz, CDCl3) δ = -102.6. 
HRMS (ESI): Calculated for C18H22BrFNO ([M+H]+): 366.0869; found: 366.0865 
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IR (neat) : ν = 1636, 1495 cm-1 
m.p.: 104-106°C 
methyl 3-bromo-4-(N,1-dimethylcyclohexane-1-carboxamido)benzoate 3.44r: 
 
Following general procedure for amides synthesis, 1-methylcyclohexane-1-carboxylic acid (1.05 
g, 6.59 mmol, 1.5 eq), methyl 4-amino-3-bromobenzoate (1.01 g, 4.39 mmol, 1 eq), Et3N (1.22 
mL, 8.78 mmol, 2 eq) were reacted in 1,2-dichloroethane (70 mL) at 60°C. After purification, 
the amide (1.1 g, 3.12 mmol, 1 eq) was reacted with sodium hydride (60 % dispersion in oil, 249 
mg, 6.2 mmol, 2 eq), iodoethane (0.4 mL, 6.2 mmol, 2 eq) in THF (30 mL). After extraction 
and purification, the desired amide was obtained as a colorless oil (800 mg, 2.17 mmol, 50 %).  
1H NMR (400 MHz, Chloroform-d) δ = 8.33 – 8.31 (m, 1H), 8.01 – 7.97 (m, 1H), 7.36 – 7.32 
(m, 1H), 3.94 (s, 3H), 3.19 (s, 3H), 1.90 – 1.78 (m, 2H), 1.54 – 1.46 (m, 3H), 1.45 – 1.31 (m, 8H), 
1.09 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ = 177.7, 165.1, 148.4, 135.1, 131.0, 130.6, 129.4, 123.9, 52.6, 
44.6, 39.6, 37.0, 35.7, 25.8, 24.2, 22.9, 22.7. 
HRMS (ESI): Calculated for C17H23BrNO3([M+H]+): 368.0861 found: 368.0862 
IR (neat) : ν = 2973, 2361, 1379 cm-1 
1-(2-(benzyloxy)ethyl)-N-(2-bromophenyl)-N-methylcyclohexane-1-carboxamide 3.45r: 
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((2-bromoethoxy)methyl)benzene (2.22 mL, 14 mmol, 1 eq) was reflux in acetone (20 mL) 
overnight with NaI (8.8 g, 58.5 mmol, 5 eq). The mixture was cooled to room temperature and 
the solvent was removed under vacuum. The crude mixture was then dissolved in water (20 
mL) and extracted with Et2O (3 x 20 mL). The combined organic layers were dried over sodium 
sulfate, filtered and evaporated under vacuum to afford  ((2-iodoethoxy)methyl)benzene as a 
colorless oil (2.72 mL, 14 mmol, 100 %).  
To diisopropylamine (1.8 mL, 12.7 mmol, 1.2 eq) in dry THF (30 mL) at 0°C was added n-
butyllithium (2.5 M in hexanes, 5.2 mL, 12.7 mml, 1.2 eq). The solution was stirred for 10 
minutes and methyl cyclohexanecarboxylate (1.6 g, 11.7 mmol, 1 eq) in dry THF (10 mL ) was 
added added. The mixture was warm to room temperature and then heated at reflux for 15 
minutes. ((2-iodoethoxy)methyl)benzene (2.72 mL, 14 mmol, 1.2 eq) in dry THF (10 mL) was 
then quickly added to the mixture which was further reacted for 3 h at reflux. The mixture was 
cooled to room temperature, quenched with water (50 mL) and extracted with AcOEt (3 x 30 
mL). The combined organic layers were dried over sodium sulfate, filtered and evaporated 
under vacuum. The intermediate ester was purified by chromatography on silica gel using 
cyclohexane/AcOEt [8:2] as solvent (1.82 g, 6.55 mmol, 56 %). 
The intermediate ester (1.81 g, 6.55 mmol, 1.5 eq) was dissolved in THF (20 mL) and slowly 
added to a turning solution of o-bromoaniline (0.47 mL, 4.33 mmol, 1 eq) in THF (20 mL) with 
LiHMDS (1.45 g, 8.66 mmol, 2 eq). The mixture was stirred overnight at reflux, cooled to rome 
temperature and quenched with water (40 mL). The aqueous phase was extracted with AcOEt 
(3 x 30 mL) and the combined organic layers were dried over sodium sulfate, filtered and 
evaporated under vacuum. The crude mixture was purified by chromatography on silica gel 
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using cyclohexane/AcOEt [7:3] to afford the intermediate amide as a yellowish solid (926 mg, 
2.22 mol, 51 %). 
The intermediate amide (926 mg 2.22 mmol, 1 eq) was dissolved in THF (20 mL) and sodium 
hydride (60 % dispersion in oil, 178 mg, 4.45 mmol, 2 eq) was added. The mixture was stirred 
for 10 min, and iodomethane (0.28 mL, 4.45 mmol, 2 eq) was added. The mixture was stirred 
at reflux for 2 h and cooled to room temperature. The crude mixture was quenched with water 
(20 mL), extracted with AcOEt (3 x 20 mL) and the combined organic layers were dried over 
sodium sulfate, filtered and evaporated under vacuum. The crude mixture was purified by 
chromatography on silica gel using cyclohexane/AcOEt [7:3] as solvent. The desired amide was 
obtained as a yellowish oil (550 mg, 1.28 mmol, 57 %, 16 % overall yield). 
Mixture of rotamers: 
1H NMR (400 MHz, Chloroform-d) δ = 7.64 – 7.61 (m, 1H), 7.58 – 7.40 (m, 2H), 7.39 – 7.31 
(m, 3H), 7.29 – 7.26 (m, 2H), 7.20 – 7.12 (m, 1H), 4.84 – 4.37 (m, 2H), 3.93 – 3.47 (m, 2H), 3.44 
– 3.03 (m, 3H), 2.05 – 1.76 (m, 3H), 1.73 – 1.63 (m, 1H), 1.57 – 1.25 (m, 7H), 1.13 – 0.99 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ = 175.7, 138.7, 133.9, 130.8, 129.3, 128.5, 128.3, 128.0, 127.7, 
73.4, 67.0, 47.1, 39.9, 37.9, 35.6, 34.7, 26.1, 23.5, 23.0. 
HRMS (ESI): Calculated for C23H28BrNO2Na ([M+Na]+): 452.1201; found: 452.1201 
IR (neat) : ν = 2909, 1631, 906 cm-1 
N-(2-bromo-4-methoxyphenyl)-N-methylbicyclo[2.2.2]octane-1-carboxamide 3.50r: 
 
Following general procedure for amides synthesis, bicyclo[2.2.2]octane-1-carbonyl chloride 
(224 mg, 1.3 mmol mmol, 1.1 eq), 2-bromo-4-methoxyaniline (238 mg, 1.18 mmol, 1.0 eq), Et3N 
(0.33 mL, 2.4 mmol, 2 eq) were reacted in dichloromethane (5 mL). After purification, the 
intermediate amide (266 mg, 0.78 mmol, 1 eq) was reacted with sodium hydride (60 % 
dispersion in oil, 63 mg, 1.57 mmol, 2 eq), iodomethane (0.1 mL, 1.57 mmol, 2 eq) in THF (5 
mL) at 65°C. After extraction and purification, the desired amide was obtained as a yellowish 
oil (180 mg, 0.51 mmol, 65 %).  
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1H NMR (400 MHz, Chloroform-d) δ = 7.16 – 7.10 (m, 2H), 6.87 – 6.82 (m, 1H), 3.83 (s, 3H), 
3.09 (s, 3H), 1.77 – 1.65 (m, 3H), 1.58 – 1.49 (m, 3H), 1.49 – 1.45 (m, 1H), 1.45 – 1.38 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ = 178.2, 159.4, 137.1, 131.1, 124.7, 118.6, 114.1, 55.9, 41.4, 
40.1, 28.8, 25.9, 23.7. 
HRMS (ESI): Calculated for C17H23BrNO2 ([M+H]+): 352.0912; found: 352.0914 
IR (neat) : ν = 1660 cm-1 
N-(2-bromo-4-cyanophenyl)-N-methylbicyclo[2.2.2]octane-1-carboxamide 3.51r:  
 
Following general procedure for amides synthesis, bicyclo[2.2.2]octane-1-carbonyl chloride 
(224 mg, 1.3 mmol mmol, 1.1 eq), 4-amino-3-bromobenzonitrile (232 mg, 1.18 mmol, 1.0 eq), 
Et3N (0.33 mL, 2.4 mmol, 2 eq) were reacted in dichloromethane (5 mL). After purification, 
the intermediate amide (157 mg, 0.47 mmol, 1 eq) was reacted with sodium hydride (60 % 
dispersion in oil, 38 mg, 0.94 mmol, 2 eq), iodomethane (0.05 mL, 0.94 mmol, 2 eq) in THF (5 
mL) at 65°C. After extraction and purification, the desired amide was obtained as a yellowish 
oil (111 mg, 0.32 mmol, 68 %).  
1H NMR (400 MHz, Chloroform-d) δ = 7.95 – 7.94 (m, 1H), 7.67 – 7.62 (m, 1H), 7.36 – 7.33 
(m, 1H), 3.15 (s, 3H), 1.68 – 1.56 (m, 6H), 1.55 – 1.52 (m, 1H), 1.50 – 1.44 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ = 177.7, 149.0, 137.3, 132.2, 131.5, 125.0, 116.8, 113.3, 41.7, 
39.6, 28.9, 25.7, 23.5. 
 
HRMS (ESI): Calculated for C17H20BrN2O ([M+H]+): 347.0759; found: 347.0761 
IR (neat) : ν = 2304 cm-1 
N-(2-bromo-5-methoxyphenyl)-N-methylbicyclo[2.2.2]octane-1-carboxamide 3.46r:  
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Following general procedure for amides synthesis, bicyclo[2.2.2]octane-1-carbonyl chloride (78 
mg, 0.454 mmol, 1.0 eq), 2-bromo-5-methoxylaniline (92 mg, 0.454 mmol, 1.0 eq), Et3N (0.128 
mL, 0.91 mmol, 2 eq) were reacted in dichloromethane (7mL). After purification, the 
intermediate amide (90 mg, 0.266 mmol, 1 eq) was reacted with sodium hydride (60 % 
dispersion in oil, 21 mg, 0.532 mmol, 2 eq), iodomethane (0.033 mL, 0.532 mmol, 2 eq) in THF 
(5 mL) at 65°C. After extraction and purification, the desired amide was obtained as a colorless 
oil (41 mg, 0.116 mmol, 26 %).  
1H NMR (500 MHz, Chloroform-d) δ = 7.50 – 7.46 (m, 1H), 6.79 – 6.76 (m, 2H), 3.80 (s, 3H), 
3.11 (s, 3H), 1.78 – 1.70 (m, 3H), 1.59 – 1.51 (m, 3H), 1.51 – 1.47 (m, 1H), 1.45 – 1.40 (m, 6H). 
13C NMR (126 MHz, CDCl3) δ = 178.0, 159.6, 145.0, 134.0, 116.6, 115.1, 114.5, 55.9, 41.6, 
39.8, 28.9, 25.9, 23.7. 
HRMS (ESI): Calculated for C17H23BrNO2 ([M+H]+): 352.0912; found: 352.0913 
IR (neat) : ν = 1622 cm-1 
methyl 4-((2-bromo-4-cyanophenyl)(methyl)carbamoyl)bicyclo[2.2.2]octane-1-
carboxylate 3.47r:  
 
Following general procedure for amides synthesis, methyl 4-
(chlorocarbonyl)bicyclo[2.2.2]octane-1-carboxylate (127 mg, 0.54 mmol, 1.2 eq), 4-amino-3-
bromobenzonitrile (90 mg, 0.45 mmol, 1.0 eq), Et3N (0.125 mL, 0.91 mmol, 2 eq) were reacted 
in dichloromethane (7 mL). After purification, the intermediate amide (141 mg, 0.36 mmol, 1 
eq) was reacted with sodium hydride (60 % dispersion in oil, 29 mg, 0.72 mmol, 2 eq), 
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iodomethane (0.047 mL, 0.72 mmol, 2 eq) in THF (5 mL) at 65°C. After extraction and 
purification, the desired amide was obtained as a yellowish oil (43 mg, 0.106 mmol, 25 %).  
1H NMR (400 MHz, Chloroform-d) δ = 7.97 – 7.93 (m, 1H), 7.68 – 7.63 (m, 1H), 7.38 – 7.30 
(m, 1H), 3.59 (s, 3H), 3.15 (s, 3H), 1.73 – 1.62 (m, 12H). 
13C NMR (101 MHz, CDCl3) δ = 177.7, 176.7, 148.6, 137.4, 132.3, 131.4, 125.0, 116.7, 113.6, 
51.8, 41.8, 39.6, 38.4, 28.5, 28.0. 
HRMS (ESI): Calculated for C19H22BrN2O3 ([M+H]+): 405.0814; found: 405.0808 
IR (neat) : ν = 2973, 2369, 1710 cm-1 
(3r,5r,7r)-N-(2-bromophenyl)-N-ethyladamantane-1-carboxamide 3.48r: 
 
Following general procedure for amides synthesis, adamantyl acid chloride (2.98 g, 15 mmol, 
1.5 eq), o-bromoaniline (1.7 g, 10 mmol, 1 eq), Et3N (2.77 mL, 20 mmol, 2 eq) were reacted in 
dichloromethane (60 mL). After purification, the adamantyl amide (2.9 g, 8.7 mmol, 1 eq) was 
reacted with sodium hydride (60 % dispersion in oil, 696 mg, 17.4 mmol, 2 eq), iodoethane (1.43 
mL, 17.4 mmol, 2 eq) in THF (50 mL). After extraction and purification, the desired amide was 
obtained as a white solid (2.3 g, 6.6 mmol, 75 %).  
1H NMR (400 MHz, Chloroform-d) δ = 7.67 – 7.62 (m, 1H), 7.36 – 7.29 (m, 1H), 7.24 – 7.19 
(m, 2H), 4.22 (dq, J = 14.0, 7.1 Hz, 1H), 2.94 (dq, J = 13.8, 7.0 Hz, 1H), 1.91 – 1.80 (m, 6H), 1.67 
– 1.46 (m, 9H), 1.10 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ = 177.1, 142.4, 133.9, 132.0, 129.4, 127.7, 125.0, 46.5, 44.0, 
39.7, 36.6, 28.5, 12.6. 
HRMS (ESI): Calculated for C19H25BrNO ([M+H]+): 362.1120; found: 362.1115 
IR (neat) : ν = 1622 cm-1 
m.p.: 121-123°C 
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Benzoxazine products: 
1'-methylspiro[cyclobutane-1,3'-indolin]-2'-one 3.19: 
 
In a 10 mL screw-cap tube charged with amide 3.15f (0.1 mmol, 27 mg, 1 equiv) was weighted 
in a glovebox Pd(PCy3)2 (0.01 mmol, 6.7 mg, 10 mol %), cesium pivalate (0.03 mmol, 7.1 mg, 
30 mol %) and Cs2CO3 (0.3 mmol, 98 mg, 3 equiv). The vial was charged with mesitylene (2 
mL), sealed and stirred under argon in a previously heated heating block at 160 °C for 15 h. The 
reaction was cooled to room temperature, filtered over celite, and evaporated under vacuum. 
The crude mixture was purified by preparative HPLC using gradient of solvent (H2O: MeCN) 
[90:10] to [10:90]. The collected fraction were evaporated under vacuum to afford the desired 
product as a yellowish oil (13.1 mg, 0.07 mmol, 70%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.53 – 7.47 (m, 1H), 7.29 – 7.20 (m, 1H), 7.13 – 7.06 
(m, 1H), 6.80 – 6.76 (m, 1H), 3.18 (s, 3H), 2.71 – 2.61 (m, 2H), 2.42 – 2.23 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ = 180.3, 143.1, 134.5, 127.9, 122.7, 122.4, 107.7, 48.3, 31.4, 
26.3, 16.9. 
HRMS (ESI): Calculated for C12H14NO ([M+H]+): 188.1075; found: 188.1070 
IR (neat) : ν = 2973, 2362, 1694, 1379 cm-1 
1,3,3-trimethyl-3,4-dihydroquinolin-2(1H)-one 3.20 25: 
  
In a 10 mL screw-cap tube charged with amide 3.15g (0.1 mmol, 27 mg, 1 equiv) was weighted 
in a glovebox Pd(PCy3)2 (0.01 mmol, 6.7 mg, 10 mol %), cesium pivalate (0.03 mmol, 7.1 mg, 
30 mol %) and Cs2CO3 (0.3 mmol, 98 mg, 3 equiv). The vial was charged with mesitylene (2 
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mL), sealed and stirred under argon in a previously heated heating block at 160 °C for 15 h. The 
reaction was cooled to room temperature, filtered over celite, and evaporated under vacuum. 
The crude mixture was purified by preparative HPLC using gradient of solvent (H2O: MeCN) 
[90:10] to [10:90]. The collected fraction were evaporated under vacuum to afford the desired 
product as a colorless oil (15.1 mg, 0.08 mmol, 80%). 
1H NMR (500 MHz, Chloroform-d) δ = 7.21 – 7.16 (m, 1H), 7.09 – 7.06 (m, 1H), 6.96 – 6.92 
(m, 1H), 6.90 – 6.87 (m, 1H), 3.29 (s, 3H), 2.69 (s, 2H), 1.09 (s, 6H). 
13C NMR (126 MHz, CDCl3) δ = 175.6, 140.3, 128.4, 127.4, 125.2, 122.8, 114.2, 40.3, 37.5, 
30.1, 24.8. 
2-((3r,5r,7r)-adamantan-1-yl)-4H-benzo[d][1,3]oxazine 3.21 26: 
 
Following general procedure for benzoxazine synthesis, 3.15h (35 mg, 0.1 mmol, 1eq) was 
reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), cesium pivalate (7.1 mg, 0.03 mmol, 30 
mol%) and Cs2CO3 (98 mg, 0.3 mmol, 3 eq) in o-xylene (2 mL) at 160°C for 15h. After 
purification, 3.21 was obtained as a yellowish oil (23 mg, 0.084 mmol, 84%). 
Scale up:  
Following general procedure for benzoxazine synthesis, 3.15h (2.17 g, 6.25 mmol, 1eq) was 
reacted with Pd-G4-PCy3 (415 mg, 0.625 mmol, 10 mol%), PCy3 (175 mg, 0.625 mmol, 10 
mol%) cesium pivalate (440 mg, 1.88 mmol, 30 mol%) and Cs2CO3 (6.1 g, 18.8 mmol, 3 eq) in 
o-xylene (125 mL) at 160°C for 15h in a 250 mL schlenk tube. The crude mixture was cooled to 
room temperature, and the solvent was flushed on silica gel using cyclohexane. The crude 
mixture was purify by chromatography on silica gel using cyclohexane/AcOEt as solvent [9:1]. 
3.21 was obtained as a yellowish oil (1.05 g, 3.92 mmol, 62%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.27 – 7.22 (m, 1H), 7.17 – 7.09 (m, 2H), 6.94 – 6.90 
(m, 1H), 5.15 (s, 2H), 2.07 – 2.03 (m, 4H), 1.97 – 1.95 (m, 6H), 1.76 – 1.72 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ = 168.8, 139.7, 128.9, 126.1, 124.4, 123.7, 122.5, 66.2, 39.6, 
39.5, 36.9, 28.3. 
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2-((3r,5r,7r)-adamantan-1-yl)-6-methyl-4H-benzo[d][1,3] 3.28: 
 
Following general procedure for benzoxazine synthesis, 3.28r (41 mg, 0.1 mmol, 1eq) was 
reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), cesium pivalate (7.1 mg, 0.03 mmol, 30 
mol%) and Cs2CO3 (98 mg, 0.3 mmol, 3 eq) in o-xylene (2 mL) at 160°C for 15h. After 
purification, 3.28 was obtained as a white solid (27 mg, 0.081 mmol, 81%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.95 – 7.91 (m, 1H), 7.65 – 7.62 (m, 1H), 7.19 – 7.14 
(m, 1H), 5.19 (s, 2H), 3.89 (s, 3H), 2.07 – 2.02 (m, 3H), 1.97 – 1.92 (m, 6H), 1.79 – 1.69 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ = 171.0, 166.7, 144.0, 130.7, 127.5, 125.4, 124.2, 122.4, 66.1, 
52.2, 39.8, 39.4, 36.8, 28.2. 
HRMS (ESI): Calculated for C20H24NO3 ([M+H]+): 326.1756; found: 326.1752 
IR (neat) : ν =1622, 1490, 911 cm-1 
m.p.: 70-72°C 
2-((3r,5r,7r)-adamantan-1-yl)-6-(trifluoromethyl)-4H-benzo[d][1,3]oxazine 3.30: 
 
Following general procedure for benzoxazine synthesis, 3.30r (42 mg, 0.1 mmol, 1eq) was 
reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), cesium pivalate (7.1 mg, 0.03 mmol, 30 
mol%) and Cs2CO3 (98 mg, 0.3 mmol, 3 eq) in o-xylene (2 mL) at 160°C for 15h. After 
purification, 3.30 was obtained as a white solid (18.5 mg, 0.055 mmol, 55%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.52 – 7.47 (m, 1H), 7.23 – 7.15 (m, 2H), 5.18 (s, 2H), 
2.08 – 2.03 (m, 3H), 1.96 – 1.90 (m, 6H), 1.79 – 1.68 (m, 6H). 
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13C NMR (126 MHz, CDCl3) δ = 170.8, 142.9 (d, J = 1.9 Hz), 127.9 (q, J = 31.9 Hz), 126.1 (q, J 
= 3.3 Hz), 124.6, 124.2 (q, J = 269.2 Hz), 122.9, 121.0 (q, J = 4.0 Hz), 65.9, 39.8, 39.4, 36.8, 28.2. 
19F NMR (376 MHz, CDCl3) δ = -62.20. 
HRMS (ESI): Calculated for C19H21F3NO ([M+H]+): 336.1575; found: 336.1573 
IR (neat) : ν = 2909, 2361, 1603, 1331 cm-1 
m.p.: 77-79°C 
2-((3r,5r,7r)-adamantan-1-yl)-6-fluoro-4H-benzo[d][1,3]oxazine 3.29:  
 
Following general procedure for benzoxazine synthesis, 3.29r (37 mg, 0.1 mmol, 1eq) was 
reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), cesium pivalate (7.1 mg, 0.03 mmol, 30 
mol%) and Cs2CO3 (98 mg, 0.3 mmol, 3 eq) in o-xylene (2 mL) at 160°C for 15h. After 
purification, 3.29 was obtained as a yellowish solid (23 mg, 0.080 mmol, 80%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.13 – 7.06 (m, 1H), 6.95 – 6.89 (m, 1H), 6.67 – 6.59 
(m, 1H), 5.12 (s, 2H), 2.07 – 2.00 (m, 3H), 1.96 – 1.90 (m, 6H), 1.78 – 1.68 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ = 168.1, 160.9 (d, J = 245 Hz), 135.8 (d, J = 2.4 Hz), 125.9 (d, J 
= 8.3 Hz), 124.0 (d, J = 8.1 Hz), 115.3 (d, J = 22.3 Hz), 110.7 (d, J = 22.7 Hz), 65.7 (d, J = 2.2 
Hz), 39.5, 39.4, 36.8, 28.3. 
19F NMR (376 MHz, CDCl3) δ = -116.0. 
HRMS (ESI): Calculated for C18H21FNO ([M+H]+): 286.1607; found: 286.1607 
IR (neat) : ν = 2361, 906 cm-1 
m.p.: 65-67°C 
2-((3r,5r,7r)-adamantan-1-yl)-4H-benzo[d][1,3]oxazine-6-carbonitrile 3.31:  
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Following general procedure for benzoxazine synthesis, 3.31r (46 mg, 0.1 mmol, 1eq) was 
reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), cesium pivalate (7.1 mg, 0.03 mmol, 30 
mol%) and Cs2CO3 (98 mg, 0.3 mmol, 3 eq) in o-xylene (2 mL) at 160°C for 15h. After 
purification, 3.31 was obtained as a yellowish solid (28.5 mg, 0.079 mmol, 79%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.56 – 7.51 (m, 1H), 7.24 – 7.22 (m, 1H), 7.20 – 7.17 
(m, 1H), 5.17 (s, 2H), 2.08 – 2.02 (m, 3H), 1.96 – 1.90 (m, 6H), 1.78 – 1.68 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ = 171.8, 143.9, 133.3, 127.6, 125.0, 123.5, 119.0, 109.1, 65.5, 
39.9, 39.4, 36.7, 28.2. 
HRMS (ESI): Calculated for C19H21N2O ([M+H]+): 293.1654; found: 293.1652 
IR (neat) : ν = 2907, 2361, 1594 cm-1 
m.p.: 69-71°C 
2-((3r,5r,7r)-adamantan-1-yl)-6-methoxy-4H-benzo[d][1,3]oxazine 3.32:   
 
Following general procedure for benzoxazine synthesis, 3.32r (38 mg, 0.1 mmol, 1eq) was 
reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), cesium pivalate (7.1 mg, 0.03 mmol, 30 
mol%) and Cs2CO3 (98 mg, 0.3 mmol, 3 eq) in o-xylene (2 mL) at 160°C for 15h. After 
purification, 3.32 was obtained as a yellowish solid (18.5 mg, 0.063 mmol, 63%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.11 – 7.05 (m, 1H), 6.79 – 6.75 (m, 1H), 6.48 – 6.45 
(m, 1H), 5.11 (s, 2H), 3.78 (s, 3H), 2.06 – 2.01 (m, 3H), 1.95 – 1.93 (m, 6H), 1.74 – 1.70 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ = 166.9, 157.9, 133.1, 125.5, 123.6, 113.5, 109.4, 66.1, 55.6, 
39.5, 39.4, 36.9, 28.3. 
HRMS (ESI): Calculated for C19H24NO2 ([M+H]+): 298.1807; found: 298.1803 
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IR (neat) : ν = 2904, 2360, 1612 cm-1 
m.p.: 70-72°C 
2-((3r,5r,7r)-adamantan-1-yl)-6-methyl-4H-benzo[d][1,3]oxazine 3.33: 
 
Following general procedure for benzoxazine synthesis, 3.33r (36 mg, 0.1 mmol, 1eq) was 
reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), cesium pivalate (7.1 mg, 0.03 mmol, 30 
mol%) and Cs2CO3 (98 mg, 0.3 mmol, 3 eq) in o-xylene (2 mL) at 160°C for 15h. After 
purification, 3.33 was obtained as a white solid (24.3 mg, 0.086 mmol, 86%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.05 – 7.03 (m, 2H), 6.75 – 6.72 (m, 1H), 5.10 (s, 2H), 
2.30 (s, 3H), 2.07 – 2.02 (m, 3H), 1.96 – 1.92 (m, 6H), 1.76 – 1.70 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ = 168.1, 137.2, 135.8, 129.4, 124.2, 124.2, 122.3, 66.2, 39.5, 
39.5, 36.9, 28.3, 21.2. 
HRMS (ESI): Calculated for C19H24NO ([M+H]+): 282.1858; found: 282.1858 
IR (neat) : ν = 2925, 2045, 911 cm-1 
m.p.: 77-79°C 
2-((3s)-adamantan-1-yl)-7-methyl-4H-benzo[d][1,3]oxazine and 2-((3r,5r,7r)-adamantan-
1-yl)-5-methyl-4H-benzo[d][1,3]oxazine 3.34/3.34’:  
 
Following general procedure for benzoxazine synthesis, 3.34r (36 mg, 0.1 mmol, 1eq) was 
reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), cesium pivalate (7.1 mg, 0.03 mmol, 30 
mol%) and Cs2CO3 (98 mg, 0.3 mmol, 3 eq) in o-xylene (2 mL) at 160°C for 15h. 1H NMR of 
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the crude mixture shows a ratio [2.9:1] (3.34/3.34’). After purification, 3.34/34’ was obtained 
mixture of 2 products (27 mg, [2.6:1] mixture, 0.096 mmol, 96%). 
Major product: 
1H NMR (500 MHz, Chloroform-d) δ = 6.99 – 6.98 (m, 1H), 6.95 – 6.91 (m, 1H), 6.82 – 6.79 
(m, 1H), 5.11 (s, 2H), 2.31 (s, 3H), 2.07 – 2.02 (m, 3H), 1.97 – 1.93 (m, 6H), 1.78 – 1.70 (m, 6H). 
13C NMR (126 MHz, CDCl3) δ = 168.7, 139.4, 138.6, 126.5, 124.9, 123.3, 119.3, 66.0, 39.4, 
36.7, 28.2, 21.2. 
Minor product: 
1H NMR (500 MHz, Chloroform-d) δ = 7.15 – 7.10 (m, 1H), 6.99 – 6.96 (m, 1H), 6.94 – 6.91 
(m, 1H), 5.17 (s, 2H), 2.15 (s, 3H), 2.06 – 2.02 (m, 3H), 1.96 – 1.92 (m, 6H), 1.77 – 1.69 (m, 6H). 
13C NMR (126 MHz, Chloroform-d) δ = 168.0, 139.4, 132.5, 128.3, 127.8, 122.2, 120.8, 64.3, 
39.5, 36.9, 28.3, 17.5. 
HRMS (ESI): Calculated for C19H24NO ([M+H]+): 282.1858; found: 282.1858 
IR (neat) : ν = 2926, 2046, 907 cm-1 
m.p.: 68-70°C 
2-((3r,5r,7r)-adamantan-1-yl)-7-methoxy-4H-benzo[d][1,3]oxazine 3.35:  
 
Following general procedure for benzoxazine synthesis, 3.35r (38 mg, 0.1 mmol, 1eq) was 
reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), adamantane carboxylic acid (5.4 mg, 
0.03 mmol, 30 mol%) and Cs2CO3 (98 mg, 0.3 mmol, 3 eq) in o-xylene (2 mL) at 160°C for 
15h. 1H NMR of the crude mixture shows a ratio [4:1] (3.35/3.35’). After purification, 3.35 was 
obtained as a yellowish solid (24 mg, 0.081 mmol, 81% and 19 mg, 0.062 mmol, 62% for the 
major isomer). 
1H NMR (400 MHz, Chloroform-d) δ = 6.84 – 6.81 (m, 1H), 6.74 – 6.72 (m, 1H), 6.70 – 6.66 
(m, 1H), 5.10 (s, 2H), 3.79 (s, 3H), 2.07 – 2.02 (m, 3H), 1.97 – 1.93 (m, 6H), 1.79 – 1.68 (m, 6H). 
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13C NMR (101 MHz, CDCl3) δ = 169.3, 160.3, 140.9, 124.4, 114.5, 112.6, 109.0, 66.0, 55.6, 
39.6, 39.5, 36.8, 28.3. 
HRMS (ESI): Calculated for C19H24NO2 ([M+H]+): 298.1807; found: 298.1802 
IR (neat) : ν = 2905, 2361, 1609 cm-1 
m.p.: 79-81°C 
2-((3r,5r,7r)-adamantan-1-yl)-7-fluoro-4H-benzo[d][1,3]oxazine 3.36:  
 
Following general procedure for benzoxazine synthesis, 3.36r (37 mg, 0.1 mmol, 1eq) was 
reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), adamantane carboxylic acid (5.4 mg, 
0.03 mmol, 30 mol%) and Cs2CO3 (98 mg, 0.3 mmol, 3 eq) in o-xylene (2 mL) at 160°C for 
15h. 1H NMR of the crude mixture shows a ratio [2.7:1] (3.36/3.36’). After purification, 3.36 was 
obtained as a yellowish solid (21 mg, 0.073 mmol, 73% for the mixture and 15 mg, 0.051 mmol, 
51% for the major isomer). 
1H NMR (400 MHz, Chloroform-d) δ = 6.90 – 6.76 (m, 3H), 5.12 (s, 2H), 2.07 – 2.01 (m, 3H), 
1.95 – 1.92 (m, 6H), 1.79 – 1.69 (m, 6H). 
13C NMR (126 MHz, CDCl3) δ = 169.76, 163.2 (d, J = 245.8 Hz), 141.5 (d, J = 11.2 Hz), 124.6 
(d, J = 9.2 Hz), 118.1 (d, J = 3.3 Hz), 112.6 (d, J = 22.3 Hz), 111.5 (d, J = 22.2 Hz), 65.9, 39.6, 
39.4, 36.8, 28.3. 
19F NMR (376 MHz, CDCl3) δ = -113.7. 
HRMS (ESI): Calculated for C18H21FNO ([M+H]+): 286.1607; found: 286.1608 
IR (neat) : ν = 2361, 906 cm-1 
m.p.: 68-70°C 
2-((3s)-adamantan-1-yl)-7-(trifluoromethoxy)-4H-benzo[d][1,3]oxazine 3.37: 
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Following general procedure for benzoxazine synthesis, 3.37r (43 mg, 0.1 mmol, 1eq) was 
reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), adamantane carboxylic acid (5.4 mg, 
0.03 mmol, 30 mol%) and Cs2CO3 (98 mg, 0.3 mmol, 3 eq) in o-xylene (2 mL) at 160°C for 
15h. 1H NMR of the crude mixture shows a ratio [6.7:1] (3.37/3.37’). After purification, 3.37 was 
obtained as a yellowish oil (23 mg, 0.066 mmol, 66% and 19 mg, 0.054 mmol, 54 % for the 
major isomer). 
1H NMR (400 MHz, Chloroform-d) δ = 7.04 – 7.03 (m, 1H), 6.98 – 6.90 (m, 2H), 5.15 (s, 2H), 
2.08 – 2.01 (m, 3H), 1.95 – 1.93 (m, 6H), 1.78 – 1.69 (m, H). 
13C NMR (126 MHz, CDCl3) δ = 169.9, 149.6 (q, J = 2.1 Hz), 141.1, 124.5, 120.8, 120.5 (q, J = 
260.1 Hz), 118.2, 116.9, 65.7, 39.6, 39.3, 36.6, 28.1. 
19F NMR (376 MHz, CDCl3) δ = -57.9. 
HRMS (ESI): Calculated for C19H21F3NO2 ([M+H]+): 352.1524; found: 352.1526 
IR (neat) : ν = 1628, 1494 cm-1 
2-((3r,5r,7r)-adamantan-1-yl)-5-fluoro-4H-benzo[d][1,3]oxazine 3.38’:  
 
Following general procedure for benzoxazine synthesis, 3.38r (37 mg, 0.1 mmol, 1eq) was 
reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), adamantane carboxylic acid (5.4 mg, 
0.03 mmol, 30 mol%) and Cs2CO3 (98 mg, 0.3 mmol, 3 eq) in o-xylene (2 mL) at 160°C for 
15h. 1H NMR of the crude mixture shows a ratio [2.2:1] (3.38/3.38’). After purification, 3.38 was 
obtained as a yellowish solid (8.5 mg, 0.03 mmol, 30%) and 3.38’ was obtained as a yellowish 
solid (4 mg, 0.014 mmol, 14%). 
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1H NMR (400 MHz, Chloroform-d) δ = 7.22 – 7.15 (m, 1H), 6.95 – 6.92 (m, 1H), 6.86 – 6.79 
(m, 1H), 5.24 (s, 2H), 2.08 – 2.02 (m, 3H), 1.96 – 1.92 (m, 6H), 1.78 – 1.68 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ = 169.1, 157.4 (d, J = 246.2 Hz), 141.1 (d, J = 4.15 Hz), 129.2 (d, 
J = 8.2 Hz), 120.0 (d, J = 2.9 Hz), 112.7 (d, J = 21.7 Hz), 109.3 (d, J = 18.2 Hz), 60.9 (d, J = 3.1 
Hz), 39.6, 39.3, 36.7, 28.1. 
19F NMR (376 MHz, CDCl3) δ = -123.3. 
HRMS (ESI): Calculated for C18H21FNO ([M+H]+): 286.1607; found: 286.1607 
IR (neat) : ν = 2361, 911 cm-1 
m.p.: 65-67°C 
methyl 2-(1-methylcyclohexyl)-4H-benzo[d][1,3]oxazine-6-carboxylate 3.44:  
 
Following general procedure for benzoxazine synthesis, 3.44r (24 mg, 0.1 mmol, 1eq) was 
reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), cesium pivalate (7.1 mg, 0.03 mmol, 30 
mol%) and Cs2CO3 (98 mg, 0.3 mmol, 3 eq) in o-xylene (2 mL) at 160°C for 15h. After 
purification, 3.44 was obtained as a colorless oil (6.2 mg, 0.033 mmol, 33%). 
1H NMR (500 MHz, Chloroform-d) δ = 7.96 – 7.92 (m, 1H), 7.67 – 7.64 (m, 1H), 7.19 – 7.16 
(m, 1H), 5.20 (s, 2H), 3.90 (s, 3H), 2.13 – 2.05 (m, 2H), 1.58 – 1.45 (m, 4H), 1.37 – 1.29 (m, 2H), 
1.22 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ = 170.7, 166.8, 144.0, 130.7, 127.6, 125.4, 124.2, 122.3, 66.2, 
52.2, 41.9, 35.7, 26.1, 23.1. 
HRMS (ESI): Calculated for C17H22NO3 ([M+H]+): 288.1600; found: 288.1601 
IR (neat) : ν = 2361, 1622, 1492 cm-1 
2-(1-(2-(benzyloxy)ethyl)cyclohexyl)-4H-benzo[d][1,3]oxazine 3.45:   
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Following general procedure for benzoxazine synthesis, 3.45r (43 mg, 0.1 mmol, 1eq) was 
reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), cesium pivalate (7.1 mg, 0.03 mmol, 30 
mol%) and Cs2CO3 (98 mg, 0.3 mmol, 3 eq) in o-xylene (2 mL) at 160°C for 15h. After 
purification, 3.45 was obtained as a yellowish oil (29 mg, 0.082 mmol, 82%). 
1H NMR (250 MHz, Chloroform-d) δ = 7.30 – 7.23 (m, 1H), 7.23 – 7.20 (m, 5H), 7.18 – 7.09 
(m, 2H), 6.91 – 6.84 (m, 1H), 5.05 (s, 2H), 4.41 (s, 2H), 3.57 (t, J = 6.9 Hz, 2H), 2.22 – 2.10 (m, 
2H), 1.93 (t, J = 7.0 Hz, 2H), 1.82 – 1.71 (m, 1H), 1.58 – 1.50 (m, 3H), 1.40 – 1.24 (m, 4H). 
13C NMR (63 MHz, CDCl3) δ = 166.4, 139.5, 138.4, 128.7, 128.2, 127.7, 127.4, 125.9, 124.1, 
123.6, 122.5, 73.1, 66.8, 65.9, 43.5, 34.4, 26.9, 26.1, 22.8.  
HRMS (ESI): Calculated for C23H28NO2 ([M+H]+): 350.2120; found: 350.2122 
IR (neat) : ν = 2361, 1622 cm-1 
2-(bicyclo[2.2.2]octan-1-yl)-6-methoxy-4H-benzo[d][1,3]oxazine 3.50:  
 
Following general procedure for benzoxazine synthesis, 3.50r (35 mg, 0.1 mmol, 1eq) was 
reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), cesium pivalate (7.1 mg, 0.03 mmol, 30 
mol%) and Cs2CO3 (98 mg, 0.3 mmol, 3 eq) in o-xylene (2 mL) at 160°C for 15h. After 
purification, 3.50 was obtained as a white solid (13.5 mg, 0.050 mmol, 50%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.08 – 7.05 (m, 1H), 6.78 – 6.74 (m, 1H), 6.46 – 6.44 
(m, 1H), 5.09 (s, 2H), 3.77 (s, 3H), 1.82 – 1.75 (m, 6H), 1.65 – 1.57 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ = 166.8, 157.8, 132.9, 125.3, 123.3, 113.4, 109.3, 65.9, 55.5, 
37.1, 28.5, 25.6, 24.1. 
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HRMS (ESI): Calculated for C17H22NO2 ([M+H]+): 272.1651; found: 272.1645 
IR (neat) : ν = 906 cm-1 
m.p.: 90-92°C 
2-(bicyclo[2.2.2]octan-1-yl)-4H-benzo[d][1,3]oxazine-6-carbonitrile 3.51:  
 
Following general procedure for benzoxazine synthesis, 3.51r (35 mg, 0.1 mmol, 1eq) was 
reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), cesium pivalate (7.1 mg, 0.03 mmol, 30 
mol%) and Cs2CO3 (98 mg, 0.3 mmol, 3 eq) in o-xylene (2 mL) at 160°C for 15h. After 
purification, 3.51 was obtained as a white solid (10.5 mg, 0.039 mmol, 39%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.54 – 7.50 (m, 1H), 7.23 – 7.20 (m, 1H), 7.18 – 7.14 
(m, 1H), 5.15 (s, 2H), 1.82 – 1.76 (m, 6H), 1.68 – 1.64 (m, 1H), 1.64 – 1.57 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ = 172.0, 143.8, 133.3, 127.6, 125.0, 123.4, 119.0, 109.1, 65.5, 
37.8, 28.6, 25.6, 24.1. 
HRMS (ESI): Calculated for C17H19N2O ([M+H]+): 267.1497; found: 267.1493 
IR (neat) : ν = 2361, 903 cm-1 
m.p.: 82-84°C 
2-(bicyclo[2.2.2]octan-1-yl)-7-methoxy-4H-benzo[d][1,3]oxazine 3.46: 
 
Following general procedure for benzoxazine synthesis, 3.46r (35 mg, 0.1 mmol, 1eq) was 
reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), adamantane carboxylic acid pivalate 
(5.6 mg, 0.03 mmol, 30 mol%) and Cs2CO3 (98 mg, 0.3 mmol, 3 eq) in o-xylene (2 mL) at 
299 
 
160°C for 15h. 1H NMR of the crude mixture shows a ratio [4:1] (3.46/3.46’). After purification, 
3.46 was obtained as a colorless oil (10 mg, 0.036 mmol, 36% for the mixture and 6 mg, 0.021 
mmol, 21% for the major isomer). 
1H NMR (500 MHz, Chloroform-d) δ = 6.83 – 6.79 (m, 1H), 6.72 – 6.70 (m, 1H), 6.69 – 6.65 
(m, 1H), 5.09 (s, 2H), 3.79 (s, 3H), 1.82 – 1.77 (m, 6H), 1.66 – 1.58 (m, 7H). 
13C NMR (126 MHz, CDCl3) δ = 169.4, 160.3, 140.8, 124.4, 114.4, 112.6, 109.0, 66.0, 55.6, 
37.4, 28.7, 25.8, 24.2. 
HRMS (ESI): Calculated for C17H22NO2 ([M+H]+): 272.1651; found: 272.1653 
IR (neat) : ν = 2361, 906 cm-1 
methyl 4-(6-cyano-4H-benzo[d][1,3]oxazin-2-yl)bicyclo[2.2.2]octane-1-carboxylate 3.47:  
 
Following general procedure for benzoxazine synthesis, 3.47r (40 mg, 0.1 mmol, 1eq) was 
reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), cesium pivalate (7.1 mg, 0.03 mmol, 30 
mol%) and Cs2CO3 (98 mg, 0.3 mmol, 3 eq) in o-xylene (2 mL) at 160°C for 15h. After 
purification, 3.47 was obtained as a yellowish oil (14.5 mg, 0.045 mmol, 45%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.56 – 7.51 (m, 1H), 7.24 – 7.21 (m, 1H), 7.18 – 7.14 
(m, 1H), 5.17 (s, 2H), 3.66 (s, 3H), 1.86 (s, 12H). 
13C NMR (126 MHz, CDCl3) δ = 178.1, 170.9, 143.5, 133.4, 127.6, 125.1, 123.2, 118.9, 109.4, 
65.6, 51.9, 39.0, 38.2, 28.3, 28.0. 
HRMS (ESI): Calculated for C19H21N2O3 ([M+H]+): 325.1552; found: 325.1544 
IR (neat) : ν = 2359, 905 cm-1 
((3r,5r,7r)-adamantan-1-yl)(indolin-1-yl)methanone 3.49:  
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Following general procedure for benzoxazine synthesis, 3.48r (36 mg, 0.1 mmol, 1eq) was 
reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), cesium pivalate (7.1 mg, 0.03 mmol, 30 
mol%) and Cs2CO3 (98 mg, 0.3 mmol, 3 eq) in o-xylene (2 mL) at 160°C for 15h. After 
purification, 3.49 was obtained as a yellowish oil (22.5 mg, 0.080 mmol, 80%). 
1H NMR (400 MHz, Chloroform-d) δ = 8.25 – 8.19 (m, 1H), 7.21 – 7.13 (m, 2H), 7.03 – 6.98 
(m, 1H), 4.32 (t, J = 8.1 Hz, 2H), 3.12 (t, J = 8.1 Hz, 2H), 2.12 – 2.06 (m, 9H), 1.78 – 1.72 (m, 
6H). 
13C NMR (101 MHz, CDCl3) δ = 176.1, 145.0, 130.7, 127.3, 124.2, 123.5, 118.6, 49.6, 43.1, 
38.3, 36.6, 29.6, 28.4. 
HRMS (ESI): Calculated for C19H24NO ([M+H]+): 282.1858; found: 282.1858 
IR (neat) : ν = 2904, 2848, 1634, 1374 cm-1 
2-((3s)-adamantan-1-yl)-7-fluoro-1,4-dihydro-2H-benzo[d][1,3]oxazine 3.52:  
 
Benzoxazine 3.36 (0.05 mmol, 14 mg, 1 equiv) was dissolved in a mixture of THF/MeOH/DMF 
[1:1:1] (0.5 mL) and cooled to 0°C with an ice bath. Then, sodium borohydride (0.15 mmol, 5.7 
mg, 3 equiv) was added and the mixture was slowly warm to room temperature. The reaction 
was monitored by TLC using Cyclohexane/AcOEt [9:1] as solvent. After completion, the 
reaction was quenched with NaOH (1M, 1 mL) and the crude mixture was extracted with AcOEt 
(3 x 2mL). The combined organic layers were dried over sodium sulfate, filtered, evaporated 
and purified by preparative HPLC using water/MeCN as solvent. The product was obtained as 
a colorless oil (9 mg, 0.031 mmol, 62 %). 
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1H NMR (500 MHz, Chloroform-d) δ = 6.84 – 6.79 (m, 1H), 6.46 – 6.41 (m, 1H), 6.37 – 6.33 
(m, 1H), 4.87 – 4.82 (m, 1H), 4.79 – 4.75 (m, 1H), 4.06 (s, 2H), 2.06 – 2.02 (m, 3H), 1.79 – 1.67 
(m, 9H), 1.66 – 1.61 (m, 3H). 
13C NMR (126 MHz, CDCl3) δ = 162.4 (d, J = 245.2 Hz), 143.8 (d, J = 11.0 Hz), 126.0 (d, J = 
11.0 Hz), 117.5 (d, J = 2.9 Hz), 105.5 (d, J = 22.0 Hz), 102.8 (d, J = 24.2 Hz), 90.5, 67.9, 37.2, 
37.1, 36.0, 28.1. 
19F NMR (471 MHz, CDCl3) δ = -115.58. 
HRMS (ESI): Calculated for C18H23FNO ([M+H]+): 288.1764; found: 288.1765 
IR (neat) : ν = 2361, 911cm-1 
N-methylskatole 3.54: 
 
The product was synthesized following a described procedure from the literature. Analysis data 
matches with previous report.27 
 1H NMR (250 MHz, Chloroform-d) δ = 7.62 – 7.56 (m, 1H), 7.31 – 7.18 (m, 2H), 7.17 – 7.09 
(m, 1H), 6.79 – 6.77 (m, 1H), 3.68 (s, 3H), 2.35 (d, J = 1.1 Hz, 3H). 
13C NMR (63 MHz, CDCl3) δ = 137.1, 128.7, 126.6, 121.5, 119.0, 118.6, 110.1, 109.1, 32.5, 
9.7. 
((3R,5R,7R)-adamantan-1-yl)((5aR,10bR)-2-fluoro-6,10b-dimethyl-5a,6,10b,11-
tetrahydro-5H-indolo[2,3-b]quinolin-5-yl)methanone 3.55:  
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In a 10 mL flask, 3.29 (0.080mmol, 23 mg, 1 eq) was refluxed in HCl/Dioxane (4 M, 3 mL) for 
3 h. The reaction was cooled to room temperature and quenched with water (5 mL). The crude 
mixture was extracted with AcOEt (3 x 5 mL) and the combined organic phases were dried over 
sodium sulfate, filtered and evaporated under vacuum. The intermediate was used without 
further purification (25.7 mg, 0.08 mmol, 100 %).  
In a 10 mL flask with N-methylskatole 3.54 (34.8 mg, 0.24 mmol, 3 eq) and Cs2CO3 (52 mg, 
0.16 mmol, 2 eq) was added the chlorobenzylintermediate (25.7 mg, 0.08 mmol, 1 eq) in 1,2-
dichloroethane (0.5 mL). The mixture was stirred overnight at 80°C, cooled to room 
temperature, quenched with water (2 mL) and extracted with AcOEt (3 x 2 mL). The combined 
organic phases were dried over sodium sulfate, filtered and evaporated. The crude mixture was 
purified by preparative HPLC using MeCN/Water as solvent, to afford 3.55 (17 mg, 0.04 mmol, 
50%) as a yellowish oil. 
1H NMR (500 MHz, Chloroform-d) δ = 7.04 – 6.98 (m, 1H), 6.90 – 6.83 (m, 2H), 6.79 – 6.73 
(m, 1H), 6.68 – 6.63 (m, 1H), 6.51 – 6.46 (m, 1H), 6.04 – 6.00 (m, 1H), 5.96 (s, 1H), 2.82 (s, 3H), 
2.79 (d, J = 13.6 Hz, 1H), 2.71 (d, J = 13.6 Hz, 1H), 1.96 – 1.89 (m, 6H), 1.80 – 1.75 (m, 3H), 1.66 
– 1.53 (m, 6H), 1.52 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ = 180.3, 161.1 (d, J = 245.2 Hz), 150.7, 137.3 (d, J = 8.5 Hz), 
135.2 (d, J = 2.9 Hz), 133.2, 128.1, 127.5 (d, J = 8.9 Hz), 121.9, 116.6, 115.3 (d, J = 21.7 Hz), 113.1 
(d, J = 24.7 Hz), 104.1, 85.3, 51.0, 45.1, 40.8, 40.5, 36.6, 30.6, 28.9, 28.6. 
19F NMR (471 MHz, CDCl3) δ = -115.1. 
HRMS (ESI): Calculated for C28H32FN2O ([M+H]+): 431.2499; found: 431.2501 
IR (neat) : ν = 2361, 903 cm-1 
(5aS,10bR)-2-fluoro-6,10b-dimethyl-5a,6,10b,11-tetrahydro-5H-indolo[2,3-b]quinolone 
3.56:  
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3.55 (17 mg, 0.04 mmol, 1 eq) was dissolved in MeOH (1 mL) and NaOH (32 mg, 0.8 mmol, 20 
eq) was added. The mixture was stirred at 90°C overnight, and the volatile were removed under 
vacuum. The crude mixture was quenched with water (2 mL) and extracted with AcOEt (3 x 2 
mL). The combined phases were dried over sodium sulfate, filtered and evaporated under 
vacuum. The crude mixture was purified by preparative HPLC using MeCN/Water as solvent 
to afford 3.56 as a yellowish oil (7.5 mg, 0.028 mmol, 69 %). 
1H NMR (500 MHz, Chloroform-d) δ = 7.14 – 7.10 (m, 1H), 7.10 – 7.08 (m, 1H), 6.78 – 6.73 
(m, 2H), 6.73 – 6.69 (m, 1H), 6.56 – 6.53 (m, 1H), 6.52 – 6.49 (m, 1H), 4.51 (br. s, 1H), 4.14 (s, 
1H), 2.79 (d, J = 15.1 Hz, 1H), 2.76 (s, 3H), 2.48 (d, J = 15.2 Hz, 1H), 1.23 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ = 156.1 (d, J = 234.9 Hz), 149.3, 137.4 (d, J = 2.1 Hz), 136.7, 
128.02, 123.2 (d, J = 7.3 Hz), 121.5, 118.8, 115.5 (d, J = 22.1 Hz), 114.2 (d, J = 8.2 Hz), 113.6 (d, J 
= 22.3 Hz), 108.0, 84.1, 39.5, 37.8, 32.2, 22.0. 
19F NMR (471 MHz, CDCl3) δ = -127.4. 
HRMS (ESI): Calculated for C17H18FN2 ([M+H]+): 269.1454; found: 269.1457 
IR (neat) : ν = 901 cm-1 
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Checkcif for compound 3.47  
 
checkCIF/PLATON report  
Structure factors have been supplied for datablock(s) 1
THIS REPORT IS FOR GUIDANCE ONLY. IF USED AS PART OF A REVIEW PROCEDURE
FOR PUBLICATION, IT SHOULD NOT REPLACE THE EXPERTISE OF AN EXPERIENCED
CRYSTALLOGRAPHIC REFEREE.
No syntax errors found.        CIF dictionary        Interpreting this report
Datablock: 1 
Bond precision: C-C = 0.0015 A Wavelength=1.54178
Cell: a=9.2604(8) b=9.5842(8) c=9.6708(8)
alpha=104.522(3) beta=90.492(3) gamma=107.125(3)
Temperature: 123 K
Calculated Reported
Volume 790.90(12) 790.90(12)
Space group P -1 P -1 
Hall group -P 1 -P 1 
Moiety formula C19 H20 N2 O3 C19 H20 N2 O3
Sum formula C19 H20 N2 O3 C19 H20 N2 O3
Mr 324.37 324.38
Dx,g cm-3 1.362 1.362
Z 2 2
Mu (mm-1) 0.753 0.753
F000 344.0 344.0
F000’ 345.05
h,k,lmax 11,11,11 11,11,11
Nref 3015 2935 
Tmin,Tmax 0.897,0.942 0.910,0.940
Tmin’ 0.854
Correction method= # Reported T Limits: Tmin=0.910 Tmax=0.940
AbsCorr = MULTI-SCAN
Data completeness= 0.973 Theta(max)= 70.118
R(reflections)= 0.0338( 2807)
wR2(reflections)= wR= 0.0370( 
2737)
S = 1.085 Npar= 217
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The following ALERTS were generated. Each ALERT has the format
       t est - name_ALERT_al er t - t ype_al er t - l evel .
Click on the hyperlinks for more details of the test.
 Al er t  l evel  B
PLAT910_ALERT_3_B Missing # of FCF Reflection(s) Below Theta(Min).         12 Note  
 Al er t  l evel  C
PLAT913_ALERT_3_C Missing # of Very Strong Reflections in FCF ....          7 Note  
PLAT920_ALERT_1_C Theta(Max)  in CIF and FCF Differ by ...........       0.21 Degree
 Al er t  l evel  G
PLAT154_ALERT_1_G The s.u.’s on the Cell Angles are Equal ..(Note)      0.003 Degree
PLAT230_ALERT_2_G Hirshfeld Test Diff for   C1       --C5        .        8.7 s.u.  
PLAT725_ALERT_2_G D-H     Calc     0.96000, Rep     0.97000 Dev...       0.01 Ang.  
              C6       -H61             1.555   1.555 ........     #   47 Check 
PLAT808_ALERT_5_G No Parseable SHELXL Style Weighting Scheme Found     Please Check
PLAT882_ALERT_1_G No Datum for _diffrn_reflns_av_unetI/netI ......     Please Do ! 
PLAT911_ALERT_3_G Missing FCF Refl Between Thmin & STh/L=    0.600        214 Report
PLAT912_ALERT_4_G Missing # of FCF Reflections Above STh/L=  0.600         51 Note  
PLAT929_ALERT_5_G No Weight Pars,Obs and Calc R1,wR2,S not Checked          ! Info 
PLAT961_ALERT_5_G Dataset Contains no Negative Intensities .......     Please Check
   0 ALERT l evel  A = Most likely a serious problem - resolve or explain
   1 ALERT l evel  B = A potentially serious problem, consider carefully
   2 ALERT l evel  C = Check. Ensure it is not caused by an omission or oversight
   9 ALERT l evel  G = General information/check it is not something unexpected
   3 ALERT type 1 CIF construction/syntax error, inconsistent or missing data
   2 ALERT type 2 Indicator that the structure model may be wrong or deficient
   3 ALERT type 3 Indicator that the structure quality may be low
   1 ALERT type 4 Improvement, methodology, query or suggestion
   3 ALERT type 5 Informative message, check
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It is advisable to attempt to resolve as many as possible of the alerts in all categories. Often the
minor alerts point to easily fixed oversights, errors and omissions in your CIF or refinement
strategy, so attention to these fine details can be worthwhile. In order to resolve some of the more
serious problems it may be necessary to carry out additional measurements or structure
refinements. However, the purpose of your study may justify the reported deviations and the more
serious of these should normally be commented upon in the discussion or experimental section of a
paper or in the "special_details" fields of the CIF. checkCIF was carefully designed to identify
outliers and unusual parameters, but every test has its limitations and alerts that are not important
in a particular case may appear. Conversely, the absence of alerts does not guarantee there are no
aspects of the results needing attention. It is up to the individual to critically assess their own
results and, if necessary, seek expert advice.
Publication of your CIF in IUCr journals 
A basic structural check has been run on your CIF. These basic checks will be run on all CIFs
submitted for publication in IUCr journals ( Acta Crystallographica, Journal of Applied 
Crystallography, Journal of Synchrotron Radiation); however, if you intend to submit to Acta
Crystallographica Section C or E or IUCrData, you should make sure that full publication checks
are run on the final version of your CIF prior to submission.
Publication of your CIF in other journals 
Please refer to the Notes for Authors of the relevant journal for any special instructions relating to
CIF submission.
PLATON version of 23/04/2018; check.def file version of 23/04/2018  
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Datablock 1 - ellipsoid plot
308 
 
Computational details 
Geometry optimizations were performed with the B97X-D functional/6-311+G** basis set in 
vacuum, using the Spartan '16 software (Wavefunction, Inc.). The geometry of the optimized 
structures is available as a single xyz file alongside the Supporting Information. 
Geometry optimizations were performed using Gaussian 16, Revision A0328 at the PBE0 level 
of hybrid density functional theory,29 with inclusion of D3(bj) corrections in the optimization 
process.30,31 The geometry of all the optimized structures is available as a single xyz file 
alongside the Supporting Information. The atoms C, H, N, P and O were represented by an svp 
basis set.32 The Pd atom was represented by Dolg’s pseudo potential and the associated basis 
set.33,34 The solvent (mesitylene) influence was taken into consideration through single-point 
calculations on the gas-phase optimized geometries with SCRF calculations within the SMD 
model.35 For the SCRF calculations, the atoms were treated with a def2-qzvp basis set.36 All 
energies reported are Gibbs free energies obtained by summing the SMD energy (including D3 
corrections) and the gas phase Gibbs contribution at 433 K and 1 atm.  
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Part 2 : Remote C(sp3)-H activation 
Chapter 2.1: 1,4-Palladium Shift/C(sp3)-H Activation 
Strategy for the Constructionf of 5-Membered Rings 
General procedures: 
GENERAL PROCEDURE FOR KNOEVENAGEL CONDENSATIONS: 
In a round bottom flask was stirred the ortho-bromobenzaldehyde derivatives (1 equiv), malonic 
acid (1.1 equiv), piperidine (1.1 equiv) in pyridine (2.5 M) at 90 °C for 15h. Pyridine was removed 
under vacuum, the crude mixture was acidified with HCl (2 M) and extracted with AcOEt (3 
times). The crude mixture was dried over sodium sulfate, filtered and evaporated under vacuum. 
The acid was purified by precipitated in Et2O or used without further purifications for next step. 
GENERAL PROCEDURE FOR ALDOLISATION REACTION:  
Aldehyde (1 equiv) and ketone (1 equiv) were dissolved in EtOH (1 M), followed by addition of 
NaOH (1 equiv) in water (1 M). The reaction was stirred at 45°C until completion and 
evaporated under vacuum. The crude was dissolved in dichloromethane and the organic phase 
was washed with water. The crude was dried over sodium sulfate, filtered and evaporated under 
vacuum. The desired chalcones were purified by chromatography on silica gel using 
cyclohexane/AcOEt as solvent.  
GENERAL PROCEDURE FOR AMIDE SYNTHESIS: 
The carboxylic acid (1 equiv) was suspended in dichloromethane (0.05 M) with DMF (0.01 
equiv). Oxalyl chloride (1.5 equiv) was carefully added to the resulting mixture, which was then 
stirred for 2h. The solvent and excess of oxalyl chloride were removed under vacuum, and the 
crude was dissolved in dichloromethane (0.05 M). Then, a solution of amine (1 equiv) and Et3N 
(2 equiv) in dichloromethane (0.05 M) was carefully added. The reaction was followed by TLC 
(cyclohexane/AcOEt). After completion, the solvent was removed and the crude was purified 
by chromatography on silica gel, using cyclohexane/AcOEt as solvent.  
GENERAL PROCEDURE FOR THE 1,4-PD SHIFT/C(SP3)-H ACTIVATION: 
In a 10 mL screw cap charged with amide (0.1 mmol, 1 equiv) was weighted in a glovebox 
Pd(PCy3)2 (0.01 mmol, 10 mol %), PCy3 (when mentioned) (2.8 mg, 0.01 mmol, 10 mol%), 
pivalic acid (0.03 mmol, 30 mol %) and Rb2CO3 (0.15 mmol, 1.5 equiv). The vial was charged 
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with mesitylene (4 mL) and stirred under argon in a previously heated heating block at 160 °C 
for 16 h. The reaction was cooled to room temperature, filtered over celite, and evaporated under 
vacuum. The crude was purified by preparative HPLC using gradient of solvent (H2O: MeCN) 
[90:10] to [10:90]. The collected fractions were evaporated under vacuum to afford the desired 
product. 
1,4-Pd shift/C(sp3)-H activation reaction optimization: 
 
Pd source Additive (30 
mol%) 
Base Solvent NMR yield 
(Isolated) 
Pd(Pt-Bu3)2 (10 
mol%) 
PivOH Rb2CO3 (1.5 
equiv.) 
Mesitylene 
[0.05M] 
0% 
Pd(PPh3)4 (10 
mol%) 
PivOH Rb2CO3 (1.5 
equiv.) 
Mesitylene 
[0.05M] 
8% 
[Pd(3-
allyl)Cl2]/PPh3 
(10 mol%) 
PivOH Cs2CO3 (2 
equiv.) 
Mesitylene 
[0.05M] 
0% 
Pd2dba3/PCy3 
(10 mol%) 
PivOH Rb2CO3 (1.5 
equiv.) 
Mesitylene 
[0.05M] 
31% 
Pd(PCy3)2 (10 
mol%) 
PivOH Rb2CO3 (1.5 
equiv.) 
Mesitylene 
[0.05M] 
65% 
Pd(PCy3)2 (10 
mol%) 
PivOH Rb2CO3 (1.5 
equiv.) 
Mesitylene 
[0.025M] 
100% (94%) 
Pd(PCy3)2 (5 
mol%) 
PivOH Rb2CO3 (1.5 
equiv.) 
Mesitylene 
[0.025M] 
51% 
*Using trichloroethylene as internal standard   
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Amines:  
N-(2,4,6-Trimethoxybenzyl)propan-2-amine 2.40r: 
  
N-(2,4,6-trimethoxybenzyl)propan-2-amine was obtained according to a known procedure. 
The physical and spectroscopic properties matched those described in the literature.37 
 
N-(2,4,6-trimethoxybenzyl)ethanamine 2.53a:  
 
N-(2,4,6-trimethoxybenzyl)ethanamine was obtained according to a known procedure. 
The physical and spectroscopic properties matched those described in the literature. 1 
2-Methyl-N-(2,4,6-trimethoxybenzyl)propan-2-amine 2.55a: 
 
2-Methyl-N-(2,4,6-trimethoxybenzyl)propan-2-amine was obtained according to a known 
procedure. 
The physical and spectroscopic properties matched those described in the literature. 1 
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N-(Cyclopentylmethyl)propan-2-amine 2.63a:  
 
N-(Cyclopentylmethyl)propan-2-amine was obtained according to a known procedure. 
The physical and spectroscopic properties matched those described in the literature. 1 
 
Synthesis of reaction substrates: 
(E)-3-(2-bromophenyl)-N-isopropyl-N-(2,4,6-trimethoxybenzyl)acrylamide 4.48: 
 
Following the general procedure for amide synthesis, 2-bromocinnamic acid (411 mg, 1.81 mmol, 1 equiv) 
was reacted with oxalyl chloride (0.26 mL, 2.72 mmol, 1.5 equiv) with DMF (1 drop) in dichloromethane. 
The acid chloride was then reacted with 2.40r (433 mg, 1.81 mmol, 1 equiv) and Et3N (0.51 mL, 3.62 mmol, 
2 equiv) in dichloromethane. After evaporation and purification, 4.48 was obtained as a white solid (720 
mg, 1.6 mmol, 89 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.88 (d, J = 15.4 Hz, 1H), 7.61 – 7.55 (m, 2H), 7.31 
– 7.28 (m, 1H), 7.24 – 7.18 (m, 1H), 7.18 – 7.10 (m, 1H), 6.10 (s, 2H), 4.60 (s, 2H), 4.14 – 4.05 
(sept, J = 7.0 Hz, 1H), 3.81 (s, 3H), 3.78 (s, 6H), 1.17 (d, J = 6.9 Hz, 6H). 
 
13C NMR (101 MHz, Chloroform-d) δ = 166.7, 161.2, 159.7, 138.1, 136.6, 133.4, 130.0, 
127.6, 127.5, 125.0, 124.9, 106.4, 90.5, 55.6, 55.4, 49.1, 39.7, 19.9. 
 
HRMS (ESI): Calculated for C22H26BrNaNO4 ([M+Na]+): 470.0943; found: 470.0937 
IR (neat) : ν = 2362, 1596, 1467 cm-1 
m.p.: 86 - 88°C 
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(E)-3-(2-bromophenyl)-N-(propan-2-yl-1,1,1,3,3,3-d6)-N-
(2,4,6)trimethoxybenzyl)acrylamide-4.48-d7:  
 
(2,4,6-trimethoxyphenyl)methanamine hydrochloride (500 mg, 2.14 mmol, 1 equiv) was 
exchanged with methanol-D4 (10 mL) by stirring at room temperature overnight. After 
evaporation of the volatiles, the free amine was reacted with acetone- D6 (2.4 mL, 32 mmol, 15 
equiv) in dry benzene (20 mL) and refluxed in a Dean-Stark apparatus overnight. The volatiles 
were removed under vacuum, and the imine was then dissolved in diglyme (15 mL) and cooled 
to 0°C with an ice batch. NaBD4 (4.28 mmol, 179 mg, 2 equiv) was carefully added to the 
solution, which was slowly warmed to room temperature. After completion, the reaction was 
quenched with 2M NaOH (20 mL) and extracted with DCM (3 x 15 mL). The combined organic 
phases were dried over sodium sulfate, filtered and evaporated under vacuum. The desired 
amine was obtained without further purification. (508 mg, 2.12 mmol, 99%).  
Malonic acid-D4 (3 g, 27.8 mmol, 1 equiv), 2-Bromobenzaldehyde (5.14 g, 27.8 mmol, 1 equiv), 
piperidine (2 drops) were refluxed in pyridine (50 mL) for 3h. Solvent were removed, and the 
reaction was quenched with 2M HCl (50 mL) and extracted with DCM (3 x 25 mL). The 
combined organic layers were dried over sodium sulfate, filtered and evaporated under vacuum 
to afford the deuterated cinnamic acid derivative (6.26 g, 27.45 mmol, 99%). 
 The deuterated cinnamic acid derivative (274 mg, 1.2 mmol, 1 equiv) was reacted with oxalyl 
chloride (0.17 mL, 1.8 mmol, 1.5 equiv) with DMF (1 drop) in dichloromethane. The acid chloride was then 
reacted with the deuterated amine (294 mg, 1.2 mmol, 1 equiv) and Et3N (0.33 mL, 2.4 mmol, 2 equiv) in 
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dichloromethane. After evaporation and purification, 4.48-d7 was obtained as a white solid (412 mg, 0.9 
mmol, 75 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.91 – 7.86 (m, 1H), 7.60 – 7.55 (m, 2H), 7.31 – 7.28 
(m, 1H), 7.18 – 7.12 (m, 1H), 6.11 (s, 2H), 4.59 (s, 2H), 4.12 – 4.04 (m, 1H), 3.81 (s, 3H), 3.78 (s, 
6H). 
 
13C NMR (101 MHz, Chloroform-d) δ = 166.7, 161.1, 159.7, 138.0, 136.6, 133.4, 129.9, 
127.6, 127.5, 124.9, 106.4, 90.5, 55.5, 55.4, 49.0, 39.7. 
 
 (E)-3-(2-bromophenyl)-N-(propan-2-yl-1,1,1,3,3,3-d6)-N-(2,4,6-
trimethoxybenzyl)acrylamide 4.48-d6:  
 
Following the general procedure for amide synthesis, 2-bromocinnamic acid (182 mg, 0.8 mmol, 1 equiv) 
was reacted with oxalyl chloride (0.11 mL, 1.2 mmol, 1.5 equiv) with DMF (1 drop) in dichloromethane. 
The acid chloride was then reacted with the deuterated amine (195 mg, 0.8 mmol, 1 equiv) and Et3N (0.22 
mL, 1.6 mmol, 2 equiv) in dichloromethane. After evaporation and purification, 4.48-d6 was obtained as a 
white solid (302 mg, 0.66 mmol, 83 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.87 (d, J = 15.5 Hz, 1H), 7.59 – 7.54 (m, 2H), 7.30 
– 7.27 (m, 1H), 7.21 (d, J = 15.4 Hz, 1H), 7.17 – 7.11 (m, 1H), 6.10 (s, 2H), 4.59 (s, 2H), 4.12 – 
4.03 (m, 1H), 3.80 (s, 3H), 3.77 (s, 6H). 
 
13C NMR (101 MHz, Chloroform-d) δ = 166.8, 161.1, 159.7, 138.0, 136.6, 133.4, 129.9, 
127.6, 127.5, 124.9, 124.9, 106.4, 90.6, 55.5, 55.4, 39.7. 
 
(E)-3-(2-bromophenyl)-N-isopropyl-N-(2,4,6-trimethoxybenzyl)acrylamide-2-d 4.48-d1:  
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The deuterated cinnamic acid derivative (251 mg, 1.1 mmol, 1 equiv) was reacted with oxalyl 
chloride (0.15 mL, 1.65 mmol, 1.5 equiv) with DMF (1 drop) in dichloromethane. The acid chloride was 
then reacted with 2.40r (261 mg, 1.1 mmol, 1 equiv) and Et3N (0.31 mL, 2.2 mmol, 2 equiv) in 
dichloromethane. After evaporation and purification, 4.48-d1 was obtained as a white solid (451 mg, 1.0 
mmol, 91 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.91 – 7.83 (m, 1H), 7.59 – 7.54 (m, 2H), 7.30 – 7.25 
(m, 1H), 7.17 – 7.10 (m, 1H), 6.10 (s, 2H), 4.58 (s, 2H), 4.08 (sept, J = 6.9 Hz, 1H), 3.80 (s, 3H), 
3.77 (s, 6H), 1.16 (d, J = 6.9 Hz, 6H). 
 
13C NMR (101 MHz, Chloroform-d) δ = 166.7, 161.1, 159.7, 138.0, 136.5, 133.4, 129.9, 
127.6, 127.5, 124.9, 106.4, 90.5, 55.5, 55.4, 49.1, 39.6, 19.9. 
 (E)-3-(2-chlorophenyl)-N-isopropyl-N-(2,4,6-trimethoxybenzyl)acrylamide 4.49r’:  
 
Following the general procedure for amide synthesis, 2-chlorocinnamic acid (139 mg, 0.76 mmol, 1 equiv) 
was reacted with oxalyl chloride (0.1 mL, 1.14 mmol, 1.5 equiv) with DMF (1 drop) in dichloromethane. 
The acid chloride was then reacted with 2.40r (182 mg, 0.76 mmol, 1 equiv) and Et3N (0.21 mL, 1.52 mmol, 
2 equiv) in dichloromethane. After evaporation and purification, 4.49r’ was obtained as a white solid (210 
mg, 0.52 mmol, 68 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.93 (d, J = 15.6 Hz, 1H), 7.61 – 7.56 (m, 1H), 7.41 – 
7.37 (m, 1H), 7.30 – 7.20 (m, 3H), 6.10 (s, 2H), 4.59 (s, 2H), 4.08 (sept, J = 6.9 Hz, 1H), 3.80 (s, 
3H), 3.77 (s, 6H), 1.17 (d, J = 6.9 Hz, 6H). 
 
13C NMR (101 MHz, CDCl3) δ = 166.8, 161.1, 159.7, 135.6, 134.8, 134.5, 130.1, 129.7, 127.5, 
126.9, 124.8, 106.4, 90.5, 55.5, 55.4, 49.1, 39.7, 19.9. 
 
HRMS (ESI): Calculated for C22H26ClNaNO4 ([M+Na]+): 426.1448; found: 426.1451 
IR (neat) : ν = 2362, 1592, 1463 cm-1 
m.p.: 67 - 69°C 
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(E)-3-(2-bromophenyl)-N-ethyl-N-(2,4,6-trimethoxybenzyl)acrylamide 4.61r:  
 
Following the general procedure for amide synthesis, 2-bromocinnamic acid (300 mg, 1.32 mmol, 1 equiv) 
was reacted with oxalyl chloride (0.17 mL, 1.98 mmol, 1.5 equiv) with DMF (1 drop) in dichloromethane. 
The acid chloride was then reacted with 2.53a  (297mg, 1.32 mmol, 1 equiv) and Et3N (0.37 mL, 2.64 
mmol, 2 equiv) in dichloromethane. After evaporation and purification, 4.61r was obtained as a yellowish 
oil (487 mg, 1.12 mmol, 85 %). 
1H NMR (400 MHz, Chloroform-d) δ = 8.04 – 7.90 (m, 1H), 7.66 – 7.54 (m, 2H), 7.36 – 7.28 
(m, 1.8H), 7.20 – 7.14 (m, 1H), 6.80 (d, J = 15.4 Hz, 0.2H), 6.15 – 6.09 (m, 2H), 4.78 (s, 0.4H), 
4.61 (s, 1.6H), 3.83 – 3.76 (m, 9H), 3.38 (q, J = 7.0 Hz, 1.6H), 3.27 (q, J = 7.0 Hz, 0.4H), 1.07 (t, 
J = 6.9 Hz, 3H). 
 
13C NMR (101 MHz, Chloroform-d) δ = 165.8, 161.2, 159.8, 138.8, 136.4, 133.3, 129.9, 127.5, 
127.4, 124.9, 123.3, 105.5, 90.3, 55.5, 55.3, 39.6, 12.6. 
 
HRMS (ESI): Calculated for C21H25BrNO4 ([M+H]+): 434.0967; found: 434.0961 
IR (neat) : ν = 1597, 1468 cm-1 
(E)-3-(2-bromophenyl)-N-(tert-butyl)-N-(2,4,6 trimethoxybenzyl)acrylamide 4.62r: 
 
Following the general procedure for amide synthesis, 2-bromocinnamic acid (1 g, 4.4 mmol, 1 equiv) was 
reacted with oxalyl chloride (0.62 mL, 6.6 mmol, 1.5 equiv) with DMF (1 drop) in dichloromethane. The 
acid chloride was then reacted with 2.55a  (1.11 g, 4.4 mmol, 1 equiv) and Et3N (1.24 mL, 8.8 mmol, 2 
equiv) in dichloromethane. After evaporation and purification, 4.62r was obtained as a colorless oil (1.45 
g, 3.13 mmol, 72 %). 
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 1H NMR (400 MHz, Chloroform-d) δ = 7.73 (d, J = 15.5 Hz, 1H), 7.57 – 7.53 (m, 1H), 7.52 
– 7.48 (m, 1H), 7.26 – 7.22 (m, 1H), 7.14 – 7.09 (m, 1H), 6.08 (s, 2H), 4.70 (s, 2H), 3.79 (s, 
3H), 3.76 (s, 6H), 1.37 (s, 9H). 
 
13C NMR (101 MHz, Chloroform-d) δ = 169.3, 160.7, 159.3, 136.6, 136.6, 133.2, 129.8, 128.0, 
127.6, 127.5, 124.7, 107.5, 90.6, 57.5, 55.4, 55.4, 40.5, 28.5. 
 
HRMS (ESI): Calculated for C23H28BrNNaO4 ([M+Na]+): 484.1099; found: 484.1094 
IR (neat) : ν = 1605, 1465, 1402, 1128 cm-1 
(E)-3-(2-bromophenyl)-N-cyclopropyl-N-(2,4,6-trimethoxybenzyl)acrylamide 4.63r:  
 
In a 250 mL round bottom flask equipped with stirring bar, cyclopropanamine (0.22 mL, 3.16 
mmol, 1.2 equiv), 2,4,6-trimethoxybenzaldehyde (496 mg, 2.53 mmol, 1 equiv) and AcOH (0.29 
mL, 5.06 mmol, 2 equiv) were stirred for 2 h in 1,2-dichloroethane (50 mL) at room temperature. 
Then, NaBH(OAc)3 (1.07 g, 5.06 mmol, 2 equiv) was added to the mixture which was stirred 
overnight. The crude was quenched with NaOH (2 M, 50 mL) and the crude was extracted with 
DCM (3 x 50 mL). The combined organic layers were dried over sodium sulfate, filtered and 
evaporated under vacuum. The intermediate amine (592 mg, 2.50 mmol, 99 %) was obtained 
as a clear oil and directly used for next step.  
Following the general procedure for amide synthesis, 2-bromocinnamic acid (143 mg, 0.632 mmol, 1 
equiv) was reacted with oxalyl chloride (0.09 mL, 0.948 mmol, 1.5 equiv) with DMF (1 drop) in 
dichloromethane. The acid chloride was then reacted with N-protected cyclopropanamine 
intermediate (150 mg, 0.632 mmol, 1 equiv) and Et3N (0.180 mL, 1.26 mmol, 2 equiv) in 
dichloromethane. After evaporation and purification, 4.63r was obtained as a yellowish oil (236 mg, 0.529 
mmol, 84 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.96 (d, J = 15.5 Hz, 1H), 7.63 – 7.53 (m, 2H), 7.31 – 
7.26 (m, 1H), 7.18 – 7.10 (m, 2H), 6.11 (s, 2H), 4.72 (s, 2H), 3.80 (s, 3H), 3.78 (s, 6H), 2.35 – 
2.25 (m, 1H), 0.81 – 0.64 (m, 4H). 
 
13C NMR (101 MHz, Chloroform-d) δ = 167.7, 160.8, 160.0, 139.2, 136.2, 133.4, 130.2, 127.8, 
127.5, 125.0, 123.7, 105.9, 90.3, 55.8, 55.4, 38.4, 28.0, 9.2. 
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HRMS (ESI): Calculated for C22H25BrNO4 ([M+H]+): 446.0967; found: 446.0961 
IR (neat) : ν = 2361, 1646, 1132 cm-1 
(E)-3-(2-bromophenyl)-N-isopropyl-N-phenylacrylamide 4.64r: 
 
Following the general procedure for amide synthesis, 2-bromocinnamic acid (143 mg, 0.63 mmol, 1 equiv) 
was reacted with oxalyl chloride (0.1 mL, 0.95 mmol, 1.5 equiv) with DMF (1 drop) in dichloromethane. 
The acid chloride was then reacted with N-isopropylaniline (86 mg, 0.63 mmol, 1 equiv) and Et3N (0.18 
mL, 1.26 mmol, 2 equiv) in dichloromethane. After evaporation and purification, 4.64r was obtained as a 
white solid (151 mg, 0.44 mmol, 69 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.97 (d, J = 15.4 Hz, 1H), 7.55 – 7.50 (m, 1H), 7.48 
– 7.39 (m, 3H), 7.18 – 7.04 (m, 5H), 6.04 (d, J = 15.4 Hz, 1H), 5.12 (sept, J = 6.8 Hz, 1H), 1.13 
(d, J = 6.8 Hz, 6H). 
 
13C NMR (101 MHz, Chloroform-d) δ = 165.0, 140.0, 138.4, 135.6, 133.3, 130.7, 130.3, 
129.4, 128.5, 127.8, 127.4, 125.1, 122.9, 46.7, 21.1. 
 
HRMS (ESI): Calculated for C18H18BrNaNO ([M+Na]+): 366.0469; found: 366.0464 
IR (neat) : ν = 2363, 1650 cm-1 
m.p.: 80 - 82°C 
(E)-3-(2-bromophenyl)-1-(2-methyl-3,4-dihydroquinolin-1(2H)-yl)prop-2-en-1-one 4.65r: 
 
Following the general procedure for amide synthesis, 2-bromocinnamic acid (568 mg, 2.5 mmol, 1 equiv) 
was reacted with oxalyl chloride (0.35 mL, 3.75 mmol, 1.5 equiv) with DMF (1 drop) in dichloromethane. 
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The acid chloride was then reacted with 2-methyl-1,2,3,4-tetrahydroquinoline (368 mg, 2.5 mmol, 1 equiv) 
and Et3N (0.69 mL, 5 mmol, 2 equiv) in dichloromethane. After evaporation and purification, 4.65r was 
obtained as a white solid (720 mg, 2.02 mmol, 81 %). 
1H NMR (400 MHz, Chloroform-d) δ = 8.06 (d, J = 15.5 Hz, 1H), 7.60 – 7.56 (m, 1H), 7.38 – 
7.34 (m, 1H), 7.24 – 7.07 (m, 6H), 6.66 (d, J = 15.5 Hz, 1H), 4.95 – 4.86 (m, 1H), 2.68 (dt, J = 
14.9, 5.1 Hz, 1H), 2.63 – 2.54 (m, 1H), 2.45 – 2.36 (m, 1H), 1.48 – 1.38 (m, 1H), 1.22 (d, J = 6.4 
Hz, 3H). 
 
13C NMR (101 MHz, Chloroform-d) δ = 165.1, 140.2, 137.2, 135.7, 133.5, 130.5, 127.8, 127.8, 
127.6, 126.5, 126.4, 125.9, 125.2, 123.3, 49.2, 32.7, 26.2, 20.4. 
 
HRMS (ESI): Calculated for C19H18BrNNaO ([M+Na]+): 378.0469; found: 378.0464 
IR (neat) : ν = 2361, 1650, 1354 cm-1 
m.p.: 97 - 99°C 
(E)-3-(2-bromophenyl)-N,N-diisopropylacrylamide 4.66r: 
 
Following the general procedure for amide synthesis, 2-bromocinnamic acid (1.5 g, 6.61 mmol, 1 equiv) 
was reacted with oxalyl chloride (0.94 mL, 9.92 mmol, 1.5 equiv) with DMF (1 drop) in dichloromethane. 
The acid chloride was then reacted with diisopropylamine (0.94 mL, 6.61 mmol, 1 equiv) and Et3N (1.9 
mL, 13.2 mmol, 2 equiv) in dichloromethane. After evaporation and purification, 4.66r was obtained as a 
colorless oil (1.76 g, 5.68 mmol, 86 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.83 (d, J = 15.5 Hz, 1H), 7.61 – 7.53 (m, 2H), 7.33 – 
7.27 (m, 1H), 7.20 – 7.15 (m, 1H), 6.76 (d, J = 15.5 Hz, 1H), 4.10 (br s, 1H), 3.83 (br s, 1H), 1.47 
– 1.23 (m, 12H). 
13C NMR (101 MHz, Chloroform-d) δ = 165.9, 139.0, 136.1, 133.5, 130.3, 127.7, 127.6, 
125.0, 124.2. 
 
HRMS (ESI): Calculated for C15H20BrNaNO ([M+Na]+): 332.0626; found: 332.0621 
IR (neat) : ν = 2362, 1598 cm-1 
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(E)-3-(2-bromophenyl)-N,N-diethylacrylamide 4.67r: 
 
Following the general procedure for amide synthesis, 2-bromocinnamic acid (232 mg, 1.02 mmol, 1 equiv) 
was reacted with oxalyl chloride (0.15 mL, 1.53 mmol, 1.5 equiv) with DMF (1 drop) in dichloromethane. 
The acid chloride was then reacted with diethylamine (0.1 mL, 1.02 mmol, 1 equiv) and Et3N (0.29 mL, 
2.04 mmol, 2 equiv) in dichloromethane. After evaporation and purification, 4.67r was obtained as a 
yellowish oil (187 mg, 0.663 mmol, 65 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.99 (d, J = 15.4 Hz, 1H), 7.61 – 7.58 (m, 1H), 7.58 – 
7.54 (m, 1H), 7.33 – 7.27 (m, 1H), 7.22 – 7.15 (m, 1H), 6.76 (d, J = 15.4 Hz, 1H), 3.56 – 3.40 (m, 
4H), 1.29 – 1.16 (m, 6H). 
13C NMR (101 MHz, Chloroform-d) δ = 165.4, 140.8, 135.9, 133.5, 130.5, 127.9, 127.6, 
125.1, 121.3, 42.5, 41.2, 15.2, 13.3. 
 
HRMS (ESI): Calculated for C13H17BrNO ([M+H]+): 282.0494; found: 282.0488 
IR (neat) : ν = 2363, 1649 cm-1 
(E)-3-(2-bromophenyl)-N-isopropyl-N-(3-phenylpropyl)acrylamide 4.68r:  
 
In a 250 mL round bottom flask equipped with stirring bar, hydrocinnamaldehyde (0.72 mL, 
5.43 mmol, 1 equiv), isopropylamine (0.93 mL, 10.9 mmol, 2 equiv) and AcOH (0.62 mL, 10.9 
mmol, 2 equiv) were stirred for 2 h in 1,2-dichloroethane (30 mL) at room temperature. Then, 
NaBH(OAc)3 (2.3 g, 10.9 mmol, 2 equiv) was added to the mixture which was stirred overnight. 
The crude was quenched with NaOH (2 M, 30 mL) and the crude was extracted with DCM (3 
x 30 mL). The combined organic layers were dried over sodium sulfate, filtered and evaporated 
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under vacuum. The intermediate amine (956 mg, 10.8 mmol, 99 %) was obtained as a clear oil 
and directly used for next step.  
Following the general procedure for amide synthesis, 2-bromocinnamic acid (136 mg, 0.6 mmol, 1 equiv) 
was reacted with oxalyl chloride (0.08 mL, 0.9 mmol, 1.5 equiv) with DMF (1 drop) in dichloromethane. 
The acid chloride was then reacted with the intermediate amine (106 mg, 0.6 mmol, 1 equiv) and Et3N 
(0.17 mL, 1.2 mmol, 2 equiv) in dichloromethane. After evaporation and purification, 4.68r was obtained 
as a colorless oil (187 mg, 0.484 mmol, 81 %). 
1H NMR (500 MHz, Chloroform-d) δ = 8.00 – 7.88 (m, 1H), 7.61 – 7.55 (m, 1H), 7.31 – 7.26 
(m, 3H), 7.25 – 7.15 (m, 5H), 6.84 – 6.78 (m, 0.4H), 6.50 – 6.44 (m, 0.6H), 4.86 – 4.75 (m, 
0.6H), 4.31 – 4.22 (m, 0.4H), 3.36 – 3.22 (m, 2H), 2.68 (t, J = 7.2 Hz, 2H), 2.04 – 1.95 (m, 2H), 
1.23 – 1.15 (m, 6H). 
 
13C NMR (126 MHz, Chloroform-d) δ = 166.2, 165.6, 141.8, 140.9, 140.8, 140.1, 135.7, 
133.5, 130.4, 128.8, 128.6, 127.9, 127.8, 127.6, 126.4, 126.0, 125.2, 122.1, 121.7, 49.0, 45.9, 
42.4, 41.4, 33.9, 33.4, 33.3, 31.1, 21.7, 20.7. 
 
HRMS (ESI): Calculated for C21H24BrNaNO ([M+Na]+): 408.0939; found: 408.0933 
IR (neat) : ν = 2363, 1647, 1420 cm-1 
(E)-3-(2-bromophenyl)-N-(cyclopentylmethyl)-N-isopropylacrylamide 4.69r: 
 
Following the general procedure for amide synthesis, 2-bromocinnamic acid (82 mg, 0.363 mmol, 1 equiv) 
was reacted with oxalyl chloride (0.047 mL, 0.543 mmol, 1.5 equiv) with DMF (1 drop) in 
dichloromethane. The acid chloride was then reacted with Sj (51 mg, 0.363 mmol, 1 equiv) and Et3N (0.1 
mL, 0.72 mmol, 2 equiv) in dichloromethane. After evaporation and purification, 4.69r was obtained as a 
colorless oil (74 mg, 0.211 mmol, 58 %). 
1H NMR (500 MHz, Chloroform-d) δ = 7.99 – 7.86 (m, 1H), 7.63 – 7.49 (m, 2H), 7.33 – 7.28 
(m, 1H), 7.20 – 7.14 (m, 1H), 6.88 – 6.77 (m, 1H), 4.44 – 4.20 (m, 1H), 3.35 – 3.28 (m, 2H), 2.33 
– 2.11 (m, 1H), 1.84 – 1.71 (m, 2H), 1.68 – 1.63 (m, 2H), 1.60 – 1.53 (m, 2H), 1.31 – 1.21 (m, 8H). 
 
13C NMR (126 MHz, Chloroform-d) δ = 180.4, 166.1, 145.1, 140.1, 139.8, 135.9, 133.4, 130.2, 
127.7, 127.5, 124.9, 122.7, 49.8, 49.1, 48.9, 46.1, 43.5, 41.7, 40.1, 35.6, 31.0, 30.8, 30.0, 27.0, 
25.8, 24.9, 23.7, 21.9, 20.5. 
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HRMS (ESI): Calculated for C18H24BrNaNO ([M+Na]+): 372.0939; found: 372.0931 
IR (neat) : ν = 2361, 1648, 1423 cm-1 
(E)-3-(2-bromophenyl)-N-isopropyl-N-(3-methoxypropyl)acrylamide 4.70r: 
 
 
In a 250 mL round bottom flask equipped with stirring bar, 3-methyloxypropylamine (0.92 mL, 
9.05 mmol, 1 equiv), acetone (2.7 mL, 36.2 mmol, 4 equiv) and AcOH (1.0 mL, 18.1 mmol, 2 
equiv) were stirred for 2 h in 1,2-dichloroethane (50 mL) at room temperature. Then, 
NaBH(OAc)3 (3.8 g, 18.1 mmol, 2 equiv) was added to the mixture which was stirred overnight. 
The crude was quenched with NaOH (2 M, 50 mL) and the crude was extracted with DCM (3 
x 50 mL). The combined organic layers were dried over sodium sulfate, filtered and evaporated 
under vacuum. The intermediate amine (976 mg, 8.33 mmol, 92 %) was obtained as a clear oil 
and directly used for next step.  
Following the general procedure for amide synthesis, 2-bromocinnamic acid (227 mg, 1 mmol, 1 equiv) 
was reacted with oxalyl chloride (0.13 mL, 1 mmol, 1.5 equiv) with DMF (1 drop) in dichloromethane. The 
acid chloride was then reacted with the intermediate amine (117 mg, 1 mmol, 1 equiv) and Et3N (0.28 
mL, 2 mmol, 2 equiv) in dichloromethane. After evaporation and purification, 4.70r was obtained as a 
colorless oil (267 mg, 0.82 mmol, 81 %). 
1H NMR (400 MHz, Chloroform-d) δ = 8.03 (d, J = 15.3 Hz, 0.6H), 7.91 (d, J = 15.4 Hz, 0.4H), 
7.66 – 7.55 (m, 2H), 7.32 – 7.30 (m, 1H), 7.20 – 7.17 (m, 1H), 6.94 (d, J = 15.3 Hz, 0.6H), 6.83 
(d, J = 15.4 Hz, 0.4H), 4.85 – 4.75 (m, 0.6H), 4.34 – 4.25 (m, 0.4H), 3.50 – 3.37 (m, 4H), 3.37 
– 3.32 (m, 3H), 1.96 – 1.85 (m, 2H), 1.29 – 1.19 (m, 6H). 
 
13C NMR (101 MHz, Chloroform-d) δ = 166.2, 165.9, 140.8, 140.0, 135.9, 133.5, 130.4, 127.9, 
127.7, 127.6, 125.2, 125.0, 122.2, 122.1, 71.1, 69.8, 58.9, 58.7, 49.1, 46.0, 40.4, 39.2, 32.3, 29.7, 
21.6, 20.6. 
 
HRMS (ESI): Calculated for C16H22BrNaNO2 ([M+Na]+): 362.0732; found: 362.0726 
IR (neat) : ν = 2361, 1642 cm-1 
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(E)-3-(2-bromophenyl)-N-(2-cyanoethyl)-N-isopropylacrylamide 4.71r: 
 
 
In a 25 mL double-neck flask charged with isopropylamine (1.1 mL, 12.6 mmol, 2 equiv ) in 
EtOH (6 mL) and cooled to 0°C was added via dropping funnel, a solution of acrylonitrile (0.41 
mL, 6.32 mmol, 1 equiv) in EtOH (6 mL). The reaction was allowed to reach room temperature, 
and the volatiles were removed under vacuum. The desired amine was pure enough to react in 
next step (454 mg, 4.04 mmol, 64%). 
Following the general procedure for amide synthesis, 2-bromocinnamic acid (143 mg, 0.63 mmol, 1 equiv) 
was reacted with oxalyl chloride (0.1 mL, 0.95 mmol, 1.5 equiv) with DMF (1 drop) in dichloromethane. 
The acid chloride was then reacted with the intermediate amine (70 mg, 0.63 mmol, 1 equiv) and Et3N 
(0.18 mL, 1.26 mmol, 2 equiv) in dichloromethane. After evaporation and purification, 4.71r was obtained 
as a yellowish oil (134 mg, 0.42 mmol, 66 %). 
 
1H NMR (400 MHz, Chloroform-d) δ = 7.95 (d, J = 15.2 Hz, 1H), 7.63 – 7.55 (m, 2H), 7.35 – 
7.30 (m, 1H), 7.24 – 7.18 (m, 1H), 6.80 (d, J = 15.3 Hz, 1H), 4.37 – 4.27 (m, 1H), 3.57 (t, J = 7.0 
Hz, 2H), 2.82 (t, J = 7.0 Hz, 2H), 1.30 (d, J = 6.7 Hz, 6H). 
 
13C NMR (101 MHz, Chloroform-d) δ = 167.0, 141.5, 135.4, 133.6, 130.9, 127.8, 127.7, 125.2, 
120.8, 118.5, 49.1, 37.8, 21.7, 17.2. 
 
HRMS (ESI): Calculated for C15H17BrNaN2O4 ([M+Na]+): 343.0422; found: 343.0416 
IR (neat) : ν = 2363, 1646, 1418 cm-1 
(E)-3-(2-bromophenyl)-N-isopropyl-N-(3 (phenylsulfonyl)propyl)acrylamide 4.72r: 
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In a 25 mL double-neck flask charged with isopropylamine (1.1 mL, 12.6 mmol, 2 equiv ) in 
EtOH (6 mL) and cooled to 0°C was added via dropping funnel, a solution of phenyl vinyl 
sulfone (1.06 g, 6.32 mmol, 1 equiv) in EtOH (6 mL). The reaction was allowed to reach room 
temperature, and the volatiles were removed under vacuum. The desired amine was pure 
enough to react in next step (1.4 g, 6.31 mmol, 99%). 
Following the general procedure for amide synthesis, 2-bromocinnamic acid (143 mg, 0.63 mmol, 1 equiv) 
was reacted with oxalyl chloride (0.1 mL, 0.95 mmol, 1.5 equiv) with DMF (1 drop) in dichloromethane. 
The acid chloride was then reacted with the intermediate amine (144 mg, 0.63 mmol, 1 equiv) and Et3N 
(0.18 mL, 1.26 mmol, 2 equiv) in dichloromethane. After evaporation and purification, 4.72r was obtained 
as a colorless oil (202 mg, 0.46 mmol, 73 %). 
1H NMR (400 MHz, Chloroform-d) δ = 8.00 – 7.82 (m, 3H), 7.70 – 7.64 (m, 1H), 7.63 – 7.43 
(m, 4H), 7.31 – 7.27 (m, 1H), 7.22 – 7.12 (m, 1H), 6.78 – 6.57 (m, 1H), 4.91 – 4.66 (m, 0.3H), 
4.33 – 4.21 (m, 0.7H), 3.81 – 3.71 (m, 0.7H), 3.68 – 3.43 (m, 3H), 3.40 – 3.26 (m, 0.4H), 1.25 (d, 
J = 6.5 Hz, 5H), 1.17 – 1.06 (m, 1H).  
 
13C NMR (101 MHz, CDCl3) δ = 166.5, 141.3, 139.1, 135.4, 134.0, 133.5, 130.8, 129.5, 128.0, 
127.8, 127.7, 125.1, 120.6, 54.5, 49.3, 35.6, 29.8, 21.4, 20.4. 
 
HRMS (ESI): Calculated for C21H24BrNaNO3S ([M+Na]+): 458.0401; found: 458.0396 
IR (neat) : ν = 2362, 904 cm-1 
ethyl (E)-3-(3-(2-bromophenyl)-N-isopropylacrylamido)propanoate 4.73r: 
 
 
In a 25 mL double-neck flask charged with isopropylamine (1.1 mL, 12.6 mmol, 2 equiv ) in 
EtOH (6 mL) and cooled to 0°C was added via dropping funnel, a solution of ethyl acrylate 
(633 mg, 6.32 mmol, 1 equiv) in EtOH (6 mL). The reaction was allowed to reach room 
temperature, and the volatiles were removed under vacuum. The desired amine was pure 
enough to react in next step (876 mg, 5.5 mmol, 87%). 
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Following the general procedure for amide synthesis, 2-bromocinnamic acid (143 mg, 0.63 mmol, 1 equiv) 
was reacted with oxalyl chloride (0.1 mL, 0.95 mmol, 1.5 equiv) with DMF (1 drop) in dichloromethane. 
The acid chloride was then reacted with the intermediate amine (101 mg, 0.63 mmol, 1 equiv) and Et3N 
(0.18 mL, 1.26 mmol, 2 equiv) in dichloromethane. After evaporation and purification, 4.73r was obtained 
as a yellowish oil (152 mg, 0.41 mmol, 65 %). 
1H NMR (400 MHz, Chloroform-d) δ = 8.07 – 7.85 (m, 1H), 7.61 – 7.53 (m, 2H), 7.33 – 7.27 
(m, 1H), 7.22 – 7.14 (m, 1H), 6.80 (d, J = 15.4 Hz, 1H), 4.88 – 4.74 (m, 0.4H), 4.33 – 4.23 (m, 
0.6H), 4.15 (q, J = 7.2 Hz, 2H), 3.70 – 3.55 (m, 2H), 2.75 – 2.58 (m, 2H), 1.31 – 1.13 (m, 10H). 
 
13C NMR (101 MHz, Chloroform-d) δ = 172.2, 171.2, 166.3, 165.7, 141.7, 140.5, 135.7, 133.5, 
130.6, 127.8, 127.7, 125.0, 121.6, 121.3, 61.1, 60.6, 49.1, 46.0, 38.7, 37.3, 36.8, 34.1, 21.5, 20.5, 
14.3. 
 
HRMS (ESI): Calculated for C17H22BrNaNO3 ([M+Na]+): 390.0681; found: 390.0677 
IR (neat) : ν = 2362, 1624, 1423 cm-1 
(E)-3-(2-bromo-5-fluorophenyl)-N-isopropyl-N-(2,4,6-trimethoxybenzyl)acrylamide 
4.74r: 
 
Following the general procedure for amide synthesis, 2-Bromo-5-fluorocinnamic acid (186 mg, 0.76 
mmol, 1 equiv) was reacted with oxalyl chloride (0.1 mL, 1.14 mmol, 1.5 equiv) with DMF (1 drop) in 
dichloromethane. The acid chloride was then reacted with Sa (182 mg, 0.76 mmol, 1 equiv) and Et3N (0.22 
mL, 1.52 mmol, 2 equiv) in dichloromethane. After evaporation and purification, 4.74r was obtained as a 
white solid (302 mg, 0.65 mmol, 85 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.80 (d, J = 15.4, 1H), 7.56 – 7.50 (m, 1H), 7.27 – 7.23 
(m, 1H), 7.18 (d, J = 15.4 Hz, 1H), 6.92 – 6.87 (m, 1H), 6.11 (s, 2H), 4.57 (s, 2H), 4.15 – 4.07 (m, 
1H), 3.81 (s, 3H), 3.78 (s, 6H), 1.18 (d, J = 6.9 Hz, 6H). 
13C NMR (101 MHz, Chloroform-d) δ = 166.2, 163.1, 161.1, 160.7, 159.5, 137.0, 134.4 (d, J = 9.3 
Hz), 125.9, 118.9 (d, J = 3.9 Hz), 117.0 (d, J = 22.1 Hz), 114.1 (d, J = 21.4 Hz), 106.2, 90.5, 55.4, 
55.3, 49.3, 39.6, 19.8. 
 
19F NMR (376 MHz, Chloroform-d) δ = -114.9. 
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HRMS (ESI): Calculated for C22H26BrFNO4 ([M+H]+): 466.1029; found: 466.1026 
IR (neat) : ν = 2360, 1597, 1464 cm-1 
m.p.: 92 - 94°C 
 
(E)-3-(2-bromo-5-(trifluoromethyl)phenyl)-N-isopropyl-N-(2,4,6-
trimethoxybenzyl)acrylamide 4.75r:  
 
Following the general procedure for Knoevenagel condensation, 2-bromo-5-
(trifluoromethyl)benzaldehyde (500 mg, 1.98 mmol, 1 equiv) was reacted with malonic acid 
(227 mg, 2.18 mmol, 1.1 equiv), piperidine (0.22 mL, 2.18 mmol, 1.1 equiv) in pyridine at 90 °C 
for 15h. After evaporation and purification, the intermediate carboxylic acid (584 mg, 1.98 
mmol, 1 equiv) was reacted with oxalyl chloride (0.28 mL, 2.97 mmol, 1.5 equiv) with DMF (1 drop) in 
dichloromethane. The acid chloride was then reacted with Sa (474 mg, 1.98 mmol, 1 equiv) and Et3N (0.55 
mL, 3.96 mmol, 2 equiv) in dichloromethane. After evaporation and purification, 4.75r was obtained as a 
colorless oil (896 mg, 1.73 mmol, 88 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.88 – 7.82 (m, 1H), 7.76 – 7.74 (m, 1H), 7.74 – 7.70 (m, 
1H), 7.41 – 7.37 (m, 1H), 7.27 – 7.20 (m, 1H), 6.11 (s, 2H), 4.58 (s, 2H), 4.15 (sept, J = 6.9 Hz, 
1H), 3.81 (s, 3H), 3.79 (s, 6H), 1.21 (d, J = 6.9 Hz, 6H). 
 
13C NMR (126 MHz, CDCl3) δ = 166.1, 161.3, 159.7, 137.6, 136.7, 134.0, 130.1 (q, J = 32.6 Hz), 
128.5, 126.6, 126.1, 124.3 (q, J = 2.9 Hz), 123.9 (q, J = 271.9 Hz), 106.4, 90.6, 55.5, 55.4, 49.4, 
39.7, 19.9. 
 
19F NMR (471 MHz, CDCl3) δ = -62.7. 
 
HRMS (ESI): Calculated for C23H25BrF3NaNO4 ([M+Na]+): 538.0817; found: 538.0812 
IR (neat) : ν = 2362, 1648 cm-1 
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(E)-3-(2-bromo-5-methoxyphenyl)-N-isopropyl-N-(2,4,6-trimethoxybenzyl)acrylamide 
4.76r: 
 
 
Following the general procedure for Knoevenagel condensation, 2-bromo-5-
methoxybenzaldehyde (2 g, 9.02 mmol, 1 equiv) was reacted with malonic acid (1.03 g, 9.92 
mmol, 1.1 equiv), piperidine (0.98 mL, 9.92 mmol, 1.1 equiv) in pyridine at 90 °C for 15h. After 
evaporation and purification, the intermediate carboxylic acid (195 mg, 0.76 mmol, 1 equiv) was 
reacted with oxalyl chloride (0.1 mL, 1.14 mmol, 1.5 equiv) with DMF (1 drop) in dichloromethane. The 
acid chloride was then reacted with Sa (182 mg, 0.76 mmol, 1 equiv) and Et3N (0.214 mL, 1.52 mmol, 2 
equiv) in dichloromethane. After evaporation and purification, 4.76r was obtained as a white solid (284 
mg, 0.594 mmol, 78 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.82 (d, J = 15.4 Hz, 1H), 7.49 – 7.42 (m, 1H), 7.18 (d, J = 
15.4 Hz, 1H), 7.12 – 7.07 (m, 1H), 6.76 – 7.70 (m, 1H), 6.10 (s, 2H), 4.58 (s, 2H), 4.09 (sept, J = 
6.9 Hz, 1H), 3.80 (s, 3H), 3.80 (s, 6H), 3.77 (s, 6H), 1.16 (d, J = 6.8 Hz, 6H). 
 
13C NMR (101 MHz, CDCl3) δ = 166.7, 161.2, 159.7, 159.0, 138.1, 137.3, 133.9, 125.1, 115.7, 
115.6, 113.2, 106.4, 90.5, 55.6, 55.6, 55.4, 49.1, 39.7, 19.9. 
 
HRMS (ESI): Calculated for C23H28BrNaNO5 ([M+Na]+): 500.1049; found: 500.1043 
IR (neat) : ν = 2364 cm-1 
m.p.: 104 - 106°C 
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(E)-3-(5-(benzyloxy)-2-bromophenyl)-N-isopropyl-N-(2,4,6-
trimethoxybenzyl)acrylamide 4.77r:  
 
In a 100 mL flask charged with 2-bromo-5-hydroxybenzaldehyde (500 mg, 2.48 mmol, 1 equiv) 
and K2CO3 (1.02 g, 7.44 mmol, 3 equiv) in DMF (10 mL) was added benzyl bromide (0.45 mL, 
3.72 mmol, 1.5 equiv). The reaction was stirred to room temperature and monitored by TLC 
using Cyclohexane/AcOEt as solvent. After completion, the reaction was quenched with water 
(10 mL) and extracted with AcOEt (3 x 10 mL). The combined organic phases were washed 
with 10% LiCl solution (3 x 10 mL) and the crude was dried over sodium sulfate, filtered and 
evaporated under vacuum. The crude was used in next step without further purification (720 
mg, 2.48 mmol, 99 %). 
Following the general procedure for Knoevenagel condensation, 5-(benzyloxy)-2-
bromobenzaldehyde (720 mg, 2.48 mmol, 1 equiv) was reacted with malonic acid (284 mg, 2.73 
mmol, 1.1 equiv), piperidine (0.25 mL, 2.73 mmol, 1.1 equiv) in pyridine at 90 °C for 15h. After 
evaporation and purification, the intermediate carboxylic acid (333 mg, 1.0 mmol, 1 equiv) was 
reacted with oxalyl chloride (0.14 mL, 1.5 mmol, 1.5 equiv) with DMF (1 drop) in dichloromethane. The 
acid chloride was then reacted with Sa (239 mg, 1.0 mmol, 1 equiv) and Et3N (0.28 mL, 2 mmol, 2 equiv) 
in dichloromethane. After evaporation and purification, 4.77r was obtained as a yellowish solid (387 mg, 
0.7 mmol, 70 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.85 – 7.79 (m, 1H), 7.48 – 7.45 (m, 1H), 7.42 – 7.29 (m, 
5H), 7.18 – 7.11 (m, 2H), 6.82 – 6.78 (m, 1H), 6.11 (s, 2H), 5.05 (s, 2H), 4.58 (s, 2H), 4.16 – 4.07 
(m, 1H), 3.79 (s, 3H), 3.76 (s, 6H), 1.17 (d, J = 6.9 Hz, 6H). 
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13C NMR (101 MHz, CDCl3) δ = 166.6, 161.1, 159.7, 158.1, 137.9, 137.3, 136.5, 133.9, 128.8, 
128.3, 127.6, 125.1, 116.6, 115.8, 114.2, 106.4, 90.6, 70.5, 55.4, 49.1, 39.6, 19.9. 
 
HRMS (ESI): Calculated for C29H33BrNO5 ([M+H]+): 554.1542; found: 554.1537 
IR (neat) : ν = 1594, 1464, 905 cm-1 
m.p.: 115 - 117°C 
(E)-3-(6-bromobenzo[d][1,3]dioxol-5-yl)-N-isopropyl-N-(2,4,6-
trimethoxybenzyl)acrylamide 4.78r: 
 
 
Following the general procedure for Knoevenagel condensation, 6-Bromopiperonal (2.29 g, 10 
mmol, 1 equiv) was reacted with malonic acid (1.15 g, 11 mmol, 1.1 equiv), piperidine (1.1 mL, 11 
mmol, 1.1 equiv) in pyridine at 90 °C for 15h. After evaporation and purification, the 
intermediate carboxylic acid (148 mg, 0.547 mmol, 1 equiv) was reacted with oxalyl chloride (0.07 
mL, 0.821 mmol, 1.5 equiv) with DMF (1 drop) in dichloromethane. The acid chloride was then reacted 
with Sa (131 mg, 0.547 mmol, 1 equiv) and Et3N (0.154 mL, 1.09 mmol, 2 equiv) in dichloromethane. After 
evaporation and purification, 4.78r was obtained as a yellowish solid (202 mg, 0.41 mmol, 75 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.83 (d, J = 15.4 Hz, 1H), 7.11 – 6.99 (m, 3H), 6.11 (s, 2H), 
5.99 (s, 2H), 4.57 (s, 2H), 4.09 (sept, J = 6.8 Hz, 1H), 3.81 (s, 3H), 3.78 (s, 6H), 1.17 (d, J = 6.9 
Hz, 6H). 
 
13C NMR (101 MHz, CDCl3) δ = 166.9, 161.2, 159.7, 149.0, 147.8, 138.0, 129.8, 123.1, 116.8, 
113.2, 106.5, 102.1, 90.6, 55.6, 55.4, 49.3, 39.7, 19.9. 
 
HRMS (ESI): Calculated for C23H26BrNaNO6 ([M+Na]+): 514.0841; found: 514.0836 
IR (neat) : ν = 2362, 1596, 1474 cm-1 
m.p.: 115- 117°C 
 (E)-3-(2-bromo-4-fluorophenyl)-N-isopropyl-N-(2,4,6-trimethoxybenzyl)acrylamide 
4.79r: 
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Following the general procedure for Knoevenagel condensation, 2-bromo-4-
fluorobenzaldehyde (812 mg, 4 mmol, 1 equiv) was reacted with malonic acid (458 mg, 4.4 
mmol, 1.1 equiv), piperidine (0.44 mL, 4.4 mmol,1.1 equiv) in pyridine at 90 °C for 15h. After 
evaporation and purification, the intermediate carboxylic acid (155 mg, 0.63 mmol, 1 equiv) was 
reacted with oxalyl chloride (0.08 mL, 0.95 mmol, 1.5 equiv) with DMF (1 drop) in dichloromethane. The 
acid chloride was then reacted with Sa (151 mg, 0.63 mmol, 1 equiv) and Et3N (0.18 mL, 1.26 mmol, 2 
equiv) in dichloromethane. After evaporation and purification, 4.79r was obtained as a yellowish solid 
(236 mg, 0.506 mmol, 80 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.82 (d, J = 15.4 Hz, 1H), 7.56 – 7.54 (m, 1H), 7.36 – 
7.32 (m, 1H), 7.15 (d, J = 15.4 Hz, 1H), 7.05 – 7.00 (m, 1H), 6.10 (s, 2H), 4.58 (s, 2H), 4.08 
(sept, J = 6.9 Hz, 1H), 3.81 (s, 3H), 3.77 (s, 6H), 1.16 (d, J = 6.9 Hz, 6H). 
 
13C NMR (101 MHz, CDCl3) δ = 166.6, 162.7 (d, J = 257 Hz) , 161.1, 159.7, 137.0, 132.9, 132.9, 
128.6 (d, J = 8.2 Hz), , 125.0, 124.9, 124.8, 120.4 (d, J = 24.7 Hz), 114.9 (d, J = 21.2 Hz), 106.4, 
55.6, 55.4, 49.2, 39.7, 19.9. 
 
19F NMR (376 MHz, CDCl3) δ = -111.1 
 
HRMS (ESI): Calculated for C22H26BrFNO4 ([M+H]+): 466.1029; found: 466.1024 
IR (neat) : ν = 2361, 159, 1460 cm-1 
m.p.: 95 - 97°C 
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(E)-3-(2-bromo-4-methylphenyl)-N-isopropyl-N-(2,4,6-trimethoxybenzyl)acrylamide 
4.80r:  
 
Following the general procedure for Knoevenagel condensation, 2-bromo-4-
methylbenzaldehyde (500 mg, 2.51 mmol, 1 equiv) was reacted with malonic acid (287 mg, 2.76 
mmol, 1.1 equiv), piperidine (0.27 mL, 2.76 mmol, 1.1 equiv) in pyridine at 90 °C for 15h. After 
evaporation and purification, the intermediate carboxylic acid (605 mg, 2.51 mmol, 1 equiv) was 
reacted with oxalyl chloride (0.35 mL, 3.76 mmol, 1.5 equiv) with DMF (1 drop) in dichloromethane. The 
acid chloride was then reacted with Sa (601 mg, 2.51 mmol, 1 equiv) and Et3N (0.70 mL, 5.0 mmol, 2 equiv) 
in dichloromethane. After evaporation and purification, 4.80r was obtained as a white solid (812 mg, 1.75 
mmol, 70 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.90 – 7.80 (m, 1H), 7.49 – 7.45 (m, 1H), 7.43 – 7.41 (m, 
1H), 7.23 – 7.16 (m, 1H), 7.11 – 7.07 (m, 1H), 6.10 (s, 2H), 4.59 (s, 2H), 4.08 (sept, J = 6.8 Hz, 
1H), 3.81 (s, 3H), 3.77 (s, 6H), 2.33 (s, 3H), 1.16 (d, J = 6.9 Hz, 6H). 
 
13C NMR (126 MHz, CDCl3) δ = 166.9, 161.1, 159.7, 140.5, 138.0, 133.8, 133.6, 128.5, 127.3, 
124.8, 123.9, 106.5, 90.6, 55.6, 55.4, 49.1, 39.7, 21.0, 19.9. 
 
HRMS (ESI): Calculated for C23H29BrNO4 ([M+H]+): 462.1280; found: 462.1274 
IR (neat) : ν = 1598, 1458, 1130 cm-1 
m.p.: 94 - 96°C 
 
(E)-3-(2-bromophenyl)-1-(2-methylpyrrolidin-1-yl)prop-2-en-1-one 4.81r: 
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Following the general procedure for amide synthesis, 2-bromocinnamic acid (330 mg, 1.45 mmol, 1 equiv) 
was reacted with oxalyl chloride (0.20 mL, 2.18 mmol, 1.5 equiv) with DMF (1 drop) in dichloromethane. 
The acid chloride was then reacted with 2-methylpyrrolidine (0.14 mL, 1.45 mmol, 1 equiv) and Et3N 
(0.41 mL, 2.90 mmol, 2 equiv) in dichloromethane. After evaporation and purification, 4.81r was obtained 
as a yellowish solid (369 mg, 1.25 mmol, 86 %). 
1H NMR (400 MHz, Chloroform-d) δ = 8.06 – 7.95 (m, 1H), 7.62 – 7.52 (m, 2H), 7.32 – 7.26 (m, 
1H), 7.19 – 7.12 (m, 1H), 6.72 – 6.61 (m, 1H), 4.39 – 4.14 (m, 1H), 3.74 – 3.51 (m, 2H), 2.13 
– 1.87 (m, 3H), 1.76 – 1.59 (m, 1H), 1.28 – 1.23 (m, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 164.1, 164.0, 140.3, 140.2, 135.9, 135.8, 133.5, 133.5, 130.5, 
127.9, 127.9, 127.6, 125.2, 125.1, 122.7, 122.2, 53.4, 53.1, 47.1, 46.1, 33.4, 32.1, 24.1, 22.3, 
22.0, 19.7. 
 
HRMS (ESI): Calculated for C14H16BrNNaO ([M+Na]+): 316.0313; found: 316.0307 
IR (neat) : ν = 1649, 1603, 1407 cm-1 
m.p.: 78 - 80°C 
(S,E)-3-(2-bromophenyl)-1-(2-methylpyrrolidin-1-yl)prop-2-en-1-one 4.98:  
 
Following the general procedure for amide synthesis, 2-bromocinnamic acid (2.65 g, 11.7 mmol, 1 equiv) 
was reacted with oxalyl chloride (1.66 mL, 17.6 mmol, 1.5 equiv) with DMF (1 drop) in dichloromethane. 
The acid chloride was then reacted with (S)-2-methylpyrrolidine (1 g, 11.7 mmol, 1 equiv) and Et3N (3.25 
mL, 23.4 mmol, 2 equiv) in dichloromethane. After evaporation and purification, 4.98 was obtained as a 
yellowish oil (3.44 g, 11.7 mmol, 100 %). 
1H NMR (400 MHz, Chloroform-d) δ = 8.04 – 7.95 (m, 1H), 7.61 – 7.50 (m, 2H), 7.33 – 7.27 (m, 
1H), 7.21 – 7.13 (m, 1H), 6.73 – 6.62 (m, 1H), 4.38 – 4.15 (m, 1H), 3.73 – 3.54 (m, 2H), 2.15 – 
1.90 (m, 3H), 1.77 – 1.58 (m, 1H), 1.29 – 1.23 (m, 3H). 
13C NMR (101 MHz, CDCl3) δ = 164.1, 164.0, 140.3, 140.1, 135.9, 135.8, 133.5, 133.5, 130.5, 
127.9, 127.9, 127.6, 125.2, 125.1, 122.7, 122.2, 53.4, 53.1, 47.1, 46.1, 33.4, 32.1, 24.1, 22.3, 22.0, 
19.7. 
 
HRMS (ESI): Calculated for C14H16BrNNaO ([M+Na]+): 316.0313; found: 316.0306 
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IR (neat) : ν = 1649, 1407 cm-1 
(E)-3-(2-bromophenyl)-1-(2-methylpiperidin-1-yl)prop-2-en-1-one 4.82r: 
 
Following the general procedure for amide synthesis, 2-bromocinnamic acid (232 mg, 1.02 mmol, 1 equiv) 
was reacted with oxalyl chloride (0.14 mL, 1.53 mmol, 1.5 equiv) with DMF (1 drop) in dichloromethane. 
The acid chloride was then reacted with 2-methylpiperidine (0.12 mL, 1.02 mmol, 1 equiv) and Et3N (0.28 
mL, 2.04 mmol, 2 equiv) in dichloromethane. After evaporation and purification, 4.82r was obtained as a 
yellowish oil (292 mg, 0.95 mmol, 93 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.88 (d, J = 15.5 Hz, 1H), 7.58 (ddd, J = 8.9, 7.9, 1.5 Hz, 
2H), 7.32 – 7.28 (m, 1H), 7.19 – 7.15 (m, 1H), 6.80 (d, J = 15.5 Hz, 1H), 4.47 (br s, 1H), 3.25 
– 2.74 (m, 1H), 1.76 – 1.54 (m, 6H), 1.54 – 1.42 (m, 1H), 1.30 – 1.18 (m, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 165.2, 140.0, 135.9, 133.3, 130.2, 127.6, 127.5, 124.8, 121.8, 
18.9. 
 
HRMS (ESI): Calculated for C15H19BrNO ([M+H]+): 308.0650; found: 308.0645 
IR (neat) : ν = 2362, 2157, 1644 cm-1 
(E)-3-(2-bromophenyl)-1-(2-methylazepan-1-yl)prop-2-en-1-one 4.83r: 
 
Following the general procedure for amide synthesis, 2-bromocinnamic acid (300 mg, 1.32 mmol, 1 equiv) 
was reacted with oxalyl chloride (0.17 mL, 1.98 mmol, 1.5 equiv) with DMF (1 drop) in dichloromethane. 
The acid chloride was then reacted with 2-methylazepane hydrochloride (198 mg, 1.32 mmol, 1 equiv) 
and Et3N (0.37 mL, 2.64 mmol, 2 equiv) in dichloromethane. After evaporation and purification, 4.83r 
was obtained as a colorless oil (205 mg, 0.64 mmol, 48 %). 
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1H NMR (400 MHz, Chloroform-d) δ = 8.06 – 7.94 (m, 1H), 7.62 – 7.58 (m, 1H), 7.57 – 7.53 (m, 
1H), 7.33 – 7.28 (m, 1H), 7.20 – 7.14 (m, 1H), 6.86 – 6.79 (m, 1H), 4.68 – 4.56 (m, 0.6H), 4.23 
– 4.15 (m, 0.4H), 4.10 – 3.97 (m, 0.4H), 3.78 – 3.67 (m, 0.6H), 3.14 – 3.04 (m, 0.5H), 2.79 – 
2.67 (m, 0.5H), 2.14 – 2.02 (m, 1H), 1.94 – 1.72 (m, 3H), 1.71 – 1.62 (m, 0.5H), 1.57 – 1.49 
(m, 0.5H), 1.47 – 1.36 (m, 1H), 1.34 – 1.23 (m, 2H), 1.21 (d, J = 6.4 Hz, 1.5H), 1.12 (d, J = 6.4 
Hz, 1.5H). 
 
13C NMR (101 MHz, CDCl3) δ = 165.7, 165.6, 140.8, 140.4, 135.9, 135.9, 133.4, 133.4, 130.3, 
130.3, 127.8, 127.7, 127.5, 125.0, 124.9, 121.6, 121.5, 53.0, 50.1, 41.7, 40.4, 36.4, 35.6, 30.7, 
29.9, 29.4, 28.3, 25.2, 25.0, 21.2, 19.4. 
 
HRMS (ESI): Calculated for C16H21BrNO ([M+H]+): 322.0807; found: 322.0801 
IR (neat) : ν = 2362, 1623 cm-1 
(E)-3-(2-bromophenyl)-1-(2-methyl-1,3-oxazinan-3-yl)prop-2-en-1-one 4.84r:  
 
Following the general procedure for amide synthesis, 2-bromocinnamic acid (350 mg, 1.54 mmol, 1 equiv) 
was reacted with oxalyl chloride (0.20 mL, 2.31 mmol, 1.5 equiv) with DMF (1 drop) in dichloromethane. 
The acid chloride was then reacted with 2-methyl-1,3-oxazinane (156 mg, 1.54 mmol, 1 equiv) and Et3N 
(0.43 mL, 3.08 mmol, 2 equiv) in dichloromethane. After evaporation and purification, 4.84r was obtained 
as a yellowish oil (361 mg, 1.16 mmol, 76 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.94 – 7.85 (m, 1H), 7.60 – 7.53 (m, 2H), 7.32 – 7.27 (m, 
1H), 7.20 – 7.15 (m, 1H), 6.75 – 6.66 (m, 1H), 5.92 – 5.85 (m, 1H), 4.27 (br. s, 1H), 3.99 (ddd, 
J = 11.9, 10.3, 4.2 Hz, 1H), 3.75 – 3.68 (m, 1H), 3.35 – 3.23 (m, 1H), 2.00 – 1.86 (m, 1H), 1.73 
– 1.65 (m, 1H), 1.52 (d, J = 6.2 Hz, 3H). 
 
 
13C NMR (101 MHz, CDCl3) δ = 164.6, 141.1, 135.4, 133.4, 130.6, 127.7, 127.6, 124.9, 120.7, 
79.5, 59.7, 25.7, 16.5. 
 
HRMS (ESI): Calculated for C14H17BrNO2 ([M+H]+): 310.0443; found: 310.0437 
IR (neat) : ν = 1625, 1424, 1107 cm-1 
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(E)-3-(2-bromophenyl)-1-(3-methylmorpholino)prop-2-en-1-one 4.85r:  
 
Following the general procedure for amide synthesis, 2-bromocinnamic acid (568 mg, 2.5 mmol, 1 equiv) 
was reacted with oxalyl chloride (0.35 mL, 3.75 mmol, 1.5 equiv) with DMF (1 drop) in dichloromethane. 
The acid chloride was then reacted with 3-methylmorpholine (253 mg, 2.5 mmol, 1 equiv) and Et3N (0.69 
mL, 5 mmol, 2 equiv) in dichloromethane. After evaporation and purification, 4.85r was obtained as a 
colorless oil (580 mg, 1.87 mmol, 75 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.96 (d, J = 15.4 Hz, 1H), 7.61 – 7.57 (m, 1H), 7.57 – 7.54 
(m, 1H), 7.32 – 7.27 (m, 1H), 7.21 – 7.16 (m, 1H), 6.74 (d, J = 15.4 Hz, 1H), 4.80 – 4.00 (m, 2H), 
3.97 – 3.91 (m, 1H), 3.76 – 3.70 (m, 1H), 3.67 – 3.61 (m, 1H), 3.52 – 3.46 (m, 1H), 3.30 (br. s, 
1H), 1.37 (d, J = 7.0 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 165.3, 141.4, 135.6, 133.5, 130.7, 127.8, 127.7, 125.0, 120.4, 
71.0, 67.1. 
 
HRMS (ESI): Calculated for C14H17BrNO2 ([M+H]+): 310.0443; found: 310.0438 
IR (neat) : ν = 1625, 1425, 1106 cm-1 
tert-butyl (E)-4-(3-(2-bromophenyl)acryloyl)-3-methylpiperazine-1-carboxylate 4.86r: 
 
(R)-2-methylpiperazine (600 mg, 6 mmol, 1 equiv)  was dissolved in dry dichloromethane (80 
mL) and cooled to 0°C. A solution of the Boc2O (1.31 g, 6 mmol, 1 equiv) in 20 mL of dry 
dichloromethanewas added dropwise in 30 min and then pyridine (0.73 mL, 9 mmol, 1.5 equiv). 
The reaction mixture was allowed to reach room temperature and was stirred overnight. The 
crude was quenched with NaOH (1M, 60 mL) and the aqueous phase was extracted with DCM 
(3 x 20 mL). The combined organic layers were dried over sodium sulfate, filtered and 
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evaporated under vacuum. The N-Boc protected piperazine was then used without further 
purification for next step. 
Following the general procedure for amide synthesis, 2-bromocinnamic acid (568 mg, 2.5 mmol, 1 equiv) 
was reacted with oxalyl chloride (0.35 mL, 3.75 mmol, 1.5 equiv) with DMF (1 drop) in dichloromethane. 
The acid chloride was then reacted with N-Boc protected piperazine (500 mg, 2.5 mmol, 1 equiv) and 
Et3N (0.69 mL, 5 mmol, 2 equiv) in dichloromethane. After evaporation and purification, 4.86r was 
obtained as a yellowish oil (684 mg, 1.67 mmol, 67 %). 
1H NMR (400 MHz, Chloroform-d) δ =  7.94 (d, J = 15.4 Hz, 1H), 7.62 – 7.54 (m, 2H), 7.33 – 7.28 
(m, 1H), 7.22 – 7.16 (m, 1H), 6.75 (d, J = 15.5 Hz, 1H), 4.98 – 3.74 (m, 4H), 3.46 – 2.79 (m, 3H), 
1.48 (s, 9H), 1.26 (d, J = 7.1 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 165.4, 155.1, 141.4, 135.6, 133.5, 130.7, 127.8, 127.7, 125.1, 
120.7, 80.4, 28.5. 
 
HRMS (ESI): Calculated for C19H25BrNaN2O3 ([M+Na]+): 431.0946; found: 431.0941 
IR (neat) : ν = 2362, 1690, 1423 cm-1 
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(E)-3-(2-bromophenyl)-1-(o-tolyl)prop-2-en-1-one 4.104r:  
 
Following the general procedure for aldolisation reaction, 2-bromobenzaldehyde (1.11 g, 6 
mmol, 1 equiv), 1-(o-tolyl)ethan-1-one (805 mg, 6 mmol, 1 equiv), and NaOH (240 mg, 6 mmol, 
1 equiv) were reacted in EtOH/water at 45 °C. After completion, the crude was extracted and 
purified by chromatography on silica gel to afford 4.104r as a yellowish solid (1.8 g, 6 mmol, 
100%). 
The physical and spectroscopic properties matched those described in the literature. 38 
1H NMR (400 MHz, Chloroform-d) δ = 7.84 (d, J = 16.0 Hz, 1H), 7.70 – 7.66 (m, 1H), 7.62 – 7.59 
(m, 1H), 7.55 – 7.52 (m, 1H), 7.42 – 7.32 (m, 2H), 7.31 – 7.26 (m, 2H), 7.26 – 7.21 (m, 1H), 7.06 
(d, J = 16.0 Hz, 1H), 2.48 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ = 196.2, 144.4, 138.7, 137.3, 134.9, 133.6, 131.5, 130.8, 129.4, 
129.3, 128.5, 128.0, 127.9, 125.9, 125.6, 20.5. 
(E)-3-(2-bromophenyl)-1-(2,6-dimethylphenyl)prop-2-en-1-one 4.105r: 
 
Following the general procedure for aldolisation reaction, 2-bromobenzaldehyde (1.11 g, 6 
mmol, 1 equiv), 1-(2,6-dimethylphenyl)ethan-1-one (889 mg, 6 mmol, 1 equiv), and NaOH (240 
mg, 6 mmol, 1 equiv) were reacted in EtOH/water at 45 °C. After completion, the crude was 
extracted and purified by chromatography on silica gel to afford 4.105r as a colorless oil (1.89 
g, 6 mmol, 99%). 
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1H NMR (400 MHz, Chloroform-d) δ = 7.68 – 7.64 (m, 1H), 7.62 – 7.58 (m, 1H), 7.58 – 7.56 (m, 
1H), 7.37 – 7.32 (m, 1H), 7.25 – 7.19 (m, 2H), 7.10 – 7.06 (m, 2H), 6.83 (d, J = 16.2 Hz, 1H), 2.25 
(s, 6H). 
 
13C NMR (101 MHz, CDCl3) δ = 201.2, 145.9, 139.6, 134.7, 134.2, 133.5, 131.8, 130.7, 129.0, 
128.1, 128.0, 127.8, 125.8, 19.6, 19.6. 
 
HRMS (ESI): Calculated for C17H16BrO ([M+H]+): 315.0385; found: 315.0379 
IR (neat) : ν = 1650, 1462 cm-1 
(E)-3-(2-bromophenyl)-1-(4-methoxy-2-methylphenyl)prop-2-en-1-one 4.106r: 
 
 
A solution of 1-(4-hydroxy-2-methylphenyl)ethan-1-one (1.0 g, 6.66 mmol, 1 equiv), K2CO3 
(1.2 g, 8.66 mmol, 1.3 equiv) and iodomethane (0.62 ml, 10 mmol, 1.5 equiv) in acetone (25 ml) 
was heated to 70 °C for 6 h. After cooling to room temperature, the crude was evaporated under 
vacuum, dissolved in DCM (30 mL) and washed with water (3 x 10 mL). The organic phase 
was dried over sodium sulfate, filtered and evaporated under vacuum. The desired product was 
used without further purification (6.65 mmol, 1.09 g, 99%). 
Following the general procedure for aldolisation reaction, 2-bromobenzaldehyde (555 mg, 3 
mmol, 1 equiv), 1-(4-methoxy-2-methylphenyl)ethan-1-one (493 mg, 3 mmol, 1 equiv), and 
NaOH (120 mg, 3 mmol, 1 equiv) were reacted in EtOH/water at 45 °C. After completion, the 
crude was extracted and purified by chromatography on silica gel to afford 4.106r as a yellowish 
oil (992 mg, 3 mmol, 99%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.89 (d, J = 15.9 Hz, 1H), 7.70 – 7.60 (m, 3H), 7.37 – 7.32 
(m, 1H), 7.26 – 7.20 (m, 1H), 7.14 (d, J = 15.9 Hz, 1H), 6.82 – 6.73 (m, 2H), 3.86 (s, 3H), 2.54 
(s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 193.8, 161.8, 143.0, 141.4, 135.3, 133.6, 131.6, 131.3, 131.1, 
129.1, 128.0, 127.8, 125.8, 117.3, 110.7, 55.5, 21.5. 
 
HRMS (ESI): Calculated for C17H16BrO2 ([M+H]+): 331.0334; found: 331.0330 
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IR (neat) : ν = 1652, 1465 cm-1 
(E)-1-(4-(benzyloxy)-2-methylphenyl)-3-(2-bromophenyl)prop-2-en-1-one 4.107r:  
 
1-(4-hydroxy-2-methylphenyl)ethan-1-one (1.0 g, 6.66 mmol, 1 equiv) and K2CO3 (1.2 g, 8.66 
mmol, 1.3 equiv) were stirred in DMF (25 mL). Benzyl bromide (0.96 mL, 8 mmol, 1.2 equiv) 
was added and the mixture was stirred at 70°C for 6 h . After cooling to room temperature, the 
crude was quenched with water (25 mL) and extracted with Et2O (3 x 30 mL). The combined 
organic layers were then washed with LiCl (10 %, 50 mL), dried over sodium sulfate, filtered 
and evaporated under vacuum. The crude was used in the next step without further purification 
(1.6 g, 6.66 mmol, 100%). 
Following the general procedure for aldolisation reaction, 2-bromobenzaldehyde (1.23 g, 6.66 
mmol, 1 equiv), 1-(4-benzyl-2-methylphenyl)ethan-1-one (1.6 g, 6.66 mmol, 1 equiv), and NaOH 
(270 mg, 6.66 mmol, 1 equiv) were reacted in EtOH/water at 45 °C. After completion, the crude 
was extracted and purified by chromatography on silica gel to afford 4.107r as a yellowish oil 
(2.7 g, 6.65 mmol, 99%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.90 (d, J = 15.9 Hz, 1H), 7.70 – 7.61 (m, 3H), 7.46 – 7.38 
(m, 4H), 7.37 – 7.31 (m, 2H), 7.25 – 7.21 (m, 1H), 7.14 (d, J = 15.9 Hz, 1H), 6.91 – 6.84 (m, 2H), 
5.13 (s, 2H), 2.53 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 193.8, 160.9, 143.0, 141.4, 136.6, 135.2, 133.6, 131.6, 131.3, 
131.3, 129.1, 128.8, 128.3, 128.0, 127.9, 127.6, 125.9, 118.2, 111.5, 70.1, 21.5. 
 
HRMS (ESI): Calculated for C23H20BrO2 ([M+H]+): 407.0647; found: 407.0641 
IR (neat) : ν = 1620, 1455 cm-1 
 (E)-3-(2-bromophenyl)-1-(2,4-dimethylphenyl)prop-2-en-1-one 4.108r: 
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Following the general procedure for aldolisation reaction, 2-bromobenzaldehyde (555 g, 3 
mmol, 1 equiv), 1-(2,4-dimethylphenyl)ethan-1-one (445 mg, 3 mmol, 1 equiv), and NaOH (120 
mg, 3 mmol, 1 equiv) were reacted in EtOH/water at 45 °C. After completion, the crude was 
extracted and purified by chromatography on silica gel to afford 4.108r as a yellowish oil (941 
mg, 2.99 mmol, 99%). 
1H NMR (500 MHz, Chloroform-d) δ = 7.86 (d, J = 16.0 Hz, 1H), 7.69 – 7.66 (m, 1H), 7.63 – 
7.60 (m, 1H), 7.50 – 7.47 (m, 1H), 7.36 – 7.32 (m, 1H), 7.25 – 7.21 (m, 1H), 7.11 – 7.05 (m, 3H), 
2.47 (s, 3H), 2.38 (s, 3H). 
 
13C NMR (126 MHz, CDCl3) δ = 195.5, 143.7, 141.4, 138.0, 135.8, 135.1, 133.6, 132.5, 131.4, 
129.4, 129.1, 128.0, 127.9, 126.3, 125.9, 21.6, 20.7. 
 
HRMS (ESI): Calculated for C17H16BrO ([M+H]+): 315.0385; found: 315.0378 
IR (neat) : ν = 1650, 1464 cm-1 
 (E)-3-(2-bromophenyl)-1-(4-fluoro-2-methylphenyl)prop-2-en-1-one 4.109r:  
 
Following the general procedure for aldolisation reaction, 2-bromobenzaldehyde (555 mg, 3 
mmol, 1 equiv), 1-(4-fluoro-2-methylphenyl)ethan-1-one (457 mg, 3 mmol, 1 equiv), and NaOH 
(120 mg, 3 mmol, 1 equiv) were reacted in EtOH/water at 45 °C. After completion, the crude 
was extracted and purified by chromatography on silica gel to afford 4.109r as a colorless oil 
(812 mg, 2.54 mmol, 85%). 
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1H NMR (500 MHz, Chloroform-d) δ = 7.84 (d, J = 16.0 Hz, 1H), 7.70 – 7.66 (m, 1H), 7.64 – 7.60 
(m, 1H), 7.59 – 7.55 (m, 1H), 7.37 – 7.33 (m, 1H), 7.27 – 7.23 (m, 1H), 7.05 (d, J = 16.0 Hz, 1H), 
7.01 – 6.95 (m, 2H), 2.49 (s, 3H). 
 
13C NMR (126 MHz, CDCl3) δ = 194.8, 163.9 (d, J = 251.8 Hz), 144.4, 141.2 (d, J = 8.5 Hz), 134.8, 
133.7, 131.6, 131.0 (d, J = 8.9 Hz), 129.1, 128.0 (d, J = 6.1 Hz), 126.0, 118.4 (d, J = 22.4 Hz), 112.6 
(d, J = 21.6 Hz), 20.8 (d, J = 1.3 Hz). 
 
19F NMR (376 MHz, CDCl3) δ = -109.1. 
 
HRMS (ESI): Calculated for C16H12BrNaFO ([M+Na]+): 340.9953; found: 340.9948 
IR (neat) : ν = 1625, 1456 cm-1 
(E)-1-(4-amino-2-methylphenyl)-3-(2-bromophenyl)prop-2-en-1-one 4.110r: 
 
Following the general procedure for aldolisation reaction, 2-bromobenzaldehyde (555 mg, 3 
mmol, 1 equiv), N-(4-acetyl-3-methylphenyl)acetamide (574 mg, 3 mmol, 1 equiv), and NaOH 
(120 mg, 3 mmol, 1 equiv) were reacted in EtOH/water at 45 °C. After completion, the crude 
was extracted and purified by chromatography on silica gel to afford 4.110r as a yellowish oil 
(178 mg, 0.56 mmol, 19%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.91 (d, J = 15.7 Hz, 1H), 7.70 – 7.66 (m, 1H), 7.65 – 7.59 
(m, 2H), 7.36 – 7.28 (m, 1H), 7.24 – 7.18 (m, 2H), 6.55 – 6.45 (m, 2H), 4.01 (br. s, 2H), 2.52 (s, 
3H). 
 
13C NMR (101 MHz, CDCl3) δ = 192.4, 149.7, 142.2, 141.8, 135.6, 133.6, 132.5, 131.0, 129.0, 
128.3, 127.9, 127.8, 125.7, 117.8, 111.2, 22.0. 
 
HRMS (ESI): Calculated for C16H15BrNO ([M+H]+): 316.0337; found: 316.0334 
IR (neat) : ν = 1652, 1449 cm-1 
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1,4-Pd shift/C(sp3)-H activation products:  
 (E)-3-benzylidene-5-methyl-1-(2,4,6-trimethoxybenzyl)pyrrolidin-2-one 4.49:  
 
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.49r (45 mg, 0.1 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), pivalic acid (3.1 mg, 0.03 mmol, 30 mol%) 
and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 160°C for 16h. After purification, 4.49 
was obtained as a yellowish oil (36.5 mg, 0.099 mmol, 100%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.49 – 7.42 (m, 2H), 7.42 – 7.33 (m, 3H), 7.33 – 7.23 (m, 
1H), 6.12 (s, 2H), 5.12 (d, J = 14.1, 1H), 4.28 (d, J = 14.2, 1H), 3.81 (s, 3H), 3.79 (s, 6H), 3.48 
– 3.39 (m, 1H), 3.08 (dd, J = 17.0 Hz, 7.6 Hz, 1H), 2.58 – 2.47 (m, 1H), 1.20 (d, J = 6.3, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 168.1, 161.1, 160.1, 136.5, 132.1, 129.5, 129.4, 128.7, 128.1, 
104.7, 90.5, 55.9, 55.4, 50.2, 33.7, 33.3, 20.9. 
 
HRMS (ESI): Calculated for C22H25NaNO4 ([M+Na]+): 390.1681; found: 390.1676 
IR (neat) : ν = 2362, 1682, 1607, 1417 cm-1 
(E)-3-benzylidene-5-methyl-1-(2,4,6-trimethoxybenzyl)pyrrolidin-2-one 4.55-d7: 
 
1H NMR (400 MHz, Chloroform-d) δ = 7.47 – 7.43 (m, 2H), 7.40 – 7.35 (m, 3H), 7.31 – 7.28 
(m, 1H), 6.12 (s, 2H), 5.12 (d, J = 14.2 Hz, 1H), 4.28 (d, J = 14.1 Hz, 1H), 3.82 (s, 3H), 3.79 (s, 
6H), 3.46 – 3.41 (m, 1H), 3.12 – 3.02 (m, 0.59H), 2.57 – 2.50 (m, 0.58H), 1.22 – 1.15 (m, 
1.63H). 
 
13C NMR (101 MHz, CDCl3) δ = 168.2, 161.2, 160.2, 136.5, 129.5, 128.7, 128.1, 104.7, 90.5, 
55.9, 55.5, 33.3, 26.5. 
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 (E)-3-benzylidene-5-methyl-1-(2,4,6-trimethoxybenzyl)pyrrolidin-2-one 4.55-d6: 
 
1H NMR (400 MHz, Chloroform-d) δ = 7.47 – 7.43 (m, 2H), 7.40 – 7.35 (m, 3H), 7.31 – 7.26 
(m, 1H), 6.12 (s, 2H), 5.12 (d, J = 14.1 Hz, 1H), 4.30 – 4.25 (m, 1H), 3.82 (s, 3H), 3.79 (s, 6H), 
3.47 – 3.41 (m, 1H), 3.11 – 3.03 (m, 0.51H), 2.57 – 2.49 (m, 0.50H), 1.22 – 1.18 (m, 1.59H). 
 
 
13C NMR (101 MHz, CDCl3) δ = 168.2, 161.2, 160.2, 136.5, 129.5, 128.7, 128.1, 104.7, 90.5, 
55.9, 55.5, 33.3, 26.5. 
 
(E)-3-benzylidene-5-methyl-1-(2,4,6-trimethoxybenzyl)pyrrolidin-2-one 4.55-d1: 
 
1H NMR (400 MHz, Chloroform-d) δ = 7.47 – 7.44 (m, 2H), 7.40 – 7.35 (m, 3H), 7.31 – 7.28 
(m, 1H), 6.12 (s, 2H), 5.12 (d, J = 14.1 Hz, 1H), 4.28 (d, J = 14.2 Hz, 1H), 3.82 (s, 3H), 3.79 (s, 
6H), 3.50 – 3.40 (m, 1H), 3.08 (ddd, J = 17.4, 8.1, 3.0 Hz, 1H), 2.57 – 2.51 (m, 1H), 1.21 (d, J = 
6.2 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 168.2, 161.2, 160.2, 136.5, 132.1, 129.6, 129.4, 128.7, 128.1, 
104.7, 90.5, 55.9, 55.5, 50.2, 33.7, 33.3, 21.0. 
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(E)-3-benzylidene-1-(2,4,6-trimethoxybenzyl)pyrrolidin-2-one 4.61: 
  
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.61r (43.4 mg, 0.1 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), pivalic acid (3.1 mg, 0.03 mmol, 30 mol%), 
PCy3 (2.8 mg, 0.01 mmol, 10 mol%) and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 
160°C for 16h. After purification, 4.61 was obtained as a yellow oil (16 mg, 0.045 mmol, 45%). 
1H NMR (500 MHz, Chloroform-d) δ = 7.47 – 7.44 (m, 2H), 7.39 – 7.34 (m, 3H), 7.30 – 7.28 (m, 
1H), 6.13 (s, 2H), 4.66 (s, 2H), 3.82 (s, 3H), 3.81 (s, 6H), 3.26 (dd, J = 7.1, 5.9 Hz, 2H), 2.92 
(ddd, J = 8.9, 5.9, 2.9 Hz, 2H).  
 
13C NMR (126 MHz, CDCl3) δ = 168.4, 161.2, 160.0, 136.3, 132.2, 129.4, 129.0, 128.6, 128.0, 
104.4, 90.3, 55.8, 55.3, 43.5, 35.3, 24.3. 
 
HRMS (ESI): Calculated for C21H23NaNO4 ([M+Na]+): 376.1525; found: 376.1519 
IR (neat) : ν = 2362, 1604 cm-1 
(E)-3-benzylidene-5,5-dimethyl-1-(2,4,6-trimethoxybenzyl)pyrrolidin-2-one 4.62:  
 
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.62r (46.2 mg, 0.1 mmol, 1 
equiv) was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), pivalic acid (3.1 mg, 0.03 mmol, 30 
mol%) and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 160°C for 16h. After purification, 
4.62 was obtained as a colorless oil (19.5 mg, 0.051 mmol, 51%). 
1H NMR (500 MHz, Chloroform-d) δ = 7.47 – 7.43 (m, 2H), 7.42 – 7.36 (m, 3H), 7.31 – 7.27 (m, 
1H), 6.10 (s, 2H), 4.71 (s, 2H), 3.81 (s, 9H), 2.80 (s, 2H), 1.13 (s, 6H). 
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13C NMR (126 MHz, CDCl3) δ = 168.3, 161.0, 159.8, 136.6, 131.7, 129.6, 129.4, 128.7, 128.1, 
107.0, 90.5, 59.3, 55.9, 55.4, 42.5, 32.3, 27.7. 
 
HRMS (ESI): Calculated for C23H28NO4 ([M+H]+): 382.2018; found: 382.2013 
IR (neat) : ν = 2363, 912 cm-1 
(E)-4-benzylidene-2-(2,4,6-trimethoxybenzyl)-2-azabicyclo[3.1.0]hexan-3-one 4.63:  
 
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.63r (44.6 mg, 0.1 mmol, 1 
equiv) was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), pivalic acid (3.1 mg, 0.03 mmol, 30 
mol%) and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 160°C for 16h. After purification, 
4.63 was obtained as a colorless oil (25.5 mg, 0.070 mmol, 70%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.55 – 7.52 (m, 2H), 7.32 – 7.25 (m, 3H), 7.23 – 7.18 (m, 
1H), 6.04 (s, 2H), 4.54 (d, J = 1.9 Hz, 2H), 3.73 (s, 3H), 3.72 (s, 6H), 3.01 – 2.92 (m, 1H), 2.22 – 
2.14 (m, 1H), 0.93 (dt, J = 8.5, 5.1 Hz, 1H), 0.49 – 0.44 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ = 168.0, 161.3, 160.1, 136.2, 134.6, 130.0, 129.6, 129.4, 128.7, 
128.5, 128.3, 104.9, 90.4, 55.9, 55.5, 35.2, 35.2, 20.4, 13.1. 
 
HRMS (ESI): Calculated for C22H23NaNO4 ([M+Na]+): 388.1525; found: 388.1519 
IR (neat) : ν = 1681, 1612, 1419 cm-1 
(E)-3-benzylidene-1-isopropylindolin-2-one 4.64: 
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Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.64r (34.4 mg, 0.1 mmol, 1 
equiv) was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), pivalic acid (3.1 mg, 0.03 mmol, 30 
mol%) and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 160°C for 16h. After purification, 
4.64 was obtained as a yellow oil (12.5 mg, 0.048 mmol, 48%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.83 (s, 1H), 7.65 – 7.60 (m, 3H), 7.49 – 7.41 (m, 3H), 
7.25 – 7.19 (m, 1H), 7.02 – 6.97 (m, 1H), 6.87 – 6.81 (m, 1H), 4.72 (sept, J = 7.0 Hz, 1H), 1.53 (d, 
J = 7.0 Hz, 6H). 
 
13C NMR (101 MHz, CDCl3) δ = 168.0, 142.9, 136.9, 135.1, 129.5, 129.4, 129.2, 128.6, 127.5, 
122.9, 121.7, 121.2, 109.8, 43.8, 19.5. 
 
HRMS (ESI): Calculated for C18H17NaNO ([M+Na]+): 286.1208; found: 286.1202 
IR (neat) : ν = 2361, 1701, 1463 cm-1 
(E)-1-benzylidene-4-methyl-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-2(1H)-one 4.65: 
 
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.65r (36 mg, 0.1 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), pivalic acid (3.1 mg, 0.03 mmol, 30 mol%) 
and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 160°C for 16h. After purification, 4.65 
was obtained as a yellow oil (24 mg, 0.088 mmol, 88%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.82 (s, 1H), 7.68 – 7.64 (m, 2H), 7.49 – 7.38 (m, 4H), 
7.05 – 6.99 (m, 1H), 6.82 – 6.76 (m, 1H), 4.56 – 4.47 (m, 1H), 2.91 – 2.80 (m, 1H), 2.71 (dt, J = 
16.6, 3.8 Hz, 1H), 1.98 – 1.92 (m, 3H), 1.34 (d, J = 6.7 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 167.3, 139.9, 137.0, 135.3, 129.6, 129.5, 128.7, 128.7, 128.5, 
121.2, 120.8, 120.0, 119.9, 44.2, 27.0, 20.8, 18.5. 
 
HRMS (ESI): Calculated for C19H17NaNO ([M+Na]+): 298.1208; found: 298.1202 
IR (neat) : ν = 2363, 1701, 1460 cm-1 
(E)-3-benzylidene-1-isopropyl-5-methylpyrrolidin-2-one 4.66:  
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Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.66r (31 mg, 0.1 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), pivalic acid (3.1 mg, 0.03 mmol, 30 mol%) 
and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 160°C for 16h. After purification, 4.66 
was obtained as a colorless oil (21 mg, 0.097 mmol, 97%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.47 – 7.43 (m, 2H), 7.41 – 7.36 (m, 2H), 7.34 – 7.29 (m, 
1H), 4.23 (sept, J = 7.0 Hz, 1H), 3.95 – 3.86 (m, 1H), 3.23 (ddd, J = 17.4, 8.1, 3.1 Hz, 1H), 2.62 – 
2.59 (m, 1H), 1.35 (t, J = 8.1 Hz, 6H), 1.31 (d, J = 6.4 Hz, 3H). 
 
13C NMR (126 MHz, CDCl3) δ = 168.8, 136.2, 131.6, 129.6, 129.6, 128.7, 128.3, 50.9, 45.2, 34.4, 
23.8, 21.8, 19.6. 
 
HRMS (ESI): Calculated for C15H19NaNO ([M+Na]+): 252.1364; found:252.1360 
IR (neat) : ν = 2363, 1682, 1423 cm-1 
(E)-3-benzylidene-1-ethylpyrrolidin-2-one 4.67: 
 
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.67r (28.2 mg, 0.1 mmol, 1 
equiv) was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), pivalic acid (3.1 mg, 0.03 mmol, 30 
mol%) and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 160°C for 16h. After purification, 
4.67 was obtained as a yellow oil (6.3 mg, 0.031 mmol, 31%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.50 – 7.46 (m, 2H), 7.43 – 7.38 (m, 2H), 7.36 – 7.28 (m, 
2H), 3.55 – 3.47 (m, 4H), 3.10 – 3.02 (m, 2H), 1.20 (t, J = 7.3 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ = 168.9, 136.1, 131.5, 129.8, 129.6, 128.8, 128.4, 44.1, 37.9, 24.5, 
12.7. 
 
HRMS (ESI): Calculated for C13H15NaNO ([M+Na]+): 224.1051; found: 224.1046 
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IR (neat) : ν = 2364, 1679, 1608, 1419 cm-1 
(E)-3-benzylidene-5-methyl-1-(3-phenylpropyl)pyrrolidin-2-one 4.68:  
 
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.68r (39 mg, 0.1 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), PCy3 (2.8 mg, 0.01 mmol, 10 %), pivalic acid 
(3.1 mg, 0.03 mmol, 30 mol%) and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 160°C 
for 16h. After purification, 4.68 was obtained as a yellowish oil (25 mg, 0.082 mmol, 82%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.48 – 7.44 (m, 2H), 7.42 – 7.34 (m, 3H), 7.34 – 7.28 
(m, 3H), 7.23 – 7.15 (m, 3H), 3.86 – 3.74 (m, 2H), 3.26 – 3.11 (m, 2H), 2.67 (t, J = 7.8 Hz, 2H), 
2.61 – 2.57 (m, 1H), 2.02 – 1.81 (m, 2H), 1.24 (d, J = 6.3 Hz, 3H). 
 
13C NMR (126 MHz, CDCl3) δ = 169.1, 141.6, 136.1, 131.0, 130.0, 129.6, 128.8, 128.6, 128.5, 
128.4, 126.1, 51.1, 40.6, 33.8, 33.5, 29.2, 20.9. 
 
HRMS (ESI): Calculated for C21H24NO ([M+H]+): 306.1858; found: 306.1852 
IR (neat) : ν = 1679, 1423 cm-1 
(E)-3-benzylidene-1-(cyclopentylmethyl)-5-methylpyrrolidin-2-one 4.69:  
 
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.69r (35 mg, 0.1 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), PCy3 (2.8 mg, 0.01 mmol, 10 %), pivalic acid 
(3.1 mg, 0.03 mmol, 30 mol%) and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 160°C 
for 16h. After purification, 4.69 was obtained as a colorless oil (18 mg, 0.067 mmol, 67%). 
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1H NMR (400 MHz, Chloroform-d) δ = 7.48 – 7.44 (m, 2H), 7.42 – 7.34 (m, 3H), 7.33 – 7.28 (m, 
1H), 3.90 – 3.81 (m, 1H), 3.76 (dd, J = 13.7, 9.5 Hz, 1H), 3.26 (ddd, J = 17.4, 7.8, 2.8 Hz, 1H), 
3.02 (dd, J = 13.7, 6.2 Hz, 1H), 2.63 – 2.60 (m, 1H), 2.29 – 2.18 (m, 1H), 1.83 – 1.73 (m, 1H), 1.71 
– 1.62 (m, 3H), 1.57 – 1.50 (m, 2H), 1.32 – 1.24 (m, 5H). 
13C NMR (126 MHz, CDCl3) δ = 169.2, 136.2, 131.2, 129.9, 129.6, 128.8, 128.4, 51.1, 45.3, 38.1, 
33.9, 31.0, 30.4, 25.4, 25.1, 20.8. 
HRMS (ESI): Calculated for C18H24NO ([M+H]+): 270.1858; found: 270.1852 
IR (neat) : ν = 1685, 1419 cm-1 
(E)-3-benzylidene-1-(3-methoxypropyl)-5-methylpyrrolidin-2-one 4.70:  
 
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.70r (34 mg, 0.1 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), pivalic acid (3.1 mg, 0.03 mmol, 30 mol%) 
and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 160°C for 16h. After purification, 4.70 
was obtained as a yellowish oil (15.5 mg, 0.060 mmol, 60%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.49 – 7.44 (m, 2H), 7.43 – 7.39 (m, 2H), 7.36 – 7.29 (m, 
2H), 3.87 – 3.72 (m, 2H), 3.44 (t, J = 6.3 Hz, 2H), 3.34 (s, 3H), 3.31 – 3.20 (m, 2H), 2.64 – 2.59 
(m, 1H), 1.99 – 1.77 (m, 2H), 1.29 (d, J = 6.3 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 169.1, 136.0, 130.9, 129.7, 129.5, 128.6, 128.3, 70.4, 58.7, 51.3, 
38.2, 33.7, 27.8, 20.9. 
 
HRMS (ESI): Calculated for C15H19NaNO2 ([M+Na]+): 282.1470; found: 282.1465 
IR (neat) : ν = 1681, 1421, 1115 cm-1 
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(E)-3-(3-benzylidene-5-methyl-2-oxopyrrolidin-1-yl)propanenitrile 4.71:  
 
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.71r (32 mg, 0.1 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), pivalic acid (3.1 mg, 0.03 mmol, 30 mol%) 
and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 160°C for 16h. After purification, 4.71 
was obtained as a colorless oil (12 mg, 0.051 mmol, 51%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.49 – 7.45 (m, 2H), 7.44 – 7.41 (m, 1H), 7.40 – 7.33 (m, 
2H), 4.03 – 3.94 (m, 1H), 3.88 (dt, J = 13.9, 6.3 Hz, 1H), 3.54 – 3.45 (m, 1H), 3.34 (ddd, J = 
17.5, 7.9, 2.8 Hz, 1H), 2.85 – 2.76 (m, 1H), 2.74 – 2.64 (m, 2H), 1.36 (d, J = 6.3 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 169.6, 135.5, 131.1, 129.6, 129.4, 128.7, 118.1, 52.0, 37.4, 33.8, 
20.9, 16.6. 
 
HRMS (ESI): Calculated for C15H16NaN2O ([M+Na]+): 263.1160; found: 263.1155 
IR (neat) : ν = 2362, 1682, 1615 cm-1 
(E)-3-benzylidene-5-methyl-1-(2-(phenylsulfonyl)ethyl)pyrrolidin-2-one 4.72: 
  
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.72r (43.6 mg, 0.1 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), pivalic acid (3.1 mg, 0.03 mmol, 30 mol%) 
and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 160°C for 16h. After purification, 4.72 
was obtained as a colorless oil (14.5 mg, 0.040 mmol, 40%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.96 – 7.92 (m, 2H), 7.69 – 7.63 (m, 1H), 7.61 – 7.55 (m, 
2H), 7.45 – 7.37 (m, 4H), 7.35 – 7.30 (m, 1H), 7.29 – 7.27 (m, 1H), 4.01 – 3.92 (m, 1H), 3.92 – 
3.83 (m, 1H), 3.68 – 3.56 (m, 2H), 3.42 – 3.31 (m, 1H), 3.23 – 3.13 (m, 1H), 2.63 – 2.59 (m, 1H), 
1.28 (d, J = 6.3 Hz, 3H). 
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13C NMR (101 MHz, CDCl3) δ = 169.5, 139.2, 135.7, 134.1, 130.8, 129.8, 129.7, 129.6, 128.8, 
128.8, 128.0, 53.3, 52.0, 35.5, 33.8, 21.0. 
 
HRMS (ESI): Calculated for C20H21NaNO3S ([M+Na]+): 378.1140; found: 378.1137 
IR (neat) : ν = 1681, 1614, 1419 cm-1 
ethyl (E)-3-(3-benzylidene-5-methyl-2-oxopyrrolidin-1-yl)propanoate 4.73:  
 
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.73r (37 mg, 0.1 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), pivalic acid (3.1 mg, 0.03 mmol, 30 mol%) 
and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 160°C for 16h. After purification, 4.73 
was obtained as a yellowish oil (18 mg, 0.062 mmol, 62%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.48 – 7.44 (m, 2H), 7.42 – 7.37 (m, 2H), 7.37 – 7.29 
(m, 2H), 4.15 (q, J = 7.2 Hz, 2H), 4.00 – 3.91 (m, 1H), 3.90 – 3.81 (m, 1H), 3.47 (dt, J = 14.3, 
7.2 Hz, 1H), 3.26 (ddd, J = 17.4, 7.9, 2.9 Hz, 1H), 2.73 (dt, J = 16.2, 7.3 Hz, 1H), 2.66 – 2.54 
(m, 2H), 1.30 (d, J = 6.3 Hz, 3H), 1.26 (t, J = 7.2 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 171.8, 169.1, 135.8, 130.4, 130.1, 129.5, 128.7, 128.4, 60.8, 
51.6, 36.8, 33.7, 32.8, 20.9, 14.2. 
 
HRMS (ESI): Calculated for C17H21NaNO3 ([M+Na]+): 310.1419; found: 310.1414 
IR (neat) : ν = 2361, 1978, 1732, 1419 cm-1 
(E)-3-(3-fluorobenzylidene)-5-methyl-1-(2,4,6-trimethoxybenzyl)pyrrolidin-2-one 4.74:  
 
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.74r (46.6 mg, 0.1 mmol, 1 
equiv) was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), pivalic acid (3.1 mg, 0.03 mmol, 30 
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mol%) and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 160°C for 16h. After purification, 
4.74 was obtained as a colorless oil (19.5 mg, 0.051 mmol, 51%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.37 – 7.29 (m, 2H), 7.24 – 7.20 (m, 1H), 7.16 – 7.11 (m, 
1H), 7.01 – 6.95 (m, 1H), 6.12 (s, 2H), 5.11 (d, J = 14.2, 1H), 4.28 (d, J = 14.2 Hz, 1H), 3.81 (s, 
3H), 3.79 (s, 6H), 3.49 – 3.42 (m, 1H), 3.10 – 3.00 (m, 1H), 2.54 – 2.48 (m, 1H), 1.21 (d, J = 6.2 
Hz, 3H). 
 
13C NMR (101 MHz, Chloroform-d) δ = 167.7, 162.9 (d, J = 245.5 Hz), 161.2, 160.1, 138.6 (d, J = 
7.7 Hz), 133.5, 130.1 (d, J = 8.4 Hz), 128.2 (d, J = 2.6 Hz), 125.5 (d, J = 2.9 Hz), 115.7 (d, J = 21.7 
Hz), 115.0 (d, J = 21.4 Hz), 104.5, 90.4, 55.9, 55.4, 50.2, 33.6, 33.3, 20.9. 
 
19F NMR (376 MHz, CDCl3) δ = -113.01. 
 
HRMS (ESI): Calculated for C22H24FNaNO4 ([M+Na]+): 408.1587; found: 408.1582 
 
IR (neat) : ν = 1679, 1608, 1419 cm-1 
(E)-5-methyl-3-(4-(trifluoromethyl)benzylidene)-1-(2,4,6-trimethoxybenzyl)pyrrolidin-2-
one 4.75:  
 
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.75r (51.6 mg, 0.1 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), pivalic acid (3.1 mg, 0.03 mmol, 30 mol%) 
and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 160°C for 16h. After purification, 4.75 
was obtained as a colorless oil (33.5 mg, 0.077 mmol, 77%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.68 (m, 1H), 7.62 – 7.60 (m, 1H), 7.56 – 7.46 (m, 2H), 
7.40 – 7.38 (m, 1H), 6.12 (s, 2H), 5.12 (d, J = 14.2 Hz, 1H), 4.29 (d, J = 14.1 Hz, 1H), 3.82 (s, 
3H), 3.80 (s, 6H), 3.53 – 3.44 (m, 1H), 3.09 (ddd, J = 17.4, 8.1, 3.1 Hz, 1H), 2.56 – 2.48 (m, 1H), 
1.23 (d, J = 6.3 Hz, 3H). 
 
13C NMR (126 MHz, CDCl3) δ = 167.6, 161.2, 160.1, 137.2, 134.2, 132.7, 131.3, 131.0, 129.2, 
127.8, 125.6 (q, J = 3.9 Hz), 124.6 (q, J = 3.1 Hz), 124.3 (q, J = 271.3 Hz), 104.5, 90.5, 55.9, 
55.5, 50.2, 33.6, 33.4, 20.9. 
 
 
 
19F NMR (471 MHz, CDCl3) δ = -62.8. 
 
HRMS (ESI): Calculated for C23H25F3NO4 ([M+H]+): 436.1736; found: 436.1730 
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IR (neat) : ν = 1681, 1609, 1329, 1132 cm-1 
(E)-3-(3-methoxybenzylidene)-5-methyl-1-(2,4,6-trimethoxybenzyl)pyrrolidin-2-one 4.76:  
 
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.76r (47.8 mg, 0.1 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), pivalic acid (3.1 mg, 0.03 mmol, 30 mol%) 
and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 160°C for 16h. After purification, 4.76 
was obtained as a yellowish oil (40 mg, 0.039 mmol, 100%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.35 – 7.33 (m, 1H), 7.29 (t, J = 7.9 Hz, 1H), 7.07 – 7.03 
(m, 1H), 7.00 – 6.96 (m, 1H), 6.87 – 6.81 (m, 1H), 6.11 (s, 2H), 5.11 (d, J = 14.1 Hz, 1H), 4.27 (d, 
J = 14.1 Hz, 1H), 3.81 (s, 6H), 3.78 (s, 6H), 3.49 – 3.38 (m, 1H), 3.07 (ddd, J = 17.4, 8.2, 3.0 Hz, 
1H), 2.56 – 2.47 (m, 1H), 1.20 (d, J = 6.2 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 168.0, 161.1, 160.1, 159.7, 137.8, 132.4, 129.6, 129.3, 122.1, 
115.0, 113.6, 104.6, 90.4, 55.9, 55.4, 55.4, 55.4, 50.2, 33.6, 33.3, 20.9. 
 
HRMS (ESI): Calculated for C23H27NaNO5 ([M+Na]+): 420.1787; found: 420.1781 
IR (neat) : ν = 1690, 1423 cm-1 
(E)-3-(3-(benzyloxy)benzylidene)-5-methyl-1-(2,4,6-trimethoxybenzyl)pyrrolidin-2-one 
4.77:  
 
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.77r (55 mg, 0.1 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), pivalic acid (3.1 mg, 0.03 mmol, 30 mol%) 
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and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 160°C for 16h. After purification, 4.77 
was obtained as a yellowish oil (34.5 mg, 0.073 mmol, 73%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.45 – 7.41 (m, 2H), 7.39 – 7.36 (m, 2H), 7.35 – 7.26 (m, 
3H), 7.08 – 7.03 (m, 2H), 6.95 – 6.90 (m, 1H), 6.12 (s, 2H), 5.13 – 5.06 (m, 3H), 4.27 (d, J = 14.1 
Hz, 1H), 3.81 (s, 3H), 3.79 (s, 6H), 3.46 – 3.37 (m, 1H), 3.00 (ddd, J = 17.4, 8.1, 3.0 Hz, 1H), 2.51 
– 2.40 (m, 1H), 1.18 (d, J = 6.8 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 167.9, 161.0, 160.0, 158.8, 137.7, 136.9, 132.4, 129.5, 129.1, 
128.6, 128.0, 127.4, 122.4, 115.7, 114.6, 104.6, 90.3, 70.1, 55.8, 55.7, 50.1, 33.5, 33.2, 20.8. 
 
HRMS (ESI): Calculated for C23H29BrNaNO4 ([M+Na]+): 496.2100; found: 496.2094 
IR (neat) : ν = 1681, 1596, 1416 cm-1 
(E)-3-(benzo[d][1,3]dioxol-5-ylmethylene)-5-methyl-1-(2,4,6-
trimethoxybenzyl)pyrrolidin-2-one 4.78:  
 
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.78r (49 mg, 0.1 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), pivalic acid (3.1 mg, 0.03 mmol, 30 mol%) 
and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 160°C for 16h. After purification, 4.78 
was obtained as a yellowish solid (29 mg, 0.071 mmol, 71%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.29 – 7.27 (m, 1H), 6.98 – 6.93 (m, 2H), 6.84 – 6.80 (m, 
1H), 6.11 (s, 2H), 5.97 (s, 2H), 5.10 (d, J = 14.2 Hz, 1H), 4.26 (d, J = 14.1 Hz, 1H), 3.81 (s, 
3H), 3.79 (s, 6H), 3.48 – 3.38 (m, 1H), 3.02 (ddd, J = 17.2, 8.2, 3.0 Hz, 1H), 2.52 – 2.42 (m, 
1H), 1.20 (d, J = 6.2 Hz, 3H). 
 
13C NMR (126 MHz, CDCl3) δ = 168.3, 161.1, 160.1, 148.0, 147.6, 130.8, 130.1, 129.2, 124.6, 
109.0, 108.7, 104.8, 101.4, 90.5, 55.9, 55.4, 50.2, 33.6, 33.3, 21.0. 
 
HRMS (ESI): Calculated for C23H25NaNO6 ([M+Na]+): 434.1580; found: 434.1574 
IR (neat) : ν = 1679, 1608, 1416 cm-1 
m.p. : 58 – 60 °C 
(E)-3-(4-fluorobenzylidene)-5-methyl-1-(2,4,6-trimethoxybenzyl)pyrrolidin-2-one 4.79:  
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Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.79r (47 mg, 0.1 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), pivalic acid (3.1 mg, 0.03 mmol, 30 mol%) 
and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 160°C for 16h. After purification, 4.79 
was obtained as a yellowish oil (25 mg, 0.064 mmol, 64%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.45 – 7.39 (m, 2H), 7.34 – 7.32 (m, 1H), 7.09 – 7.02 (m, 
2H), 6.12 (s, 2H), 5.11 (d, J = 14.1 Hz, 1H), 4.27 (d, J = 14.1 Hz, 1H), 3.81 (s, 3H), 3.79 (s, 6H), 
3.50 – 3.40 (m, 1H), 3.04 (ddd, J = 17.3, 8.1, 3.1 Hz, 1H), 2.55 – 2.45 (m, 1H), 1.21 (d, J = 6.3 Hz, 
3H). 
13C NMR (101 MHz, CDCl3) δ = 168.0, 163.6, 161.1, 160.1, 132.67 (d, J = 3.5 Hz) 131.6 (d, J = 2.4 
Hz), 131.2 (d, J = 8.0 Hz), 128.2, 115.7 (d, J = 22.0 Hz), 104.6, 90.4, 55.9, 55.5, 50.2, 33.5, 33.3, 
21.0. 
 
 
19F NMR (376 MHz, CDCl3) δ = -112.8. 
 
HRMS (ESI): Calculated for C22H24FNaNO4 ([M+Na]+): 408.1587; found: 408.1583 
 
IR (neat) : ν = 1677, 1608, 1422 cm-1 
(E)-5-methyl-3-(4-methylbenzylidene)-1-(2,4,6-trimethoxybenzyl)pyrrolidin-2-one 4.80:  
 
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.80r (46 mg, 0.1 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), PCy3 (2.8 mg, 0.01 mmol, 10 %), pivalic acid 
(3.1 mg, 0.03 mmol, 30 mol%) and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 160°C 
for 16h. After purification, 4.80 was obtained as a colorless oil (25 mg, 0.076 mmol, 76%). 
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1H NMR (500 MHz, Chloroform-d) δ = 7.36 – 7.33 (m, 3H), 7.19 – 7.16 (m, 2H), 6.12 (s, 2H), 5.11 
(d, J = 14.1 Hz, 1H), 4.26 (d, J = 14.1 Hz, 1H), 3.81 (s, 3H), 3.79 (s, 6H), 3.44 (ddt, J = 8.3, 6.2, 
3.1 Hz, 1H), 3.06 (ddd, J = 17.2, 8.1, 3.0 Hz, 1H), 2.56 – 2.48 (m, 1H), 2.36 (s, 3H), 1.20 (d, J = 
6.3 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ = 168.2, 161.0, 160.0, 138.1, 133.6, 130.9, 129.4, 129.3, 129.2, 
104.7, 90.3, 55.8, 55.3, 50.1, 33.6, 33.1, 21.3, 20.8. 
HRMS (ESI): Calculated for C23H28NO4 ([M+H]+): 382.2018; found: 382.2013 
IR (neat) : ν = 2361, 1680, 1608, 1416 cm-1 
(E)-2-benzylidenehexahydro-3H-pyrrolizin-3-one 4.81: 
 
 
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.81r (29.4 mg, 0.1 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), PCy3 (2.8 mg, 0.01 mmol, 10 mol%), pivalic 
acid (3.1 mg, 0.03 mmol, 30 mol%) and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 
160°C for 16h. After purification, 4.81 was obtained as a yellowish oil (11 mg, 0.051 mmol, 51%). 
 
1H NMR (400 MHz, Chloroform-d) δ = 7.49 – 7.45 (m, 2H), 7.43 – 7.37 (m, 2H), 7.34 – 7.29 (m, 
2H), 3.89 – 3.86 (m, 1H), 3.75 (dt, J = 12.0, 8.2 Hz, 1H), 3.34 – 3.22 (m, 2H), 2.86 – 2.78 (m, 
1H), 2.22 – 2.00 (m, 3H), 1.33 – 1.19 (m, 1H). 
 
13C NMR (101 MHz, CDCl3) δ = 170.4, 136.0, 133.9, 130.5, 129.7, 128.8, 128.6, 59.3, 42.2, 32.4, 
31.4, 26.3. 
 
HRMS (ESI): Calculated for C14H15NaNO ([M+Na]+): 236.1051; found: 236.1046 
 
IR (neat) : ν = 2361, 1681, 1419 cm-1 
(R,E)-2-benzylidenehexahydro-3H-pyrrolizin-3-one 4.99:  
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Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.99r (29.4 mg, 0.1 mmol, 1 
equiv) was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), PCy3 (2.8 mg, 0.01 mmol, 10 mol%), 
pivalic acid (3.1 mg, 0.03 mmol, 30 mol%) and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 
mL) at 160°C for 16h. After purification, 4.99 was obtained as a yellowish oil (10.5 mg, 0.050 mmol, 50%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.49 – 7.45 (m, 2H), 7.42 – 7.37 (m, 2H), 7.34 – 7.29 
(m, 2H), 3.91 – 3.82 (m, 1H), 3.79 – 3.72 (m, 1H), 3.34 – 3.22 (m, 2H), 2.82 (dt, J = 17.6, 3.3 
Hz, 1H), 2.21 – 1.97 (m, 3H), 1.33 – 1.21 (m, 1H). 
 
13C NMR (126 MHz, CDCl3) δ = 170.4, 136.0, 133.9, 130.6, 129.7, 128.8, 128.6, 59.3, 42.2, 
32.4, 31.5, 26.3. 
 
(E)-2-benzylidenehexahydroindolizin-3(2H)-one 4.82: 
 
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.82r (30.8 mg, 0.1 mmol, 1 
equiv) was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), pivalic acid (3.1 mg, 0.03 mmol, 30 
mol%) and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 160°C for 16h. After purification, 
4.82 was obtained as a colorless oil (22.2 mg, 0.098 mmol, 98%). 
 
1H NMR (500 MHz, Chloroform-d) δ = 7.49 – 7.44 (m, 2H), 7.42 – 7.37 (m, 2H), 7.36 – 7.34 (m, 
1H), 7.33 – 7.28 (m, 1H), 4.35 – 4.28 (m, 1H), 3.58 – 3.51 (m, 1H), 3.24 (ddd, J = 17.5, 7.8, 
2.7 Hz, 1H), 2.81 – 2.77 (m, 1H), 2.66 – 2.58 (m, 1H), 2.01 – 1.86 (m, 2H), 1.77 – 1.70 (m, 
1H), 1.57 – 1.36 (m, 2H), 1.27 – 1.13 (m, 1H). 
 
13C NMR (126 MHz, CDCl3) δ = 167.7, 136.2, 131.0, 129.9, 129.6, 128.8, 128.4, 55.2, 40.9, 34.1, 
32.3, 24.8, 24.1. 
 
HRMS (ESI): Calculated for C15H17NaNO ([M+Na]+): 250.1208; found: 250.1202 
IR (neat) : ν = 2937, 1632, 1444 cm-1 
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(E)-2-benzylideneoctahydro-3H-pyrrolo[1,2-a]azepin-3-one 4.83: 
  
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.83r (32.2 mg, 0.1 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), pivalic acid (3.1 mg, 0.03 mmol, 30 mol%) 
and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 160°C for 16h. After purification, 4.83 
was obtained as a yellowish oil (9.5 mg, 0.039 mmol, 40%). 
 
1H NMR (400 MHz, Chloroform-d) δ = 7.48 – 7.44 (m, 2H), 7.42 – 7.36 (m, 2H), 7.34 – 7.28 
(m, 2H), 3.94 – 3.81 (m, 2H), 3.29 – 3.15 (m, 2H), 2.64 – 2.57 (m, 1H), 1.98 – 1.89 (m, 1H), 
1.85 – 1.75 (m, 1H), 1.75 – 1.62 (m, 4H), 1.60 – 1.51 (m, 2H). 
 
13C NMR (101 MHz, CDCl3) δ = 169.4, 136.2, 131.8, 129.6, 129.1, 128.8, 128.3, 57.0, 43.5, 36.8, 
33.6, 29.6, 27.4, 25.3. 
 
HRMS (ESI): Calculated for C16H19NaNO ([M+Na]+): 264.1364; found: 264.1359 
IR (neat) : ν = 1650, 1421 cm-1 
(E)-7-benzylidenetetrahydro-2H-pyrrolo[2,1-b][1,3]oxazin-6(7H)-one 4.84:  
 
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.84r (31 mg, 0.1 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), pivalic acid (3.1 mg, 0.03 mmol, 30 mol%) 
and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 160°C for 16h. After purification, 4.84 
was obtained as a colorless oil (20.5 mg, 0.090 mmol, 90%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.48 – 7.45 (m, 2H), 7.42 – 7.37 (m, 3H), 7.35 – 7.30 (m, 
1H), 5.06 (dd, J = 6.7, 1.8 Hz, 1H), 4.36 (ddt, J = 13.3, 5.4, 1.7 Hz, 1H), 4.12 (ddt, J = 11.6, 4.5, 1.7 
Hz, 1H), 3.78 (ddd, J = 12.6, 11.8, 2.3 Hz, 1H), 3.26 (ddd, J = 17.9, 6.6, 2.7 Hz, 1H), 3.17 – 3.08 
(m, 1H), 2.88 (dt, J = 17.9, 2.3 Hz, 1H), 1.93 – 1.80 (m, 1H), 1.58 – 1.51 (m, 1H). 
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13C NMR (101 MHz, CDCl3) δ = 167.6, 135.6, 131.4, 129.7, 128.8, 128.4, 127.9, 85.4, 67.2, 39.0, 
32.7, 24.8. 
 
HRMS (ESI): Calculated for C14H16NO2 ([M+H]+): 230.1181; found: 230.1178 
IR (neat) : ν = 2364, 1685, 1449 cm-1 
(E)-7-benzylidenehexahydro-6H-pyrrolo[2,1-c][1,4]oxazin-6-one 4.85:  
 
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.85r (31 mg, 0.1 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), PCy3 (2.8 mg, 0.01 mmol, 10 mol%), pivalic 
acid (3.1 mg, 0.03 mmol, 30 mol%) and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 
160°C for 16h. After purification, 4.85 was obtained as a colorless oil (16 mg, 0.069 mmol, 69%). 
1H NMR (500 MHz, Chloroform-d) δ = 7.51 – 7.48 (m, 2H), 7.45 – 7.41 (m, 3H), 7.38 – 7.34 (m, 
1H), 4.18 (dd, J = 13.3, 3.0 Hz, 1H), 4.08 (dd, J = 11.1, 3.9 Hz, 1H), 4.00 – 3.96 (m, 1H), 3.91 – 
3.84 (m, 1H), 3.48 – 3.42 (m, 1H), 3.24 – 3.12 (m, 3H), 2.60 – 2.52 (m, 1H). 
 
13C NMR (126 MHz, CDCl3) δ = 167.6, 135.7, 131.1, 129.7, 129.4, 128.9, 128.8, 72.6, 66.5, 53.2, 
41.1, 27.5. 
HRMS (ESI): Calculated for C14H16NO2 ([M+H]+): 230.1181; found: 230.1176 
IR (neat) : ν = 2361, 1682, 1447 cm-1 
tert-butyl (E)-7-benzylidene-6-oxohexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate 
4.86:  
 
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.86r (41 mg, 0.1 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), pivalic acid (3.1 mg, 0.03 mmol, 30 mol%) 
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and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 160°C for 16h. After purification, 4.86 
was obtained as a colorless oil (17 mg, 0.052 mmol, 52%). 
1H NMR (500 MHz, Chloroform-d) δ = 7.49 – 7.45 (m, 2H), 7.43 – 7.39 (m, 3H), 7.36 – 7.32 (m, 
1H), 4.35 (br. s, 1H), 4.25 – 4.19 (m, 1H), 4.15 (br. s, 1H), 3.72 – 3.65 (m, 1H), 3.22 (ddd, J = 17.7, 
7.9, 2.7 Hz, 1H), 2.99 – 2.93 (m, 1H), 2.77 (br. s, 1H), 2.64 – 2.57 (m, 1H), 2.47 (br. s, 1H), 1.49 
(s, 9H). 
 
13C NMR (126 MHz, CDCl3) δ = 167.7, 154.5, 135.7, 131.1, 129.7, 129.5, 129.0, 128.9, 128.8, 
127.9, 80.8, 53.4, 40.3, 28.8, 28.5. 
 
HRMS (ESI): Calculated for C19H24NaN2O3 ([M+Na]+): 351.1685; found: 351.1679 
IR (neat) : ν = 2361, 1688, 1422 cm-1 
 (E)-2-benzylidene-2,3-dihydro-1H-inden-1-one 4.104:  
 
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.104r (30 mg, 0.1 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), PCy3 (2.8 mg, 0.01 mmol, 10 mol%), pivalic 
acid (3.1 mg, 0.03 mmol, 30 mol%) and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 
160°C for 16h. After purification, 4.104 was obtained as a white solid (14.5 mg, 0.066 mmol, 66%). 
The physical and spectroscopic properties matched those described in the literature. 39 
1H NMR (400 MHz, Chloroform-d) δ = 7.94 – 7.91 (m, 1H), 7.70 – 7.67 (m, 3H), 7.64 – 7.60 (m, 
1H), 7.58 – 7.55 (m, 1H), 7.49 – 7.38 (m, 4H), 4.06 (d, J = 2.1 Hz, 2H). 
13C NMR (101 MHz, CDCl3) δ = 194.5, 149.8, 138.2, 135.6, 134.9, 134.8, 134.1, 130.9, 129.8, 
129.1, 127.8, 126.3, 124.6, 32.6. 
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(E)-2-benzylidene-7-methyl-2,3-dihydro-1H-inden-1-one 4.105: 
 
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.105r (31.5 mg, 0.1 mmol, 1 
equiv) was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), PCy3 (2.8 mg, 0.01 mmol, 10 mol%), 
pivalic acid (3.1 mg, 0.03 mmol, 30 mol%) and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 
mL) at 160°C for 16h. After purification, 4.105 was obtained as a white solid (16.5 mg, 0.070 mmol, 70%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.69 – 7.65 (m, 2H), 7.62 – 7.60 (m, 1H), 7.48 – 7.43 (m, 
3H), 7.42 – 7.38 (m, 1H), 7.38 – 7.34 (m, 1H), 7.18 – 7.14 (m, 1H), 4.01 (d, J = 2.2 Hz, 2H), 2.75 
(s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 195.4, 150.4, 139.7, 135.7, 135.6, 135.4, 134.1, 133.1, 130.8, 
129.7, 129.8, 129.0, 123.6, 32.3, 18.7. 
 
HRMS (ESI): Calculated for C17H15O ([M+H]+): 235.1123; found: 235.1118 
IR (neat) : ν = 1693, 1629 cm-1 
m.p.: 230 - 232°C (decomp.) 
 (E)-2-benzylidene-5-methoxy-2,3-dihydro-1H-inden-1-one 4.106: 
  
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.106r (33 mg, 0.1 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), PCy3 (2.8 mg, 0.01 mmol, 10 mol%), pivalic 
acid (3.1 mg, 0.03 mmol, 30 mol%) and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 
160°C for 16h. After purification, 4.106 was obtained as a white solid (20 mg, 0.081 mmol, 81%). 
The physical and spectroscopic properties matched those described in the literature. 40 
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1H NMR (500 MHz, Chloroform-d) δ = 7.88 – 7.85 (m, 1H), 7.68 – 7.66 (m, 2H), 7.63 – 7.61 (m, 
1H), 7.48 – 7.44 (m, 2H), 7.41 – 7.37 (m, 1H), 7.01 – 6.99 (m, 1H), 6.98 – 6.95 (m, 1H), 4.02 
(d, J = 1.7 Hz, 2H), 3.92 (s, 3H). 
 
13C NMR (126 MHz, CDCl3) δ = 192.9, 165.4, 152.7, 135.8, 135.4, 132.8, 131.6, 130.7, 129.5, 
129.0, 126.4, 115.4, 109.9, 55.9, 32.7. 
 (E)-2-benzylidene-5-(benzyloxy)-2,3-dihydro-1H-inden-1-one 4.107:  
 
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.107r (41 mg, 0.1 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), PCy3 (2.8 mg, 0.01 mmol, 10 mol%), pivalic 
acid (3.1 mg, 0.03 mmol, 30 mol%) and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 
160°C for 16h. After purification, 4.107 was obtained as a white solid (26 mg, 0.080 mmol, 80%). 
1H NMR (500 MHz, Chloroform-d) δ = 7.87 – 7.85 (m, 1H), 7.67 – 7.65 (m, 2H), 7.63 – 7.61 (m, 
1H), 7.47 – 7.42 (m, 4H), 7.42 – 7.35 (m, 4H), 7.07 – 7.03 (m, 2H), 5.18 (s, 2H), 4.00 (d, J = 1.6 
Hz, 2H). 
 
13C NMR (126 MHz, CDCl3) δ = 192.9, 164.5, 152.6, 136.2, 135.7, 135.4, 132.9, 131.8, 130.7, 
129.5, 129.0, 128.9, 128.5, 127.6, 126.4, 116.1, 110.9, 70.6, 32.7. 
 
HRMS (ESI): Calculated for C23H19O2 ([M+H]+): 327.1385; found: 327.1380 
IR (neat) : ν = 1682 cm-1 
m.p.: 256 - 258°C (decomp.) 
(E)-2-benzylidene-5-methyl-2,3-dihydro-1H-inden-1-one 4.108: 
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Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.108r (31.5 mg, 0.1 mmol, 1 
equiv) was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), pivalic acid (3.1 mg, 0.03 mmol, 30 
mol%) and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 160°C for 16h. After purification, 
4.108 was obtained as a white solid (11.5 mg, 0.050 mmol, 50%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.81 (d, J = 7.8 Hz, 1H), 7.71 – 7.63 (m, 3H), 7.51 – 7.42 
(m, 2H), 7.44 – 7.37 (m, 1H), 7.37 – 7.33 (m, 1H), 7.28 – 7.20 (m, 1H), 4.01 (s, 2H), 2.48 (s, 
3H). 
 
13C NMR (126 MHz, CDCl3) δ = 193.9, 150.1, 145.9, 135.8, 135.5, 135.2, 133.4, 130.6, 129.5, 128.9, 
128.9, 126.5, 124.3, 32.3, 22.3. 
 
HRMS (ESI): Calculated for C17H15O ([M+H]+): 235.1123; found: 235.1117 
IR (neat) : ν = 1692, 1631, 1273 cm-1 
m.p.: 222 - 224°C (decomp.) 
(E)-2-benzylidene-5-fluoro-2,3-dihydro-1H-inden-1-one 4.109:  
 
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.109r (32 mg, 0.1 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), PCy3 (2.8 mg, 0.01 mmol, 10 mol%), pivalic 
acid (3.1 mg, 0.03 mmol, 30 mol%) and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 mL) at 
160°C for 16h. After purification, 4.109 was obtained as a white solid (21 mg, 0.089 mmol, 89%). 
The physical and spectroscopic properties matched those described in the literature. 41 
1H NMR (400 MHz, Chloroform-d) δ = 7.94 – 7.90 (m, 1H), 7.69 – 7.64 (m, 3H), 7.50 – 7.38 (m, 
3H), 7.24 – 7.20 (m, 1H), 7.16 – 7.10 (m, 1H), 4.05 (s, 2H). 
 
13C NMR (101 MHz, CDCl3) δ = 192.7, 167.2 (d, J = 256.2 Hz), 152.5 (d, J = 10.1 Hz), 135.3, 
134.6 (d, J = 1.9 Hz), 134.4, 134.2, 130.8, 129.9, 129.1, 126.9 (d, J = 10.2 Hz), 116.1 (d, J = 23.8 
Hz), 113.1 (d, J = 22.9 Hz), 32.6 (d, J = 2.2 Hz). 
 
19F NMR (376 MHz, CDCl3) δ = -102.5. 
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(E)-5-amino-2-benzylidene-2,3-dihydro-1H-inden-1-one 4.110: 
  
Following the general procedure for the 1,4-Pd shift/C(sp3)-H activation, 4.110r (31.5 mg, 0.1 mmol, 1 
equiv) was reacted with Pd(PCy3)2 (6.7 mg, 0.01 mmol, 10 mol%), PCy3 (2.8 mg, 0.01 mmol, 10 mol%), 
pivalic acid (3.1 mg, 0.03 mmol, 30 mol%) and Rb2CO3 (35 mg, 0.15 mmol, 1.5 equiv) in mesitylene (4 
mL) at 160°C for 16h. After purification, 4.110 was obtained as a white solid (14 mg, 0.060 mmol, 60%). 
The physical and spectroscopic properties matched those described in the literature. 42 
1H NMR (400 MHz, Chloroform-d) δ = 7.76 – 7.72 (m, 1H), 7.66 – 7.62 (m, 2H), 7.58 – 7.55 
(m, 1H), 7.47 – 7.41 (m, 2H), 7.39 – 7.34 (m, 1H), 6.70 – 6.68 (m, 1H), 6.67 – 6.63 (m, 1H), 
4.30 (br. s, 2H), 3.91 (d, J = 2.1 Hz, 2H). 
 
13C NMR (101 MHz, CDCl3) δ = 192.3, 152.9, 152.8, 135.9, 135.9, 131.7, 130.4, 129.2, 129.1, 
128.8, 126.6, 114.9, 109.5, 32.3. 
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Checkcif for compound 4.84:  
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Chapter 2.2: Redox-neutral Coupling between Two 
C(sp3)–H Bonds Enabled by 1,4-Palladium Shift for the 
Synthesis of Fused Heterocycles  
General information: 
Techniques 
All reactions involving air-sensitive material were carried out in pre-dried glassware under an 
argon atmosphere by using Schlenk techniques employing double-line argon-vacuum lines 
and working in an argon-filled glove box. Analytical thin layer chromatography (TLC) was 
performed using pre-coated Merck silica gel 60 F254 plates (0.25 mm). Visualization of the 
developed chromatogram was performed by UV absorbance (254 nm) or TLC stains (KMnO4 
and Phosphomolybdic acid). Flash chromatography was performed using Silicycle SiliaFlash 
P60 (230-400 mesh) with the indicated eluent system, using gradients of increasing polarity 
in most cases. 
Chemicals 
Anhydrous THF, DMF, DCM, toluene were purchased from Acros Organics or Sigma-Aldrich. 
The solvents were degassed by three cycles of freeze-pump-thaw and storing in single-necked 
flasks equipped with a J-Young PTFE valve when necessary. Pd(PCy3)2 was synthesized from 
known procedure. 43All other chemical reagents were purchased from Sigma-Aldrich, Acros 
Organics, Fisher, and Fluorochem and used as received without further purification unless 
otherwise stated. 
Instrumentation 
Preparative HPLC was performed using a preparative Shimadzu HPLC system with a Gemini 
10 μm NX-C18, LC Column 150 × 30mm. 
Melting points were obtained on a Büchi B-565, and are uncorrected. IR spectra were recorded 
on an ATR Varian Scimitar 800 and are reported in reciprocal centimeters (cm-1). 
Nuclear magnetic resonance spectra were recorded on a Bruker Advance 400 (400 MHz), on 
a Bruker Advance 500 (500 MHz) or a Bruker Advance 600 (600 MHz) in deuterated 
chloroform S4 (residual peaks 1H δ 7.26 ppm, 13C δ 77.16 ppm) unless otherwise noted. 19F 
NMR spectra were referenced to external CFCl3. Data are reported in parts per million (ppm) 
as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quint = 
quintuplet, sept = septuplet, m = multiplet and br. s = broad singlet), coupling constant in Hz 
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and integration. High resolution mass spectra were recorded by Dr. M. Pfeffer (Department of 
Chemistry, University of Basel) on a Bruker maXis 4G QTOF ESI mass spectrometer.  
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General procedures: 
GENERAL PROCEDURE A FOR BROMINATION OF PHENOLS: 
To a 1M solution of phenol (1 equiv) in DMF was added dropwise a 1M solution of NBS (1.1 
equiv) in DMF. The reaction evolution was followed by TLC using cyclohexane/AcOEt as 
eluent. After completion, the mixture was quenchinged with water, and extracted with Et2O. 
The combined organic layers were washed with brine, dried over sodium sulfate, filtered and 
evaporated. The crude mixture was used without further purification or purified by 
chromatography on silica gel using cyclohexane/AcOEt as eluent to afford the pure brominated 
phenols.  
GENERAL PROCEDURE B FOR METHYLATION OF PHENOLS: 
Phenols were dissolved in acetone or DMF as precised (0.1M), followed by addition of K2CO3 
(1.5 equiv) and MeI (3 equiv). The mixture was stirred until completion. Volatiles were removed 
under vacuum and the crude mixture was extracted with DCM, washed with water and brine, 
dried over sodium sulfate, filtered and evaporated. The methylated phenols were purified by 
chromatography on silica gel using cyclohexane/AcOEt as eluent to afford the pure compounds. 
GENERAL PROCEDURE C FOR BROMINATION OF ANILINES: 
Anilines (1 equiv) were dissolved in DCM (0.12 M) and NBS (1.1 equiv) was added portionwise 
to the stirred solution. After completion, the reaction was quenchinged with water, and extracted 
with DCM. The combined organic layers were dried over sodium sulfate, filtered and 
evaporated under vacuum. The crude mixture was purified by chromatography on silica gel 
using cyclohexane/AcOEt as eluent to afford the pure brominated anilines. 
GENERAL PROCEDURE D FOR TRIFLUOROACETYLATION OF ANILINES: 
Anilines (1 equiv) were dissolved in 1,2-dichloroethane (0.2 M) followed by addition of DMAP 
(0.05 equiv) and trifluoroacetic anhydride (2 equiv). After completion, the reaction was 
quenchinged with water, extracted with DCM, and the combined organic layers were dried over 
sodium sulfate, filtered and evaporated under vacuum. Trifluoroacetylanilines were purified by 
chromatography on silica gel using cyclohexane/AcOEt as eluent.  
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GENERAL PROCEDURE E FOR METHYLATION OF ANILINES: 
Anilines (1 equiv) were dissolved in dry THF (0.12 M) or dry DMF (0.12 M) as precised under 
argon atmosphere and NaH (60% dispersion in oil, 3 equiv) was added portionwise. The 
reaction was stirred for 5 minutes, followed by addition of MeI (3 equiv). After completion, the 
reaction was carefully quenchinged with water. The aqueous phase was then extracted with 
AcOEt, and the combined organic layers were dried over sodium sulfate, filtered and 
evaporated under vacuum. The crude mixture was purified by chromatography on silica gel 
using cyclohexane/AcOEt as eluent. 
Note: In case of deprotection of the aniline during methylation step, the obtained methylated 
aniline was treated with trifluoroacetic anhydride (2 equiv), and DMAP (0.05 equiv) in 1,2-
dichloroethane (0.2 M). The crude mixture was quenchinged with water, extracted with DCM, 
and the combined organic layers were dried over sodium sulfate, filtered and evaporated under 
vacuum. Anilines could then be used without further purification.  
GENERAL PROCEDURE F FOR KETONE SYNTHESIS: 
Aldehydes (1 equiv) were dissolved in dry THF (0.2 M) under argon and cooled to -78°C. Then, 
a solution of Grignard reagent (2 equiv) was added dropwise. After addition, the cooling bath 
was removed and the reaction was further stirred for one hour at room temperature. The reaction 
was then quenchinged with water, and extracted with AcOEt. The combined organic layers 
were dried over sodium sulfate, filtered and evaporated under vacuum. The crude mixture 
secondary alcohols were then dissolved in DCM (0.1 M), followed by addition of PCC (2.5 
equiv) and celite (1 g celite for 1 g PCC). The mixture was stirred overnight, filtered through 
celite, evaporated over vacuum and purified by chromatography on silica gel using 
cyclohexane/AcOEt as eluent.  
GENERAL PROCEDURE G FOR THE DIHYDROBENZOFURANS SYNTHESIS: 
In a 10 mL screw cap charged with substrate (0.15 mmol, 1 equiv) was weighted in a glovebox 
Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol %,) and cesium pivalate (35 mg, 0.15 mmol, 1 equiv) 
The vial was charged with toluene (6 mL) and stirred under argon in a heating block preheated 
at 140 °C or (160°C as mentioned) for 16 h. The reaction was cooled to room temperature, 
filtered through celite, and evaporated under vacuum. The crude mixture was analysed by 1H 
NMR and purified by chromatography on silica gel to afford the pure compounds. 
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GENERAL PROCEDURE H FOR INDOLINES SYNTHESIS: 
In a 10 mL screw cap charged with substrate (0.15 mmol, 1 equiv) was weighted in a glovebox 
Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol %,) AdCO2H (8.1 mg, 0.45 mmol, 30 mol%) and Rb2CO3 
(52 mg, 0.23 mmol, 1.5 equiv). The vial was charged with toluene (6 mL) and stirred under 
argon in a heating block preheated at 160 °C for 16 h. The reaction was cooled to room 
temperature, filtered through celite, and evaporated under vacuum. The crude mixture was 
analysed by 1H NMR and purified by chromatography on silica gel to afford the pure 
compounds. 
GENERAL PROCEDURE I FOR THE CHROMANONES SYNTHESIS: 
In a 10 mL screw cap charged with substrate (0.15 mmol, 1 equiv) was weighted in a glovebox 
Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol %,) AdCO2H (8.1 mg, 0.45 mmol, 30 mol%) and Cs2CO3 
(49 mg, 1 equiv, 0.15 mmol). The vial was charged with toluene (6 mL) and stirred under argon 
in a heating block preheated at 120 °C for 16 h. The reaction was cooled to room temperature, 
filtered through celite, and evaporated under vacuum. The crude mixture was analysed by 1H 
NMR and purified by chromatography on silica gel to afford the pure compounds. 
GENERAL PROCEDURE J FOR NUCLEOPHILIC ADDITION: 
In a 10 mL screw cap charged with substrate (0.15 mmol, 1 equiv) was weighted in a glovebox 
Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol %,) and CsOPiv (105 mg, 3 equiv, 0.45 mmol). The vial 
was charged with toluene (6 mL) and stirred under argon in a heating block preheated at 160 °C 
for 16 h. The reaction was cooled to room temperature, filtered through celite, and evaporated 
under vacuum. The crude mixture was analysed by 1H NMR and purified by preparative HPLC 
to afford the pure compounds. 1H NMR was performed in C6D6 to avoid elimination product. 
Elimination products were obtained after leaving the tertiary alcool in “old” CDCl3 for 24h and 
extracted with CHCl3, dried over sodium sulfate, filtered and evaporated under vacuum. 
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Optimizations tables: 
Benzofurans: 
 
 
Additive (equiv.) Base (equiv.) T°C NMR yield * 
(isolated) 
CsOPiv (30 mol%) Cs2CO3 (1 equiv) 120°C Traces 
CsOPiv (30 mol%) Rb2CO3 (1 equiv) 120°C 20% 
CsOPiv (1 equiv) - 120°C 25% 
CsOPiv (3 equiv) - 120°C 25% 
CsOPiv (1 equiv) - 140°C 88% (92%) 
*Using trichloroethylene as internal standard 
Indolines:  
 
 
Additive (equiv.) Base (equiv.) T°C NMR yield* 
(isolated) 
CsOPiv (1 equiv) - 160°C 10% 
PivOH (30 mol%) Cs2CO3 (1.5 equiv) 160°C 0% 
PivOH (30 mol%) Rb2CO3 (1.5 equiv) 160°C 23% 
AdCO2H (30 mol%) Rb2CO3 (1.5 equiv) 160°C 72% (74%) 
*Using trichloroethylene as internal standard 
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Chromanones: 
 
 
Additive (equiv.) Base (equiv.) T°C NMR yield* 
(isolated) 
PivOH (30 mol%) Rb2CO3 (1.5 equiv) 120°C 35% 
PivOH (30 mol%) Rb2CO3 (1 equiv) 120°C 45% 
AdCO2H (30 mol%) Rb2CO3 (1 equiv) 120°C 60% 
AdCO2H (30 mol%) Cs2CO3 (1 equiv) 120°C 71% (72%) 
*Using trichloroethylene as internal standard 
 
Nucleophilic addition: 
 
Additive (equiv.) Base (equiv.) T°C NMR yield* 
(isolated) 
PivOH (30 mol%) Cs2CO3 (1.5 equiv) 160°C 10% 
PivOH (30 mol%) Rb2CO3 (1.5 equiv) 160°C 18% 
PivOH (3 equiv) Cs2CO3 (3 equiv) 160°C 50% 
CsOPiv (1.5 equiv) - 160°C 40% 
CsOPiv (3 equiv) - 160°C 77% (69%) 
*Using trichloroethylene as internal standard 
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Synthesis of substrates: 
methyl 3-bromo-4-methoxy-5-methylbenzoate 5.39:  
 
Following General procedure A for bromination of phenols methyl 4-hydroxy-3-
methylbenzoate (997 mg, 6.0 mmol, 1 equiv) was reacted with NBS (1.17 g, 6.6 mmol, 1.1 equiv) 
in DMF. After quenching with water, the crude mixture was extracted with Et2O, and the 
combined organic layers were washed with brine, and purified by chromatography on silica gel 
using cyclohexane/AcOEt [9:1] to afford the phenol (910 mg, 3.7 mmol, 62%).  
Following General procedure B for methylation of phenols, methyl 3-bromo-4-hydroxy-5-
methylbenzoate (910 mg, 3.7 mmol, 1 equiv), K2CO3 (770 mg, 5.6 mmol, 1.5 equiv) and MeI 
(0.69 mL, 11.1 mmol, 3 equiv) were reacted in acetone. After evaporation, extraction and 
purification, the desired product 5.39r was obtained as a colorless oil (770 mg, 2.97 mmol, 80 
%). 
1H NMR (400 MHz, Chloroform-d) δ = 8.10 – 8.08 (m, 1H), 7.84 – 7.82 (m, 1H), 3.92 (s, 
3H), 3.87 (s, 3H), 2.38 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 165.8, 159.4, 133.4, 132.7, 131.9, 127.1, 117.4, 60.4, 52.4, 
16.8. 
 
HRMS (ESI): Calculated for C10H12BrO3 ([M+H]+): 258.9970; found: 258.9973 
IR (neat) : ν = 1766 cm-1 
 
1-bromo-2-methoxy-3-methylbenzene 5.46r: 44 
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Following General procedure B for methylation of phenols, 2-bromo-6-methylphenol (436 mg, 
2.33 mmol, 1 equiv), K2CO3 (483 mg, 3.49 mmol, 1.5 equiv) and MeI (0.43 mL, 7.0 mmol, 3 
equiv) were reacted in acetone. After evaporation, extraction and purification, the desired 
product 5.46r was obtained as a yellowish oil (460 mg, 2.30 mmol, 98 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.40 – 7.35 (m, 1H), 7.14 – 7.09 (m, 1H), 6.91 – 6.86 
(m, 1H), 3.82 (s, 3H), 2.33 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 155.5, 133.4, 131.2, 130.5, 125.3, 117.5, 60.3, 16.7. 
 
1-bromo-5-fluoro-2-methoxy-3-methylbenzene 5.46r: 
 
Following General procedure A for bromination of phenols, 4-fluoro-2-methylphenol (1.26 g, 
10.0 mmol, 1 equiv) was reacted with NBS (1.96 g, 11 mmol, 1.1 equiv) in DMF. After quenching 
with water, the crude mixture was extracted with Et2O, and the combined organic layers were 
washed with brine, and purified by chromatography on silica gel using cyclohexane/AcOEt 
[9:1] to afford the phenol (1.45 g, 7.0 mmol, 70%).  
Following General procedure B for methylation of phenols, 2-bromo-4-fluoro-6-methylphenol 
(1.45 g, 7.0 mmol, 1 equiv), K2CO3 (1.45 g, 10.5 mmol, 1.5 equiv) and MeI (1.3 mL, 21.0 mmol, 
3 equiv) were reacted in acetone. After evaporation, extraction and purification, the desired 
product  was obtained as a yellowish oil (1.08 g, 4.93 mmol, 70 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.16 – 7.11 (m, 1H), 6.89 – 6.85 (m, 1H), 3.80 (s, 3H), 
2.34 (s, 3H). 
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13C NMR (101 MHz, Chloroform-d) δ = 158.4 (d, J = 246.0 Hz), 151.9 (d, J = 3.2 Hz), 134.4 
(d, J = 8.5 Hz), 117.8 (d, J = 25.5 Hz), 117.3 (d, J = 10.8 Hz), 117.0 (d, J = 22.2 Hz), 60.5 (d, J = 
1.5 Hz), 16.9 (d, J = 1.5 Hz). 
 
19F NMR (376 MHz, CDCl3) δ = -117.6. 
 
HRMS (ESI): Calculated for C8H9BrFO ([M+H]+): 218.9821; found: 218.9824 
IR (neat) : ν = 1245 cm-1 
 
3-bromo-4-methoxy-5-methylbenzaldehyde 5.45r: 45 
  
Following General procedure A for bromination of phenols, 4-hydroxy-3-methylbenzaldehyde 
(820 mg, 6.0 mmol, 1 equiv) was reacted with NBS (1.17 g, 6.6 mmol, 1.1 equiv) in DMF. After 
quenching with water, the crude mixture was extracted with Et2O, and the combined organic 
layers were washed with brine, and purified by chromatography on silica gel using 
cyclohexane/AcOEt [9:1] to afford the phenol (645 mg, 3.0 mmol, 50%).  
Following General procedure B for methylation of phenols, 3-bromo-4-hydroxy-5-
methylbenzaldehyde (645 mg, 3.0 mmol, 1 equiv), K2CO3 (622mg, 4.5mmol, 1.5 equiv) and 
MeI (0.55 mL, 9.0 mmol, 3 equiv) were reacted in DMF. After evaporation, extraction and 
purification, the desired product was obtained as a colorless oil (285 mg, 1.24 mmol, 42 %). 
1H NMR (400 MHz, Chloroform-d) δ = 9.86 (s, 1H), 7.93 – 7.91 (m, 1H), 7.67 – 7.65 (m, 
1H), 3.88 (s, 3H), 2.40 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 190.2, 160.7, 134.4, 133.5, 133.0, 131.8, 118.4, 60.5, 16.8. 
 
methyl 4-bromo-3-methoxy-2-methylbenzoate 5.48r: 46  
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In a 250 mL round bottom flask, toluene (50 mL) and tBuNH2 (1.2 mL, 11.4 mmol, 1.9 equiv) 
were stirred and cooled to -78°C. Bromine (0.29 mL, 5.72 mmol, 0.95 equiv) in toluene (5 mL) 
was then slowly added to the stirred mixture, which was further reacted for 1h at this 
temperature. methyl 3-hydroxy-2-methylbenzoate (1 g, 6 mmol, 1 equiv) in dichloromethane 
(30 mL) was then added slowly to the mixture, which was warm to room temperature over 5h.  
The reaction was quenched with water (60 mL) and extracted with DCM (3 x 30 mL) and the 
combined organic layers were dried over sodium sulfate, filtered and evaporated under vacuum. 
The crude mixture was purified by chromatography on silicagel to afford the brominated 
product (420 mg, 1.71 mmol, 28 %). 
Following general procedure B for methylation of phenols, intermediate phenol ester (120 mg, 
0.49 mmol, 1 equiv) was reacted with K2CO3 (102 mg, 0.74 mmol, 1.5 equiv) and MeI (0.1 mL, 
1.47 mmol, 3 equiv) in DMF. After extraction and purification, methoxy phenol was obtained 
(112 mg, 0.43 mmol, 88%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.52 – 7.49 (m, 1H), 7.45 – 7.42 (m, 1H), 3.89 (s, 
3H), 3.80 (s, 3H), 2.56 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 167.5, 156.1, 135.6, 131.1, 130.5, 127.2, 122.2, 60.5, 52.2, 
14.2. 
 
 
methyl 2-(2-bromo-6-methylphenoxy)acetate 5.53r: 
 
Following general procedure for alkylation of phenols, 2-bromo-6-methylphenol (500 mg, 2.67 
mmol, 1 equiv), K2CO3 (557 mg, 4.0 mmol, 1.5 equiv) and methyl 2-bromoacetate (0.76 mL, 
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8.0 mmol, 3 equiv) were reacted in DMF. After evaporation, extraction and purification, the 
desired product was obtained as a colorless oil (600 mg, 2.32 mmol, 86 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.38 – 7.35 (m, 1H), 7.14 – 7.10 (m, 1H), 6.94 – 6.89 
(m, 1H), 4.56 (s, 2H), 3.84 (s, 3H), 2.35 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 169.1, 153.6, 133.5, 131.3, 130.6, 126.0, 116.9, 69.1, 52.3, 
16.8. 
 
HRMS (ESI): Calculated for C10H12BrO3 ([M+H]+): Exact Mass: 258.9970; found: 258.9964 
IR (neat) : ν = 1764, 1461, 1207 cm-1 
methyl 2-(3-bromo-2-methoxyphenyl)acetate 5.49r: 47 
 
 
In a 250 mL round bottom flask, toluene (60 mL) and tBuNH2 (1.9 mL, 18 mmol, 1.5 equiv) 
were stirred and cooled to -78°C. Bromine (0.5 mL, 9.6 mmol, 0.8 equiv) in toluene (5 mL) 
was then slowly added to the stirred mixture, which was further reacted for 1h at this 
temperature. Methyl 2-(2-hydroxyphenyl)acetate (2 g, 12 mmol, 1 equiv) in dichloromethane 
(30 mL) was then added slowly to the mixture, which was cooled to room temperature over 5h.  
The reaction was quenched with water (60 mL) and extracted with DCM (3 x 30 mL) and the 
combined organic layers were dried over sodium sulfate, filtered and evaporated under vacuum. 
The crude mixture was purified by chromatography on silicagel to afford a mixture of 
mono/dibrominated product (80/20) (1.25 g, 5.1 mmol, 53 %). 
Following general procedure B for methylation of phenols, intermediate phenol ester mixture 
(80/20) (490 mg, 2 mmol, 1 equiv) was reacted with K2CO3 (415 mg, 3 mmol, 1.5 equiv) and 
MeI (0.37 mL, 6 mmol, 3 equiv) in DMF. After extraction and purification, methoxy phenol 
was obtained (370 mg, 1.43 mmol, 71%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.50 – 7.45 (m, 1H), 7.21 – 7.18 (m, 1H), 6.99 – 6.94 
(m, 1H), 3.84 (s, 3H), 3.71 (s, 3H), 3.70 (s, 2H). 
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13C NMR (101 MHz, CDCl3) δ = 171.8, 155.6, 133.0, 130.5, 130.0, 125.5, 117.4, 61.1, 52.3, 
36.0. 
 
methyl 2-(3-bromo-5-fluoro-2-methoxyphenyl)acetate 5.50r:  
 
In a 50 mL flask was charged 2-(5-fluoro-2-hydroxyphenyl)acetic acid (500 mg, 2.94 mmol, 1 
equiv) in methanol (10 mL). Then, SOCl2 (2.13 mL, 29.4 mmol, 10 equiv) was added dropwise 
to the mixture, which was stirred to reflux for 2 h. The volatiles were removed under vacuum, 
and the crude mixture was quenched with NaOH 3M (30 mL) and extracted with Et2O (3 x 15 
mL). The combined organic layers were dried over sodium sulfate, filtered and evaporated 
under vacuum. The desired product methyl-ester product was obtained and used without further 
purification (540 mg, 2.94 mmol, 99%). 
Following General procedure A for bromination of phenols, methyl 2-(5-fluoro-2-
methoxyphenyl)acetate (220 mg, 1.11 mmol, 1 equiv) was reacted with NBS (395 mg, 2.2 mmol, 
2 equiv) in DMF at 70°C. After quenching with water, the crude mixture was extracted with 
Et2O, and the combined organic layers were washed with brine, and purified by 
chromatography on silica gel using cyclohexane/AcOEt [9:1] to afford the phenol (235 mg, 0.85 
mmol, 76%). 
 Following general procedure for methylation of phenol, intermediate phenol ester mixture 
(80/20) (235 mg, 0.85 mmol, 1 equiv) was reacted with K2CO3 (250 mg, 3 mmol, 1.5 equiv) and 
MeI (0.15 mL, 2.5 mmol, 3 equiv) in DMF. After extraction and purification, methoxy phenol 
was obtained (208 mg, 0.71 mmol, 83%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.24 – 7.18 (m, 1H), 6.99 – 6.95 (m, 1H), 3.81 (s, 
3H), 3.73 (s, 3H), 3.69 (s, 2H). 
 
13C NMR (126 MHz, Chloroform-d) δ = 171.2, 158.4 (d, J = 247.1 Hz), 152.1 (d, J = 3.3 Hz), 
130.7 (d, J = 8.7 Hz), 119.8 (d, J = 25.4 Hz), 117.4 (d, J = 10.6 Hz), 117.2 (d, J = 22.9 Hz), 61.3 
(d, J = 1.4 Hz), 52.4, 35.9 (d, J = 1.5 Hz). 
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19F NMR (376 MHz, Chloroform-d) δ = -116.7 (dd, J = 8.5, 7.6 Hz). 
 
HRMS (ESI): Calculated for C10H11BrFO3 ([M+H]+): 276.9876; found: 276.9879 
IR (neat) : ν = 1768, 1459 cm-1 
2-(3-bromo-2-methoxyphenyl)-N,N-diisopropylacetamide 5.51r: 
 
In a 250 mL round bottom flask, toluene (60 mL) and tBuNH2 (1.9 mL, 18 mmol, 1.5 equiv) 
were stirred and cooled to -78°C. Bromine (0.5 mL, 9.6 mmol, 0.8 equiv) in toluene (5 mL) 
was then slowly added to the stirred mixture, which was further reacted for 1h at this 
temperature. Methyl 2-(2-hydroxyphenyl)acetate (2 g, 12 mmol, 1 equiv) in dichloromethane 
(30 mL) was then added slowly to the mixture, which was cooled to room temperature over 5h.  
The reaction was quenched with water (60 mL) and extracted with DCM (3 x 30 mL) and the 
combined organic layers were dried over sodium sulfate, filtered and evaporated under vacuum. 
The crude mixture was purified by chromatography on silicagel to afford a mixture of 
mono/dibrominated product (80/20) (1.25 g, 5.1 mmol, 53 %). 
Following general procedure B for methylation of phenols, intermediate phenol ester mixture 
(80/20) (490 mg, 2 mmol, 1 equiv) was reacted with K2CO3 (415 mg, 3 mmol, 1.5 equiv) and 
MeI (0.37 mL, 6 mmol, 3 equiv) in DMF. After extraction and purification, methoxy phenol 
was obtained (370 mg, 1.43 mmol, 71%). 
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Methyl ester intermediate (181 mg, 0.7 mmol, 1 equiv) was dissolved in THF/water [3:1] (10 mL) 
followed by addition of LiOH (84 mg, 3.5 mmol, 5 equiv) and heated at 80°C for 2h. After 
cooling to room temperature, the crude mixture was quenched with 2 M HCl, extracted with 
AcOEt (3 x 5 mL) and the combined organic layers were dried over sodium sulftate, filtered 
and evaporated under vacuum. The carboxylic acid was used without further purification (170 
mg, 0.7 mmol, 100%).  
To this carboxylic acid (75 mg, 0.3 mmol, 1 equiv) in dichloromethane (5 mL) was added oxalyl 
chloride (0.06 mL, 0.6 mmol, 2 equiv). The mixture was stirred for 1h, before volatiles were 
removed under vacuum. Then, the acid chloride was redissolved in dichloromethane (5 mL) 
followed by addition of diisopropylamine (0.09 mL, 0.6 mmol, 2 equiv) and Et3N (0.08 mL, 
0.6 mmol, 2 equiv ) in dichloromethane (2 mL). After completion, the mixture was quenched 
with water (5 mL), extracted with dichloromethane (3 x 5 mL) and the combined organic layers 
were dried over sodium sulfate, filtered and evaporated under vacuum. The crude mixture was 
purified under vacuum to afford the desired product as a yellow oil (71 mg, 0.22 mmol, 72%).  
1H NMR (400 MHz, Chloroform-d) δ = 7.46 – 7.41 (m, 1H), 7.24 – 7.19 (m, 1H), 6.99 – 6.90 
(m, 1H), 3.93 (sept, J = 6.7 Hz, 1H), 3.81 (s, 3H), 3.72 (s, 2H), 3.42 (br. s, 1H), 1.40 (d, J = 6.8 
Hz, 6H), 1.08 (d, J = 6.7 Hz, 6H). 
 
13C NMR (101 MHz, CDCl3) δ = 169.6, 154.8, 132.3, 131.7, 129.7, 125.6, 117.3, 61.0, 46.0, 
37.3, 20.8, 20.7. 
 
HRMS (ESI): Calculated for C15H23BrNO2 ([M+H]+): Exact Mass: 328.0912; found: 328.0907 
IR (neat) : ν = 1641, 1443 cm-1 
2-(3-bromo-2-methoxyphenyl)-1-morpholinoethan-1-one 5.52r:  
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In a 250 mL round bottom flask, toluene (60 mL) and tBuNH2 (1.9 mL, 18 mmol, 1.5 equiv) 
were stirred and cooled to -78°C. Bromine (0.5 mL, 9.6 mmol, 0.8 equiv) in toluene (5 mL) 
was then slowly added to the stirred mixture, which was further reacted for 1h at this 
temperature. Methyl 2-(2-hydroxyphenyl)acetate (2 g, 12 mmol, 1 equiv) in dichloromethane 
(30 mL) was then added slowly to the mixture, which was cooled to room temperature over 5h.  
The reaction was quenched with water (60 mL) and extracted with DCM (3 x 30 mL) and the 
combined organic layers were dried over sodium sulfate, filtered and evaporated under vacuum. 
The crude mixture was purified by chromatography on silicagel to afford a mixture of 
mono/dibrominated product (80/20) (1.25 g, 5.1 mmol, 53 %). 
Following general procedure B for methylation of phenols, intermediate phenol ester mixture 
(80/20) (490 mg, 2 mmol, 1 equiv) was reacted with K2CO3 (415 mg, 3 mmol, 1.5 equiv) and 
MeI (0.37 mL, 6 mmol, 3 equiv) in DMF. After extraction and purification, methoxy phenol 
was obtained (370 mg, 1.43 mmol, 71%). 
Methyl ester intermediate (181 mg, 0.7 mmol, 1 equiv) was dissolved in THF/water [3:1] (10 mL) 
followed by addition of LiOH (84 mg, 3.5 mmol, 5 equiv) and heated at 80°C for 2h. After 
cooling to room temperature, the crude mixture was quenched with 2 M HCl, extracted with 
AcOEt (3 x 5 mL) and the combined organic layers were dried over sodium sulftate, filtered 
and evaporated under vacuum. The carboxylic acid was used without further purification (170 
mg, 0.7 mmol, 100%).  
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To this carboxylic acid (75 mg, 0.3 mmol, 1 equiv) in dichloromethane (5 mL) was added oxalyl 
chloride (0.06 mL, 0.6 mmol, 2 equiv). The mixture was stirred for 1h, before volatiles were 
removed under vacuum. Then, the acid chloride was redissolved in dichloromethane (5 mL) 
followed by addition of morpholine (0.06 mL, 0.6 mmol, 2 equiv) and Et3N (0.08 mL, 0.6 
mmol, 2 equiv ) in dichloromethane (2 mL). After completion, the mixture was quenched with 
water (5 mL), extracted with dichloromethane (3 x 5 mL) and the combined organic layers were 
dried over sodium sulfate, filtered and evaporated under vacuum. The crude mixture was 
purified under vacuum to afford the desired product as a colorless oil (86 mg, 0.27 mmol, 89%).  
1H NMR (400 MHz, Chloroform-d) δ = 7.48 – 7.44 (m, 1H), 7.24 – 7.21 (m, 1H), 7.00 – 6.94 
(m, 1H), 3.82 (s, 3H), 3.76 (s, 2H), 3.64 (s, 4H), 3.54 – 3.51 (m, 2H), 3.45 – 3.41 (m, 2H). 
 
13C NMR (101 MHz, CDCl3) δ = 169.4, 154.7, 132.7, 130.6, 129.6, 125.8, 117.4, 66.9, 66.7, 
61.1, 46.5, 42.4, 34.9. 
 
HRMS (ESI): Calculated for C13H17BrNO3 ([M+H]+): Exact Mass: 314.0386; found: 314.0392 
IR (neat) : ν = 1644, 1426 cm-1 
methyl 2-(3-bromo-2-(2-methoxy-2-oxoethoxy)phenyl)acetate 5.54r: 48 
 
In a 250 mL round bottom flask, toluene (60 mL) and tBuNH2 (1.9 mL, 18 mmol, 1.5 equiv) 
were stirred and cooled to -78°C. Bromine (0.5 mL, 9.6 mmol, 0.8 equiv) in toluene (5 mL) 
was then slowly added to the stirred mixture, which was further reacted for 1h at this 
temperature. Methyl 2-(2-hydroxyphenyl)acetate (2 g, 12 mmol, 1 equiv) in dichloromethane 
(30 mL) was then added slowly to the mixture, which was cooled to room temperature over 5h.  
The reaction was quenched with water (60 mL) and extracted with DCM (3 x 30 mL) and the 
combined organic layers were dried over sodium sulfate, filtered and evaporated under vacuum. 
The crude mixture was purified by chromatography on silicagel to afford a mixture of 
mono/dibrominated product (80/20) (1.25 g, 5.1 mmol, 53 %).  
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Following general procedure B for alkylation of phenols, the mixture of mono/dibrominated 
phenol (80/20) (250 mg, 1 mmol, 1 equiv) was reacted with K2CO3 (211 mg, 1.5 mmol, 1.5 equiv) 
and methylbromoacetate (0.29 mL, 3 mmol, 3 equiv) in DMF. After extraction and purification, 
the product was obtained as a colorless oil (250 mg, 0.77 mmol, 77%).  
1H NMR (400 MHz, Chloroform-d) δ = 7.50 – 7.46 (m, 1H), 7.21 – 7.18 (m, 1H), 7.02 – 6.97 
(m, 1H), 4.69 (s, 2H), 3.84 (s, 2H), 3.82 (s, 3H), 3.69 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 172.0, 169.3, 154.2, 133.1, 130.6, 130.2, 126.1, 116.9, 70.0, 
52.3, 52.2, 35.9. 
 
5,5'-(propane-2,2-diyl)bis(1-bromo-2-methoxy-3-methylbenzene) 5.55r:  
 
 
Following General procedure A for bromination of phenols, 4,4'-(propane-2,2-diyl)bis(2-
methylphenol) (1 g, 3.9 mmol, 1 equiv) was reacted with NBS (1.52 g, 8.6 mmol, 1.1 equiv) in 
DMF. After quenching with water, the crude mixture was extracted with Et2O, and the 
combined organic layers were washed with brine, and purified by chromatography on silica gel 
using cyclohexane/AcOEt [9:1] to afford the phenol (880 mg, 2.12 mmol, 55%).  
Following General procedure B for methylation of phenols, 4,4'-(propane-2,2-diyl)bis(2-
bromo-6-methylphenol) (400 mg, 0.96 mmol, 1 equiv), K2CO3 (400 mg, 2.9 mmol, 3 equiv) 
and MeI (0.36 mL, 5.8 mmol, 6 equiv) were reacted in acetone. After evaporation, extraction 
and purification, the desired product was obtained as a colorless oil (420 mg, 0.95 mmol, 98 
%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.23 – 7.21 (m, 2H), 6.90 – 6.88 (m, H), 3.80 (s, 
6H), 2.28 (s, 6H), 1.58 (s, 6H). 
 
13C NMR (101 MHz, CDCl3) δ = 153.4, 147.2, 132.6, 129.2, 129.1, 117.0, 60.3, 42.2, 30.9, 
17.0. 
 
387 
 
HRMS (ESI): Calculated for C19H23Br2O2 ([M+H]+): 441.0065; found: 441.0062 
IR (neat) : ν = 906 cm-1 
N-(2-bromo-6-methylphenyl)-2,2,2-trifluoro-N-methylacetamide 5.77:  
 
Following General procedure D for trifluoroacetylation of anilines, 2-bromo-6-methylaniline (1 
g, 5.37 mmol, 1 equiv), DMAP (33 mg, 0.27 mmol, 0.05 equiv), and anhydride trifluoroacetic 
(1.49 mL, 10.7 mmol, 2 equiv) were reacted in 1,2-dichloroethane.  After evaporation, extraction 
and purification, the desired product was obtained as a yellowish oil (1.45 g, 5.1 mmol, 96 %). 
Following General procedure E for methylation of anilines, intermediate aniline (1.45 g, 5.1 
mmol, 1 equiv), NaH (60% dispersion in oil, 620 mg, 15.3 mmol, 3 equiv), and MeI (0.95 mL, 
15.3 mmol, 3 equiv) were reacted in DMF. After evaporation, extraction and purification, the 
desired product was obtained as a yellowish oil (1.1 g, 3.4 mmol, 67 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.52 – 7.49 (m, 1H), 7.26 – 7.23 (m, 1H), 7.20 – 7.15 
(m, 1H), 3.27 (s, 3H), 2.30 (s, 3H). 
 
13C NMR (101 MHz, Chloroform-d) δ = 157.5, 157.1, 156.8, 138.7 (q, J = 0.9 Hz)), 138.2, 
137.4, 131.5, 131.3, 130.6, 130.5, 130.4, 130.0, 124.2 (q, J = 1.0 Hz), 121.9, 120.4, 117.5, 114.6, 
36.6, 18.3 (q, J = 1.4 Hz), 18.0. 
 
19F NMR (376 MHz, CDCl3) δ = -70.6. 
 
HRMS (ESI): Calculated for C10H10BrF3NO ([M+H]+): Exact Mass: 295.9898; found: 
295.9892 
IR (neat) : ν = 1704, 1198 cm-1 
N-(2-bromo-4,6-dimethylphenyl)-2,2,2-trifluoro-N-methylacetamide 5.82r:  
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Following General procedure D for trifluoroacetylation of anilines, 2-bromo-4,6-
dimethylaniline (2 g, 10 mmol, 1 equiv), DMAP (61 mg, 0.5 mmol, 0.05 equiv), and anhydride 
trifluoroacetic (2.78 mL, 20 mmol, 2 equiv) were reacted in 1,2-dichloroethane.  After 
evaporation, extraction and purification, the desired product was obtained as a yellowish oil 
(2.62 g, 8.85 mmol, 88 %). 
Following General procedure E for methylation of anilines, intermediate aniline (2.62 g, 8.85 
mmol, 1 equiv), NaH (60% dispersion in oil, 1.1 g, 26.6 mmol, 3 equiv), and MeI (1.65 mL, 26.6 
mmol, 3 equiv) were reacted in DMF. After evaporation, extraction and purification, the desired 
product was obtained as a yellow oil (2.1 g, 6.77 mmol, 77 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.32 – 7.31 (m, 1H), 7.05 – 7.03 (m, 1H), 3.37 – 3.35 
(m, 0.5H), 3.24 (s, 2.5H), 2.32 (s, 2.5H), 2.31 (s, 0.5H), 2.25 (s, 2.5H), 2.20 (s, 0.5H). 
 
13C NMR (101 MHz, CDCl3) δ = 157.6, 157.3, 140.9, 140.4, 138.1, 138.1, 136.7, 135.6, 131.9, 
131.7, 131.6, 131.3, 131.1, 130.6, 123.7 (q, J = 1.1 Hz), 121.5, 117.5, 114.7, 36.8, 20.9, 20.9, 
18.3 (q, J = 1.3 Hz), 17.9. 
 
19F NMR (376 MHz, CDCl3) δ = -70.2, -70.5. 
 
HRMS (ESI): Calculated for C11H12BrF3NO ([M+H]+): Exact Mass: 310.0054; found: 310.0049 
IR (neat) : ν = 1702, 1195 cm-1 
methyl 3-bromo-5-methyl-4-(2,2,2-trifluoro-N-methylacetamido)benzoate 5.83r: 
 
Following General procedure D for trifluoroacetylation of anilines, methyl 4-amino-3-bromo-
5-methylbenzoate (1 g, 4.1 mmol, 1 equiv), DMAP (25 mg, 0.25 mmol, 0.05 equiv), and 
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anhydride trifluoroacetic (1.14 mL, 8.2 mmol, 2 equiv) were reacted in 1,2-dichloroethane.  After 
evaporation, extraction and purification, the desired product was obtained as a yellowish oil 
(1.32 g, 3.88 mmol, 95 %). 
Following General procedure E for methylation of anilines, intermediate aniline (1.32 g, 3.88 
mmol, 1 equiv), NaH (60% dispersion in oil, 470 mg, 11.6 mmol, 3 equiv), and MeI (0.72 mL, 
11.6 mmol, 3 equiv) were reacted in DMF. After evaporation, extraction and purification, the 
desired product was obtained as a colorless oil (910 mg, 2.57 mmol, 66 %). 
1H NMR (400 MHz, Chloroform-d) δ = 8.17 – 8.15 (m, 1H), 7.93 – 7.91 (m, 1H), 3.93 (s, 
2.4H), 3.92 (s, 0.6H), 3.39 – 3.37 (m, 0.6H), 3.26 (s, 2.4H), 2.35 (s, 2.4H), 2.30 (s, 0.6H). 
 
13C NMR (101 MHz, CDCl3) δ = 165.2, 165.0, 157.2, 156.8, 156.4, 142.0, 139.0, 139.0, 
137.7, 132.6, 132.3, 132.1, 131.7, 131.7, 131.5, 124.4, 124.4, 122.2, 117.4, 114.5, 52.8, 52.7, 36.4, 
36.4, 36.3, 18.4 (q, J = 1.4 Hz), 18.1. 
 
19F NMR (376 MHz, CDCl3) δ = -70.4, -70.6. 
 
HRMS (ESI): Calculated for C12H11BrF3NO3 ([M+H]+): Exact Mass: 353.9953; found: 353.9947 
IR (neat) : ν = 1702, 1682, 1192 cm-1 
N-(2-bromo-4-fluoro-6-methylphenyl)-2,2,2-trifluoro-N-methylacetamide 5.84r:  
 
Following General procedure D for trifluoroacetylation of anilines, 2-bromo-4,6-
dimethylaniline (1.5 g, 7.35 mmol, 1 equiv), DMAP (45 mg, 0.36 mmol, 0.05 equiv), and 
anhydride trifluoroacetic (2.1 mL, 14.7 mmol, 2 equiv) were reacted in 1,2-dichloroethane.  After 
evaporation, extraction and purification, the desired product was obtained as a yellowish oil (2.1 
g, 6.96 mmol, 94 %). 
Following General procedure E for methylation of anilines, , intermediate aniline (1.3 g, 4.33 
mmol, 1 equiv), NaH (60% dispersion in oil, 520 mg, 13.3 mmol, 3 equiv), and MeI (0.8 mL, 
13.3 mmol, 3 equiv) were reacted in DMF. After evaporation, extraction and purification, the 
desired product was quickly treated anhydride trifluoroacetic (0.8 mL) and DMAP (20 mg) in 
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dichloromethane (20 mL). After extraction, the product was obtained as a colorless oil (800 
mg, 2.55 mmol, 59 %). 
 
1H NMR (400 MHz, Chloroform-d) δ = 7.27 – 7.23 (m, 1H), 7.00 – 6.96 (m, 1H), 3.38 – 3.36 
(m, 0.6H), 3.25 (s, 2.4H), 2.30 (s, 2.4H), 2.25 (s, 0.6H). 
 
13C NMR (126 MHz, CDCl3) δ = 162.9, 162.7, 160.9, 160.7, 157.8, 157.6, 157.3, 156.4, 
140.6, 140.5, 139.2, 139.1, 135.9, 134.6, 134.6, 124.9, 124.8, 122.5, 122.4, 119.4, 118.9, 118.8, 
118.7, 118.6, 117.7, 117.6, 117.4, 117.3, 117.2, 117.1, 115.4, 114.9, 112.6, 36.8, 36.7, 36.7, 29.7, 29.6, 
18.7, 18.7, 18.7, 18.6, 18.3, 18.3. 
 
19F NMR (376 MHz, CDCl3) δ = -70.3, -70.6, -109.7, -110.9. 
 
HRMS (ESI): Calculated for C10H9BrF4NO ([M+H]+): Exact Mass: 313.9804; found: 313.9798 
IR (neat) : ν = 1705 cm-1 
N-(2-bromo-4-cyano-6-methylphenyl)-2,2,2-trifluoro-N-methylacetamide 5.85r: 
 
Following General procedure C for bromination of anilines, 4-amino-3-methylbenzonitrile (2 
g, 15.1 mmol, 1 equiv), NBS (2.95 g, 16.6 mmol, 1.1 equiv) were reacted in DCM at room 
temperature. After completion, quenching, extraction and purification the desired product 
brominated aniline was obtained (1.61 g, 7.63 mmol, 50%). 
Following General procedure D for trifluoroacetylation of anilines 4-amino-3-bromo-5-
methylbenzonitrile (610 mg, 2.89 mmol, 1 equiv), DMAP (17 mg, 0.15 mmol, 0.05 equiv), and 
anhydride trifluoroacetic (0.81 mL, 5.8 mmol, 2 equiv) were reacted in 1,2-dichloroethane.  
After evaporation, extraction and purification, the desired product was obtained as a yellowish 
oil (790 mg, 2.6 mmol, 89 %). 
Following General procedure E for methylation of anilines, , intermediate aniline (450 mg, 1.47 
mmol, 1 equiv), NaH (60% dispersion in oil, 180 mg, 4.4 mmol, 3 equiv), and MeI (0.27 mL, 
4.4 mmol, 3 equiv) were reacted in DMF. After evaporation, extraction and purification, the 
desired product was quickly treated anhydride trifluoroacetic (0.8 mL) and DMAP (20 mg) in 
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dichloromethane (20 mL). After extraction, the product was obtained as a colorless oil (260 
mg, 0.81 mmol, 55 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.83 – 7.80 (m, 1H), 7.58 – 7.56 (m, 1H), 3.40 – 3.38 
(m, 0.6H), 3.27 (s, 2.4H), 2.36 (s, 2.4H), 2.31 – 2.31 (m, 0.6H). 
 
13C NMR (126 MHz, CDCl3) δ = 157.2, 156.9, 156.6, 156.4, 143.8, 142.5, 140.4, 139.2, 
134.8, 134.5, 134.0, 133.9, 125.3, 123.2, 119.3, 117.5, 117.0, 116.7, 116.4, 115.2, 114.8, 114.7, 114.3, 
112.4, 36.4, 18.4, 18.4, 18.1. 
 
19F NMR (376 MHz, CDCl3) δ = -70.4, -70.6. 
 
HRMS (ESI): Calculated for C11H9BrF3N2O ([M+H]+): Exact Mass: 320.9850; found: 320.9848 
IR (neat) : ν = 1712 cm-1 
1-(3-bromo-2-methoxyphenyl)ethan-1-one 5.91: 49 
 
Following General procedure B for methylation of phenols, 1-(3-bromo-2-
hydroxyphenyl)ethan-1-one (500 mg, 2.33 mmol, 1 equiv), K2CO3 (483 mg, 3.49 mmol, 1.5 
equiv) and MeI (0.43 mL, 7 mmol, 3 equiv) were reacted in acetone. After evaporation, 
extraction and purification, the desired product was obtained as a colorless oil (498 mg, 2.17 
mmol, 93 %). 
1H NMR (400 MHz, Chloroform-d) δ= 7.71 – 7.68 (m, 1H), 7.57 – 7.54 (m, 1H), 7.08 – 7.03 
(m, 1H), 3.87 (s, 3H), 2.64 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 199.7, 156.2, 137.2, 135.3, 129.2, 125.6, 118.5, 62.6, 30.7. 
 
1-(3-bromo-2-methoxy-5-methylphenyl)ethan-1-one 5.95r: 50  
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Following General procedure A for bromination of phenols, 1-(2-hydroxy-5-
methylphenyl)ethan-1-one (2.04 g, 13.3 mmol, 1 equiv) was reacted with NBS (2.6 g, 14.6 mmol, 
1.1 equiv) in DMF. After quenching with water, the crude mixture was extracted with Et2O, and 
the combined organic layers were washed with brine, and purified by chromatography on silica 
gel using cyclohexane/AcOEt [9:1] to afford the phenol (1.8 g, 7.9 mmol, 60%).  
Following General procedure B for methylation of phenols, 1-(3-bromo-2-hydroxy-5-
methylphenyl)ethan-1-one (1.8 g, 7.9 mmol, 1 equiv), K2CO3 (1.64 g, 11.9 mmol, 1.5 equiv) and 
MeI (1.5 mL, 23.7 mmol, 3 equiv) were reacted in acetone. After evaporation, extraction and 
purification, the desired product was obtained as a yellowish oil (1.5 g, 6.17 mmol, 78 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.50 – 7.49 (m, 1H), 7.34 – 7.33 (m, 1H), 3.83 (s, 
3H), 2.62 (s, 3H), 2.30 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 199.9, 153.9, 137.6, 135.6, 134.6, 129.5, 118.0, 62.5, 30.7, 
20.5. 
 
1-(3-bromo-5-fluoro-2-methoxyphenyl)ethan-1-one 5.96r:  
 
Following General procedure A for bromination of phenols, 1-(5-fluoro-2-
hydroxyphenyl)ethan-1-one (2 g, 13 mmol, 1 equiv) was reacted with NBS (2.54 g, 14.3 mmol, 
1.1 equiv) in DMF. After quenching with water, the crude mixture was extracted with Et2O, and 
the combined organic layers were washed with brine, and purified by chromatography on silica 
gel using cyclohexane/AcOEt [9:1] to afford the phenol (1.4 g, 6.0 mmol, 46%).  
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Following General procedure B for methylation of phenols, 1-(3-bromo-5-fluoro-2-
hydroxyphenyl)ethan-1-one (1.4 g, 6.0 mmol, 1 equiv), K2CO3 (1.24 g, 9 mmol, 1.5 equiv) and 
MeI (1.1 mL, 18 mmol, 3 equiv) were reacted in acetone. After evaporation, extraction and 
purification, the desired product was obtained as a yellowish oil (940 mg, 3.8 mmol, 64 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.45 – 7.42 (m, 1H), 7.30 – 7.27 (m, 1H), 3.85 (s, 
3H), 2.64 (s, 3H). 
 
13C NMR (101 MHz, Chloroform-d) δ = 198.2 (d, J = 1.5 Hz), 158.4 (d, J = 249.2 Hz), 152.7 
(d, J = 3.3 Hz), 135.5 (d, J = 6.5 Hz), 124.2 (d, J = 25.7 Hz), 118.9 (d, J = 9.4 Hz), 115.7 (d, J = 
23.7 Hz), 62.7 (d, J = 1.4 Hz), 30.5 (d, J = 0.7 Hz). 
 
19F NMR (376 MHz, CDCl3) δ = -115.4. 
 
HRMS (ESI): Calculated for C9H9BrFO2 ([M+H]+): Exact mass: 246.9770; found: 246.9767 
IR (neat) : ν = 1682 cm-1 
1-(3-bromo-5-fluoro-2-(methoxy-d3)phenyl)ethan-1-one 5.96r-d3-1: 
 
Following General procedure A for bromination of phenols, 1-(5-fluoro-2-
hydroxyphenyl)ethan-1-one (2 g, 13 mmol, 1 equiv) was reacted with NBS (2.54 g, 14.3 mmol, 
1.1 equiv) in DMF. After quenching with water, the crude mixture was extracted with Et2O, and 
the combined organic layers were washed with brine, and purified by chromatography on silica 
gel using cyclohexane/AcOEt [9:1] to afford the phenol (1.4 g, 6.0 mmol, 46%).  
Following General procedure B for methylation of phenols, 1-(3-bromo-5-fluoro-2-
hydroxyphenyl)ethan-1-one (233 mg, 1 mmol, 1 equiv), K2CO3 (207 mg, 1.5 mmol, 1.5 equiv) 
and CD3I (0.19 mL, 3 mmol, 3 equiv) were reacted in acetone. After evaporation, extraction and 
purification, the desired product was obtained as a yellowish oil (202 mg, 0.82 mmol, 82 %). 
 
1H NMR (400 MHz, Chloroform-d) δ = 7.32 – 7.27 (m, 1H), 7.17 – 7.13 (m, 1H), 2.52 – 2.50 
(m, 3H). 
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13C NMR (101 MHz, Chloroform-d) δ = 197.3 (d, J = 1.5 Hz), 157.9 (d, J = 248.9 Hz), 152.5 
(d, J = 3.2 Hz), 135.1 (d, J = 6.5 Hz), 123.7 (d, J = 25.7 Hz), 118.6 (d, J = 9.3 Hz), 115.3 (d, J = 
23.7 Hz), 61.5 (m), 30.1 (d, J = 0.8 Hz). 
 
19F NMR (376 MHz, CDCl3) δ = -115.5. 
 
1-(3-bromo-5-ethyl-2-methoxyphenyl)ethan-1-one 5.97r:  
 
Following General procedure A for bromination of phenols, 1-(5-ethyl-2-hydroxyphenyl)ethan-
1-one (985 mg, 6 mmol, 1 equiv) was reacted with NBS (1.17 g, 6.6 mmol, 1.1 equiv) in DMF. 
After quenching with water, the crude mixture was extracted with Et2O, and the combined 
organic layers were washed with brine, and purified by chromatography on silica gel using 
cyclohexane/AcOEt [9:1] to afford the phenol (1.2 g, 4.94 mmol, 82%).  
Following General procedure B for methylation of phenols, 1-(3-bromo-5-ethyl-2-
hydroxyphenyl)ethan-1-one (1.11 g, 4.9 mmol, 1 equiv), K2CO3 (1.0 g, 7.35 mmol, 1.5 equiv) and 
MeI (0.9 mL, 14.7 mmol, 3 equiv) were reacted in acetone. After evaporation, extraction and 
purification, the desired product was obtained as a colorless oil (1.24 g, 4.82 mmol, 98 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.54 – 7.52 (m, 1H), 7.38 – 7.36 (m, 1H), 3.84 (s, 
3H), 2.64 – 2.57 (m, 4H), 1.22 (t, J = 7.7 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 200.0, 154.1, 141.9, 136.5, 134.8, 128.4, 118.1, 62.5, 30.7, 
28.0, 15.4. 
 
HRMS (ESI): Calculated for C11H14BrO2 ([M+H]+): Exact mass: 257.0177; found: 257.0179 
IR (neat) : ν = 1685, 1469 cm-1 
 
1-(3-bromo-2-methoxy-5-methylphenyl)propan-1-one 5.98r: 51 
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Following General procedure A for bromination of phenols, 1-(2-hydroxy-5-
methylphenyl)propan-1-one (985 mg, 6 mmol, 1 equiv) was reacted with NBS (1.17 g, 6.6 mmol, 
1.1 equiv) in DMF. After quenching with water, the crude mixture was extracted with Et2O, and 
the combined organic layers were washed with brine, and purified by chromatography on silica 
gel using cyclohexane/AcOEt [9:1] to afford the phenol (735 mg, 3.0 mmol, 50%).  
Following General procedure B for methylation of phenols, 1-(2-hydroxy-3-methyl-5-bromo-
phenyl)propan-1-one (735 mg, 3.0 mmol, 1 equiv), K2CO3 (622 mg, 4.5 mmol, 1.5 equiv) and 
MeI (0.55 mL, 9 mmol, 3 equiv) were reacted in acetone. After evaporation, extraction and 
purification, the desired product was obtained as a colorless oil (380 mg, 1.5 mmol, 50 %). 
1H NMR (400 MHz, Chloroform-d) δ = 7.49 – 7.48 (m, 1H), 7.25 – 7.24 (m, 1H), 3.81 (s, 
3H), 2.96 (q, J = 7.3 Hz, 2H), 2.31 (s, 3H), 1.17 (t, J = 7.3 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 203.8, 153.3, 136.9, 135.6, 135.2, 129.1, 117.9, 62.6, 36.3, 
20.6, 8.5. 
 
1-(3-bromo-2-methoxyphenyl)-3-phenylpropan-1-one 5.99r:  
 
In a 250 mL round bottom flask, toluene (22 mL) and tBuNH2 (0.69 mL, 6.63 mmol, 1.5 equiv) 
were stirred and cooled to -78°C. Bromine (0.18 mL, 3.54 mmol, 0.8 equiv) in toluene (5 mL) 
was then slowly added to the stirred mixture, which was further reacted for 1h at this 
temperature. 1-(2-hydroxyphenyl)-3-phenylpropan-1-one (2 g, 12 mmol, 1 equiv) in 
dichloromethane (12 mL) was then added slowly to the mixture, which was cooled to room 
temperature over 5h.  The reaction was quenched with water (40 mL) and extracted with DCM 
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(3 x 15 mL) and the combined organic layers were dried over sodium sulfate, filtered and 
evaporated under vacuum. The crude mixture was purified by chromatography on silicagel to 
afford the desired product brominated phenol (600 mg, 1.96 mmol, 40 %).  
Following General procedure B for methylation of phenols, 1-(3-bromo-2-hydroxyphenyl)-3-
phenylpropan-1-one (600 mg, 1.96 mmol, 1 equiv), K2CO3 (406 mg, 2.94 mmol, 1.5 equiv) and 
iodomethane (0.36 mL, 5.88 mmol, 3 equiv) were reacted in DMF. After evaporation, extraction 
and purification, the desired product was obtained as a yellowish oil (620 mg, 1.95 mmol, 99 
%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.57 – 7.52 (m, 1H), 7.34 – 7.29 (m, 1H), 7.19 – 7.14 
(m, 2H), 7.13 – 7.04 (m, 3H), 6.94 – 6.87 (m, 1H), 3.66 (s, 3H), 3.18 (t, J = 7.9, 2H), 2.93 (t, J = 
7.5 Hz, 2H). 
 
13C NMR (101 MHz, CDCl3) δ = 201.6, 155.5, 141.0, 136.7, 135.6, 128.7, 128.5, 126.2, 
125.5, 118.3, 62.5, 44.5, 30.2. 
 
HRMS (ESI): Calculated for C16H16BrO2 ([M+H]+): Exact Mass: 319.0334; found: 319.0337 
IR (neat) : ν = 1687 cm-1 
3-bromo-2-methoxybenzaldehyde 5.106a: 52 
 
Following General procedure B for methylation of phenols, 3-bromo-2-hydroxybenzaldehyde 
(4 g, 19.9 mmol, 1 equiv), K2CO3 (4.12 g, 29.8 mmol, 1.5 equiv) and iodomethane (3.68 mL, 
59.7 mmol, 3 equiv) were reacted in DMF. After evaporation, extraction and purification, the 
desired product was obtained as a yellowish oil (3.2 g, 14.9 mmol, 74 %). 
1H NMR (400 MHz, Chloroform-d) δ = 10.35 (d, J = 0.8 Hz, 1H), 7.82 – 7.77 (m, 2H), 7.15 – 
7.09 (m, 1H), 3.98 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 189.2, 160.2, 139.6, 131.1, 128.0, 125.9, 118.3, 63.6. 
 
3-bromo-2-methoxy-5-methylbenzaldehyde 5.106b: 53 
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Following General procedure B for methylation of phenols, 2-hydroxy-5-methylbenzaldehyde 
(1.6 g, 7.34 mmol, 1 equiv), K2CO3 (1.5 g, 11 mmol, 1.5 equiv) and iodomethane (1.37 mL, 22 
mmol, 3 equiv) were reacted in DMF. After evaporation, extraction and purification, the desired 
product was obtained as a colorless oil (1.59 g, 6.95 mmol, 95 %). 
1H NMR (400 MHz, Chloroform-d) δ = 10.30 (s, 1H), 7.62 – 7.60 (m, 1H), 7.58 – 7.56 (m, 
1H), 3.94 (s, 3H), 2.33 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 189.4, 158.1, 140.1, 136.0, 130.4, 128.1, 117.8, 63.6, 20.5. 
 
3-bromo-5-fluoro-2-methoxybenzaldehyde 5.106c: 54 
 
Following General procedure B for methylation of phenols, 3-bromo-5-fluoro-2-
hydroxybenzaldehyde (1.6 g, 7.34 mmol, 1 equiv), K2CO3 (1.5 g, 11 mmol, 1.5 equiv) and 
iodomethane (1.37 mL, 22 mmol, 3 equiv) were reacted in DMF. After evaporation, extraction 
and purification, the desired product was obtained as a colorless oil (1.52 g, 6.52 mmol, 89 %). 
1H NMR (400 MHz, Chloroform-d) δ = 10.30 (d, J = 3.2 Hz, 1H), 7.57 – 7.53 (m, 1H), 7.50 – 
7.47 (m, 1H), 3.96 (s, 3H). 
 
13C NMR (101 MHz, Chloroform-d) δ = 188.1 (d, J = 1.8 Hz), 158.8 (d, J = 250.2 Hz), 156.9 
(d, J = 3.1 Hz), 131.3 (d, J = 6.7 Hz), 126.7 (d, J = 26.2 Hz), 118.9 (d, J = 8.9 Hz), 113.8 (d, J = 
23.3 Hz), 64.0 (d, J = 1.4 Hz). 
 
19F NMR (376 MHz, CDCl3) δ = -114.3. 
 
(3-bromo-2-methoxyphenyl)(phenyl)methanone 5.103: 
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Following General procedure F for ketone synthesis, 5.106a (500 mg, 2.33 mmol, 1 equiv) was 
reacted with phenyl magnesium bromide (3 M in THF, 1.55 mL, 4.7 mmol, 2 equiv) in THF at 
-78°C. After quenching and extraction, the crude mixture was reacted with PCC (1.26 g, 5.83 
mmol, 2.5 equiv) on celite in DCM. After purification, the desired product ketone was obtained 
as a colorless oil (420 mg, 1.44 mmol, 62%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.84 – 7.79 (m, 2H), 7.73 – 7.69 (m, 1H), 7.62 – 7.57 
(m, 1H), 7.48 – 7.44 (m, 2H), 7.32 – 7.29 (m, 1H), 7.11 – 7.06 (m, 1H), 3.74 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 195.4, 155.0, 136.9, 135.7, 135.2, 133.7, 130.2, 128.7, 
128.6, 125.2, 118.0, 62.6. 
 
HRMS (ESI): Calculated for C14H12BrO2 ([M+H]+): Exact Mass: 291.0021; found: 291.0026 
IR (neat) : ν = 1658 cm-1 
(3-bromo-2-methoxy-5-methylphenyl)(phenyl)methanone 5.109r:  
 
 
Following General procedure F for ketone synthesis, 5.106b (535 mg, 2.33 mmol, 1 equiv) was 
reacted with phenyl magnesium bromide (3 M in THF, 1.55 mL, 4.7 mmol, 2 equiv) in THF at 
-78°C. After quenching and extraction, the crude mixture was reacted with PCC (1.26 g, 5.83 
mmol, 2.5 equiv) on celite in DCM. After purification, the desired product ketone was obtained 
as a colorless oil (523 mg, 1.71 mmol, 74%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.84 – 7.78 (m, 2H), 7.61 – 7.56 (m, 1H), 7.53 – 7.51 
(m, 1H), 7.48 – 7.43 (m, 2H), 7.10 – 7.07 (m, 1H), 3.69 (s, 3H), 2.33 – 2.33 (m, 3H). 
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13C NMR (101 MHz, CDCl3) δ = 195.6, 152.7, 137.0, 136.1, 135.3, 134.8, 133.7, 130.1, 
129.0, 128.6, 117.5, 62.6, 20.6. 
 
HRMS (ESI): Calculated for C15H14BrO2 ([M+H]+): Exact Mass: 305.0177; found: 305.0179 
IR (neat) : ν = 1661 cm-1 
(3-bromo-5-fluoro-2-methoxyphenyl)(phenyl)methanone 5.110r:  
 
Following General procedure F for ketone synthesis, 5.106c (543 mg, 2.33 mmol, 1 equiv) was 
reacted with phenyl magnesium bromide (3 M in THF, 1.55 mL, 4.7 mmol, 2 equiv) in THF at 
-78°C. After quenching and extraction, the crude mixture was reacted with PCC (1.26 g, 5.83 
mmol, 2.5 equiv) on celite in DCM. After purification, the desired product ketone was obtained 
as a colorless oil (320 mg, 1.03 mmol, 44%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.83 – 7.76 (m, 2H), 7.62 – 7.58 (m, 1H), 7.50 – 7.42 
(m, 3H), 7.05 – 6.99 (m, 1H), 3.70 (s, 3H). 
 
13C NMR (101 MHz, Chloroform-d) δ = 193.8 (d, J = 1.6 Hz), 157.9 (d, J = 249.6 Hz), 151.3 
(d, J = 3.4 Hz), 136.2, 135.6 (d, J = 6.8 Hz), 133.9, 132.4, 130.0, 128.6, 128.3, 122.4 (d, J = 25.5 
Hz), 118.3 (d, J = 9.5 Hz), 115.1 (d, J = 23.8 Hz), 62.7 (d, J = 1.3 Hz). 
 
19F NMR (376 MHz, CDCl3) δ = -115.78. 
 
HRMS (ESI): Calculated for C14H11BrFO2 ([M+H]+): Exact Mass: 308.9926; found: 308.9929 
IR (neat) : ν = 1652 cm-1 
(3-bromo-2-methoxyphenyl)(3,5-dimethoxyphenyl)methanone 5.111r:  
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Following General procedure F for ketone synthesis, 5.106a (500 mg, 2.33 mmol, 1 equiv) was 
reacted with 3,5-dimethoxyphenyl magnesium bromide (1 M in THF, 4.7 mL, 4.7 mmol, 2 
equiv) in THF at -78°C. After quenching and extraction, the crude mixture was reacted with 
PCC (1.26 g, 5.83 mmol, 2.5 equiv) on celite in DCM. After purification, the desired product 
ketone was obtained as a colorless oil (587 mg, 1.67 mmol, 72%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.71 – 7.66 (m, 1H), 7.29 – 7.25 (m, 1H), 7.09 – 7.03 
(m, 1H), 6.96 – 6.93 (m, 2H), 6.69 – 6.66 (m, 1H), 3.80 (s, 6H), 3.77 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 194.9, 160.9, 155.1, 138.9, 135.7, 135.1, 128.5, 124.9, 
118.0, 108.0, 106.1, 62.7, 55.7. 
 
HRMS (ESI): Calculated for C16H16BrO4 ([M+H]+): Exact Mass: 351.0232; found: 351.0235 
IR (neat) : ν = 1662 cm-1 
(3-bromo-2-methoxyphenyl)(3-methoxy-4-(trifluoromethyl)phenyl)methanone 5.112r:  
 
 
Following General procedure F for ketone synthesis, 5.106a (500 mg, 2.33 mmol, 1 equiv) was 
reacted with 3-methoxy, 4-trifluoromethylphenyl magnesium bromide (1 M in THF, 4.7 mL, 
4.7 mmol, 2 equiv) in THF at -78°C. After quenching and extraction, the crude mixture was 
reacted with PCC (1.26 g, 5.83 mmol, 2.5 equiv) on celite in DCM. After purification, the 
desired product ketone was obtained as a colorless oil (350 mg, 0.89 mmol, 38%). 
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1H NMR (400 MHz, Chloroform-d) δ = 8.15 – 8.12 (m, 1H), 7.94 – 7.90 (m, 1H), 7.73 – 7.70 
(m, 1H), 7.30 – 7.27 (m, 1H), 7.13 – 7.08 (m, 1H), 7.05 – 7.02 (m, 1H), 3.98 (s, 3H), 3.73 (s, 
3H). 
 
 
13C NMR (101 MHz, Chloroform-d) δ = 192.9, 161.6 (q, J = 1.5 Hz), 154.9, 136.3 (d, J = 1.0 
Hz), 135.9, 134.7, 129.4 (q, J = 5.3 Hz), 129.2, 128.5, 125.4, 123.2 (q, J = 272.3 Hz), 119.1 (q, J = 
31.9 Hz), 118.1, 111.6, 62.7, 56.5. 
 
 
19F NMR (376 MHz, CDCl3) δ = -62.9. 
 
HRMS (ESI): Calculated for C16H13BrF3O3 ([M+H]+): Exact Mass: 389.0000; found: 389.0004 
IR (neat) : ν = 1658 cm-1 
(3-bromo-2-methoxyphenyl)(4-methoxyphenyl)methanone 5.113r:  
 
Following General procedure F for ketone synthesis, 5.106a (500 mg, 2.33 mmol, 1 equiv) was 
reacted with p-methoxyphenyl magnesium bromide (1 M in THF, 4.7 mL, 4.7 mmol, 2 equiv) 
in THF at -78°C. After quenching and extraction, the crude mixture was reacted with PCC (1.26 
g, 5.83 mmol, 2.5 equiv) on celite in DCM. After purification, the desired product ketone was 
obtained as a colorless oil (510 mg, 1.58 mmol, 68%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.82 – 7.78 (m, 2H), 7.70 – 7.66 (m, 1H), 7.28 – 7.25 
(m, 1H), 7.09 – 7.04 (m, 1H), 6.95 – 6.90 (m, 2H), 3.87 (s, 3H), 3.74 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 193.9, 164.2, 154.7, 135.5, 135.3, 132.6, 129.9, 128.5, 
125.1, 117.9, 113.9, 62.6, 55.7. 
 
HRMS (ESI): Calculated for C15H14BrO3 ([M+H]+): Exact Mass: 321.0126; found: 321.0129 
IR (neat) : ν = 1658, 1596 cm-1 
(3-bromo-2-methoxyphenyl)(4-fluorophenyl)methanone 5.114r: 
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Following General procedure F for ketone synthesis, 5.106a (500 mg, 2.33 mmol, 1 equiv) was 
reacted with p-fluorophenyl magnesium bromide (1 M in THF, 4.7 mL, 4.7 mmol, 2 equiv) in 
THF at -78°C. After quenching and extraction, the crude mixture was reacted with PCC (1.26 
g, 5.83 mmol, 2.5 equiv) on celite in DCM. After purification, the desired product ketone was 
obtained as a colorless oil (410 mg, 1.32 mmol, 56%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.87 – 7.80 (m, 2H), 7.73 – 7.69 (m, 1H), 7.31 – 7.28 
(m, 1H), 7.16 – 7.07 (m, 3H), 3.73 (s, 3H). 
 
13C NMR (101 MHz, Chloroform-d) δ = 193.8, 166.2 (d, J = 256.0 Hz), 154.9, 135.9, 134.9, 
133.3 (d, J = 2.9 Hz), 132.8 (d, J = 9.5 Hz), 128.6, 125.3, 118.0, 115.9 (d, J = 22.1 Hz), 62.7. 
 
19F NMR (376 MHz, CDCl3) δ = -104.0. 
 
HRMS (ESI): Calculated for C14H11BrFO2 ([M+H]+): Exact Mass: 308.9926; found: 308.9928 
IR (neat) : ν = 1661 cm-1 
Experiments with deuterated substrates: 
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1) Following the General procedure I for the chromanones synthesis, 5.96r-d3 (37 mg, 0.15 mmol, 
1 equiv) was reacted with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%), AdCO2H (8.1 mg, 0.045 
mmol, 30 mol%), Cs2CO3 (49 mg, 0.15 mmol, 1 equiv) in toluene (6 mL) at 120°C for 16h. After 
filtration and evaporation of volatiles, 1H NMR shows no traces of desired product product. 
2) Following the General procedure I for the chromanones synthesis, 5.96r (17 mg, 0.075 mmol, 0.5 
equiv) and 5.96r-d3-2 (17 mg, 0.075 mmol, 0.5 equiv) were reacted with Pd(PCy3)2 (10 mg, 0.015 
mmol, 10 mol%), AdCO2H (8.1 mg, 0.045 mmol, 30 mol%), Cs2CO3 (49 mg, 0.15 mmol, 1 equiv) 
in toluene (6 mL) at 120°C for 5h. After filtration and evaporation of volatiles, the deuterium 
content was determined by integration of the 1H NMR spectrum of the crude reaction 
mixture. 
C-H activation products: 
methyl 2,3-dihydrobenzofuran-5-carboxylate 5.40:  55  
 
Following the General procedure G for the dihydrobenzofurans synthesis, 5.39 (39 mg, 0.15 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%), cesium pivalate (35 mg, 0.15 mmol, 1 equiv) 
in toluene (6 mL) at 140°C for 16h. After purification, 5.40 was obtained as a colorless oil (24.5 mg, 0.137 
mmol, 92%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.88 – 7.81 (m, 2H), 6.79 – 6.74 (m, 1H), 4.67 – 4.56 
(m, 2H), 3.86 (s, 3H), 3.24 – 3.16 (m, 2H). 
 
13C NMR (101 MHz, CDCl3) δ = 167.0, 164.2, 131.1, 127.4, 126.8, 122.6, 109.0, 72.1, 51.9, 
29.1. 
 
2,3-dihydrobenzofuran 5.46: 56 
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Following the General procedure G for the dihydrobenzofurans synthesis, 5.46r (30 mg, 0.15 mmol, 1 
equiv) was reacted with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%), cesium pivalate (35 mg, 0.15 mmol, 1 
equiv) in toluene (6 mL) at 140°C for 16h. After purification, 5.46 was obtained as a colorless oil (7.2 mg, 
0.06 mmol, 40%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.24 – 7.21 (m, 1H), 7.16 – 7.11 (m, 1H), 6.90 – 6.85 
(m, 1H), 6.84 – 6.81 (m, 1H), 4.58 (t, J = 8.7 Hz, 2H), 3.23 (t, J = 8.7 Hz, 2H). 
 
13C NMR (101 MHz, CDCl3) δ = 160.1, 128.0, 126.9, 125.0, 120.4, 109.4, 71.1, 29.8. 
 
5-fluoro-2,3-dihydrobenzofuran 5.47: 57 
 
Following the General procedure G for the dihydrobenzofurans synthesis, 5.47r (33 mg, 0.15 mmol, 1 
equiv) was reacted with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%), cesium pivalate (35 mg, 0.15 mmol, 1 
equiv) in toluene (6 mL) at 140°C for 16h. After purification, 5.47 was obtained as a yellowish oil (12 mg, 
0.087 mmol, 57%). 
1H NMR (400 MHz, Chloroform-d) δ = 6.91 – 6.87 (m, 1H), 6.78 (td, J = 8.9, 2.8 Hz, 1H), 
6.70 – 6.86 (m, 1H), 4.59 – 4.54 (m, 2H), 3.21 – 3.15 (m, 2H). 
 
13C NMR (101 MHz, Chloroform-d) δ = 157.5 (d, J = 236.4 Hz), 156.1 (d, J = 1.4 Hz), 128.4 
(d, J = 8.8 Hz), 114.0 (d, J = 24.1 Hz), 112.1 (d, J = 24.8 Hz), 109.3 (d, J = 8.6 Hz), 71.7, 30.1 (d, 
J = 1.8 Hz). 
 
19F NMR (376 MHz, CDCl3) δ = -125.0 (m) 
 
2,3-dihydrobenzofuran-5-carbaldehyde 5.45: 58 
 
Following the General procedure G for the dihydrobenzofurans synthesis, 5.45r (35 mg, 0.15 mmol, 1 
equiv) was reacted with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%), cesium pivalate (35 mg, 0.15 mmol, 1 
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equiv) in toluene (6 mL) at 140°C for 16h. After purification, 5.45 was obtained as a yellowish oil (20.5 
mg, 0.136 mmol, 91%). 
 
1H NMR (400 MHz, Chloroform-d) δ = 9.77 (s, 1H), 7.71 – 7.65 (m, 1H), 7.64 – 7.59 (m, 1H), 
6.84 – 6.79 (m, 1H), 4.67 – 4.57 (m, 3H), 3.21 (t, J = 8.8 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 190.6, 165.6, 132.9, 130.4, 128.5, 125.9, 109.6, 72.4, 28.7. 
 
methyl 2,3-dihydrobenzofuran-4-carboxylate 5.48: 59  
 
Following the General procedure G for the dihydrobenzofurans synthesis, 5.48r (39 mg, 0.15 mmol, 1 
equiv) was reacted with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%), cesium pivalate (35 mg, 0.15 mmol, 1 
equiv) in toluene (6 mL) at 160°C for 16h. After purification, 5.48 was obtained as a colorless oil (21 mg, 
0.118 mmol, 79%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.52 – 7.49 (m, 1H), 7.20 – 7.15 (m, 1H), 6.98 – 6.94 
(m, 1H), 4.60 (t, J = 8.8 Hz, 2H), 3.90 (s, 3H), 3.54 (t, J = 8.9, 2H). 
 
13C NMR (101 MHz, CDCl3) δ = 167.0, 161.0, 129.9, 128.1, 127.1, 121.9, 113.6, 71.6, 52.0, 
31.2. 
 
 
methyl 2,3-dihydrobenzofuran-2-carboxylate 5.53: 60 
 
Following the General procedure G for the dihydrobenzofurans synthesis, 5.53r (39 mg, 0.15 mmol, 1 
equiv) was reacted with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%), cesium pivalate (35 mg, 0.15 mmol, 1 
equiv) in toluene (6 mL) at 160°C for 16h. After purification, 5.53 was obtained as a colorless oil (19.5 mg, 
0.109 mmol, 73%). 
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1H NMR (400 MHz, Chloroform-d) δ = 7.19 – 7.11 (m, 2H), 6.92 – 6.87 (m, 2H), 5.21 (dd, J 
= 10.5, 6.8 Hz, 1H), 3.81 (s, 3H), 3.61 – 3.51 (m, 1H), 3.43 – 3.34 (m, 1H). 
 
13C NMR (126 MHz, CDCl3) δ = 171.90, 159.1, 128.6, 124.9, 124.8, 121.4, 110.0, 79.1, 52.7, 
34.0. 
 
methyl 2,3-dihydrobenzofuran-3-carboxylate 5.49: 61 
 
Following the General procedure G for the dihydrobenzofurans synthesis, 5.49r (39 mg, 0.15 mmol, 1 
equiv) was reacted with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%), cesium pivalate (35 mg, 0.15 mmol, 1 
equiv) in toluene (6 mL) at 160°C for 16h. After cooling to room temperature, the crude mixture was 
filtered through celite and evaporated under vacuum. The crude mixture was then dissolved in dry DCM 
(2 mL) and cooled to -78°C. BBr3 (5.1 L, 0.3 mmol, 2 equiv) was added and the reaction was stirred for 
30 minutes at this temperature. After quenching with water (2 mL), the crude mixture was extracted with 
DCM (3 x 3 mL) and the combined organic layers were dried over sodium sulfate, filtered and evaporated 
under vacuum. After purification by chromatography on silica gel, 5.49 was obtained as a yellowish oil 
(23.5 mg, 0.109 mmol, 88%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.39 – 7.35 (m, 1H), 7.22 – 7.16 (m, 1H), 6.91 – 6.86 
(m, 1H), 6.84 – 6.81 (m, 1H), 4.93 (dd, J = 9.2, 6.6 Hz, 1H), 4.67 (t, J = 9.5 Hz, 1H), 4.35 (dd, J 
= 9.8, 6.6 Hz, 1H), 3.78 (s, 3H). 
 
13C NMR (126 MHz, CDCl3) δ = 171.8, 159.9, 129.6, 125.5, 124.3, 120.8, 110.1, 72.6, 52.7, 
47.3. 
 
methyl 5-fluoro-2,3-dihydrobenzofuran-3-carboxylate 5.50: 
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Following the General procedure G for the dihydrobenzofurans synthesis, 5.50r (42 mg, 0.15 mmol, 1 
equiv) was reacted with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%), cesium pivalate (35 mg, 0.15 mmol, 1 
equiv) in toluene (6 mL) at 140°C for 16h. After cooling to room temperature, the crude mixture was 
filtered through celite and evaporated under vacuum. The crude mixture was then dissolved in dry DCM 
(2 mL) and cooled to -78°C. BBr3 (5.1 L, 0.3 mmol, 2 equiv) was added and the reaction was stirred for 
30 minutes at this temperature. After quenching with water (2 mL), the crude mixture was extracted with 
DCM (3 x 3 mL) and the combined organic layers were dried over sodium sulfate, filtered and evaporated 
under vacuum. After purification by chromatography on silica gel, 5.50 was obtained as a colorless oil 
(20.5 mg, 0.104 mmol, 70%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.11 – 7.07 (m, 1H), 6.91 – 6.85 (m, 1H), 6.75 – 6.70 
(m, 1H), 4.94 (dd, J = 9.3, 6.8 Hz, 1H), 4.69 (t, J = 9.6 Hz, 1H), 4.36 – 4.30 (m, 1H), 3.79 (s, 
3H). 
 
13C NMR (126 MHz, Chloroform-d) δ = 171.2, 157.5 (d, J = 237.6 Hz), 156.0 (d, J = 1.6 Hz), 
125.4 (d, J = 9.3 Hz), 116.0 (d, J = 24.2 Hz), 112.7 (d, J = 25.5 Hz), 110.2 (d, J = 8.5 Hz), 73.2, 
52.9, 47.4 (d, J = 1.8 Hz). 
 
19F NMR (376 MHz, CDCl3) δ = -124.0. 
 
N,N-diisopropyl-2,3-dihydrobenzofuran-3-carboxamide 5.51:  
 
Following the General procedure G for the dihydrobenzofurans synthesis, 5.51r (49 mg, 0.15 mmol, 1 
equiv) was reacted with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%), cesium pivalate (35 mg, 0.15 mmol, 1 
equiv) in toluene (6 mL) at 160°C for 16h. After purification, 5.51 was obtained as a colorless oil (30 mg, 
0.121 mmol, 81%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.17 – 7.13 (m, 1H), 7.12 – 7.09 (m, 1H), 6.88 – 6.84 
(m, 1H), 6.84 – 6.80 (m, 1H), 4.86 – 4.80 (m, 1H), 4.72 – 4.65 (m, 1H), 4.57 – 4.50 (m, 1H), 
4.22 – 4.13 (m, 1H), 3.72 – 3.59 (m, 1H), 1.41 – 1.37 (m, 9H), 1.26 (d, J = 6.6 Hz, 3H). 
 
13C NMR (126 MHz, CDCl3) δ = 160.4, 129.1, 124.4, 120.7, 110.1, 74.4, 46.7, 46.4, 21.7, 
20.8, 20.7. 
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HRMS (ESI): Calculated for C15H22NO2 ([M+H]+): Exact Mass: 248.1651; found: 248.1654 
IR (neat) : ν = 1645 cm-1 
(2,3-dihydrobenzofuran-3-yl)(morpholino)methanone 5.52:  
 
Following the General procedure G for the dihydrobenzofurans synthesis, 5.52r (47 mg, 0.15 mmol, 1 
equiv) was reacted with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%), cesium pivalate (35 mg, 0.15 mmol, 1 
equiv) in toluene (6 mL) at 160°C for 16h. After purification, 5.52 was obtained as a colorless oil (18.5 mg, 
0.079 mmol, 53%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.14 – 7.08 (m, 1H), 7.06 – 7.03 (m, 1H), 6.82 – 6.75 
(m, 2H), 4.89 – 4.84 (m, 1H), 4.64 – 4.58 (m, 1H), 4.55 – 4.49 (m, 1H), 3.73 – 3.55 (m, 8H). 
 
13C NMR (126 MHz, CDCl3) δ = 169.9, 160.3, 129.5, 125.6, 124.2, 120.8, 110.4, 73.8, 67.1, 
66.9, 46.6, 44.6, 42.9. 
 
HRMS (ESI): Calculated for C13H16NO2 ([M+H]+): Exact Mass: 234.1130; found: 234.1135 
IR (neat) : ν = 1647 cm-1 
dimethyl 2,3-dihydrobenzofuran-2,3-dicarboxylate 5.54:  
 
Following the General procedure G for the dihydrobenzofurans synthesis, 5.54r (48 mg, 0.15 mmol, 1 
equiv) was reacted with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%), cesium pivalate (35 mg, 0.15 mmol, 1 
equiv) in toluene (6 mL) at 160°C for 16h. After purification, 5.54 was obtained as a yellowish oil (14.5 
mg, 0.061 mmol, 41%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.32 – 7.29 (m, 1H), 7.19 – 7.13 (m, 1H), 6.90 – 6.84 
(m, 2H), 5.59 (d, J = 6.0 Hz, 1H), 4.48 – 4.46 (m, 1H), 3.75 (s, 6H). 
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13C NMR (126 MHz, CDCl3) δ = 170.6, 170.5, 158.7, 130.1, 125.3, 122.6, 121.7, 110.5, 81.0, 
53.2, 53.1, 51.1. 
 
HRMS (ESI): Calculated for C12H13O5 ([M+H]+): Exact Mass: 237.0763; found: 237.0766 
IR (neat) : ν = 1740 cm-1 
5,5'-(propane-2,2-diyl)bis(2,3-dihydrobenzofuran) 5.55:  
 
 
Following the General procedure G for the dihydrobenzofurans synthesis, 5.55r (66 mg, 0.15 mmol, 1 
equiv) was reacted with Pd(PCy3)2 (20 mg, 0.03 mmol, 20 mol%), cesium pivalate (70 mg, 0.30 mmol, 2 
equiv) in toluene (6 mL) at 160°C for 16h. After purification, 5.55 was obtained as a colorless oil (28.5 mg, 
0.102 mmol, 68%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.07 – 7.05 (m, 2H), 7.04 – 7.00 (m, 2H), 6.72 – 
6.68 (m, 2H), 4.56 (t, J = 8.7 Hz, 4H), 3.17 (t, J = 9.2, 8.1 Hz, 4H), 1.65 (s, 6H). 
 
13C NMR (126 MHz, CDCl3) δ = 158.0, 143.6, 126.7, 126.2, 123.7, 108.5, 71.4, 42.2, 31.6, 
30.1. 
 
HRMS (ESI): Calculated for C19H21O2 ([M+H]+): Exact mass: 281.1542; found: 281.1545 
IR (neat) : ν = 906 cm-1 
2,2,2-trifluoro-1-(indolin-1-yl)ethan-1-one 5.78: 62 
 
Following the General procedure H for indolines synthesis, 5.77 (45 mg, 0.15 mmol, 1 equiv) was reacted 
with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%), AdCO2H (8.1 mg, 0.045 mmol, 30 mol%), Rb2CO3 (52 
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mg, 0.15 mmol, 1 equiv) in toluene (6 mL) at 160°C for 16h. After purification, 5.78 was obtained as a 
colorless oil (24 mg, 0.112 mmol, 74%). 
1H NMR (400 MHz, Chloroform-d) δ = 8.22 – 8.19 (m, 1H), 7.30 – 7.27 (m, 2H), 7.18 – 7.14 
(m, 1H), 4.31 – 4.24 (m, 2H), 3.27 (t, J = 8.3 Hz, 2H). 
 
13C NMR (101 MHz, Chloroform-d) δ = 154.1 (q, J = 37.2 Hz), 141.6, 131.8, 127.6, 125.8, 
124.8, 117.7, 116.1 (q, J = 287.9 Hz), 47.7 (q, J = 4.2 Hz), 28.3 (q, J = 1.1 Hz). 
 
19F NMR (376 MHz, CDCl3) δ = -72.7. 
 
2,2,2-trifluoro-1-(5-methylindolin-1-yl)ethan-1-one 5.82: 63 
 
Following the General procedure H for indolines synthesis, 5.82r (47 mg, 0.15 mmol, 1 equiv) was reacted 
with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%), AdCO2H (8.1 mg, 0.045 mmol, 30 mol%), Rb2CO3 (52 
mg, 0.15 mmol, 1 equiv) in toluene (6 mL) at 160°C for 16h. After purification, 5.82 was obtained as a 
colorless oil (21 mg, 0.092 mmol, 62%). 
1H NMR (400 MHz, Chloroform-d) δ = 8.08 – 8.04 (m, 1H), 7.09 – 7.04 (m, 2H), 4.28 – 
4.21 (m, 2H), 3.24 – 3.17 (m, 2H), 2.34 (s, 3H). 
 
13C NMR (101 MHz, Chloroform-d) δ = 154.0 (q, J = 37.2 Hz), 139.4, 135.9, 131.9, 128.4, 
125.6, 117.7, 116.3 (q, J = 287.1 Hz) 48.0 (q, J = 4.2 Hz), 28.5 (q, J = 1.1 Hz), 21.2. 
 
19F NMR (376 MHz, CDCl3) δ = -72.5, -72.5, -72.5. 
 
methyl 1-(2,2,2-trifluoroacetyl)indoline-5-carboxylate 5.83: 64 
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Following the General procedure H for indolines synthesis, 5.83r (53 mg, 0.15 mmol, 1 equiv) was reacted 
with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%), AdCO2H (8.1 mg, 0.045 mmol, 30 mol%), Rb2CO3 (52 
mg, 0.15 mmol, 1 equiv) in toluene (6 mL) at 160°C for 16h. After purification, 5.83 was obtained as a 
yellowish oil (25 mg, 0.092 mmol, 61%). 
1H NMR (400 MHz, Chloroform-d) δ = 8.22 – 8.18 (m, 1H), 7.97 – 7.93 (m, 1H), 7.92 – 7.89 
(m, 1H), 4.36 – 4.27 (m, 2H), 3.90 (s, 3H), 3.31 – 3.25 (m, 2H). 
 
13C NMR (101 MHz, Chloroform-d) δ = 166.5, 154.7 (q, J = 37.8 Hz), 145.6, 132.0, 130.2, 
1277, 126.3, 117.4, 116.0 (q, J = 287.8 Hz), 52.3, 48.3 (q, J = 4.2 Hz), 28.1 (d, J = 1.2 Hz). 
 
19F NMR (376 MHz, CDCl3) δ = -72.8. 
 
2,2,2-trifluoro-1-(5-fluoroindolin-1-yl)ethan-1-one 5.84: 65 
 
Following the General procedure H for indolines synthesis, 5.84r (47 mg, 0.15 mmol, 1 equiv) was reacted 
with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%), AdCO2H (8.1 mg, 0.045 mmol, 30 mol%), Rb2CO3 (52 
mg, 0.15 mmol, 1 equiv) in toluene (6 mL) at 160°C for 16h. After purification, 5.84 was obtained as a 
yellowish oil (13 mg, 0.056 mmol, 38%). 
1H NMR (400 MHz, Chloroform-d) δ = 8.20 – 8.14 (m, 1H), 6.99 – 6.92 (m, 2H), 4.34 – 4.27 
(m, 2H), 3.30 – 3.21 (m, 2H). 
 
13C NMR (101 MHz, Chloroform-d) δ = 160.6 (d, J = 245.2 Hz), 154.1 (q, J = 37.4 Hz), 137.8, 
134.0 (d, J = 8.8 Hz), 119.0 (d, J = 8.5 Hz), 116.2 (q, J = 286.2 Hz), 114.4 (d, J = 23.1 Hz), 112.3 
(d, J = 24.3 Hz), 48.2 (q, J = 4.2 Hz), 28.5 (q, J = 2.1, 1.1 Hz). 
 
19F NMR (376 MHz, CDCl3) δ = -72.5, -72.6. 
 
indoline-5-carbonitrile 5.85: 66 
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Following the General procedure H for indolines synthesis, 5.85r (48 mg, 0.15 mmol, 1 equiv) was reacted 
with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%), AdCO2H (8.1 mg, 0.045 mmol, 30 mol%), Rb2CO3 (52 
mg, 0.15 mmol, 1 equiv) in toluene (6 mL) at 160°C for 16h. After purification, 5.85 was obtained as a 
yellowish oil (10 mg, 0.069 mmol, 45%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.31 – 7.27 (m, 2H), 6.55 – 6.51 (m, 1H), 4.23 (br. s, 
1H), 3.66 (t, J = 8.6 Hz, 2H), 3.09 – 2.97 (m, 2H). 
 
13C NMR (101 MHz, CDCl3) δ = 155.5, 133.2, 129.6, 128.1, 128.1, 120.9, 108.1, 99.7, 47.1, 
28.9. 
 
chroman-4-one 5.92: 67 
 
Following the General procedure I for the chromanones synthesis, 5.91 (35 mg, 0.15 mmol, 1 equiv) was 
reacted with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%), AdCO2H (8.1 mg, 0.045 mmol, 30 mol%), Cs2CO3 
(49 mg, 0.15 mmol, 1 equiv) in toluene (6 mL) at 120°C for 16h. After purification, 5.92 was obtained as a 
colorless oil (16 mg, 0.108 mmol, 72%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.87 – 7.82 (m, 1H), 7.45 – 7.39 (m, 1H), 6.99 – 6.90 
(m, 2H), 4.51 – 4.46 (m, 2H), 2.78 – 2.74 (m, 2H). 
 
13C NMR (101 MHz, CDCl3) δ = 191.8, 161.8, 135.9, 127.1, 121.3, 121.3, 117.9, 67.0, 37.8. 
 
6-methylchroman-4-one 5.95: 68 
 
Following the General procedure I for the chromanones synthesis, 5.95r (37 mg, 0.15 mmol, 1 equiv) was 
reacted with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%), AdCO2H (8.1 mg, 0.045 mmol, 30 mol%), Cs2CO3 
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(49 mg, 0.15 mmol, 1 equiv) in toluene (6 mL) at 120°C for 16h. After purification, 5.95 was obtained as a 
colorless oil (16.5 mg, 0.102 mmol, 68%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.68 – 7.66 (m, 1H), 7.29 – 7.25 (m, 1H), 6.88 – 6.84 
(m, 1H), 4.51 – 4.47 (m, 2H), 2.80 – 2.75 (m, 2H), 2.29 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 192.2, 160.0, 137.1, 130.9, 126.8, 121.0, 117.8, 67.1, 37.9, 
20.5. 
 
6-fluorochroman-4-one 5.96: 69 
 
Following the General procedure I for the chromanones synthesis, 5.96r (37 mg, 0.15 mmol, 1 equiv) was 
reacted with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%), AdCO2H (8.1 mg, 0.045 mmol, 30 mol%), Cs2CO3 
(49 mg, 0.15 mmol, 1 equiv) in toluene (6 mL) at 120°C for 16h. After purification, 5.96 was obtained as a 
colorless oil (15.5 mg, 0.093 mmol, 62%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.53 – 7.47 (m, 1H), 7.20 – 7.14 (m, 1H), 6.96 – 6.90 
(m, 1H), 4.52 – 4.48 (m, 2H), 2.80 – 2.76 (m, 2H). 
 
13C NMR (101 MHz, Chloroform-d) δ = 191.1 (d, J = 1.9 Hz), 158.2 (d, J = 1.8 Hz), 157.3 (d, J 
= 241 Hz), 123.6 (d, J = 24.6 Hz), 121.8 (d, J = 6.4 Hz), 119.7 (d, J = 7.3 Hz), 112.1 (d, J = 23.2 
Hz), 67.3, 37.6 (d, J = 1.3 Hz). 
 
19F NMR (376 MHz, CDCl3) δ = -121.5. 
 
6-ethylchroman-4-one 5.97: 70 
 
Following the General procedure I for the chromanones synthesis, 5.97r (39 mg, 0.15 mmol, 1 equiv) was 
reacted with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%), AdCO2H (8.1 mg, 0.045 mmol, 30 mol%), Cs2CO3 
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(49 mg, 0.15 mmol, 1 equiv) in toluene (6 mL) at 120°C for 16h. After purification, 5.97 was obtained as a 
colorless oil (14 mg, 0.079 mmol, 52%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.66 – 7.63 (m, 1H), 7.28 – 7.23 (m, 1H), 6.85 – 6.81 
(m, 1H), 4.46 – 4.42 (m, 2H), 2.75 – 2.70 (m, 2H), 2.54 (q, J = 7.5 Hz, 2H), 1.15 (t, J = 7.6 Hz, 
3H). 
 
13C NMR (126 MHz, CDCl3) δ = 192.3, 160.2, 137.4, 136.2, 125.7, 121.2, 117.9, 67.2, 38.0, 
28.1, 15.7. 
 
HRMS (ESI): Calculated for C11H13O2 ([M+H]+): Exact Mass: 177.0916; found: 177.0920 
IR (neat) : ν = 1685, 1469 cm-1 
3,6-dimethylchroman-4-one 5.98: 
 
Following the General procedure I for the chromanones synthesis, 5.98r (39 mg, 0.15 mmol, 1 equiv) was 
reacted with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%), AdCO2H (8.1 mg, 0.045 mmol, 30 mol%), Cs2CO3 
(49 mg, 0.15 mmol, 1 equiv) in toluene (6 mL) at 120°C for 16h. After purification, 5.98 was obtained as a 
yellowish oil (22 mg, 0.125 mmol, 82%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.70 – 7.67 (m, 1H), 7.30 – 7.27 (m, 1H), 6.88 – 6.84 
(m, 1H), 4.47 (dd, J = 11.3, 5.0 Hz, 1H), 4.12 (t, J = 11.0 Hz, 1H), 2.89 – 2.78 (m, 1H), 2.31 (s, 
3H), 1.21 (d, J = 7.0 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ = 195.3, 159.9, 136.9, 130.9, 127.0, 120.3, 117.6, 72.4, 40.9, 
20.6, 11.0. 
 
HRMS (ESI): Calculated for C11H13O2 ([M+H]+): Exact Mass: 177.0916; found: 177.0919 
IR (neat) : ν = 1682 cm-1 
3-benzylchroman-4-one 5.99: 71 
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Following the General procedure I for the chromanones synthesis, 5.99r (48 mg, 0.15 mmol, 1 equiv) was 
reacted with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%), AdCO2H (8.1 mg, 0.045 mmol, 30 mol%), Cs2CO3 
(49 mg, 0.15 mmol, 1 equiv) in toluene (6 mL) at 120°C for 16h. After purification, 5.99 was obtained as a 
yellowish oil (26 mg, 0.082 mmol, 55%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.97 – 7.93 (m, 1H), 7.52 – 7.46 (m, 1H), 7.37 – 7.31 
(m, 2H), 7.29 – 7.23 (m, 3H), 7.08 – 7.02 (m, 1H), 7.01 – 6.96 (m, 1H), 4.39 (dd, J = 11.5, 4.4 
Hz, 1H), 4.19 (dd, J = 11.5, 8.4 Hz, 1H), 3.31 (dd, J = 13.9, 4.5 Hz, 1H), 3.00 – 2.91 (m, 1H), 2.73 
(dd, J = 14.0, 10.3 Hz, 1H). 
 
13C NMR (101 MHz, CDCl3) δ = 193.9, 161.7, 138.4, 136.0, 129.2, 128.8, 127.6, 126.8, 
121.6, 120.7, 117.9, 69.5, 47.8, 32.5. 
 
3-phenyl-2,3-dihydrobenzofuran-3-ol 5.104 : 72 
 
Following General procedure J for nucleophilic addition, 5.103 (44 mg, 0.15 mmol, 1 equiv) was 
reacted with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%) and CsOPiv (105 mg, 0.45 mmol, 3 equiv) in 
toluene (6 mL) at 160°C for 16h. After purification, 5.104 was obtained as a colorless oil (22 mg, 0.104 
mmol, 69%). 
1H NMR (400 MHz, Chloroform-d) δ = 7.53 – 7.49 (m, 2H), 7.40 – 7.35 (m, 2H), 7.34 – 
7.29 (m, 2H), 7.12 – 7.09 (m, 1H), 6.99 – 6.93 (m, 2H), 4.71 (d, J = 10.3 Hz, 1H), 4.52 (d, J = 
10.3 Hz, 1H), 2.29 (s, 1H). 
 
13C NMR (101 MHz, CDCl3) δ = 160.8, 142.7, 132.3, 130.8, 128.4, 127.7, 126.2, 124.5, 
121.6, 110.9, 86.3, 82.7. 
 
5-methyl-3-phenyl-2,3-dihydrobenzofuran-3-ol 5.109: 73 
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Following General procedure J for nucleophilic addition, 5.109r (46 mg, 0.15 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%) and CsOPiv (105 mg, 0.45 mmol, 3 equiv) 
in toluene (6 mL) at 160°C for 16h. After purification, 5.109 was obtained as a colorless oil (21 mg, 0.093 
mmol, 63%). 
1H NMR (400 MHz, Benzene-d6) δ = 7.46 – 7.38 (m, 2H), 7.13 – 7.08 (m, 2H), 7.06 – 7.00 
(m, 1H), 6.86 – 6.84 (m, 2H), 6.68 (br. s, 1H), 4.43 (d, J = 10.1 Hz, 1H), 4.32 (d, J = 10.1 Hz, 
1H), 1.98 (s, 3H). 
 
13C NMR (126 MHz, C6D6) δ = 159.1, 143.5, 132.9, 130.9, 130.2, 128.0, 127.1, 126.1, 124.8, 
110.1, 86.4, 82.3, 20.3. 
 
5-fluoro-3-phenyl-2,3-dihydrobenzofuran-3-ol 5.110: 74 
 
Following General procedure J for nucleophilic addition, 5.110r (46 mg, 0.15 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%) and CsOPiv (105 mg, 0.45 mmol, 3 equiv) 
in toluene (6 mL) at 160°C for 16h. After purification, 5.110 was obtained as a colorless oil (27 mg, 0.117 
mmol, 78%). 
1H NMR (400 MHz, Benzene-d6) δ = 7.30 – 7.23 (m, 2H), 7.09 – 7.00 (m, 3H), 6.71 – 6.64 
(m, 1H), 6.62 – 6.57 (m, 1H), 6.54 – 6.50 (m, 1H), 4.33 (d, J = 10.2 Hz, 1H), 4.22 (d, J = 10.2 
Hz, 1H). 
 
13C NMR (126 MHz, Benzene-d6) δ = 158.7, 156.8 (d, J = 6.7 Hz), 142.6, 133.8 (d, J = 7.6 Hz), 
128.1, 125.8, 116.8 (d, J = 24.5 Hz), 111.1 (d, J = 24.5 Hz), 111.0 (d, J = 8.1 Hz), 86.5, 82.1 (d, J = 
1.8 Hz). 
 
19F NMR (471 MHz, C6D6) δ = -122.7 
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3-(3,5-dimethoxyphenyl)-2,3-dihydrobenzofuran-3-ol 5.111: 
  
Following General procedure J for nucleophilic addition, 5.111r (53 mg, 0.15 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%) and CsOPiv (105 mg, 0.45 mmol, 3 equiv) 
in toluene (6 mL) at 160°C for 16h. After purification, 5.111 was obtained as a yellowish oil (24 mg, 0.088 
mmol, 59%). 
 
1H NMR (400 MHz, Benzene-d6) δ = 7.05 – 7.00 (m, 1H), 6.99 – 6.95 (m, 1H), 6.92 – 6.88 
(m, 1H), 6.82 – 6.79 (m, 2H), 6.75 – 6.65 (m, 1H), 6.50 – 6.47 (m, 1H), 4.46 (d, J = 10.1 Hz, 
1H), 4.41 (d, J = 10.1 Hz, 1H), 3.25 (s, 6H). 
 
13C NMR (101 MHz, C6D6) δ = 161.1, 161.0, 145.9, 132.6, 130.4, 124.5, 121.1, 110.6, 104.5, 
99.7, 86.2, 82.3, 54.5. 
 
HRMS (ESI): Calculated for C16H17O4 ([M+H]+): Exact Mass: 273.1127; found: 273.1129 
IR (neat) : ν = 1340 cm-1 
3-(3-methoxy-4-(trifluoromethyl)phenyl)-2,3-dihydrobenzofuran-3-ol 5.112:  
 
Following General procedure J for nucleophilic addition, 5.112r (58 mg, 0.15 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%) and CsOPiv (105 mg, 0.45 mmol, 3 equiv) 
in toluene (6 mL) at 160°C for 16h. After purification, 5.112 was obtained as a yellowish oil (23 mg, 0.075 
mmol, 50%). 
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1H NMR (400 MHz, Benzene-d6) δ = 8.01 – 7.97 (m, 1H), 7.19 – 7.16 (m, 1H), 7.05 – 7.00 (m, 
1H), 6.91 – 6.87 (m, 1H), 6.82 – 6.78 (m, 1H), 6.72 – 6.66 (m, 1H), 6.31 – 6.25 (m, 1H), 4.33 (d, 
J = 10.3 Hz, 1H), 4.15 (d, J = 10.3 Hz, 1H), 3.15 (s, 3H). 
 
13C NMR (101 MHz, Benzene-d6) δ = 160.9, 156.8 (q, J = 1.6 Hz), 135.1, 132.2, 131.0 (q, J = 1.1 
Hz), 130.6, 124.7 (q, J = 5.3 Hz), 124.3, 124.2 (q, J = 275.2 Hz), 121.2, 118.2, 111.6, 110.7, 85.8, 
81.5, 55.0. 
 
 
19F NMR (376 MHz, C6D6) δ = -61.9. 
 
HRMS (ESI): Calculated for C16H14F3O3 ([M+H]+): Exact Mass: 311.0895; found: 311.0899 
IR (neat) : ν = 2361, 1330 cm-1 
 
3-(4-methoxyphenyl)-2,3-dihydrobenzofuran-3-ol 5.113: 75 
 
Following General procedure J for nucleophilic addition, 5.113r (48 mg, 0.15 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%) and CsOPiv (105 mg, 0.45 mmol, 3 equiv) 
in toluene (6 mL) at 160°C for 16h. After purification, 5.113 was obtained as a colorless oil (21 mg, 0.087 
mmol, 57%). 
1H NMR (400 MHz, Benzene-d6) δ = 7.34 – 7.28 (m, 2H), 7.07 – 7.01 (m, 1H), 6.94 – 6.90 
(m, 2H), 6.76 – 6.67 (m, 3H), 4.44 (d, J = 10.1 Hz, 1H), 4.31 (d, J = 10.1 Hz, 1H), 3.27 (s, 3H). 
 
13C NMR (126 MHz, C6D6) δ = 161.0, 159.1, 135.3, 133.0, 130.2, 127.3, 124.5, 121.0, 113.5, 
110.6, 86.2, 81.9, 54.4. 
 
3-(4-fluorophenyl)-2,3-dihydrobenzofuran-3-ol 5.114:  
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Following General procedure J for nucleophilic addition, 5.114r (46 mg, 0.15 mmol, 1 equiv) 
was reacted with Pd(PCy3)2 (10 mg, 0.015 mmol, 10 mol%) and CsOPiv (105 mg, 0.45 mmol, 3 equiv) 
in toluene (6 mL) at 160°C for 16h. After purification, 5.114 was obtained as a colorless oil (26 mg, 0.113 
mmol, 74%). 
1H NMR (400 MHz, Benzene-d6) δ = 7.14 – 7.10 (m, 2H), 7.05 – 7.00 (m, 1H), 6.90 – 6.87 
(m, 1H), 6.78 – 6.75 (m, 1H), 6.75 – 6.66 (m, 3H), 4.32 (d, J = 10.2 Hz, 1H), 4.13 (d, J = 10.2 
Hz, 1H). 
 
13C NMR (126 MHz, Benzene-d6) δ = 163.1, 161.2, 160.9, 139.0 (d, J = 3.1 Hz), 132.5, 130.4, 
124.3, 121.1, 114.7 (d, J = 21.3 Hz), 110.6, 86.0, 81.2. 
 
19F NMR (471 MHz, C6D6) δ = -115.6. 
 
HRMS (ESI): Calculated for C14H12FO2 ([M+H]+): Exact Mass: 231.0821; found: 231.0825 
IR (neat) : ν = 1351 cm-1 
3-(4-methoxyphenyl)benzofuran 5.118: 76 
 
After leaving 5.113 in CDCl3 overnight at 25°C, the organic phase was washed with water, dried 
over sodium sulfate, filtered and evaporated to give the desired product pure product 5.118 as a 
colorless oil (19 mg, 0.087 mmol, 100%). 
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1H NMR (400 MHz, Chloroform-d) δ = 7.82 – 7.79 (m, 1H), 7.73 (s, 1H), 7.60 – 7.52 (m, 
3H), 7.38 – 7.28 (m, 2H), 7.05 – 7.00 (m, 2H), 3.87 (s, 3H). 
 
13C NMR (126 MHz, CDCl3) δ = 159.2, 155.9, 140.8, 128.8, 126.8, 124.6, 123.0, 122.0, 
120.5, 114.6, 111.9, 55.5. 
 
3-(4-fluorophenyl)benzofuran 5.119: 77 
 
After leaving 5.114 in CDCl3 overnight at 25°C, the organic phase was washed with water, dried 
over sodium sulfate, filtered and evaporated to give the desired product pure product 5.119 as a 
colorless oil (24 mg, 0.112 mmol, 100%). 
 
1H NMR (400 MHz, Chloroform-d) δ = 7.80 – 7.77 (m, 1H), 7.76 (s, 1H), 7.63 – 7.58 (m, 
2H), 7.57 – 7.54 (m, 1H), 7.39 – 7.29 (m, 2H), 7.21 – 7.13 (m, 2H). 
 
13C NMR (126 MHz, Chloroform-d) δ = 162.4 (d, J = 246.7 Hz), 155.9, 141.3 (d, J = 1.3 Hz), 
129.3 (d, J = 8.0 Hz), 128.2 (d, J = 3.4 Hz), 126.5, 124.8, 123.2, 121.5, 120.3, 116.1 (d, J = 21.5 
Hz), 112.0. 
 
19F NMR (376 MHz, CDCl3) δ = -114.6. 
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1.1: A Four-Step Synthesis of (±)-γ-lycorane via Pd0-
Catalyzed Double C(sp2)–H/C(sp3)–H Arylation 
 
(Numbering based on Org. Lett. 2018, 203, 772-775) 
  
422 
 
 
 
  
423 
 
 
 
424 
 
  
425 
 
  
426 
 
  
427 
 
  
428 
 
  
429 
 
  
430 
 
  
431 
 
  
432 
 
  
433 
 
  
434 
 
  
435 
 
  
436 
 
  
437 
 
  
438 
 
  
439 
 
  
440 
 
  
441 
 
  
442 
 
  
443 
 
  
444 
 
  
445 
 
  
446 
 
  
447 
 
  
448 
 
  
449 
 
  
450 
 
  
451 
 
  
452 
 
  
453 
 
 
  
454 
 
  
455 
 
  
456 
 
  
457 
 
  
458 
 
  
459 
 
  
460 
 
  
461 
 
  
462 
 
  
463 
 
  
464 
 
  
465 
 
  
466 
 
 
  
467 
 
  
  
468 
 
  
469 
 
  
470 
 
  
471 
 
  
472 
 
  
473 
 
 
 
 
 
474 
 
 
475 
 
1.2: Synthesis of β-Lactams by Palladium(0)-Catalyzed 
C(sp3 )-H Carbamoylation 
 
(Numbering based on Angew. Chem. Int. Ed. 2017, 56, 7218 –7222) 
  
476 
 
 
 
477 
 
  
478 
 
 
 
  
479 
 
 
 
 
  
480 
 
 
 
  
481 
 
 
 
  
482 
 
 
 
  
483 
 
 
 
  
484 
 
 
 
  
485 
 
 
 
  
486 
 
 
 
  
487 
 
 
 
  
488 
 
 
 
  
489 
 
 
 
  
490 
 
 
 
  
491 
 
 
 
  
492 
 
 
 
  
493 
 
 
 
  
494 
 
 
 
  
495 
 
 
 
  
496 
 
 
 
  
497 
 
 
 
  
498 
 
 
 
  
499 
 
 
 
  
500 
 
 
  
501 
 
 
 
  
502 
 
 
 
  
503 
 
 
 
  
504 
 
 
 
  
505 
 
 
 
  
506 
 
 
 
 
507 
 
 
  
508 
 
 
 
  
509 
 
 
 
 
  
510 
 
 
 
  
511 
 
 
 
  
512 
 
 
 
  
513 
 
 
 
  
514 
 
 
 
  
515 
 
 
 
  
516 
 
 
 
  
517 
 
 
 
  
518 
 
 
 
  
519 
 
 
 
  
520 
 
 
 
  
521 
 
 
  
522 
 
 
 
 
523 
 
 
  
524 
 
 
 
 
 
525 
 
13C labeled reaction : 
 
   
526 
 
 
 
  
527 
 
 
 
  
528 
 
 
 
  
529 
 
 
 
  
530 
 
 
 
  
531 
 
 
 
  
532 
 
 
  
533 
 
 
 
  
534 
 
 
 
  
535 
 
 
 
  
536 
 
 
 
  
537 
 
 
 
 
  
538 
 
 
 
  
539 
 
 
 
  
540 
 
 
 
  
541 
 
 
 
  
542 
 
 
 
  
543 
 
 
 
  
544 
 
 
 
  
545 
 
 
 
  
546 
 
 
 
 
  
547 
 
 
 
 
  
548 
 
 
 
 
  
549 
 
 
 
  
550 
 
 
 
  
551 
 
 
 
  
552 
 
 
 
  
553 
 
 
 
 
554 
 
 
 
 
 
 
 
 
 
 
555 
 
 
 
556 
 
 
 
  
557 
 
 
 
  
558 
 
 
 
559 
 
1.3: Domino Pd0-Catalyzed C(sp3)–H Arylation/Electrocyclic 
Reactions via Benzazetidine Intermediates 
 
(Numbering base on Angew. Chem. Int. Ed. 2018, 57, 12131 –12135) 
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2.1: 1,4-Palladium Shift/C(sp3)−H Activation Strategy for the 
Remote Construction of Five-Membered Rings 
 
 (Numbering base on Org. Lett. 2019, 21, 1434−1437)  
  
628 
 
1-  
 
 
629 
 
 
  
630 
 
 
 
  
631 
 
  
632 
 
 
 
633 
 
 
 
 
634 
 
 
 
  
635 
 
  
636 
 
 
 
637 
 
 
 
 
638 
 
 
 
 
639 
 
 
 
640 
 
 
 
 
641 
 
 
 
 
 
642 
 
 
 
 
643 
 
 
 
 
644 
 
 
  
645 
 
 
 
646 
 
 
 
 
647 
 
 
 
648 
 
 
 
 
649 
 
 
 
650 
 
 
 
 
 
651 
 
 
 
 
652 
 
 
  
653 
 
 
654 
 
 
 
 
 
655 
 
 
 
 
656 
 
 
  
657 
 
 
  
658 
 
 
 
 
659 
 
 
 
 
660 
 
 
 
 
661 
 
 
 
 
662 
 
 
 
663 
 
 
 
664 
 
 
 
 
665 
 
 
 
666 
 
 
 
 
667 
 
 
 
 
668 
 
 
 
 
 
669 
 
 
 
 
 
670 
 
 
  
671 
 
 
  
672 
 
 
 
  
673 
 
 
  
674 
 
 
 
 
675 
 
 
 
676 
 
 
 
677 
 
 
 
678 
 
 
 
679 
 
 
 
680 
 
 
  
681 
 
 
 
682 
 
 
 
683 
 
 
 
 
684 
 
 
 
685 
 
 
 
 
686 
 
 
 
 
687 
 
 
 
 
688 
 
 
 
689 
 
 
 
690 
 
 
 
691 
 
 
 
692 
 
 
 
693 
 
 
 
694 
 
 
 
 
695 
 
 
 
 
696 
 
 
 
 
697 
 
 
 
 
698 
 
 
 
 
699 
 
 
 
 
700 
 
 
 
 
 
701 
 
 
 
702 
 
 
 
703 
 
 
 
704 
 
 
 
 
705 
 
 
 
706 
 
 
 
707 
 
 
 
708 
 
 
 
 
709 
 
 
 
 
710 
 
  
711 
 
2.3: Redox-Neutral Coupling between Two C(sp3)–H Bonds 
Enabled by 1,4-Palladium Shift for the Synthesis of Fused 
Heterocycles 
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